"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT00479778","Study Of Pharmacokinetic (PK) Profile of Bazedoxifene (BZA) in 2 BZA/Conjugated Estrogen Forms",,"Completed","No Results Available","Postmenopause","Drug: Bazedoxifene/conjugated estrogens","Pharmacokinetic analyses.","Wyeth is now a wholly owned subsidiary of Pfizer","Female","40 Years to 65 Years   (Adult, Older Adult)","Phase 1","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3115A1-1121","April 2007",,"July 2007","May 28, 2007",,"December 28, 2007","Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00479778"
2,"NCT00195455","Study Evaluating Estradiol/Trimegestone in Vasomotor Symptoms (VMS) in Post-Menopausal Women.",,"Completed","No Results Available","Postmenopause","Drug: Trimegestone|Drug: 17b Estradiol","To assess vasomotor symptoms control with a continuous regimen of 17 b estradiol 1mg and Trimegestone (TMG) 0.125 mg.|Study bleeding patterns throughout the treatment period (6 months)|Evaluate changes in the Menopause-Specific Quality of Life Questionnaire","Wyeth is now a wholly owned subsidiary of Pfizer","Female","45 Years to 55 Years   (Adult)","Phase 4","133","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0753T-101538","February 2005",,"March 2007","September 19, 2005",,"December 20, 2007","Guadalajara, Jal., Mexico|Monterrey, N.l., Mexico|Monterrey, N.l., Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT00195455"
3,"NCT00185328","Efficacy and Tolerability of Angeliq in Thai Women",,"Completed","No Results Available","Postmenopause","Drug: Estradiol/DRSP (Angeliq, BAY86-4891)","The relative change in the frequency of hot flushes|The change in intensity of hot flushes|The relative change in frequency of hot flushes|The proportions of subjects with urogenital symptoms|Bleeding pattern|Adverse events collection","Bayer","Female","45 Years and older   (Adult, Older Adult)","Phase 4","55","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91436|309367","September 2005",,"December 2006","September 16, 2005",,"December 12, 2008",,,"https://ClinicalTrials.gov/show/NCT00185328"
4,"NCT05346445","Comparison of Fluoxetine Versus Citalopram Therapy to Control Postmenopausal Vasomotor Syndrome",,"Completed","No Results Available","Postmenopause|Hot Flashes","Drug: Fluoxetine 20 MG|Drug: Citalopram 20mg","Change from baseline Menopause Rating Scale (MRS) total score at 3 months|Change from baseline Menopause Rating Scale (MRS) total score at 6 months|Change from baseline Menopause Rating Scale (MRS) somatic domain score at 3 months|Change from baseline Menopause Rating Scale (MRS) somatic domain score at 6 months|Change from baseline Menopause Rating Scale (MRS) urogenital domain score at 3 months|Change from baseline Menopause Rating Scale (MRS) urogenital domain score at 6 months|Change from baseline Menopause Rating Scale (MRS) psychological domain score at 3 months|Change from baseline Menopause Rating Scale (MRS) psychological domain score at 6 months|Change from baseline score in Item 1 of the Menopause Rating Scale (MRS) at 3 months|Change from baseline score in Item 1 of the Menopause Rating Scale (MRS) at 6 months|Change from the severity of individual Menopause Rating Scale (MRS) items at 6 months","Hospital Regional 1o de Octubre|Universidad Nacional Autonoma de Mexico|National Polytechnic Institute, Mexico","Female","Child, Adult, Older Adult","Not Applicable","91","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","122.2021","January 20, 2021","November 20, 2021","December 20, 2021","April 26, 2022",,"July 26, 2022","Peri-postmenopause and bone metabolism clinic. Regional Hospital October 1st ISSSTE, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT05346445"
5,"NCT01046149","Effects of Breathing Training on Psychosocial Functioning and Heart Rate Variability in Postmenopausal Women With Depressive Symptoms-2",,"Withdrawn","No Results Available","Postmenopause","Behavioral: Breathing training|Behavioral: Stress management","Depressive symptoms|Heart rate variability (Resting, reactivity to stress, and recovery from stress)","National Science Council, Taiwan","Female","45 Years to 64 Years   (Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NSC98-2629-B-038-002-MY3-TMUH","February 2010",,,"January 11, 2010",,"September 26, 2014","Taipei Medical University Hospital, Taipei, Xinyi Dist., Taiwan",,"https://ClinicalTrials.gov/show/NCT01046149"
6,"NCT01045811","Effects of Breathing Training on Psychosocial Functioning and Heart Rate Variability in Postmenopausal Women With Depressive Symptoms-3",,"Withdrawn","No Results Available","Postmenopause","Behavioral: Breathing training|Behavioral: Stress management","Depressive symptoms|Heart rate variability (Resting, reactivity to stress, and recovery from stress)","National Science Council, Taiwan","Female","45 Years to 64 Years   (Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NSC98-2629-B-038-002-MY3-WFH","May 2010",,,"January 11, 2010",,"September 26, 2014","Taipei Medical University Wangfang Hospital, Taipei, Wenshan Dist., Taiwan",,"https://ClinicalTrials.gov/show/NCT01045811"
7,"NCT01044563","Effects of Breathing Training on Psychosocial Functioning and Heart Rate Variability in Postmenopausal Women With Depressive Symptoms",,"Completed","No Results Available","Postmenopause","Behavioral: Breathing training|Behavioral: Stress management","Depressive symptoms|Heart rate variability (Resting, reactivity to stress, and recovery from stress)","National Science Council, Taiwan","Female","45 Years to 64 Years   (Adult)","Not Applicable","81","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NSC98-2629-B-038-002-MY3-TMU","May 2010","August 2010","May 2012","January 8, 2010",,"September 26, 2014","Taipei Medical University, Taipei, Xinyi Dist., Taiwan",,"https://ClinicalTrials.gov/show/NCT01044563"
8,"NCT05401630","Mental Stress Reactivity in Women With CMD",,"Recruiting","No Results Available","Post-menopause","Other: Study Procedures","Planar late Heart to Mediastinal Ratio (MIBG imaging)|Changes in HRV with mental stress|Changes in pre-ejection period (PEP) with mental stress|Changes in flow mediated dilation (FMD test) to acute mental stress in CMD women.|Changes in Peripheral arterial tonometry (PAT) test to acute mental stress in CMD women.|Examine whether chronic stress burden and autonomic dysfunction during daily life is elevated in CMD women.","Emory University|National Heart, Lung, and Blood Institute (NHLBI)","Female","45 Years and older   (Adult, Older Adult)","Not Applicable","150","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","STUDY00003154|1R01HL157311-01A1","July 19, 2022","September 30, 2026","December 31, 2026","June 2, 2022",,"December 8, 2022","Emory Hospital Midtown, Atlanta, Georgia, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|Emory Clinic, Atlanta, Georgia, United States|Emory Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT05401630"
9,"NCT05052749","High Intensity Resistance Training In Postmenopausal Women (HIRT)","HIRT","Completed","No Results Available","Post Menopause","Other: High Intensity Resistance Training (HIRT)|Other: Low-moderate Resistance Exercise Training","10RM leg press|10RM dead lift (kg)|Sit and reach test (cm)|Sit and stand test (reps)|Plank test (sec)|6 - minutes' walk test (sec)|Gait speed|Menopause specific Quality of life (MENQOL)","Riphah International University","Female","45 Years to 70 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","REC/00915 Qurat-ul-Ain","March 1, 2021","December 15, 2021","December 31, 2021","September 22, 2021",,"February 2, 2022","Riphah Rehabilitation Center, RCRAHS Westridge campus, Rawalpindi, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT05052749"
10,"NCT00152295","A Long-Term Study to Evaluate the Safety of Asoprisnil and Estrogen Administration to Postmenopausal Women",,"Completed","No Results Available","Postmenopause","Drug: Asoprisnil/Premarin","The percent of subjects in each endometrial biopsy diagnostic category summarized using SPRM Classification System.|The percentage of subjects in each endometrial biopsy diagnostic category summarized using SPRM Classification System|Change from baseline in endometrial thickness (mm) as measured by transvaginal ultrasound.|Frequency and amount of vaginal bleeding assessed via daily diary.|Frequency and severity of hot flushes assessed via daily diary.|Mean change from baseline in endocrine determinations.|Global efficacy question","Abbott","Female","48 Years to 65 Years   (Adult, Older Adult)","Phase 2","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M01-280","April 2001","December 2001","December 2001","September 9, 2005",,"May 29, 2008",,,"https://ClinicalTrials.gov/show/NCT00152295"
11,"NCT04841499","Effects of a Seven-day BASIS™ Supplementation on Menopausal Syndromes and Measurements of the Urinary Vitamin B3 and Estradiol Levels in Pre-, Peri- and Post-menopause",,"Completed","No Results Available","Menopause","Drug: BASIS™ (Crystalline Nicotinamide Riboside 250mg and Pterostilbene 50mg)","Production of Estradiol|Change undesirable effects of menopause","University of South Alabama|Elysium Health, Inc.","Female","35 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","USAH-EH301","April 5, 2021","July 15, 2021","July 15, 2021","April 12, 2021",,"November 18, 2021","University of South Alabama, Mobile, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT04841499"
12,"NCT01556737","Effect of Two Different Isoflavone Supplement Preparations on Gene-expression in Postmenopausal Women","ISOII","Completed","No Results Available","Postmenopause","Dietary Supplement: High daidzein supplement|Dietary Supplement: High genistein supplement","Gene-expression in PBMCs|Isoflavone levels in plasma|Gene - expression in adipose tissue|Isoflavone levels in adipose tissue","Wageningen University","Female","50 Years to 70 Years   (Adult, Older Adult)","Not Applicable","72","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)","NL37475.081.11|ISO II study","November 2011","September 2012","September 2012","March 16, 2012",,"October 31, 2012","Wageningen University, Wageningen, Gelderland, Netherlands",,"https://ClinicalTrials.gov/show/NCT01556737"
13,"NCT01432028","Pharmacogenetic Study of Different Hormone Therapies in Recent Menopause Women",,"Completed","No Results Available","Postmenopause","Drug: Estradiol and Progesterone|Drug: Estradiol and Drospirenone","Polymorphisms of estrogen receptor|Polymorphisms in the fat mass-and obesity-associated (FTO) gene","Denusa Wiltgen|Hospital de Clinicas de Porto Alegre|Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.|Conselho Nacional de Desenvolvimento Científico e Tecnológico|Federal University of Rio Grande do Sul","Female","42 Years to 58 Years   (Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","05053","March 2007","April 2011","April 2011","September 12, 2011",,"January 27, 2014","Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil",,"https://ClinicalTrials.gov/show/NCT01432028"
14,"NCT01338142","Amorphous Calcium Carbonate (Acc) Versus Crystalline Calcium Carbonate (Ccc) Using Stable Calcium Isotopes In Postmenopausal Women",,"Unknown status","No Results Available","Postmenopause","Other: CCC|Other: ACC","Mean change in fractional absorption of calcium from amorphous calcium carbonate (ACC) Vs. crystalline calcium carbonate (CCC).","Tel-Aviv Sourasky Medical Center|Amorphical Ltd.","Female","40 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TASMC-10-NV-571-CTIL","May 2011","May 2012","July 2012","April 19, 2011",,"April 19, 2011","Tel Aviv Medical Center, Tel Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT01338142"
15,"NCT01232751","Effects of Isoflavones on Gene-expression","ISO","Completed","No Results Available","Postmenopause","Dietary Supplement: Isoflavone supplement","Gene-expression measured by micro-arrays|Isoflavone levels in plasma and spoturine|Confirmation of gene-expression with quantitative real time polymerase chain reaction (QPCR)","Wageningen University","Female","45 Years to 70 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)","NL 32375.081.10","August 2010","October 2011","October 2011","November 2, 2010",,"January 10, 2012","Wageningen University, Wageningen, Gelderland, Netherlands",,"https://ClinicalTrials.gov/show/NCT01232751"
16,"NCT00913926","Effects of Wellnara on Climacteric Symptoms",,"Completed","No Results Available","Postmenopause","Drug: E2/LNG oral (Wellnara, BAY86-5029)","Primary endpoint in the observation of efficacy concerning climacteric complaints is the change in Menopause Rating Scale (MRS II) in relation to the status immediately before starting treatment (Baseline).|Effects on climacteric-related skin, hair, and sexual problems|Subjective assessment of efficacy|Body weight|Blood Pressure|Waist-hip-ratio (as far as routinely used in the practice)|Occurrence of vaginal bleeding|Subjective assessment of tolerability|Adverse drug reactions","Bayer","Female","Child, Adult, Older Adult",,"749","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14575|WN0810DE","September 2007","May 2009","May 2009","June 4, 2009",,"April 22, 2015","Many Locations, Germany",,"https://ClinicalTrials.gov/show/NCT00913926"
17,"NCT00847821","Observational Study Analyzing RNA Expression Of Endometrial Biopsy Samples From Placebo, Bazedoxifene/Conjugated Estrogens And Raloxifene",,"Terminated","No Results Available","Postmenopause","Drug: Bazedoxifene 10 mg/CE 0.625 mg|Drug: Bazedoxifene 20 mg/CE 0.625 mg|Drug: Bazedoxifene 40 mg/CE 0.625 mg|Drug: Bazedoxifene 10 mg/CE 0.45 mg|Drug: Bazedoxifene 20 mg/CE 0.45 mg|Drug: Bazedoxifene 40 mg/CE 0.45 mg|Drug: Raloxifene 60 mg|Drug: Placebo","Endometrial gene regulation at the level of mRNA expression in placebo, Bazedoxifene/CE, and raloxifene treated groups","Wyeth is now a wholly owned subsidiary of Pfizer","Female","40 Years to 75 Years   (Adult, Older Adult)",,"185","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","3115A1-1125|B2311003","May 2009","August 2010","August 2010","February 19, 2009",,"September 6, 2010","Pfizer Investigational Site, Fort Myers, Florida, United States|Pfizer Investigational Site, Gainesville, Florida, United States|Pfizer Investigational Site, New Port Richey, Florida, United States|Pfizer Investigational Site, West Palm Beach, Florida, United States|Pfizer Investigational Site, Decatur, Georgia, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Lexington, Kentucky, United States|Pfizer Investigational Site, Louisville, Kentucky, United States|Pfizer Investigational Site, Southfield, Michigan, United States|Pfizer Investigational Site, Chaska, Minnesota, United States|Pfizer Investigational Site, Billings, Montana, United States|Pfizer Investigational Site, New Brunswick, New Jersey, United States|Pfizer Investigational Site, Las Vegas, New Mexico, United States|Pfizer Investigational Site, Rochester, New York, United States|Pfizer Investigational Site, Raleigh, North Carolina, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Wexford, Pennsylvania, United States|Pfizer Investigational Site, Greenville, South Carolina, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Charlottesville, Virginia, United States|Pfizer Investigational Site, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00847821"
18,"NCT00799708","A Study of the Effect of Estrogen on Estrogen Receptor Biomarkers in Healthy Postmenopausal Women (0000-094)(COMPLETED)",,"Completed","Has Results","Postmenopause","Drug: Comparator: placebo|Drug: Comparator: Estrace","Change From Baseline in Estrogen Receptor Beta (ERbeta) -Specific Gene Signature After Treatment With 2 mg, 0.5 mg, or no Estradiol (Placebo) at Day 7|Change From Baseline in Minor Gland Salivary Flow Rate After Treatment With 2 mg Estradiol vs Placebo at Day 7.","Merck Sharp & Dohme LLC","Female","40 Years and older   (Adult, Older Adult)","Phase 1","27","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","0000-094|094|2008_592","May 2008","October 2008","October 2008","December 1, 2008","July 29, 2010","March 16, 2016",,,"https://ClinicalTrials.gov/show/NCT00799708"
19,"NCT00235924","Study Assessing the Effects on Endometrium and Breast of Isoflavone in Post Menopausal Women",,"Unknown status","No Results Available","Postmenopause","Drug: soy isoflavone","- Endometrial innocuity (endometrial biopsy result)|- Mammary innocuity (mammography results)|- climacteric symptoms|-Lipid profile|-gynaecological and general safety","Laboratoires Arkopharma","Female","45 Years to 65 Years   (Adult, Older Adult)","Phase 3","300","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PHY04GE01","June 2004",,,"October 12, 2005",,"December 8, 2005",,,"https://ClinicalTrials.gov/show/NCT00235924"
20,"NCT00745173","Study Evaluating Premarin and Bazedoxifene Potential Interaction",,"Completed","No Results Available","Postmenopause","Drug: Premarin","Pharmacokinetic (absorption, distribution, breakdown and elimination in the body) parameters|To continue assessment of the safety profile as well as the tolerability the two drugs administered in combination in this population.","Wyeth is now a wholly owned subsidiary of Pfizer","Female","35 Years to 70 Years   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3115A1-1135","September 2008","October 2008","October 2008","September 3, 2008",,"February 12, 2009","Dr. David Carter, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00745173"
21,"NCT00706225","Study Evaluating Potential Drug Interaction Of Bazedoxifene & Premarin In Healthy Postmenopausal Women",,"Completed","No Results Available","Postmenopause","Drug: Bazedoxifene and conjugated estrogens","To evaluate the potential pharmacokinetic (PK) interaction of multiple oral doses of bazedoxifene (BZA) and a single dose of conjugated estrogens (CE) when co administered to healthy postmenopausal women.|To assess the safety of conjugated estrogens (CE) and bazedoxifene (BZA) when co administered to healthy postmenopausal women.","Wyeth is now a wholly owned subsidiary of Pfizer","Female","35 Years to 70 Years   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","3115A1-1134","June 2008","July 2008","July 2008","June 27, 2008",,"September 23, 2010","Daytona Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00706225"
22,"NCT00522873","Endometrial Safety Study",,"Completed","Has Results","Postmenopause","Drug: 0.25mg DRSP / 0.5mg E2 (BAY86-4891)|Drug: 0.5mg NETA / 1.0mg E2 (Activella)","Number of Participants in the DRSP/E2 Group With an Assessment of Endometrial Hyperplasia or Worse at End of Study (EoS) (1 Year of Treatment)|Number of Participants With Amenorrhea During Month 1 to 3 of Treatment|Number of Participants With Amenorrhea During Month 10 to 12 of Treatment","Bayer|Laboratorium für Klinische Forschung|Diagnostic Cytology Laboratory|University of California, San Francisco","Female","40 Years to 65 Years   (Adult, Older Adult)","Phase 3","662","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","91508|2006-006199-39|310523","August 2007","August 2009","August 2009","August 30, 2007","June 28, 2012","December 31, 2014","Chandler, Arizona, United States|San Diego, California, United States|San Diego, California, United States|Denver, Colorado, United States|Greenwood Village, Colorado, United States|Boynton Beach, Florida, United States|Clearwater, Florida, United States|Boise, Idaho, United States|Amite, Louisiana, United States|Marrero, Louisiana, United States|Las Vegas, Nevada, United States|Cleveland, Ohio, United States|Philadelphia, Pennsylvania, United States|Columbia, South Carolina, United States|Corpus Christi, Texas, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Lanus Oeste, Buenos Aires, Argentina|San Isidro, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Mödling, Niederösterreich, Austria|Wiener Neustadt, Niederösterreich, Austria|Fuerstenfeld, Steiermark, Austria|Wörgl, Tirol, Austria|Bregenz, Vorarlberg, Austria|Innsbruck, Austria|Klagenfurt, Austria|Mürzzuschlag, Austria|St. Poelten, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Zeltweg, Austria|Goiania, Goiás, Brazil|Curitiba, Parana, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Sao Paulo, Brazil|Alborg, Denmark|Ballerup, Denmark|Vejle, Denmark|Bologna, Italy|Cagliari, Italy|Modena, Italy|Novara, Italy|Parma, Italy|Pisa, Italy|Sassari, Italy|Siena, Italy|Mexico, Distrito Federal, Mexico|Mexico, Mexico|Monterrey, Mexico|México, D.F., Mexico|Moscow, Russian Federation|Moscow, Russian Federation|Moskva, Russian Federation|Moskva, Russian Federation|Moskva, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00522873"
23,"NCT00550433","Study Evaluating Bazedoxifene/CE in Postmenopausal Women",,"Completed","No Results Available","Postmenopause","Device: Bazedoxifene/Conjugated Estrogens","The plasma concentration data and pharmacokinetic (PK) parameters of BZA and CE.","Wyeth is now a wholly owned subsidiary of Pfizer","Female","35 Years to 70 Years   (Adult, Older Adult)","Phase 1",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3115A1-1117","September 2007",,"November 2007","October 29, 2007",,"January 16, 2008",,,"https://ClinicalTrials.gov/show/NCT00550433"
24,"NCT00543634","Study Comparing Premarin®/MPA, PREMPRO® and Provera® in Healthy Postmenopausal Women",,"Completed","No Results Available","Postmenopause","Drug: Premarin/MPA|Drug: Provera 10 mg","Plasma concentration data and pharmacokinetic (PK) parameters of MPA and Premarin® (estrone, equilin and MPA).","Wyeth is now a wholly owned subsidiary of Pfizer|MDS Pharma Services","Female","35 Years to 70 Years   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","0713E1-1138","October 2007","December 2007","December 2007","October 15, 2007",,"June 22, 2010","Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT00543634"
25,"NCT00484107","Tolerability & Safety of Premarin Vaginal Cream in Indian Postmenopausal Women",,"Completed","No Results Available","Postmenopause","Drug: Conjugated Estrogen Cream (Premarin®)",,"Wyeth is now a wholly owned subsidiary of Pfizer","Female","40 Years to 65 Years   (Adult, Older Adult)",,"200","Industry","Observational",,"0713V-101833","September 2005",,"October 2006","June 8, 2007",,"December 28, 2007",,,"https://ClinicalTrials.gov/show/NCT00484107"
26,"NCT00472927","Bioequivalence Study of 3 New Formulations of Premarin/MPA Compared With Premarin/MPA (Prempro)",,"Completed","No Results Available","Postmenopause","Drug: Premarin/MPA 0.45 mg/1.5 mg","Plasma concentration data and PK parameters of MPA and Premarin (esrone and equilin components)","Wyeth is now a wholly owned subsidiary of Pfizer","Female","35 Years to 70 Years   (Adult, Older Adult)","Phase 1",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0713E1-1142","May 2007",,"August 2007","May 14, 2007",,"December 6, 2007","Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00472927"
27,"NCT00149604","AFTER: Altering Fat Through Estrogen and Raloxifene",,"Completed","No Results Available","Postmenopause","Drug: conjugated estrogens|Drug: Raloxifene|Behavioral: exercise plus mild caloric restriction for weight loss","total body fat mass|total abdominal fat area|visceral abdominal fat area|fat-free mass|total abdominal area|resting metabolic rate|dietary energy intake|cardiovascular fitness|glucose tolerance|blood lipids and lipoproteins|sex hormones (estradiol, estrone, testosterone, sex hormone binding globulin)|glucoregulatory and anti-lipolytic insulin action","National Institute on Aging (NIA)","Female","50 Years to 70 Years   (Adult, Older Adult)","Phase 2","108","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","AG0036|R01AG018198","March 2000","February 2006","February 2006","September 8, 2005",,"December 2, 2009","University of Colorado at Denver and Health Sciences Center, Denver, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT00149604"
28,"NCT00435175","Acute Metabolic Effects of Estradiol",,"Completed","No Results Available","Postmenopause","Drug: estradiol","Regional lipolysis assessed by microdialysis|Systemic lipolysis assessed by the isotope dilution technique|Lipoprotein lipase activity|Adrenergic receptor mRNA expression|Estrogen receptor mRNA expression|UCP2 mRNA expression","University of Aarhus","Female","45 Years to 70 Years   (Adult, Older Adult)","Not Applicable","8","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single|Primary Purpose: Treatment","2002-0242","June 2005",,"July 2006","February 14, 2007",,"February 14, 2007","Medical Research Laboratories, Aarhus, Denmark",,"https://ClinicalTrials.gov/show/NCT00435175"
29,"NCT03557398","Efficacy and Safety of HYDEAL-D Vaginal Pessaries Application on the Treatment of Vaginal Atrophy in Post-menopause Women",,"Completed","No Results Available","Vulvovaginal Atrophy","Device: Hydeal-D vaginal pessaries","Change of the average score of Vaginal Health Index (VHI)|Change of vaginal pH|Change of patient's perception of vulvovaginal symptoms|Improvement of sexual function through questionnaire Female Sexual Function Index (FSFI)|Improvement of sexual function through questionnaire Female Sexual Distress Scale-Revised (FSDS-R)|Amelioration of the vaginal maturation (VM) index|Patient's global assessment of overall satisfaction|Local tolerability at the application site|Safety of the treatment: Collection of adverse events","Fidia Farmaceutici s.p.a.","Female","45 Years to 75 Years   (Adult, Older Adult)","Not Applicable","40","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","QQ53-17-01","November 29, 2017","May 29, 2018","May 29, 2018","June 15, 2018",,"June 15, 2018","Gynkomed s.r.o., Bratislava, Slovakia|ULMUS, s r.o., Hlohovec, Slovakia",,"https://ClinicalTrials.gov/show/NCT03557398"
30,"NCT00380887","Study Comparing Four New Formulations for Premarin in Healthy Postmenopausal Women",,"Completed","No Results Available","Postmenopause","Drug: Premarin",,"Wyeth is now a wholly owned subsidiary of Pfizer","Female","35 Years to 70 Years   (Adult, Older Adult)",,"54","Industry","Observational","Observational Model: Defined Population|Time Perspective: Other","0713E1-133, 0713E1-135","June 2005",,,"September 27, 2006",,"September 27, 2006",,,"https://ClinicalTrials.gov/show/NCT00380887"
31,"NCT00372099","Bone Microstructure in Nasal Salmon Calcitonin Treated Postmenopausal Women",,"Completed","No Results Available","Postmenopause","Drug: Salmon calcitonin","Bone micro-architecture evaluated by high resolution p-QCT|Bone turn-over markers","Rene Rizzoli|University Hospital, Geneva","Female","45 Years to 70 Years   (Adult, Older Adult)","Phase 3","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","05-262/Psy 05-038|CSMC051ACH01","January 2007","October 2011","November 2011","September 6, 2006",,"December 23, 2011",,,"https://ClinicalTrials.gov/show/NCT00372099"
32,"NCT00367536","Study Evaluating Three Bazedoxifene/Conjugated Estrogens Combination Tablet Formulations Versus BZA Oral Solution",,"Completed","No Results Available","Postmenopause","Drug: bazedoxifene/conjugated estrogens combination tablet",,"Wyeth is now a wholly owned subsidiary of Pfizer","Female","35 Years to 70 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional",,"3115A1-115","August 2006",,"August 2006","August 23, 2006",,"May 1, 2015",,,"https://ClinicalTrials.gov/show/NCT00367536"
33,"NCT00251082","Vasomotoric Symptoms Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination",,"Completed","No Results Available","Postmenopause","Drug: continuous combined estradiol and dydrogesterone|Drug: Placebo","The change in the number of moderate to severe hot flushes from baseline to week 13|Change in the number of hot flushes from baseline to week 13; Change in the number of hot flushes and moderate to severe hot flushes from baseline to weeks 4 and 8;|Change in the Menopause Rating Scale from baseline to weeks 4 and 13;|Number of days with bleeding/spotting; Number of bleeding/spotting episodes; Number of days with a certain bleeding intensity (e.g. bleeding intensity =2);|Length of bleeding free intervals; Amenorrhoea yes/no (absence of spotting and bleeding); Absence of bleeding yes/no;|QualiPause Inventory 7D: weighted sum score of the symptoms","Solvay Pharmaceuticals","Female","45 Years to 65 Years   (Adult, Older Adult)","Phase 3","391","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","S102.3.119|2004-00215-25","December 2005","October 2007","October 2007","November 9, 2005",,"March 12, 2008","Site 11, Zagreb, Croatia|Site 12, Zagreb, Croatia|Site 13, Zagreb, Croatia|Site 23, Cannes, France|Site 24, Cannes, France|Site 21, Montpellier, France|Site 22, Montpellier, France|Site 34, Katowice, Poland|Site 33, Kraków, Poland|Site 32, Lódź, Poland|Site 31, Warszawa, Poland|Site 41, Bucharest, Romania|Site 42, Bucharest, Romania|Site 44, Bucharest, Romania|Site 43, Craiova, Jud.Dolj, Romania|Site 51, Moscow, Russian Federation|Site 52, Moscow, Russian Federation|Site 53, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00251082"
34,"NCT00160316","Endometrial Safety Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination",,"Completed","No Results Available","Postmenopause","Drug: 0.5 Mg Estradiol and 2.5 Mg Dydrogesterone","Presence of endometrial hyperplasia or a more serious endometrial outcome during the 52 week treatment period|Number of days with bleeding/spotting; Number of bleeding/spotting episodes; Number of days with a certain bleeding intensity (e.g. bleeding intensity =2);|Length of bleeding free intervals; Amenorrhoea yes/no (absence of spotting and bleeding); Absence of bleeding yes/no;|QualiPause Inventory (domains: psychological, vasomotor, somatic, sexual, menstrual, androgenic): average score of the single items within the domain; QualiPause Inventory 7D: weighted sum score of the symptoms","Solvay Pharmaceuticals","Female","45 Years and older   (Adult, Older Adult)","Phase 3","454","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S102.3.117|2004-000227-15","April 2005","December 2007","December 2007","September 12, 2005",,"March 12, 2008","Site 10, Zagreb, Croatia|Site 11, Zagreb, Croatia|Site 12, Zagreb, Croatia|Site 13, Zagreb, Croatia|Site 32, Katowice, Poland|Site 30, Kraków, Poland|Site 35, Kraków, Poland|Site 36, Kraków, Poland|Site 34, Lublin, Poland|Site 31, Miechów, Poland|Site 33, Warszawa, Poland|Site 40, Bucharest, Romania|Site 41, Bucharest, Romania|Site 42, Bucharest, Romania|Site 43, Bucharest, Romania|Site 44, Bucharest, Romania|Site 45, Bucharest, Romania|Site 24, Donetsk, Ukraine|Site 20, Kiev, Ukraine|Site 21, Kiev, Ukraine|Site 22, Kiev, Ukraine|Site 23, Zaporozhye, Ukraine",,"https://ClinicalTrials.gov/show/NCT00160316"
35,"NCT00009659","Use of the Synthetic Hormone CDB-2914 in Treating Symptoms of Menopause",,"Completed","No Results Available","Postmenopause","Drug: CDB 2914",,"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Female","Child, Adult, Older Adult","Phase 2","58","NIH","Interventional","Primary Purpose: Treatment","010081|01-CH-0081","January 2001",,"December 2001","February 5, 2001",,"March 4, 2008","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00009659"
36,"NCT00160342","Comparison of Estrogen and Methyltestosterone Combination Treatments for Postmenopausal Hot Flushes",,"Completed","No Results Available","Hot Flushes, Menopause, Postmenopause","Drug: Esterified Estrogens (EE) and Methyltestosterone (MT)","Mean change in frequency of moderate to severe vasomotor symptoms (VMS) from baseline to Week 4|Mean change in frequency of moderate to severe VMS from baseline to Week 12|Mean change in severity of moderate to severe VMS from baseline to Week 4|Mean change in severity of moderate to severe VMS from baseline to Week 12|Frequency and severity of moderate to severe and all hot flushes at each week|Mean change from baseline to Week 12 in the moderate to severe vulvar and vaginal atrophy symptom identified by the subject as most bothersome|Mean change from baseline to Week 12 in vaginal pH|Mean change from baseline to Week 12 in vaginal maturation index (parabasal and superficial cells)","Solvay Pharmaceuticals","Female","45 Years to 65 Years   (Adult, Older Adult)","Phase 2","1251","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","S030.2.112|2005-002887-27","June 2005","September 2007","September 2007","September 12, 2005",,"August 15, 2008","Site 37, Montgomery, Alabama, United States|Site 69, Montgomery, Alabama, United States|Site 44, Tucson, Arizona, United States|Site 6, Jonesboro, Arkansas, United States|Site 62, Little Rock, Arkansas, United States|Site 70, Carmichael, California, United States|Site 85, Carmichael, California, United States|Site 87, Northridge, California, United States|Site 18, San Diego, California, United States|Site 27, San Diego, California, United States|Site 54, San Diego, California, United States|Site 31, Vista, California, United States|Site 68, Walnut Creek, California, United States|Site 66, Denver, Colorado, United States|Site 4, Groton, Connecticut, United States|Site 35, New Britain, Connecticut, United States|Site 14, Waterbury, Connecticut, United States|Site 25, Aventura, Florida, United States|Site 26, Aventura, Florida, United States|Site 51, Clearwater, Florida, United States|Site 71, Clearwater, Florida, United States|Site 61, Daytona Beach, Florida, United States|Site 75, Gainesville, Florida, United States|Site 33, Pensacola, Florida, United States|Site 21, Stuart, Florida, United States|Site 82, Tampa, Florida, United States|Site 9, Venice, Florida, United States|Site 83, West Palm Beach, Florida, United States|Site 40, Alpharetta, Georgia, United States|Site 90, Alpharetta, Georgia, United States|Site 23, Atlanta, Georgia, United States|Site 8, Atlanta, Georgia, United States|Site 60, Powder Springs, Georgia, United States|Site 55, Savannah, Georgia, United States|Site 76, Boise, Idaho, United States|Site 64, Champaign, Illinois, United States|Site 58, Chicago, Illinois, United States|Site 72, Chicago, Illinois, United States|Site 74, Chicago, Illinois, United States|Site 50, Evansville, Indiana, United States|Site 52, Baton Rouge, Louisiana, United States|Site 65, Mandeville, Louisiana, United States|Site 73, Metarie, Louisiana, United States|Site 15, Lutherville, Maryland, United States|Site 43, Ann Arbor, Michigan, United States|Site 12, Chaska, Minnesota, United States|Site 80, Chesterfield, Missouri, United States|Site 16, Kansas City, Missouri, United States|Site 19, Kansas City, Missouri, United States|Site 3, St. Louis, Missouri, United States|Site 17, Billings, Montana, United States|Site 36, Lincoln, Nebraska, United States|Site 7, Las Vegas, Nevada, United States|Site 28, Reno, Nevada, United States|Site 39, New Bern, North Carolina, United States|Site 79, Raleigh, North Carolina, United States|Site 46, Winston Salem, North Carolina, United States|Site 59, Winston Salem, North Carolina, United States|Site 45, Cincinnati, Ohio, United States|Site 81, Cincinnati, Ohio, United States|Site 53, Columbus, Ohio, United States|Site 34, Mayfield Heights, Ohio, United States|Site 78, Mogadore, Ohio, United States|Site 77, Tulsa, Oklahoma, United States|Site 13, Portland, Oregon, United States|Site 89, Portland, Oregon, United States|Site 84, Philadelphia, Pennsylvania, United States|Site 63, Pottstown, Pennsylvania, United States|Site 22, Warwick, Rhode Island, United States|Site 24, Greenville, South Carolina, United States|Site 67, Hilton Head, South Carolina, United States|Site 10, Chattanooga, Tennessee, United States|Site 88, Memphis, Tennessee, United States|Site 56, Nashville, Tennessee, United States|Site 86, Bryan, Texas, United States|Site 20, Corpus Christi, Texas, United States|Site 11, Houston, Texas, United States|Site 30, San Antonio, Texas, United States|Site 41, San Antonio, Texas, United States|Site 49, Salt Lake City, Utah, United States|Site 47, Charlottesville, Virginia, United States|Site 2, Norfolk, Virginia, United States|Site 29, Richmond, Virginia, United States|Site 48, Richmond, Virginia, United States|Site 42, Virginia Beach, Virginia, United States|Site 5, Seattle, Washington, United States|Site 38, Spokane, Washington, United States|Site 32, Tacoma, Washington, United States|Site 120, Abbotsford, British Columbia, Canada|Site 100, North Vancouver, British Columbia, Canada|Site 135, Victoria, British Columbia, Canada|Site 116, West Vancouver, British Columbia, Canada|Site 122, Winnipeg, Manitoba, Canada|Site 93, Winnipeg, Manitoba, Canada|Site 111, St. John's, Newfoundland and Labrador, Canada|Site 109, Burlington, Ontario, Canada|Site 114, Corunna, Ontario, Canada|Site 95, Hamilton, Ontario, Canada|Site 115, Kingston, Ontario, Canada|Site 107, London, Ontario, Canada|Site 106, Newmarket, Ontario, Canada|Site 137, Ottawa, Ontario, Canada|Site 117, Peterborough, Ontario, Canada|Site 113, Sarnia, Ontario, Canada|Site 92, Sarnia, Ontario, Canada|Site 96, Strathroy, Ontario, Canada|Site 112, Montreal, Quebec, Canada|Site 103, Rimouski, Quebec, Canada|Site 119, Sainte Foy, Quebec, Canada|Site 94, Sainte Foy, Quebec, Canada|Site 91, Shawinigan, Quebec, Canada|Site 105, Sherbrooke, Quebec, Canada|Site 136, Sherbrooke, Quebec, Canada|Site 124, Moscow, Russian Federation|Site 125, Moscow, Russian Federation|Site 126, Moscow, Russian Federation|Site 128, Moscow, Russian Federation|Site 129, Moscow, Russian Federation|Site 130, Moscow, Russian Federation|Site 132, Moscow, Russian Federation|Site 133, Moscow, Russian Federation|Site 127, St. Petersburg, Russian Federation|Site 131, St. Petersburg, Russian Federation|Site 134, St. Petersburg, Russian Federation|Site 138, St. Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00160342"
37,"NCT05557799","Photobiomodulation in Post Menopause Genitourinary Syndrome",,"Not yet recruiting","No Results Available","Postmenopausal Symptoms","Radiation: Photobiomodulation|Radiation: Placebo Photobiomodulation","Changes in the Female Sexual Function Index (FSFI)|Changes in the International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF)|Changes in the Vaginal Health Index Score|Changes in the Vaginal pH|Changes in Pain using a Visual Analog Scale (VAS)|Changes in the Pelvic Floor Muscles (PFMs)|Changes in Urinary Loss using Ped-Test|Changes in Vulva Temperature","University of Nove de Julho","Female","50 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","SGPM","October 30, 2022","June 30, 2023","July 30, 2023","September 28, 2022",,"September 28, 2022",,,"https://ClinicalTrials.gov/show/NCT05557799"
38,"NCT03149419","Hot Flash as a Marker of Cardiovascular Risk in Recent Postmenopause: Effects of Non-hormonal Treatments",,"Completed","No Results Available","Postmenopausal Flushing|Cardiovascular Risk Factor|Endothelial Dysfunction","Drug: Paroxetine|Drug: Placebo oral capsule","Endothelial function in non invasive venous occlusion plethysmography","Rio de Janeiro State University","Female","45 Years to 65 Years   (Adult, Older Adult)","Phase 4","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CAAE 6717515.1.0000.5259","March 1, 2016","September 30, 2017","March 30, 2018","May 11, 2017",,"April 12, 2018","Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil",,"https://ClinicalTrials.gov/show/NCT03149419"
39,"NCT03137849","Yoga Poses and Breath Control Cardiovascular Changes in Hypertensive Post-Menopause Women","YOGINI","Completed","No Results Available","Hypertension|Postmenopausal Symptoms","Other: Yoga Poses|Other: Breath Control|Other: Stretching exercises","Cardiovascular autonomic control by heart rate variability(HRV) and blood pressure variability (BPV) in frequency domain acquired by Finometer|Carotid -femoral pulse wave velocity (Complior)|Maximal Oxygen Uptake by Cardiopulmonary Exercise Test|Ambulatory Arterial Pressure Monitoring|Respiratory rate and movements of rib cage and abdomen by Pneumotrace respiratory belt|Blood samples laboratorial analysis|Flow mediated dilation (FMD) of brachial artery by ultrasound|Fat percentage by Bioimpedance|Cognitive function|Diaphragm Thickness by ultrasound|Intima Media Thickness of carotid artery by ultrasound|Blood sample analysis of oxidative stress markers (Spectrophotometry)|Blood levels of sample analysis of Inflammatory markers (ELISA)|Assessment of center of pressure (COP) and balance by baropodometry platform|Sit and reach flexibility test","Instituto de Cardiologia do Rio Grande do Sul","Female","45 Years to 65 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Health Services Research","5273/16","July 18, 2017","June 30, 2018","December 20, 2018","May 3, 2017",,"July 23, 2019","Cardiology Institute of Rio Grande do Sul, Pôrto Alegre, Rio Grande Do Sul, Brazil",,"https://ClinicalTrials.gov/show/NCT03137849"
40,"NCT05188027","Aerobic vs Resistance Exercise in Post-menopausal Women With Type 1 Diabetes",,"Recruiting","No Results Available","Type 1 Diabetes|Post-menopause","Other: Aerobic Exercise|Other: Resistance Exercise|Other: No exercise","Blood glucose|mean continuous glucose monitoring (CGM) glucose|coefficient of variation (CV) of CGM glucose|standard deviation (SD)|frequency of hypoglycemia|frequency of hyperglycemia|percent time spent in hyperglycemia|percent time spent in hypoglycemia|percent time spent in range|carbohydrate supplementation","University of Alberta|Women and Children's Health Research Institute, Canada","Female","45 Years to 75 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Pro00107673","November 16, 2021","December 30, 2023","December 30, 2023","January 12, 2022",,"February 1, 2023","Alberta Diabetes Institute, Edmonton, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT05188027"
41,"NCT00294463","Effects of Tibolone Treatment on the Endometrium",,"Completed","No Results Available","Postmenopause|Osteoporosis","Drug: Tibolone|Drug: Estradiol|Drug: Estradiol + Medroxy Progesterone Acetate","Histologic evaluation of the endometrium at the end of treatment|Biochemical evaluation (hormone measurements) of uterine tissue at the end of treatment|Biochemical evaluation of sera, obtained just prior to treatment and at surgery|Molecular assessment of gene expression","Erasmus Medical Center|Organon","Female","0 Years and older   (Child, Adult, Older Adult)","Phase 4","35","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEC 217.640/2002/220","February 2003",,"March 2005","February 22, 2006",,"February 22, 2006","Erasmus MC, Rotterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT00294463"
42,"NCT05483413","The Effect of Progressive Relaxation Exercises on Sleep Quality and Fatigue in Postmenopausal Period",,"Enrolling by invitation","No Results Available","Postmenopausal Period|Fatigue|Sleep Quality","Behavioral: progressive relaxation exercises","Change in fatugue|Change in sleep quality","Kutahya Health Sciences University","Female","40 Years to 65 Years   (Adult, Older Adult)","Not Applicable","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","E-41997688-050.99-34916","February 15, 2022","June 15, 2022","September 15, 2023","August 2, 2022",,"January 17, 2023","Kütahya Health Science University, Kütahya, Turkey",,"https://ClinicalTrials.gov/show/NCT05483413"
43,"NCT03644329","Effect of Resistance Training Variable Manipulation in Postmenopausal Breast Cancer Survivors.",,"Unknown status","No Results Available","Breast Cancer Survivors|Postmenopause","Other: Control group|Other: Lower-load resistance training (LL)|Other: Higher-load resistance training (HL)|Other: Higher-volume resistance training (HV)","Evaluation the Fatigability|Four- meter walk test|Fat mass|Muscle strength|Six Minutes-walk test (6MWT)|Timed Up and Go test|Five-times-sit-to-stand test|Muscle mass|10-meter walk test|400-meter walk test|900-meter walk test","Universidade Federal do Triangulo Mineiro","Female","50 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CAAE: 82691818.0.0000.5154","May 13, 2018","November 10, 2018","December 20, 2019","August 23, 2018",,"August 23, 2018","Post-degree program in physical education, Uberaba, MG - Minas Gerais, Brazil",,"https://ClinicalTrials.gov/show/NCT03644329"
44,"NCT01432470","Study of Oxytocin to Treat Vaginal Atrophy in Postmenopausal Women",,"Completed","No Results Available","Postmenopause|Vaginal Atrophy","Drug: Oxytocin|Drug: Placebo","The Maturation Value (MV)|Vaginal Atrophy|Quality of Life|The Maturation Value|Vaginal pH|Concentration of Oxytocin in serum|Clinician evaluation of vaginal mucosal appearance|Laboratory assessments|Concentration of 17 beta-estradiol in serum|Vital signs","PepTonic Medical AB","Female","40 Years and older   (Adult, Older Adult)","Phase 2","74","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","OxyPeP-001","August 2010","June 2011","June 2011","September 13, 2011",,"September 13, 2011","Karolinska University Hospital-Huddinge, Huddinge, Sweden|Uppsala University Hospital, Uppsala, Sweden|Northwick Park & St Marks Hospital NHS Trust, Harrow Middlesex, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01432470"
45,"NCT02887885","Sustainability of Vaginal Estrogen Therapy in Postmenopausal Women",,"Completed","No Results Available","Atrophy of Vagina|Postmenopause","Drug: Gynoflor","Mean change in vaginal maturation index (VMI)|Mean change in VMI|Mean change in vaginal pH|Number of lactobacilli|Lactobacillary grade (LBG),|Mean change in the most bothersome moderate and severe symptom of vaginal atrophy (MBS) . The symptoms include dryness, pain/burning sensation, pruritus, discharge, and dyspareunia.|Mean change in health-related quality of life (EQ-5D-5L). Mean change in Female Sexual Function Index (FSFI).","University Hospital Inselspital, Berne|Medinova AG","Female","18 Years to 99 Years   (Adult, Older Adult)",,"32","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2016-00380","January 22, 2018","March 19, 2020","April 10, 2020","September 2, 2016",,"April 27, 2022","Dep. of Obstetrics and Gynecology, Bern University Hospital, Bern, Berne, Switzerland",,"https://ClinicalTrials.gov/show/NCT02887885"
46,"NCT01171417","A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast Cancer","ACT-FASTER:","Completed","No Results Available","Postmenopause|Breast Cancer",,"Evaluation of the effectiveness of Faslodex 500 mg in terms of time to progression (TTP) of disease.|Disease management data|Real-life data on patient outcomes by line of treatment (i.e. 1st vs. 2nd vs. 3rd line).|Real-life pharmacoeconomic data and use of health care resources.|Health-related quality of life (HRQoL) in patients undergoing treatment with Faslodex 500 mg or exemestane.","AstraZeneca","Female","18 Years and older   (Adult, Older Adult)",,"570","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NIS-ODE-FAS-2009/1","August 2010","November 2013","November 2013","July 28, 2010",,"February 27, 2014","Research Site, Aachen, Germany|Research Site, Ahaus, Germany|Research Site, Amberg, Germany|Research Site, Aschaffenburg, Germany|Research Site, Aschersleben, Germany|Research Site, Bad Nauheim, Germany|Research Site, Bad Segeberg, Germany|Research Site, Bamberg, Germany|Research Site, Bergisch Gladbach, Germany|Research Site, Berlin, Germany|Research Site, Bielefeld, Germany|Research Site, Boblingen, Germany|Research Site, Bonn, Germany|Research Site, Braunschweig, Germany|Research Site, Castrop-Rauxel, Germany|Research Site, Chemnitz, Germany|Research Site, Dachau, Germany|Research Site, Donauwurth, Germany|Research Site, Dortmund, Germany|Research Site, Dresden, Germany|Research Site, Dusseldorf, Germany|Research Site, Eggenfelden, Germany|Research Site, Erfurt, Germany|Research Site, Eschweiler, Germany|Research Site, Essen, Germany|Research Site, Esslingen, Germany|Research Site, Euskirchen, Germany|Research Site, Frankfurt, Germany|Research Site, Frechen, Germany|Research Site, Freiburg, Germany|Research Site, Furstenwalde, Germany|Research Site, Geesthacht, Germany|Research Site, Gera, Germany|Research Site, Goslar, Germany|Research Site, Gottingen, Germany|Research Site, Grobenzell, Germany|Research Site, Hamburg, Germany|Research Site, Hanau, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Heidenheim, Germany|Research Site, Herdecke, Germany|Research Site, Hof, Germany|Research Site, Ilsede, Germany|Research Site, Ingolstadt, Germany|Research Site, Karlsruhe, Germany|Research Site, Kassel, Germany|Research Site, Kiel, Germany|Research Site, Koln, Germany|Research Site, Landshut, Germany|Research Site, Langen, Germany|Research Site, Lehrte, Germany|Research Site, Lubeck, Germany|Research Site, Ludwigsburg, Germany|Research Site, Magdeburg, Germany|Research Site, Mayen, Germany|Research Site, Memmingen, Germany|Research Site, Mittweida, Germany|Research Site, Moers, Germany|Research Site, Monchengladbach, Germany|Research Site, Muhlhausen, Germany|Research Site, Munchen, Germany|Research Site, Munster, Germany|Research Site, Naunhof, Germany|Research Site, Nordhausen, Germany|Research Site, Nordhorn, Germany|Research Site, Nurnberg, Germany|Research Site, Oberhausen, Germany|Research Site, Offenbach, Germany|Research Site, Osnabruck, Germany|Research Site, Passau, Germany|Research Site, Pluderhausen, Germany|Research Site, Remagen, Germany|Research Site, Remscheid, Germany|Research Site, Rendsburg, Germany|Research Site, Rodewisch, Germany|Research Site, Rodgau, Germany|Research Site, Simmern, Germany|Research Site, Soest, Germany|Research Site, Stendal, Germany|Research Site, Stralsund, Germany|Research Site, Stuttgart, Germany|Research Site, Troisdorf, Germany|Research Site, Tubingen, Germany|Research Site, Villingen-Schwenningen, Germany|Research Site, Weiden, Germany|Research Site, Wetzlar, Germany|Research Site, Wiesbaden, Germany|Research Site, Worms, Germany|Research Site, Wurselen, Germany|Research Site, Wurzburg, Germany|Research Site, Zittau, Germany",,"https://ClinicalTrials.gov/show/NCT01171417"
47,"NCT03640962","Relationship in Sleep With Low Back Pain in Postmenopausal Period",,"Unknown status","No Results Available","Postmenopausal Symptoms","Other: Evaluation","Pain of low back pain: Visual Analog Scale|Emotional status: Hospital Anxiety and Depression Scale|Quality of life of women: Nottingham Health Profile|Sleep quality: Pittsburgh Sleep Quality Index","Istanbul Bilgi University","Female","40 Years to 65 Years   (Adult, Older Adult)",,"368","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","IBU17.02.2015/28-210","April 2, 2018","June 25, 2018","September 22, 2018","August 21, 2018",,"September 7, 2018","Tomris Duymaz, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT03640962"
48,"NCT02339051","The Effect of Mechanical Loading on Bone Material Strength and Microarchitecture in Postmenopausal Women",,"Completed","No Results Available","Osteoporosis|Postmenopause","Behavioral: Jumping on one leg","Changes in bone material strength in the tibia (measured using OsteoProbe®)|Changes in total volumetric density in the tibia (Measured using high-resolution pQCT device (HR-pQCT)|Changes in cortical volumetric density in the tibia (Measured using high-resolution pQCT device (HR-pQCT)|Changes in cortical cross sectional area in the tibia (Measured using high-resolution pQCT device (HR-pQCT)|Changes in trabecular bone volume fraction in the tibia (Measured using high-resolution pQCT device (HR-pQCT)","Mattias Lorentzon|Sahlgrenska University Hospital, Sweden","Female","50 Years to 60 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Dnr 563-14","January 2015","July 2015","July 2015","January 15, 2015",,"July 11, 2016",,,"https://ClinicalTrials.gov/show/NCT02339051"
49,"NCT00901589","Marine n-3 Polyunsaturated Fatty Acids in Pre- and Postmenopausal Women",,"Completed","No Results Available","Postmenopause|Premenopause","Dietary Supplement: marine n-3 polyunsaturated fatty acids|Dietary Supplement: thistle oil|Dietary Supplement: Thistle oil","Content of marine n-PUFAs as percent of total content of fatty acids in adipose tissue and in platelets before and after intervention|Measurement of oestrogen concentrations in blood before and after intervention","Aalborg University Hospital","Female","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","92","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Petra Witt","August 2007","May 2009","May 2009","May 14, 2009",,"May 14, 2009","Center for cardiovascular research, Aalborg Hospital, Aalborg, Denmark",,"https://ClinicalTrials.gov/show/NCT00901589"
50,"NCT00515593","PROPOSE Quality - PReOtact in Postmenopausal OStEoporosis - Quality of Life Study (FP-004-DE)",,"Completed","No Results Available","Postmenopause|Osteoporosis","Drug: Parathyroid hormone (PTH) (Preotact)",,"Nycomed","Female","18 Years and older   (Adult, Older Adult)",,"110","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","FP-004-DE","September 2006",,"July 2008","August 14, 2007",,"May 7, 2012","Nycomed Deutschland GmbH, Cities in Germany, Germany",,"https://ClinicalTrials.gov/show/NCT00515593"
51,"NCT00455741","Postmenopausal Women Estrogen and Progesterone Infusion",,"Completed","Has Results","Postmenopause|Aging","Drug: Estradiol infusion|Drug: Progesterone infusion","Effect of Aging on Estrogen Negative Feedback on LH|Effect of Aging on Estrogen Positive Feedback on LH|18 FDG Uptake at the Pituitary During Estrogen Infusion: LH Negative Feedback|18 FDG Uptake at the Hypothalamus During Estrogen Infusion: LH Negative Feedback|18 FDG Uptake at the Pituitary During Estrogen Infusion: LH Positive Feedback|18 FDG Uptake at the Hypothalamus During Estrogen Infusion: LH Positive Feedback","Massachusetts General Hospital|National Institute on Aging (NIA)","Female","45 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","2000P-002496|R01AG013241","November 2000","February 2007","August 22, 2015","April 4, 2007","May 18, 2018","May 18, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00455741"
52,"NCT00384072","Study Evaluating the Safety and Efficacy of Bazedoxifene in Postmenopausal Asian Women",,"Completed","No Results Available","Postmenopause|Osteoporosis","Drug: bazedoxifene BZA-20","The percent change from baseline in lumbar spine bone mineral density (BMD) after 6 months of treatment|Additional BMD evaluation including total hip, femoral neck and trochanter at 6 months|Serum bone markers at 3 and 6 months|Lipid profile at 3 and 6 months","Wyeth is now a wholly owned subsidiary of Pfizer","Female","45 Years and older   (Adult, Older Adult)","Phase 3","500","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","3068A1-303","May 2006",,"September 2007","October 4, 2006",,"December 28, 2007","Beijing, China|Beijing, China|Nanjing, China|Shanghai, China|Shanghai, China|Shanghai, China|Tianjin, China|Tianjin, China|Tianjin, China|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Suwon, Korea, Republic of|Kaohsuing, Taiwan|Kaoshsuing, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Tapei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00384072"
53,"NCT02512848","The Feasibility Study of the Li Brush for the Screening of Endometrial Cancer in the Postmenopausal Period",,"Active, not recruiting","No Results Available","Endometrial Neoplasms",,"Compare the new diagnosis method with gold standard via Kappa statistic","First Affiliated Hospital Xi'an Jiaotong University","Female","40 Years to 80 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Other|Time Perspective: Other","XJTU1AHCR2014-007","April 2015","April 2022","July 2022","July 31, 2015",,"August 25, 2021","The First Affliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China",,"https://ClinicalTrials.gov/show/NCT02512848"
54,"NCT00425776","Treatment of Hot Flushes in Breast Cancer Patients With Acupuncture",,"Completed","No Results Available","Breast Cancer|Postmenopause","Device: acupuncture|Device: Sham acupuncture","using a hot flushes rating scale.|Sleep disturbances yes or no|Measuring se-estrogen and se-endorhine before and after acupuncture","Vejle Hospital","Female","35 Years and older   (Adult, Older Adult)","Phase 1","94","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","K07-01","February 2007","January 2010","January 2010","January 23, 2007",,"August 21, 2015","Vejle Hospital, Vejle, Kabbeltoft 25, Denmark",,"https://ClinicalTrials.gov/show/NCT00425776"
55,"NCT00381251","Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.",,"Completed","No Results Available","Postmenopausal Osteoporosis|Postmenopause","Drug: Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg","Pharmacokinetic blood samples for unconjugated and total (unconjugated plus conjugated) estrogens and MPA will be obtained. The following pharmacokinetic parameters will be determined: Cmax, Tmax, t½, AUC0-T, AUC0-¥.","Wyeth is now a wholly owned subsidiary of Pfizer","Female","35 Years to 70 Years   (Adult, Older Adult)","Phase 1",,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","0713E1-134","September 2006",,"January 2007","September 27, 2006",,"June 11, 2007",,,"https://ClinicalTrials.gov/show/NCT00381251"
56,"NCT00335218","Fat Distribution in Healthy Early Postmenopausal Women",,"Completed","No Results Available","Healthy|Postmenopause","Drug: Climodien / Lafamme (BAY86-5027)|Drug: Placebo","Individual relative change of abdominal visceral fat measured by magnetic resonance imaging|Parameters of body composition and lipid metabolism|Adverse events collection","Bayer","Female","48 Years to 60 Years   (Adult)","Phase 4","67","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","91161|306387","July 2002",,"August 2004","June 9, 2006",,"December 30, 2014","Wien, Austria|Wien, Austria|Wien, Austria",,"https://ClinicalTrials.gov/show/NCT00335218"
57,"NCT00152282","A Study to Evaluate the Safety and Effectiveness of Asoprisnil and Estrogen Administration to Postmenopausal Women",,"Completed","No Results Available","Amenorrhea|Postmenopause","Drug: Asoprisnil/Premarin|Drug: Placebo and Premarin","Assessment of endometrium by endometrial biopsy|Change from baseline in endometrial thickness as assessed by ultrasound|Frequency and amount of vaginal bleeding via patient diary.|Incidence of hot flushes|Presence or absence of endometrial hyperplasia.|Response to global efficacy question regarding improvement in menopause symptoms.","Abbott","Female","48 Years to 65 Years   (Adult, Older Adult)","Phase 2","105","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M00-198","September 2000","August 2001","August 2001","September 9, 2005",,"May 29, 2008",,,"https://ClinicalTrials.gov/show/NCT00152282"
58,"NCT00123110","Insulin Resistance and Testosterone in Women",,"Completed","Has Results","Insulin Resistance|Postmenopause","Drug: metformin|Drug: leuprolide injection|Drug: placebo pill|Drug: placebo injection","Percent Change in Free Testosterone (T)|Change in Insulin Sensitivity|Percent Change in Luteinizing Hormone (LH) From Baseline|Percent Change in Homeostasis Model Assessment Index of Insulin Resistance (HOMA-IR)|Percent Change in Low Density Lipoprotein (LDL)|Percent Change in Systolic Blood Pressure|Free T and IR in Women in Whom Metabolic Syndrome is Present vs. Absent|Dehydroepiandrosterone Sulfate (DHEA-S)|Body Mass Index (BMI)","University of Pennsylvania|National Institute on Aging (NIA)|The John A. Hartford Foundation|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Pennsylvania Diabetes and Endocrinology Research Center (DERC)|TAP Pharmaceutical Products Inc.","Female","50 Years to 79 Years   (Adult, Older Adult)","Phase 2","35","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AG0031|K23AG019161|K23AG1916101A1|5P30DK019525","July 2005","December 2011","December 2011","July 22, 2005","May 23, 2019","May 23, 2019","University of Pennsylvania Clinical and Translational Research Center, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00123110"
59,"NCT00115024","EPAT: Estrogen in the Prevention of Atherosclerosis Trial",,"Completed","No Results Available","Atherosclerosis|Postmenopause","Drug: Micronized 17B-estradiol","rate of change of distal common carotid artery (CCA) far wall intima-media thickness (IMT)|lipid and non-lipid factors","National Institute on Aging (NIA)|Mead Johnson Nutrition","Female","46 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","222","NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","AG0026|R01AG018798","April 1994","November 1998","November 1998","June 21, 2005",,"December 11, 2009","Atherosclerosis Research Unit, Division of Cardiovascular Medicine, Department of Medicine, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00115024"
60,"NCT00102141","Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women",,"Completed","No Results Available","Hypertension|Postmenopause","Drug: Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Drug: Placebo","Mean change in systolic office blood pressure measured at through|Mean change in 24-hour systolic ambulatory blood pressure measurement (ABPM)|Mean change in diastolic blood pressure measured at through|Mean changes in 24-hour diastolic ABPM|Mean change in daytime systolic ABPM|Mean change in daytime diastolic ABPM|Mean change in nighttime systolic ABPM|Mean change in nighttime diastolic ABPM|Mean change in systolic APBM at through|Mean change in diastolic APBM at through","Bayer","Female","45 Years to 75 Years   (Adult, Older Adult)","Phase 3","750","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","91202|306743","April 2004",,"July 2005","January 24, 2005",,"December 15, 2014",,,"https://ClinicalTrials.gov/show/NCT00102141"
61,"NCT00051402","Phytoestrogens and Memory Decline in Menopause",,"Completed","No Results Available","Memory Loss|Postmenopause","Drug: Isoflavones",,"National Center for Complementary and Integrative Health (NCCIH)","Female","62 Years and older   (Adult, Older Adult)","Phase 2","96","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","R21AT000567-01A1","December 2002",,"August 2007","January 15, 2003",,"October 26, 2007","University of Cincinnati College of Medicine, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00051402"
62,"NCT00001752","Vascular and Metabolic Effects of Hormone Therapy Combined With L-Arginine in Postmenopausal Women",,"Completed","No Results Available","Hypercholesterolemia|Postmenopause","Drug: L-arginine|Drug: Estrogen",,"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","Female","Child, Adult, Older Adult","Phase 2","30","NIH","Interventional","Primary Purpose: Treatment","980158|98-H-0158","September 1998",,"July 2000","December 10, 2002",,"March 4, 2008","National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00001752"
63,"NCT00029757","Buccal Estrogen in Toothpaste Study: Systemic Absorption of Estradiol When Administered Mixed With Toothpaste in Postmenopausal or Surgically Menopausal Women",,"Completed","No Results Available","Menopause|Postmenopause","Drug: Estrogen",,"National Center for Research Resources (NCRR)","Female","35 Years to 75 Years   (Adult, Older Adult)","Not Applicable","15","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCRR-M01RR02558-1056",,,,"January 23, 2002",,"November 7, 2005","University of Texas--Houston Medical School, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00029757"
64,"NCT02667561","Pharmacokinetics, Pharmacodinamic and Safety of Testosterone Gel 1%",,"Withdrawn","No Results Available","Post-menopausal Period","Drug: Testosterone gel 1% 2.2 mg|Drug: Testosterone gel 1% 4.4 mg|Drug: Testosterone gel 1% 8.8 mg|Drug: Placebo of Testosterone Gel 1%","Pharmacokinetics, area under the curve (AUC)|Pharmacokinetics, maximum concentration (Cmax)|Pharmacokinetics, time to maximum concentration (Tmax)|Pharmacokinetics, half-life (t1/2)|Pharmacodynamics, response rate, by Female Sexual Function Index|Safety, number of adverse events","Biolab Sanus Farmaceutica","Female","42 Years to 65 Years   (Adult, Older Adult)","Phase 1","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","GDN 060/15","July 2017","December 2017","May 2018","January 29, 2016",,"June 6, 2018",,,"https://ClinicalTrials.gov/show/NCT02667561"
65,"NCT03061799","Efficacy and Safety of HPC-03 for Postmenopausal Symptom",,"Unknown status","No Results Available","Postmenopausal Period","Dietary Supplement: HPC-03|Dietary Supplement: Placebo","Change from baseline Modified Kupperman Index score at 6 weeks and 12 weeks|endometrial thickness measured by transvaginal ultrasonography|serum estradiol (E2)|serum FSH (Follicular stimulating hormone)","Jae Hoon Lee|Gachon University Gil Medical Center|Daejeon University|Severance Hospital","Female","40 Years to 60 Years   (Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","4-2016-0680","January 2017","May 2017","December 2017","February 23, 2017",,"February 23, 2017","Severance hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03061799"
66,"NCT04370756","Beetroot Supplementation in Women Enjoying Exercise Together","BEE SWEET","Recruiting","No Results Available","Aging|Postmenopause|Obesity","Dietary Supplement: Beetroot Juice|Other: Exercise Training","Recruitment rate|Retention rate|Adherence to exercise training intervention|Adherence to dietary nitrate intervention|Perceived difficulty of training sessions|Distance covered during a six-minute walk test|Soluble endothelial microparticles","Indiana University|IU Health University Hospital|Indiana CTSI Clinical Research Center|Bloomington Crossfit","Female","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","1907026303","January 30, 2020","December 2022","December 2022","May 1, 2020",,"March 14, 2022","Indiana University, Bloomington, Indiana, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT04370756/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04370756"
67,"NCT05560178","The Effect of Sexual Health Education Given to Women in the Postmenopausal Period on Sexual Life",,"Recruiting","No Results Available","Sexuality|Menopause|Sexual Behavior","Other: SEXUAL HEALTH EDUCATION","Sexual Myths Scale-SMS|Female Sexual Distress Scale-Revised- FSDS- R","Necmettin Erbakan University","Female","41 Years to 64 Years   (Adult)","Not Applicable","124","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","KMUserapkirici","April 1, 2022","September 27, 2022","April 1, 2023","September 29, 2022",,"September 29, 2022","Karamanoğlu Mehmetbey University, Karaman, Turkey",,"https://ClinicalTrials.gov/show/NCT05560178"
68,"NCT03167827","Effects of Physical Training and Isoflavone Supplementation On Pelvic Floor in Women in the Postmenopausal Period",,"Completed","No Results Available","Pelvic Floor","Other: Exercise|Other: isoflavone|Other: placebo","The change vaginal squeeze pressure|The change Muscle function|The change electromyography pelvic floor","Federal University of Uberlandia","Female","50 Years to 70 Years   (Adult, Older Adult)","Phase 4","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","CEP UFU 52969515.1.0000.5152","September 2016","December 2016","March 2017","May 30, 2017",,"May 30, 2017",,,"https://ClinicalTrials.gov/show/NCT03167827"
69,"NCT05448079","The Effect of Sexual Counseling Given According to the PLISSIT Model on FSFI, MAS and SQOL-F of Postmenopausal Women",,"Completed","No Results Available","Postmenopause|Sexual Function|Marital Relationship","Other: Sexual counseling according to the PLISSIT model, randomized pretest-posttest","Female Sexual Function Index|Marital Adjustment Subscale|The Sexual Quality Of Life-Female|Menopause Rating Scale","Suleyman Demirel University","Female","42 Years to 55 Years   (Adult)","Not Applicable","58","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","SuleymanDUAyşeAKBAYKISA-001","September 28, 2020","December 26, 2020","February 26, 2021","July 7, 2022",,"July 7, 2022","Suleyman Demirel University, Isparta, Turkey",,"https://ClinicalTrials.gov/show/NCT05448079"
70,"NCT05690295","Resistance-type Exercise Training in Postmenopausal Women Survivors of Breast Cancer","MUSCLE-CLIM","Not yet recruiting","No Results Available","Breast Cancer Survivors|Postmenopause|Resistance Training","Other: Prolonged resistance-type exercise training","Change in kilograms of the skeletal muscle mass of whole-body measured via dual energy x-ray absorptiometry (DEXA)|Change in kilograms of the arms strength measured via 1-Repetition Maximum (1RM) testing) after prolonged resistance-type exercise training|Change in kilograms of the legs strength measured via 1-Repetition Maximum (1RM) testing) after prolonged resistance-type exercise training|Change in kilograms of the hand grip strength measured via JAMAR handheld dynamometer after prolonged resistance-type exercise training|Change in points of the physical performance measured via Short physical performance battery (SPPB) after prolonged resistance-type exercise training|Change in points quality of life measured via questionnaire European Organisation for Research and Treatment of Cancer (EORTC QLQ-C30) after prolonged resistance-type exercise training|Change in microgram per milliliter (µg/ml) of Human Insulin via ELISA after prolonged resistance-type exercise training|Change in milligrams per deciliter (mg/dL) of glucose via methods enzymatic-colorimetric|Change in milligrams per deciliter (mg/dL) of lipid profile via methods enzymatic-colorimetric","Universidad de La Frontera","Female","45 Years to 49 Years   (Adult)","Not Applicable","52","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","DFP22-0020","January 2023","December 2023","August 2024","January 19, 2023",,"January 19, 2023","Department of Rehabilitation Sciences, Faculty of Medicine, Universidad de La Frontera. Temuco, Chile, Temuco, Chile",,"https://ClinicalTrials.gov/show/NCT05690295"
71,"NCT05299983","MyMenoPlan: Online Resource for Improving Women's Menopause Knowledge and Informed Decision-making",,"Active, not recruiting","No Results Available","Menopause|Premenopause|Postmenopause","Other: MyMenoPlan|Other: Control","Perceived Quality of Information|Readability|Self-Efficacy for Managing Menopause Symptoms|Credibility","University of California, San Diego","Female","40 Years to 60 Years   (Adult)","Not Applicable","410","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Health Services Research","140604","January 15, 2022","March 31, 2022","March 31, 2022","March 29, 2022",,"April 8, 2022","UC San Diego, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT05299983"
72,"NCT04136093","Diet for the Maintenance of Weight Loss and Metabolic Health in Obese Postmenopausal Women","WELCOME","Unknown status","No Results Available","Metabolic Syndrome|Diet Modification|Postmenopause","Other: the MED|Other: the DASH|Other: Control diet","Changes in body weight [kg]|Changes in waist circumferences (WC) [cm]|Changes in fat mass [kg]|Changes in HDL cholesterol [mg/dL]|changes in triglycerides (TG) [mg/dL]|changes in glucose (GLU)|Changes in systolic blood pressure (SBP)|Changes in diastolic blood pressure (DBP)|Physical activity level (PAL)|Eating behaviour (by measurement of dietary restraint, disinhibition and hunger)|Adherence to the prescribed diets (assessment of the plasma AR levels and concentration and fatty acids in red blood cells)|Dietary intake","Poznan University of Life Sciences","Female","50 Years to 65 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science","445446","February 29, 2020","May 2022","September 2022","October 23, 2019",,"April 9, 2020","Poznan University of Life Science, Poznań, Poland",,"https://ClinicalTrials.gov/show/NCT04136093"
73,"NCT00420342","Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension",,"Completed","Has Results","Postmenopause|Hypertension|Pre-Hypertension","Drug: Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)|Drug: SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)","Change From Baseline to Week 8 in Mean 24-hour SBP From the Ambulatory Blood Pressure Monitoring (ABPM) Measurements in Full Analysis Set (FAS) Population|Change From Baseline to Week 8 in Mean 24-hour SBP From the ABPM Measurements in Per Protocol Population|Change From Baseline to Week 8 in Mean 24-hour DBP From the ABPM Measurements|Change From Baseline to Week 8 in Office Cuff SBP and DBP at Trough|Change From Baseline to Week 8 in Mean Day Time, Mean Nighttime and Mean Trough SBP From the ABPM Measurements|Change From Baseline to Week 8 in Mean Day Time, Mean Nighttime and Mean Trough DBP From the ABPM Measurements|Number of Subjects Who Are Sodium Sensitive at Baseline and Week 8|Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 112 mmHg (Posthoc Analysis)|Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 116 mmHg (Posthoc Analysis)|Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 120 mmHg (Posthoc Analysis)|Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 124 mmHg (Posthoc Analysis)|Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 130 mmHg (Posthoc Analysis)","Bayer","Female","45 Years to 65 Years   (Adult, Older Adult)","Phase 2","92","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","91507|310522","January 2007","September 2008","September 2008","January 11, 2007","January 20, 2010","June 2, 2015","Greenbrae, California, United States|San Diego, California, United States|Daytona Beach, Florida, United States|Miami, Florida, United States|Paw Paw, Michigan, United States|Las Vegas, Nevada, United States|Philadelphia, Pennsylvania, United States|Columbia, South Carolina, United States|Arlington, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00420342"
74,"NCT01064453","Angeliq Regulatory Post Marketing Surveillance","Angeliq rPMS","Completed","No Results Available","Postmenopausal Period|Osteoporosis, Postmenopausal","Drug: E2/DRSP (Angeliq, BAY86-4891)","Adverse event collection|Improvement of menopausal symptoms","Bayer","Female","Child, Adult, Older Adult",,"4078","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14841|AQ0710KR","June 2007","December 2012","December 2012","February 8, 2010",,"November 19, 2013","Many Locations, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01064453"
75,"NCT00010712","Effects of Black Cohosh on Menopausal Hot Flashes",,"Completed","No Results Available","Postmenopause|Hot Flashes|Osteoporosis, Postmenopausal","Drug: Black Cohosh",,"National Center for Complementary and Integrative Health (NCCIH)","Female","45 Years to 70 Years   (Adult, Older Adult)","Phase 2",,"NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","P50AT000090-01P3|P50AT000090-01","September 1999",,"July 2005","February 5, 2001",,"August 18, 2006","Columbia University Rosenthal Center for CAM, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00010712"
76,"NCT00574574","Effects of Anthocyanin on Skin Health and Markers of Cardiovascular Disease Risk",,"Completed","No Results Available","Cardiovascular Disease|Skin Health|Postmenopause","Dietary Supplement: anthocyanin","Measure: Evidence of significant differences in skin health parameters, between active treatment and placebo supplementation period.|Measure: Evidence of significant differences in inflammatory status, between active treatment and placebo supplementation period.","University of East Anglia|Quadram Institute Bioscience|Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)|Unilever R&D","Female","up to 70 Years   (Child, Adult, Older Adult)","Not Applicable","62","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","R14764|BWF008","August 2007","February 2008","February 2008","December 17, 2007",,"July 14, 2009","University of East Anglia, Norwich, Norfolk, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00574574"
77,"NCT00005515","Mutations, Hormone Therapy (HRT) and Venous Thromboembolism",,"Completed","No Results Available","Cardiovascular Diseases|Venous Thromboembolism|Postmenopause",,,"University of Washington|National Heart, Lung, and Blood Institute (NHLBI)","Female","30 Years to 89 Years   (Adult, Older Adult)",,,"Other|NIH","Observational",,"5033|R01HL060739","September 1998",,"August 2003","May 26, 2000",,"February 10, 2016",,,"https://ClinicalTrials.gov/show/NCT00005515"
78,"NCT02274571","Raising Insulin Sensitivity in Post Menopause","RISE","Completed","No Results Available","Menopause","Drug: TSEC (Tissue-selective estrogen complexes)|Other: Placebo","2-step hyperinsulinemic clamp at 90 mg/dl glucose with resting metabolic rate measure|Metabolic rate|Body Composition","Pennington Biomedical Research Center","Female","50 Years to 60 Years   (Adult)","Early Phase 1","8","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","PBRC 2014-039","September 2015","April 11, 2017","April 11, 2017","October 24, 2014",,"January 21, 2022","Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT02274571"
79,"NCT01177761","The Erlangen Fitness and Prevention Study (EFOPS).","EFOPS","Active, not recruiting","No Results Available","Osteoporosis|Osteopenia|Early Postmenopause","Procedure: physical exercise","overall-fractures (low-trauma)|Bone Mineral Density at Lumbar Spine and Proximal Femur|10-year coronary heart disease (CHD) risk|Metabolic Syndrome Z-Score","University of Erlangen-Nürnberg Medical School|Behinderten- und Versehrten-Sportverband Bayern e.V.|Netzwerk Knochengesundheit e.V.","Female","48 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","OFZ-EFOPS","October 1998","December 2023","December 2023","August 9, 2010",,"November 3, 2022","Institute of Medical Physics, University of Erlangen-Nurnberg, Erlangen, Bavaria, Germany",,"https://ClinicalTrials.gov/show/NCT01177761"
80,"NCT03116022","Use of Estriol at Distal Third of Vagina Improving Coital Pain in Post-menopause Women",,"Unknown status","No Results Available","Dyspareunia|Menopause|Sexual Dysfunction","Drug: Estriol|Drug: Distal estriol|Drug: Vaginal Gel","Improvement in pain score after estriol use|Number of participants with risk for sexual dysfunction after estriol use|Number of participants with risk for anxiety after estriol use|Number of participants with risk for depression after estriol use|Reduction of de degree of coital pain|Variation in serum levels of estriol after estriol use|Variation in serum levels of follicle-stimulating hormone after estriol use|Variation in serum levels of thyroid-stimulating hormone after estriol use|Number of participants with adverse events that are related to estriol use|Variation in blood glucose after estriol use|Variation in weight after estriol use Weight|Variation in body mass index (BMI) after estriol use","University of Sao Paulo","Female","40 Years to 65 Years   (Adult, Older Adult)","Phase 1","132","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","62443916.5.0000.5440","June 1, 2017","December 31, 2018","January 31, 2019","April 14, 2017",,"May 4, 2018","Hospital das Clínicas de Ribeirão Preto, Ribeirão Preto, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT03116022"
81,"NCT03404154","Vocal in Assessment of Endometrium in Postmenopause",,"Completed","No Results Available","Postmenopausal Bleeding","Diagnostic Test: 3D ultrasound|Procedure: Dilatation and curretage","the number of participants who where diagnosed by 3D vocal to have endometrial carcinoma","Aljazeera Hospital|Kasr El Aini Hospital|om almasreen hospital ,Egypt|National Research Centre, Egypt","Female","50 Years to 80 Years   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","vocal","January 18, 2018","August 1, 2018","August 25, 2018","January 19, 2018",,"October 2, 2018","Algazeerah, Giza, Egypt",,"https://ClinicalTrials.gov/show/NCT03404154"
82,"NCT03672760","Inspiratory Muscle Training X CardioBreath App Effects On Vagal Modulation And Pulse Wave Velocity","CardioBreath","Unknown status","No Results Available","Postmenopausal Disorder|Autonomic Imbalance|Vascular Stiffness","Device: CardioBreathApp|Device: IMT PowerBreath|Device: IMT PowerBreath Placebo","Cardiovascular autonomic control by heart rate variability(HRV)|Carotid -femoral pulse wave velocity (Complior)","Instituto de Cardiologia do Rio Grande do Sul","Female","45 Years to 65 Years   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","Cardiology","July 1, 2021","July 30, 2022","December 30, 2022","September 14, 2018",,"January 26, 2021","Cardiology Institute of Rio Grande do Sul, Pôrto Alegre, Rio Grande Do Sul, Brazil",,"https://ClinicalTrials.gov/show/NCT03672760"
83,"NCT05031702","Camelia Sinensis for Basal Metabolism and Body Composition",,"Recruiting","No Results Available","Postmenopausal Disorder","Dietary Supplement: Camellia Sinensis leaf extract|Combination Product: Placebo","Changes on energy expenditure|Changes on body composition|Changes on anthropometry|Changes on insulin resistance|Changes on carbohydrate profile|Changes on lipid profile|Changes on inflammation|Changes on incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Changes on citokine profile|Changes on plasma catecholamine profile|Changes on satiety","Azienda di Servizi alla Persona di Pavia","Female","50 Years to 70 Years   (Adult, Older Adult)","Not Applicable","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","0905/14122018","March 8, 2021","January 3, 2022","July 25, 2022","September 2, 2021",,"March 3, 2022","Mariangela Rondanelli, Pavia, Italy",,"https://ClinicalTrials.gov/show/NCT05031702"
84,"NCT02775448","Dose-response Study of Carduus Marianus in Centesimal Scale for Dyslipidemia in Climacteric Overweighed or Obese Women.",,"Terminated","No Results Available","Dyslipidemia|Menopause|Obesity","Drug: Carduus marianus 6cH|Drug: Carduus marianus 12cH|Drug: Carduus marianus 30cH|Drug: Placebo|Behavioral: Exercise|Other: Diet","Change from baseline level of triglycerides at 4 and 8 weeks.|Change from baseline level of total cholesterol at 4 and 8 weeks.|Change from baseline level of LDL cholesterol at 4 and 8 weeks.|Change from baseline level of HDL cholesterol at 4 and 8 weeks.|Change from baseline level of fasting glucose at 4 and 8 weeks.|Change from baseline level of glycosylated hemoglobin at 4 and 8 weeks.|Change from baseline [HOMA-IR=insulin(mU/ml) X glucose (mg/dl)/405] at 4 and 8 weeks.|Change from baseline weight (kg) at 4 and 8 weeks.|Change from baseline body mass index (Kg/m2) at 4 and 8 weeks.|Change from baseline waist circumference (cm) at 4 and 8 weeks.|Adverse events","Hospital Nacional Homeopático, Mexico|Laboratorio Similia, México","Female","40 Years to 65 Years   (Adult, Older Adult)","Phase 2","62","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HospitalNHMexico","February 2016","August 2017","September 2017","May 17, 2016",,"February 28, 2019","Hospital Nacional Homeopático, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT02775448"
85,"NCT05335317","Treatment of Vaginal Atrophy With Low Intensity Nanosecond Neodymium Laser",,"Recruiting","No Results Available","Postmenopausal Period|Vaginal Atrophy|Vaginal Prolapse","Device: Laser Treatment|Drug: Topical hormone estriol|Diagnostic Test: Сlinical blood analysis|Diagnostic Test: Сlinical urine test|Diagnostic Test: Vaginal smear|Diagnostic Test: Cervical oncocytology test.|Diagnostic Test: Extended colposcopy|Diagnostic Test: Pelvic ultrasound|Other: King's Health Questionnaire|Diagnostic Test: Vaginal Health Index|Diagnostic Test: Ultrasound investigation|Diagnostic Test: Perineometry|Diagnostic Test: Optical coherence tomography|Diagnostic Test: Biopsy|Diagnostic Test: Femoflor screen","Mean Change from Baseline of Vaginal Health Index Score|Mean Change from Baseline of Periodic Acid Schiff Reaction Percentage in Vaginal Smear|Mean Change from Baseline of Resistive Index by Doppler Sonography","MeLSyTech, Ltd","Female","40 Years to 75 Years   (Adult, Older Adult)","Not Applicable","120","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","TVALINNL-2019","April 18, 2022","April 30, 2024","June 30, 2024","April 19, 2022",,"November 10, 2022","State-Funded Healthcare Institution of the Nizhny Novgorod region ""Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko"", Nizhny Novgorod, Russian Federation",,"https://ClinicalTrials.gov/show/NCT05335317"
86,"NCT04735549","Vulvovaginal Atrophy Correction Using Neodymium Laser",,"Recruiting","No Results Available","Postmenopausal Period|Vaginal Atrophy|Female Urogenital Diseases","Device: Laser Treatment|Drug: Topical hormone estriol|Diagnostic Test: Сlinical blood analysis|Diagnostic Test: Сlinical urine test|Diagnostic Test: Vaginal smear|Diagnostic Test: Pelvic ultrasound|Other: Female Sexual Function Index|Other: The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire|Other: Vulvovaginal Symptoms Questionnaire|Diagnostic Test: Vaginal Health Index|Diagnostic Test: Elastography (ultrasound investigation)|Diagnostic Test: Perineometry|Other: Visual Analogue Scale (VAS)","Mean Change from Baseline of Vaginal Health Index Score","MeLSyTech, Ltd","Female","50 Years and older   (Adult, Older Adult)","Not Applicable","120","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","VACUNL-2020","February 15, 2021","June 1, 2023","December 1, 2023","February 3, 2021",,"January 23, 2023","Federal State Budget Institution ""National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I.Kulakov"", Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04735549"
87,"NCT00420940","The Influence of Vibration on Bone Mineral Density in Women Who Have Weak Bones After Menopause",,"Completed","No Results Available","Bone Density|Osteopenia|Osteoporosis|Post-Menopause","Device: Juvent 1000 Dynamic Motion Therapy (DMT) Platform","Trabecul volumetric bone mineral density (BMD) of the lower tibia (using peripheral quantitative computed tomography; pQCT))|Total BMD of the lower tibia (using pQCT)|Cortical BMD and cortical thickness of the lower tibia (using pQCT)|Trabecular thickness, separation, and number of the lower tibia (using pQCT)|Total BMD of the distal radius (using pQCT)|Cortical BMD and cortical thickness of the distal radius (using pQCT)|Trabecular BMD and thickness, separation, and number of the distal radius (using pQCT)|BMD at the total hip (using dual x-ray absorptiometry; DXA)|BMD at the femoral neck (using DXA)|BMD lumbar spine (using DXA)|BMD at the calcaneus (using quantitative ultrasound; QUS)|Speed of sound and broadband ultrasound attenuation at the calcaneus (QUS)","University Health Network, Toronto|The Physicians' Services Incorporated Foundation","Female","Child, Adult, Older Adult","Phase 3","202","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","06-0332-AE|PSI 06-28","November 2006","December 2009","December 2009","January 11, 2007",,"April 8, 2010","University Health Network, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00420940"
88,"NCT00361075","Midlife Cholesterol Study",,"Completed","No Results Available","Menopause|Postmenopause|Premenopause|Cardiovascular Disease","Drug: transdermal estradiol patch (Vivelle), oral estrogen (Estrace), progesterone (Prometrium)","LDL particle size and density|Total body adiposity (Dexa scans)|Intra-abdominal fat (CT scans)|Lipid Profile|Inflammatory Factors|Adipocytokines","Northwestern University|University of Washington","Female","47 Years to 55 Years   (Adult)","Phase 4","120","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","5K23RR016067-05","July 1998",,"May 2005","August 7, 2006",,"November 5, 2014","Northwestern University, Chicago, Illinois, United States|University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00361075"
89,"NCT00023543","Reduction of Triglycerides in Women on Hormone Replacement Therapy",,"Completed","No Results Available","Cardiovascular Diseases|Atherosclerosis|Postmenopause|Heart Diseases","Behavioral: Diet, fat-restricted|Behavioral: Exercise","Measures of subclinical disease|Change in coronary calcium (EBCT)|Change in carotid intima media wall thickness|Change in vascular stiffness (PWV)|Change in waist circumference and weight|Change in LDL particles, triglycerides and small, medium and large LDL particles|Change in HDL particles|Change in insulin and glucose|Change in systolic blood pressure, diastolic blood pressure","University of Pittsburgh|National Heart, Lung, and Blood Institute (NHLBI)","Female","52 Years to 60 Years   (Adult)","Phase 2","508","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","981|R01HL066468-06|R01HL066468","September 2001","May 2010","May 2010","September 7, 2001",,"June 19, 2013","University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00023543"
90,"NCT00006539","Thrombotic, Inflammatory & Gene Markers of CVD in Women",,"Completed","No Results Available","Cardiovascular Diseases|Heart Diseases|Myocardial Infarction|Postmenopause",,,"National Heart, Lung, and Blood Institute (NHLBI)","Female","50 Years to 79 Years   (Adult, Older Adult)",,,"NIH","Observational",,"952|R01HL063293","September 1999",,"August 2004","November 28, 2000",,"March 16, 2016",,,"https://ClinicalTrials.gov/show/NCT00006539"
91,"NCT00006313","Hormone Therapy Effects on CVD Risk Factors",,"Completed","No Results Available","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Postmenopause",,,"National Heart, Lung, and Blood Institute (NHLBI)","Male","up to 100 Years   (Child, Adult, Older Adult)",,,"NIH","Observational","Time Perspective: Retrospective","921|R03HL062429","June 1999",,"June 2000","September 29, 2000",,"May 13, 2016",,,"https://ClinicalTrials.gov/show/NCT00006313"
92,"NCT00000598","Diet and Exercise for Elevated Risk (DEER)",,"Completed","No Results Available","Cardiovascular Diseases|Heart Diseases|Hypercholesterolemia|Postmenopause","Behavioral: diet, fat-restricted|Behavioral: exercise",,"Stanford University|National Heart, Lung, and Blood Institute (NHLBI)","All","30 Years to 64 Years   (Adult)","Phase 3",,"Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Primary Purpose: Prevention","501|R01HL045733","August 1991",,"August 1996","October 28, 1999",,"January 12, 2016",,,"https://ClinicalTrials.gov/show/NCT00000598"
93,"NCT04140240","Menopause Symptom Management in Perimenopause and Postmenopausal Period","Menopause","Completed","No Results Available","Menopause","Behavioral: intervention group","Menopause Rating Scale-MRS|The Menopause Specific Quality of Life Questionnaire-MENQOL","Akdeniz University","Female","40 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","Akd04050","January 1, 2019","February 20, 2020","March 18, 2020","October 25, 2019",,"June 11, 2020","Gülşen Ak Sözer, Antalya, Pınarbaşı Neighborhood, Turkey",,"https://ClinicalTrials.gov/show/NCT04140240"
94,"NCT05347082","Frequency of Hyperparathyroidism in Postmenopausal Osteoporosis and Its Treatment",,"Completed","No Results Available","Postmenopausal Osteoporosis|Postmenopause|Hyperparathyroidism, Secondary|Hypovitaminosis D|Hyperparathyroidism, Primary","Drug: Cholecalciferol","Number of Participants with Remission of Hyperparathyroidism|Number of Participants with Remission of Hypovitaminosis D|Change from baseline hip T score at 4 weeks|Change from baseline lumbar spine T score at 4 weeks|Change from baseline general T score at 4 weeks","Hospital Regional 1o de Octubre|Universidad Nacional Autonoma de Mexico|National Polytechnic Institute, Mexico","Female","Child, Adult, Older Adult","Not Applicable","47","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","120.2021","April 29, 2021","December 29, 2021","February 20, 2022","April 26, 2022",,"May 6, 2022","Peri-postmenopause and bone metabolism clinic. Regional Hospital October 1st ISSSTE, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT05347082"
95,"NCT00001890","Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections",,"Completed","No Results Available","Atherosclerosis|Chlamydia Infections|Cytomegalovirus Infections|Pneumonia, Bacterial|Postmenopause","Drug: Estrogen therapy",,"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","Female","Child, Adult, Older Adult","Phase 2","80","NIH","Interventional","Primary Purpose: Treatment","990100|99-H-0100","May 1999",,"March 2001","December 10, 2002",,"March 4, 2008","National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00001890"
96,"NCT04867109","HE4 in the Diagnostic Approach of Endometrial Cancer in Patients With Postmenopausal Bleeding","METRODEC","Recruiting","No Results Available","Endometrial Neoplasms|Postmenopause|Uterine Hemorrhage|Cancer Biomarker|CA 125 Antigen","Other: Patients with Post menopausal bleeding|Diagnostic Test: CA125 and HE4 assays","To evaluate the sensitivity of the HE4 marker in patients with postmenopausal bleeding in the diagnosis of endometrial cancer|Assess other diagnostic parameters (specificity, PPV, NPV) of HE4|Establish the optimal threshold of HE4 for the diagnosis of endometrial cancer (use of an ROC curve)|Evaluate the diagnostic capabilities of CA125 alone and in combination with HE4, as well as the REM and REM-B algorithms for the diagnosis of endometrial cancer|Establish the existence of thresholds for HE4 and/or CA125 markers predictive of disease severity (FIGO stage)|Reassess the pathological threshold value of endometrial thickness on ultrasound|Assess the relationship between endometrial thickness on ultrasound and HE4 and CA125 marker values|To evaluate the diagnostic capabilities of HE4 and CA125 in subgroups of smoking patients and patients with renal failure|Identify potential confounding factors associated with the value of the HE4 marker like treatments, comorbidities (renal insufficiency, high BMI) and others criteria that are collected in the medical files","Nantes University Hospital|Roche Diagnostics","Female","18 Years and older   (Adult, Older Adult)",,"100","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","RC21_0166","June 25, 2021","August 1, 2022","September 1, 2022","April 30, 2021",,"September 17, 2021","Saint-Nazaire Hospital, Saint-Nazaire, Loire-Atlantique, France|Vendee Hospital Center, La Roche-sur-Yon, Vendee, France",,"https://ClinicalTrials.gov/show/NCT04867109"
97,"NCT03854396","Clinical Trial on the Preventive Effect of Intravaginal Prasterone on Recurrent Urinary Tract Infections in Postmenopausal Women",,"Withdrawn","No Results Available","Recurrent Urinary Tract Infection|Postmenopause|Postmenopausal Syndrome|Postmenopausal Symptoms|Menopause","Drug: Prasterone|Drug: Placebo","Incidence of urinary tract infections (UTIs)|Mean days of antibiotic use","Olivia Cardenas-Trowers, M.D.|AMAG Pharmaceuticals, Inc.|University of Louisville","Female","18 Years and older   (Adult, Older Adult)","Phase 3","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","19.0075","May 2020","February 2021","February 2021","February 26, 2019",,"June 30, 2021","University of Louisville Urogynecology at Springs Medical Center, Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT03854396"
98,"NCT00125476","Effects of Exercise Training on Diastolic Heart Function in Postmenopausal Women",,"Completed","No Results Available","Heart Failure, Congestive|Cardiovascular Diseases","Behavioral: Exercise","Diastolic function as assessed by mitral inflow filling pattern (E/A ratio) (measured at Month 6)|Pulmonary vein flow pattern|Tissue Doppler|Color M-mode mitral inflow propagation velocity|Left ventricular mass (measured at Month 6)","National Heart, Lung, and Blood Institute (NHLBI)","Female","45 Years to 75 Years   (Adult, Older Adult)","Not Applicable","215","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","235|R21HL077165","July 2004",,,"August 1, 2005",,"October 11, 2006","The Cooper Institute, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00125476"
99,"NCT00081952","Amino Acid Therapy for Hot Flashes in Postmenopausal Women",,"Completed","No Results Available","Hot Flashes","Drug: L-norleucine",,"National Center for Complementary and Integrative Health (NCCIH)","Female","Child, Adult, Older Adult","Phase 1|Phase 2","15","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","K23AT001709-01","October 2003","October 2007","October 2007","April 28, 2004",,"March 22, 2013","Women's Health Initiative, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT00081952"
100,"NCT00006407","Sex Steroid Hormones and Risk of CHD in Women",,"Completed","No Results Available","Cardiovascular Diseases|Heart Diseases|Coronary Disease|Postmenopause|Coronary Arteriosclerosis",,,"National Heart, Lung, and Blood Institute (NHLBI)","Female","50 Years to 79 Years   (Adult, Older Adult)",,,"NIH","Observational",,"932|R01HL065531","September 2000",,"July 2004","October 13, 2000",,"March 16, 2016",,,"https://ClinicalTrials.gov/show/NCT00006407"
101,"NCT00005446","Endogenous Estrogen and Coronary Heart Disease in Women",,"Completed","No Results Available","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Myocardial Infarction|Postmenopause",,,"NYU Langone Health|National Heart, Lung, and Blood Institute (NHLBI)","Female","up to 100 Years   (Child, Adult, Older Adult)",,,"Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","4375|R29HL052123","April 1994","March 1999",,"May 26, 2000",,"December 31, 2015",,,"https://ClinicalTrials.gov/show/NCT00005446"
102,"NCT00005185","Myocardial Infarction and Non-contraceptive Estrogen Use",,"Completed","No Results Available","Cardiovascular Diseases|Heart Diseases|Myocardial Infarction|Menopause|Postmenopause",,,"National Heart, Lung, and Blood Institute (NHLBI)","Male","up to 100 Years   (Child, Adult, Older Adult)",,,"NIH","Observational",,"1063|R01HL032174","April 1986",,"March 1990","May 26, 2000",,"May 13, 2016",,,"https://ClinicalTrials.gov/show/NCT00005185"
103,"NCT00000601","Postmenopausal Hormone Therapy in Unstable Angina",,"Completed","No Results Available","Angina, Unstable|Cardiovascular Diseases|Coronary Disease|Heart Diseases|Postmenopause","Drug: estrogen replacement therapy|Drug: estrogens|Drug: progesterone|Drug: hormone replacement therapy",,"National Heart, Lung, and Blood Institute (NHLBI)","Female","45 Years to 75 Years   (Adult, Older Adult)","Phase 3",,"NIH","Interventional","Allocation: Randomized|Masking: Double|Primary Purpose: Prevention","107|R01HL050839","July 1995",,"June 2000","October 28, 1999",,"February 18, 2016",,,"https://ClinicalTrials.gov/show/NCT00000601"
104,"NCT00000559","Women's Estrogen/Progestin Lipid Lowering Hormone Atherosclerosis Regression Trial (WELL-HART)",,"Completed","No Results Available","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Myocardial Ischemia|Postmenopause","Drug: estrogen replacement therapy|Drug: hormone replacement therapy|Drug: estradiol|Drug: medroxyprogesterone",,"National Heart, Lung, and Blood Institute (NHLBI)","Female","45 Years to 75 Years   (Adult, Older Adult)","Phase 3",,"NIH","Interventional","Allocation: Randomized|Masking: Double|Primary Purpose: Prevention","103","March 1995",,"August 2001","October 28, 1999",,"July 12, 2016",,,"https://ClinicalTrials.gov/show/NCT00000559"
105,"NCT00000481","Women's Health Trial: Feasibility Study in Minority Populations",,"Completed","No Results Available","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Myocardial Ischemia|Postmenopause","Behavioral: diet, fat-restricted",,"National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI)","Female","50 Years to 69 Years   (Adult, Older Adult)","Phase 3",,"NIH","Interventional","Allocation: Randomized|Primary Purpose: Prevention","71|N01CN025427-010","September 1991",,"January 1996","October 28, 1999",,"February 14, 2017",,,"https://ClinicalTrials.gov/show/NCT00000481"
106,"NCT00399321","A Pilot Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer",,"Completed","No Results Available","Postmenopausal Bone Loss|Breast Cancer",,"Changes in bone mineral density in post-menopausal women receiving treatment for early stage breast cancer.","University of Michigan Rogel Cancer Center|Susan G. Komen Breast Cancer Foundation","Female","18 Years and older   (Adult, Older Adult)",,"9","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","UMCC 2006.016|HUM 3457","April 2006","September 2010","September 2010","November 14, 2006",,"July 5, 2017","University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT00399321"
107,"NCT01579734","Phase III, Randomized, Double Blind Trial Low Dose Tamoxifen Versus Placebo in Hormone Replacement Therapy (HRT) Users","HOT","Active, not recruiting","No Results Available","Breast Cancer","Drug: Tamoxifen|Drug: Placebo","breast cancer incidence|Incidence of adverse events","European Institute of Oncology","Female","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","1884","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","IEO S51/200","March 2002","December 2018","December 2021","April 18, 2012",,"August 13, 2021","European Institute of Oncology, Milan, Italy",,"https://ClinicalTrials.gov/show/NCT01579734"
108,"NCT00530582","Progesterone Reduces Wakefulness in Sleep EEG and Has no Effect on Cognition in Healthy Postmenopausal Women",,"Completed","No Results Available","Healthy|Postmenopausal","Drug: progesterone","sleep-EEG parameters","Max-Planck-Institute of Psychiatry|Dr. Kade/Besins Pharma GmbH, Rigistr. 2, 12277 Berlin","Female","54 Years to 70 Years   (Adult, Older Adult)","Phase 4","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","KAD 108 ex","November 2003",,"July 2004","September 17, 2007",,"September 17, 2007","Max Planck Institute of Psychiatry, Munich, Bavaria, Germany",,"https://ClinicalTrials.gov/show/NCT00530582"
109,"NCT00141570","Study of the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women",,"Completed","No Results Available","Menopause","Drug: esterified estrogens 0.625 mg and methyltestosterone 1.25 mg","Change from baseline in the total score of the Menopause Rating Scale (MRS) at Week 12|Change from baseline in the MRS at Week 12 & monthly change from baseline to Week 12 in the MENQOL; Comparison of changes in SHBG & testosterone & how these changes correlate with the MRS","Solvay Pharmaceuticals","Female","30 Years to 65 Years   (Adult, Older Adult)","Phase 2","350","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","S030.2.106","June 2004","June 2007","June 2007","September 1, 2005",,"January 16, 2015","Site 66, Huntsville, Alabama, United States|Site 57, Mobile, Alabama, United States|Site 46, Montgomery, Alabama, United States|Site 29, Phoenix, Arizona, United States|Site 15, Tucson, Arizona, United States|Site 3, Jonesboro, Arkansas, United States|Site 22, Little Rock, Arkansas, United States|Site 68, Carmichael, California, United States|Site 55, Encinitas, California, United States|Site 6, San Diego, California, United States|Site 45, Santa Rosa, California, United States|Site 25, Walnut Creek, California, United States|Site 26, Denver, Colorado, United States|Site 1, Groton, Connecticut, United States|Site 54, Hartford, Connecticut, United States|Site 30, Trumbull, Connecticut, United States|Site 34, Waterbury, Connecticut, United States|Site 10, Aventura, Florida, United States|Site 73, Ft. Myers, Florida, United States|Site 51, Leesburg, Florida, United States|Site 49, Melbourne, Florida, United States|Site 64, New Port Richey, Florida, United States|Site 61, Ocala, Florida, United States|Site 27, Palm Springs, Florida, United States|Site 11, Pinellas Park, Florida, United States|Site 75, Sarasota, Florida, United States|Site 69, St. Petersburg, Florida, United States|Site 70, Venice, Florida, United States|Site 17, West Palm Beach, Florida, United States|Site 50, Alpharetta, Georgia, United States|Site 5, Atlanta, Georgia, United States|Site 44, Decatur, Georgia, United States|Site 77, Douglasville, Georgia, United States|Site 9, Riverdale, Georgia, United States|Site 7, Savannah, Georgia, United States|Site 47, Boise, Idaho, United States|Site 24, Champaign, Illinois, United States|Site 20, Chicago, Illinois, United States|Site 76, Peoria, Illinois, United States|Site 58, Evansville, Indiana, United States|Site 39, Wichita, Kansas, United States|Site 59, Baton Rouge, Louisiana, United States|Site 52, New Orleans, Louisiana, United States|Site 53, Ann Arbor, Michigan, United States|Site 63, Kansas City, Missouri, United States|Site 32, Richmond Heights, Missouri, United States|Site 36, St. Louis, Missouri, United States|Site 72, Billings, Montana, United States|Site 21, Lincoln, Nebraska, United States|Site 37, Reno, Nevada, United States|Site 65, Cary, North Carolina, United States|Site 13, New Bern, North Carolina, United States|Site 16, Winston-Salem, North Carolina, United States|Site 60, Columbus, Ohio, United States|Site 67, Oklahoma City, Oklahoma, United States|Site 40, Tulsa, Oklahoma, United States|Site 62, Eugene, Oregon, United States|Site 41, Medford, Oregon, United States|Site 33, Portland, Oregon, United States|Site 18, Erie, Pennsylvania, United States|Site 19, Philadelphia, Pennsylvania, United States|Site 23, Pottstown, Pennsylvania, United States|Site 31, Anderson, South Carolina, United States|Site 35, Greer, South Carolina, United States|Site 4, Chattanooga, Tennessee, United States|Site 74, Conroe, Texas, United States|Site 8, Corpus Christi, Texas, United States|Site 71, Dallas, Texas, United States|Site 42, Houston, Texas, United States|Site 14, San Antonio, Texas, United States|Site 38, Salt Lake City, Utah, United States|Site 28, Norfolk, Virginia, United States|Site 12, Richmond, Virginia, United States|Site 56, Renton, Washington, United States|Site 2, Seattle, Washington, United States|Site 48, Spokane, Washington, United States|Site 43, Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00141570"
110,"NCT00141557","The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Hysterectomized Postmenopausal Women",,"Terminated","No Results Available","Menopause","Drug: esterified estrogens 1.25mg and methyltestosterone 2.5mg|Drug: Esterified estrogens 1.25 mg","Change from baseline in the total score of the Menopause Rating Scale (MRS)|Change from baseline in the domain and individual item scores of the MRS|Change from baseline in the domain scores of the MENQOL|Comparison of changes in hormone levels and correlation with changes in the MRS","Solvay Pharmaceuticals","Female","35 Years to 65 Years   (Adult, Older Adult)","Phase 2","133","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","S030.2.110","July 2004","April 2007","March 2008","September 1, 2005",,"April 11, 2008","Site 66, Huntsville, Alabama, United States|Site 57, Mobile, Alabama, United States|Site 46, Montgomery, Alabama, United States|Site 29, Phoenix, Arizona, United States|Site 15, Tucson, Arizona, United States|Site 3, Jonesboro, Arkansas, United States|Site 22, Little Rock, Arkansas, United States|Site 68, Carmichael, California, United States|Site 55, Encinitas, California, United States|Site 6, San Diego, California, United States|Site 45, Santa Rosa, California, United States|Site 25, Walnut Creek, California, United States|Site 26, Denver, Colorado, United States|Site 1, Groton, Connecticut, United States|Site 54, Hartford, Connecticut, United States|Site 30, Trumbull, Connecticut, United States|Site 34, Waterbury, Connecticut, United States|Site 10, Aventura, Florida, United States|Site 78, Clearwater, Florida, United States|Site 73, Ft. Myers, Florida, United States|Site 51, Leesburg, Florida, United States|Site 49, Melbourne, Florida, United States|Site 64, New Port Richey, Florida, United States|Site 61, Ocala, Florida, United States|Site 27, Palm Springs, Florida, United States|Site 11, Pinellas Park, Florida, United States|Site 75, Sarasota, Florida, United States|Site 69, St. Petersburg, Florida, United States|Site 70, Venice, Florida, United States|Site 17, West Palm Beach, Florida, United States|Site 50, Alpharetta, Georgia, United States|Site 5, Atlanta, Georgia, United States|Site 44, Decatur, Georgia, United States|Site 77, Douglasville, Georgia, United States|Site 9, Riverdale, Georgia, United States|Site 7, Savannah, Georgia, United States|Site 47, Boise, Idaho, United States|Site 24, Champaign, Illinois, United States|Site 20, Chicago, Illinois, United States|Site 76, Peoria, Illinois, United States|Site 58, Evansville, Indiana, United States|Site 39, Wichita, Kansas, United States|Site 59, Baton Rouge, Louisiana, United States|Site 52, New Orleans, Louisiana, United States|Site 53, Ann Arbor, Michigan, United States|Site 63, Kansas City, Missouri, United States|Site 32, Richmond Heights, Missouri, United States|Site 36, St. Louis, Missouri, United States|Site 72, Billings, Montana, United States|Site 21, Lincoln, Nebraska, United States|Site 37, Reno, Nevada, United States|Site 65, Cary, North Carolina, United States|Site 13, New Bern, North Carolina, United States|Site 16, Winston-Salem, North Carolina, United States|Site 60, Columbus, Ohio, United States|Site 67, Oklahoma City, Oklahoma, United States|Site 40, Tulsa, Oklahoma, United States|Site 62, Eugene, Oregon, United States|Site 41, Medford, Oregon, United States|Site 33, Portland, Oregon, United States|Site 18, Erie, Pennsylvania, United States|Site 19, Philadelphia, Pennsylvania, United States|Site 23, Pottstown, Pennsylvania, United States|Site 31, Anderson, South Carolina, United States|Site 35, Greer, South Carolina, United States|Site 4, Chattanooga, Tennessee, United States|Site 74, Conroe, Texas, United States|Site 8, Corpus Christi, Texas, United States|Site 71, Dallas, Texas, United States|Site 42, Houston, Texas, United States|Site 14, San Antonio, Texas, United States|Site 38, Salt Lake City, Utah, United States|Site 28, Norfolk, Virginia, United States|Site 12, Richmond, Virginia, United States|Site 56, Renton, Washington, United States|Site 2, Seattle, Washington, United States|Site 48, Spokane, Washington, United States|Site 43, Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00141557"
111,"NCT00141544","The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Non-Hysterectomized Postmenopausal Women",,"Terminated","No Results Available","Menopause","Drug: esterified estrogens 1.25 mg and methyltestosterone 2.5 mg|Drug: Esterified estrogens 1.25 mg","Change from baseline in the total score of the Menopause Rating Scale (MRS)|Change from baseline in the domain and individual item scores of the MRS|Change from baseline in the domain scores of the MENQOL|Comparison of changes in hormone levels and correlation with changes in the MRS","Solvay Pharmaceuticals","Female","35 Years to 65 Years   (Adult, Older Adult)","Phase 2","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","S030.2.107","July 2004","April 2007","March 2008","September 1, 2005",,"April 11, 2008","Site 66, Huntsville, Alabama, United States|Site 57, Mobile, Alabama, United States|Site 46, Montgomery, Alabama, United States|Site 29, Phoenix, Arizona, United States|Site 15, Tucson, Arizona, United States|Site 3, Jonesboro, Arkansas, United States|Site 22, Little Rock, Arkansas, United States|Site 68, Carmichael, California, United States|Site 55, Encinitas, California, United States|Site 6, San Diego, California, United States|Site 45, Santa Rosa, California, United States|Site 25, Walnut Creek, California, United States|Site 26, Denver, Colorado, United States|Site 1, Groton, Connecticut, United States|Site 54, Hartford, Connecticut, United States|Site 30, Trumbull, Connecticut, United States|Site 34, Waterbury, Connecticut, United States|Site 10, Aventura, Florida, United States|Site 78, Clearwater, Florida, United States|Site 73, Ft. Myers, Florida, United States|Site 51, Leesburg, Florida, United States|Site 49, Melbourne, Florida, United States|Site 64, New Port Richey, Florida, United States|Site 61, Ocala, Florida, United States|Site 27, Palm Springs, Florida, United States|Site 11, Pinellas Park, Florida, United States|Site 75, Sarasota, Florida, United States|Site 69, St. Petersburg, Florida, United States|Site 70, Venice, Florida, United States|Site 17, West Palm Beach, Florida, United States|Site 50, Alpharetta, Georgia, United States|Site 5, Atlanta, Georgia, United States|Site 44, Decatur, Georgia, United States|Site 77, Douglasville, Georgia, United States|Site 9, Riverdale, Georgia, United States|Site 7, Savannah, Georgia, United States|Site 47, Boise, Idaho, United States|Site 24, Champaign, Illinois, United States|Site 20, Chicago, Illinois, United States|Site 76, Peoria, Illinois, United States|Site 58, Evansville, Indiana, United States|Site 39, Wichita, Kansas, United States|Site 59, Baton Rouge, Louisiana, United States|Site 52, New Orleans, Louisiana, United States|Site 53, Ann Arbor, Michigan, United States|Site 63, Kansas City, Missouri, United States|Site 32, Richmond Heights, Missouri, United States|Site 36, St. Louis, Missouri, United States|Site 72, Billings, Montana, United States|Site 21, Lincoln, Nebraska, United States|Site 37, Reno, Nevada, United States|Site 65, Cary, North Carolina, United States|Site 13, New Bern, North Carolina, United States|Site 16, Winston-Salem, North Carolina, United States|Site 60, Columbus, Ohio, United States|Site 67, Oklahoma City, Oklahoma, United States|Site 40, Tulsa, Oklahoma, United States|Site 62, Eugene, Oregon, United States|Site 41, Medford, Oregon, United States|Site 33, Portland, Oregon, United States|Site 18, Erie, Pennsylvania, United States|Site 19, Philadelphia, Pennsylvania, United States|Site 23, Pottstown, Pennsylvania, United States|Site 31, Anderson, South Carolina, United States|Site 35, Greer, South Carolina, United States|Site 4, Chattanooga, Tennessee, United States|Site 74, Conroe, Texas, United States|Site 8, Corpus Christi, Texas, United States|Site 71, Dallas, Texas, United States|Site 42, Houston, Texas, United States|Site 14, San Antonio, Texas, United States|Site 38, Salt Lake City, Utah, United States|Site 28, Norfolk, Virginia, United States|Site 12, Richmond, Virginia, United States|Site 56, Renton, Washington, United States|Site 2, Seattle, Washington, United States|Site 48, Spokane, Washington, United States|Site 43, Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00141544"
112,"NCT00160264","Study to Investigate if Adding Lactulose to Vitamin D and Calcium Has an Effect on the Preservation of Bone in Postmenopausal Women",,"Completed","No Results Available","Osteopenia","Drug: Lactulose, Vitamin D, Calcium","bone mass preservation by bone densitometry values in 1 year period|evolution of bone remodelling parameters","Solvay Pharmaceuticals","Female","55 Years to 65 Years   (Adult, Older Adult)","Phase 4","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double","S105.4.107","January 2003",,,"September 12, 2005",,"January 30, 2009","Site 1, Barcelona, Spain|Site 2, Barcelona, Spain|Site 3, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT00160264"
113,"NCT04355403","Performance and Safety of Hyalo Gyn Gel on the Treatment of Vaginal Atrophy in Postmenopausal Women",,"Completed","No Results Available","Vulvovaginal Atrophy","Device: Hyalo Gyn gel in prefilled applicators","Change of patient's perception of vulvovaginal dryness|Change of patient's perception of vulvovaginal symptoms|Change of the average score of Vaginal Health Index (VHI)|Change of vaginal pH|Improvement of sexual function through questionnaire Female Sexual Function Index (FSFI)|Improvement of sexual function through questionnaire Female Sexual Distress Scale-Revised (FSDS-R)|Amelioration of the vaginal maturation (VM) index|Patient's global assessment of overall satisfaction|Ease in the method of Hyalo Gyn gel administration|Local tolerability at the application site|Safety of the treatment: Collection of adverse events","Fidia Farmaceutici s.p.a.","Female","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","QQ53-18-01","February 5, 2019","June 28, 2019","June 28, 2019","April 21, 2020",,"April 21, 2020","Gynkomed s.r.o., Bratislava, Slovakia|ULMUS, s r.o., Hlohovec, Slovakia",,"https://ClinicalTrials.gov/show/NCT04355403"
114,"NCT05697133","Symptom Management Program Based on Story Theory for Postmenopausal Women (SEMSTOP)","SEMSTOP","Not yet recruiting","No Results Available","Menopause","Other: SEMSTOP|Other: control","The Pittsburgh Sleep Quality Index|Menopause Symptoms Rating Scale|Menopause Symptoms Rating Scale:","Ondokuz Mayıs University","Female","35 Years to 60 Years   (Adult)","Not Applicable","76","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","21063324","January 2023","March 2023","July 2023","January 25, 2023",,"January 25, 2023",,,"https://ClinicalTrials.gov/show/NCT05697133"
115,"NCT05417698","Evaluation of Lifestyle Modification on Cardiovascular Risk","GHRexD","Recruiting","No Results Available","Metabolic Syndrome|Menopause|Cardiovascular Diseases|Obesity|Type2diabetes","Other: Exercise Only (Ex only)|Other: Exercise and Mediterranean Diet (Ex + MedDiet)","Visceral adiposity index (VAI)|Inflammatory markers|Blood lipid levels|Blood pressure|Insulin resistance index (HOMA-IR)|Circulatory levels of ghrelin","Swansea University","Female","45 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","RIO 035-20","August 15, 2022","August 15, 2025","August 15, 2025","June 14, 2022",,"September 9, 2022","Swansea University, Swansea, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05417698"
116,"NCT03895333","Hearing Loss and Osteoporosis",,"Completed","No Results Available","Hearing Loss|Osteoporosis, Postmenopausal","Other: Audiological profiling and bone mineral densitometry measurement","hearing test results|bone mineral densitometry measurements","Kanuni Sultan Suleyman Training and Research Hospital","Female","45 Years to 60 Years   (Adult)",,"160","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2019.01.01","March 1, 2019","March 1, 2020","March 1, 2020","March 29, 2019",,"April 28, 2020","Kanuni Sultan Süleyman Training and Research Hospital, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT03895333"
117,"NCT02129816","Bryophyllum Pinnatum Versus Solifenacin Versus Placebo for Overactive Bladder","BryoSoliP","Terminated","No Results Available","Overactive Bladder|Urge Urinary Incontinence","Drug: Bryophyllum","Change of the micturition frequency|Changes in quality of life parameters|Voiding diary parameters|Assessments of the patient's compliance|Assessment of AE/SAE","University of Zurich|PD Dr. med. Verena Geissbühler|Prof. pharm. Ursula von Mandach|Dr. med. David Scheiner|Dr. med. Matthias Werner","Female","40 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","9","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BryoSoliP-2014|KEK 2012-0530 (Zurich)","May 2014","April 20, 2016","July 9, 2017","May 2, 2014",,"October 26, 2017","Gynecologic Department, University Hospital Zurich, Zurich, Switzerland|Gynecology Department, University Hospital Zurich, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT02129816"
118,"NCT00201773","Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer",,"Completed","Has Results","Breast Cancer","Drug: Exemestane|Drug: Celecoxib|Other: Correlative studies","Number of Patients With Decreased Gene Expression of CYP19 in Breast Cancer by Adding COX-2 Inhibitor to Exemestane|Evaluate Response Rate of Neoadjuvant Exemestane and Celecoxib in Postmenopausal Women.","Ohio State University Comprehensive Cancer Center|Pfizer","Female","18 Years and older   (Adult, Older Adult)","Phase 2","22","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSU-0245","July 2003","November 2007","June 2011","September 20, 2005","June 30, 2015","June 30, 2015","Ohio State University, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00201773"
119,"NCT00214903","European Active Surveillance Study of Women Taking Hormone Replacement Therapy (HRT)",,"Completed","Has Results","Menopausal Symptoms",,"Venous Thromboembolism (e.g., Deep Venous Thrombosis and Pulmonary Embolism)|Arterial Thromboembolism (e.g., Acute Myocardial Infarction and Stroke)","Center for Epidemiology and Health Research, Germany|Bayer","Female","40 Years and older   (Adult, Older Adult)",,"30597","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ZEG 2000_3","November 2004","May 2011","November 2011","September 22, 2005","November 14, 2014","December 1, 2014","Center for Epidemiology and Health Research, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00214903"
120,"NCT00137371","Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis",,"Completed","No Results Available","Atrophic Vaginitis|Atrophy|Vaginitis","Drug: PVC (daily for 21 days, 7 days off)|Drug: PVC (twice weekly)","To evaluate the efficacy of 2 low dose regimens of conjugated estrogen in the treatment of atrophic vaginitis from baseline to 12 weeks.|To evaluate change from baseline in the percentage of superficial cells, symptom relief, the effect of both regimens on endometrial stimulation and genital health.","Wyeth is now a wholly owned subsidiary of Pfizer","Female","45 Years to 80 Years   (Adult, Older Adult)","Phase 3","480","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","0713S5-413","August 2005",,"September 2007","August 29, 2005",,"December 10, 2007","Tucson, Arizona, United States|Encinitas, California, United States|San Diego, California, United States|Torrance, California, United States|Aurora, Colorado, United States|Brooksville, Florida, United States|Miami, Florida, United States|St. Petersburg, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Chicago, Illinois, United States|Metairie, Louisiana, United States|Troy, Michigan, United States|St. Louis, Missouri, United States|Omaha, Nebraska, United States|New Brunswick, New Jersey, United States|Chapel Hill, North Carolina, United States|Winston-Salem, North Carolina, United States|Oklahoma City, Oklahoma, United States|Danville, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Carrollton, Texas, United States|Carrollton, Texas, United States|Colleyville, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Plano, Texas, United States|Charlottesville, Virginia, United States|Norfolk, Virginia, United States|Calgary, Alberta, Canada|Coquitlam, British Columbia, Canada|Langley, British Columbia, Canada|Winnipeg, Manitoba, Canada|Winnipeg, Manitoba, Canada|Kingston, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|MontrÃ©al, Quebec, Canada|MontrÃ©al, Quebec, Canada|Pointe Claire, Quebec, Canada|QuÃ©bec, Quebec, Canada|Shawinigan, Quebec, Canada|Sherbrooke, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00137371"
121,"NCT00238732","Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause",,"Completed","No Results Available","Vaginal Atrophy","Drug: Bazedoxifene/Conjugated Estrogen","Superficial cells (by cervical/vaginal cytologic smear) at screening, and weeks 4 and 12.|Parabasal cells (by cervical/vaginal cytologic smear) at screening, and weeks 4 and 12.|Vaginal pH at screening, and weeks 4 and 12.|Most bothersome moderate or severe vulvar/vaginal atrophy sympton at screening, and weeks 4 and 12.","Wyeth is now a wholly owned subsidiary of Pfizer","Female","40 Years to 65 Years   (Adult, Older Adult)","Phase 3","650","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Diagnostic","3115A1-306","October 2005",,"March 2007","October 13, 2005",,"December 28, 2007","Birmingham, Alabama, United States|Montgomery, Alabama, United States|Scottsdale, Arizona, United States|Tucson, Arizona, United States|Oakland, California, United States|San Diego, California, United States|Upland, California, United States|Denver, Colorado, United States|Avon, Connecticut, United States|Groton, Connecticut, United States|Waterbury, Connecticut, United States|Aventura, Florida, United States|Gainesville, Florida, United States|Miami, Florida, United States|Palm Harbor, Florida, United States|Palm Springs, Florida, United States|Pinnellas Park, Florida, United States|Stuart, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Conyers, Georgia, United States|Douglasville, Georgia, United States|Savannah, Georgia, United States|Idaho Falls, Idaho, United States|Champaign, Illinois, United States|Chicago, Illinois, United States|Kansas City, Kansas, United States|Shreveport, Louisiana, United States|Baltimore, Maryland, United States|Ann Arbor, Michigan, United States|Booklyn Center, Minnesota, United States|Chaska, Minnesota, United States|Jackson, Mississippi, United States|Kansas, Mississippi, United States|Creve Cour, Missouri, United States|St. Louis, Missouri, United States|Lebanon, New Hampshire, United States|Livingston, New Jersey, United States|New Brunswick, New Jersey, United States|Winston-Salem, North Carolina, United States|Fargo, North Dakota, United States|Jamestown, North Dakota, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|Medford, Oregon, United States|Erie, Pennsylvania, United States|Media, Pennsylvania, United States|West Reading, Pennsylvania, United States|Hilton Head Island, South Carolina, United States|Sioux Falls, South Dakota, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Denton, Texas, United States|Galveston, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Burlington, Vermont, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00238732"
122,"NCT00205777","Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women",,"Completed","Has Results","Osteoporosis","Drug: Bazedoxifene Acetate|Other: Placebo","Percentage of Participants With New Vertebral Fractures Through Month 36|Percentage of Participants With New Vertebral Fractures Through Month 60|Percentage of Participants With New Vertebral Fractures Through Month 84|Incidence of Breast Cancer Through Month 36|Incidence of Breast Cancer Through Month 60|Incidence of Breast Cancer Through Month 84|Percentage of Participants With New Clinical Vertebral Fractures Through Month 36|Percentage of Participants With New Clinical Vertebral Fractures Through Month 60|Percentage of Participants With New Clinical Vertebral Fractures Through Month 84|Number of Participants With Worsening Vertebral Fractures Through Month 36|Number of Participants With Worsening Vertebral Fractures Through Month 60|Number of Participants With Worsening Vertebral Fractures Through Month 84|Percentage of Participants With Non-vertebral Fractures Through Month 36|Percentage of Participants With Non-vertebral Fractures Through Month 60|Percentage of Participants With Non-vertebral Fractures Through Month 84|Change From Baseline in Height at Month 36|Change From Baseline in Height at Month 60|Change From Baseline in Height at Month 84|Percent Change From Baseline in Bone Mineral Density (BMD) at Month 6, 12, 18, 24 and 36|Percent Change From Baseline in Bone Mineral Density (BMD) at Months 48, 60|Percent Change From Baseline in Bone Mineral Density (BMD) at Months 72 and 84|Percent Change From Baseline in Osteocalcin at Month 3, 6 and 12|Percent Change From Baseline in Osteocalcin at Months 36 and 60|Percent Change From Baseline in Osteocalcin at Months 72 and 84|Percent Change From Baseline in C-telopeptide (CTx) at Month 3, 6 and 12|Percent Change From Baseline in C-telopeptide (CTx) at Months 36 and 60|Percent Change From Baseline in C-telopeptide (CTx) at Months 72 and 84|Percent Change From Baseline in Lipid Parameters at Months 6, 12, 24 and 36|Bone Histomorphometric Indices at Month 36: BV, OV, OS, OcS, ObS, MS, ES, OMS, CP|Bone Histomorphometric Indices at Month 60: BV, OV, OS, OcS, ObS, MS, ES, OMS, CP|Bone Histomorphometric Indices at Month 36: WTh, OTh, TbTh, TbSp and CTh|Bone Histomorphometric Indices at Month 60: WTh, OTh, TbTh, TbSp and CTh|Bone Histomorphometric Indices at Month 36: Total Surface (Goldner Slide) [TSG]|Bone Histomorphometric Indices at Month 60: TSG|Bone Histomorphometric Indices at Month 36: TtAr|Bone Histomorphometric Indices at Month 60: TtAr|Bone Histomorphometric Indices at Month 36: BFP, RP and RmP|Bone Histomorphometric Indices at Month 60: BFP, RP and RmP|Bone Histomorphometric Indices at Month 36: SuD|Bone Histomorphometric Indices at Month 60: SuD|Bone Histomorphometric Indices at Month 36: BFRTS|Bone Histomorphometric Indices at Month 60: BFRTS|Bone Histomorphometric Indices at Month 36: ACF|Bone Histomorphometric Indices at Month 60: ACF|Bone Histomorphometric Indices at Month 36: Mlt|Bone Histomorphometric Indices at Month 60: Mlt|Bone Histomorphometric Indices at Month 36: MAR|Bone Histomorphometric Indices at Month 60: MAR|Bone Histomorphometric Indices at Month 36: TbN|Bone Histomorphometric Indices at Month 60: TbN|Bone Histomorphometric Indices at Month 36: BFRBV|Bone Histomorphometric Indices at Month 60: BFRBV|Women's Health Questionnaire (WHQ)|Change From Baseline in Women's Health Questionnaire (WHQ) at Month 12, 24 and 36|European Foundation for Osteoporosis Quality of Life Questionnaire (QUALEFFO)|Change From Baseline in European Foundation for Osteoporosis Quality of Life Questionnaire (QUALEFFO) at Month 12, 24 and 36|Euro Quality of Life-5 Dimensions (EQ-5D) Visual Analog Scale (VAS)|Change From Baseline in Euro Quality of Life-5 Dimensions (EQ-5D) Visual Analog Scale (VAS) at Month 12, 24 and 36|Euro Quality of Life-5 Dimensions (EQ-5D)- Health State Profile Utility Score|Change From Baseline in Euro Quality of Life-5 Dimensions (EQ-5D)- Health State Profile Utility Score at Month 12, 24 and 36","Pfizer","Female","55 Years to 80 Years   (Adult, Older Adult)","Phase 3","7609","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","3068A1-301|B1781001","December 2001","September 2010","September 2010","September 20, 2005","April 10, 2013","April 10, 2013","Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Huntsville, Alabama, United States|Pfizer Investigational Site, Mobile, Alabama, United States|Pfizer Investigational Site, Glendale, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Scottsdale, Arizona, United States|Pfizer Investigational Site, Scottsdale, Arizona, United States|Pfizer Investigational Site, Anaheim, California, United States|Pfizer Investigational Site, Berkeley, California, United States|Pfizer Investigational Site, Beverly Hills, California, United States|Pfizer Investigational Site, Fresno, California, United States|Pfizer Investigational Site, Fresno, California, United States|Pfizer Investigational Site, La Jolla, California, United States|Pfizer Investigational Site, Oakland, California, United States|Pfizer Investigational Site, Palm Desert, California, United States|Pfizer Investigational Site, Palm Springs, California, United States|Pfizer Investigational Site, Palm Springs, California, United States|Pfizer Investigational Site, Palm Springs, California, United States|Pfizer Investigational Site, Rancho Mirage, California, United States|Pfizer Investigational Site, Sacramento, California, United States|Pfizer Investigational Site, Sacramento, California, United States|Pfizer Investigational Site, Sacramento, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, Upland, California, United States|Pfizer Investigational Site, Whittier, California, United States|Pfizer Investigational Site, Lakewood, Colorado, United States|Pfizer Investigational Site, Longmont, Colorado, United States|Pfizer Investigational Site, Wheat Ridge, Colorado, United States|Pfizer Investigational Site, Bridgeport, Connecticut, United States|Pfizer Investigational Site, Hamden, Connecticut, United States|Pfizer Investigational Site, Madison, Connecticut, United States|Pfizer Investigational Site, Waterbury, Connecticut, United States|Pfizer Investigational Site, Newark, Delaware, United States|Pfizer Investigational Site, Washington, District of Columbia, United States|Pfizer Investigational Site, Washington, District of Columbia, United States|Pfizer Investigational Site, Washington, District of Columbia, United States|Pfizer Investigational Site, Washington, District of Columbia, United States|Pfizer Investigational Site, Aventura, Florida, United States|Pfizer Investigational Site, Boca Raton, Florida, United States|Pfizer Investigational Site, Cape Coral, Florida, United States|Pfizer Investigational Site, Clearwater, Florida, United States|Pfizer Investigational Site, Daytona Beach, Florida, United States|Pfizer Investigational Site, Daytona Beach, Florida, United States|Pfizer Investigational Site, Delray Beach, Florida, United States|Pfizer Investigational Site, Fort Myers, Florida, United States|Pfizer Investigational Site, Ft. Myers, Florida, United States|Pfizer Investigational Site, Gainesville, Florida, United States|Pfizer Investigational Site, Holiday, Florida, United States|Pfizer Investigational Site, Lake Worth, Florida, United States|Pfizer Investigational Site, Largo, Florida, United States|Pfizer Investigational Site, Ormond Beach, Florida, United States|Pfizer Investigational Site, Palm Beach Gardens, Florida, United States|Pfizer Investigational Site, Palm Harbor, Florida, United States|Pfizer Investigational Site, Pembroke Pines, Florida, United States|Pfizer Investigational Site, Pembroke Pines, Florida, United States|Pfizer Investigational Site, Plantation, Florida, United States|Pfizer Investigational Site, Port Orange, Florida, United States|Pfizer Investigational Site, Sarasota, Florida, United States|Pfizer Investigational Site, Sarasota, Florida, United States|Pfizer Investigational Site, St Petersburg, Florida, United States|Pfizer Investigational Site, West Palm Beach, Florida, United States|Pfizer Investigational Site, West Palm Beach, Florida, United States|Pfizer Investigational Site, West Palm Beach, Florida, United States|Pfizer Investigational Site, West Palm Beach, Florida, United States|Pfizer Investigational Site, Augusta, Georgia, United States|Pfizer Investigational Site, Decatur, Georgia, United States|Pfizer Investigational Site, Riverdale, Georgia, United States|Pfizer Investigational Site, Boise, Idaho, United States|Pfizer Investigational Site, Boise, Idaho, United States|Pfizer Investigational Site, Boise, Idaho, United States|Pfizer Investigational Site, Cadwell, Idaho, United States|Pfizer Investigational Site, Idaho Falls, Idaho, United States|Pfizer Investigational Site, Meridian, Idaho, United States|Pfizer Investigational Site, Champaign, Illinois, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Libertyville, Illinois, United States|Pfizer Investigational Site, Peoria, Illinois, United States|Pfizer Investigational Site, Avon, Indiana, United States|Pfizer Investigational Site, Evansville, Indiana, United States|Pfizer Investigational Site, Evansville, Indiana, United States|Pfizer Investigational Site, Evansville, Indiana, United States|Pfizer Investigational Site, Kansas City, Kansas, United States|Pfizer Investigational Site, Louisville, Kentucky, United States|Pfizer Investigational Site, Louisville, Kentucky, United States|Pfizer Investigational Site, Lousiville, Kentucky, United States|Pfizer Investigational Site, Bangor, Maine, United States|Pfizer Investigational Site, Bangor, Maine, United States|Pfizer Investigational Site, Bethesda, Maryland, United States|Pfizer Investigational Site, Silver Spring, Maryland, United States|Pfizer Investigational Site, Wheaton, Maryland, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Brookline, Massachusetts, United States|Pfizer Investigational Site, Fall River, Massachusetts, United States|Pfizer Investigational Site, Fall River, Massachusetts, United States|Pfizer Investigational Site, Grand Rapids, Michigan, United States|Pfizer Investigational Site, Grand Rapids, Michigan, United States|Pfizer Investigational Site, Kalamazaoo, Michigan, United States|Pfizer Investigational Site, Kalamazoo, Michigan, United States|Pfizer Investigational Site, Brooklyn Center, Minnesota, United States|Pfizer Investigational Site, Robbinsdale, Minnesota, United States|Pfizer Investigational Site, Shoreview, Minnesota, United States|Pfizer Investigational Site, Flowood, Mississippi, United States|Pfizer Investigational Site, Jackson, Mississippi, United States|Pfizer Investigational Site, Jefferson City, Missouri, United States|Pfizer Investigational Site, St Louis, Missouri, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, Billings, Montana, United States|Pfizer Investigational Site, Bozeman, Montana, United States|Pfizer Investigational Site, Missoula, Montana, United States|Pfizer Investigational Site, Missoula, Montana, United States|Pfizer Investigational Site, Missoula, Montana, United States|Pfizer Investigational Site, Lincoln, Nebraska, United States|Pfizer Investigational Site, Henderson, Nevada, United States|Pfizer Investigational Site, North Las Vegas, Nevada, United States|Pfizer Investigational Site, Reno, Nevada, United States|Pfizer Investigational Site, Reno, Nevada, United States|Pfizer Investigational Site, Manchester Twp, New Jersey, United States|Pfizer Investigational Site, Ocean, New Jersey, United States|Pfizer Investigational Site, Princeton, New Jersey, United States|Pfizer Investigational Site, Albuquerque, New Mexico, United States|Pfizer Investigational Site, Albuquerque, New Mexico, United States|Pfizer Investigational Site, Albuquerque, New Mexico, United States|Pfizer Investigational Site, Bronx, New York, United States|Pfizer Investigational Site, New Hyde Park, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Charlotte, North Carolina, United States|Pfizer Investigational Site, Charlotte, North Carolina, United States|Pfizer Investigational Site, Charlotte, North Carolina, United States|Pfizer Investigational Site, Winston-Salem, North Carolina, United States|Pfizer Investigational Site, Bismarck, North Dakota, United States|Pfizer Investigational Site, Bismark, North Dakota, United States|Pfizer Investigational Site, Bismark, North Dakota, United States|Pfizer Investigational Site, Fargo, North Dakota, United States|Pfizer Investigational Site, Fargo, North Dakota, United States|Pfizer Investigational Site, Jamestown, North Dakota, United States|Pfizer Investigational Site, Minot, North Dakota, United States|Pfizer Investigational Site, Minot, North Dakota, United States|Pfizer Investigational Site, Oakes, North Dakota, United States|Pfizer Investigational Site, Akron, Ohio, United States|Pfizer Investigational Site, Akron, Ohio, United States|Pfizer Investigational Site, Centerville, Ohio, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Cleveland, Ohio, United States|Pfizer Investigational Site, Kettering, Ohio, United States|Pfizer Investigational Site, Lyndhurst, Ohio, United States|Pfizer Investigational Site, Mayfield Village, Ohio, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Oklahoma, Oklahoma, United States|Pfizer Investigational Site, Oklahoma, Oklahoma, United States|Pfizer Investigational Site, Tulsa, Oklahoma, United States|Pfizer Investigational Site, Yukon, Oklahoma, United States|Pfizer Investigational Site, Altoona, Pennsylvania, United States|Pfizer Investigational Site, Camp Hill, Pennsylvania, United States|Pfizer Investigational Site, Duncansville, Pennsylvania, United States|Pfizer Investigational Site, Johnstown, Pennsylvania, United States|Pfizer Investigational Site, Langhome, Pennsylvania, United States|Pfizer Investigational Site, Lemoyne, Pennsylvania, United States|Pfizer Investigational Site, Newtown, Pennsylvania, United States|Pfizer Investigational Site, Sellersville, Pennsylvania, United States|Pfizer Investigational Site, West Reading, Pennsylvania, United States|Pfizer Investigational Site, Wyomissing, Pennsylvania, United States|Pfizer Investigational Site, Anderson, South Carolina, United States|Pfizer Investigational Site, Belton, South Carolina, United States|Pfizer Investigational Site, Mt. Pleasant, South Carolina, United States|Pfizer Investigational Site, Aberdeen, South Dakota, United States|Pfizer Investigational Site, Sioux Falls, South Dakota, United States|Pfizer Investigational Site, Waterdown, South Dakota, United States|Pfizer Investigational Site, Watertown, South Dakota, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Bellaire, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Temple, Texas, United States|Pfizer Investigational Site, Waco, Texas, United States|Pfizer Investigational Site, Salt Lake City, Utah, United States|Pfizer Investigational Site, Norfolk, Virginia, United States|Pfizer Investigational Site, Virginia Beach, Virginia, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Spokane, Washington, United States|Pfizer Investigational Site, Milwaukee, Wisconsin, United States|Pfizer Investigational Site, Milwaukee, Wisconsin, United States|Pfizer Investigational Site, Cheyenne, Wyoming, United States|Pfizer Investigational Site, Provincia de Buenos Aires, Argentina|Pfizer Investigational Site, Concord, New South Wales, Australia|Pfizer Investigational Site, St Leonards, New South Wales, Australia|Pfizer Investigational Site, Nedlands, Western Australia, Australia|Pfizer Investigational Site, Herston, Australia|Pfizer Investigational Site, Keswick, Australia|Pfizer Investigational Site, Graz, Austria|Pfizer Investigational Site, Diepenbeek, Belgium|Pfizer Investigational Site, Genk, Belgium|Pfizer Investigational Site, Gent, Belgium|Pfizer Investigational Site, Leuven, Belgium|Pfizer Investigational Site, Liege, Belgium|Pfizer Investigational Site, Schiepsebos, Belgium|Pfizer Investigational Site, Goiania, GO, Brazil|Pfizer Investigational Site, Duque de Caxias - Cuiaba, MT, Brazil|Pfizer Investigational Site, Rio de Janeiro, RJ, Brazil|Pfizer Investigational Site, Rio de Janeiro, RJ, Brazil|Pfizer Investigational Site, Sorocaba, Sao Paulo, Brazil|Pfizer Investigational Site, São Paulo, SP, Brazil|Pfizer Investigational Site, Pleven, Bulgaria|Pfizer Investigational Site, Plovdiv, Bulgaria|Pfizer Investigational Site, Sofia, Bulgaria|Pfizer Investigational Site, Sofia, Bulgaria|Pfizer Investigational Site, Sofia, Bulgaria|Pfizer Investigational Site, Sofia, Bulgaria|Pfizer Investigational Site, Sofia, Bulgaria|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Hamilton, Ontario, Canada|Pfizer Investigational Site, Hawkesbury, Ontario, Canada|Pfizer Investigational Site, Hawkesbury, Ontario, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Gatineau, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Pointe-Claire, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, Trois-Rivieres, Quebec, Canada|Pfizer Investigational Site, Saskatoon, Saskatchewan, Canada|Pfizer Investigational Site, Saskatoon, Saskatchewan, Canada|Pfizer Investigational Site, Quebec, Canada|Pfizer Investigational Site, Quebec, Canada|Pfizer Investigational Site, Santiago, Chile|Pfizer Investigational Site, Zadar, Croatia|Pfizer Investigational Site, Zagreb, Croatia|Pfizer Investigational Site, Aalborg, Denmark|Pfizer Investigational Site, Ballerup, Denmark|Pfizer Investigational Site, Vejle, Denmark|Pfizer Investigational Site, Tallinn, Estonia|Pfizer Investigational Site, Tartu, Estonia|Pfizer Investigational Site, Tartu, Estonia|Pfizer Investigational Site, Tartu, Estonia|Pfizer Investigational Site, Jyvaskyla, FIN, Finland|Pfizer Investigational Site, Jyvaskyla, Finland|Pfizer Investigational Site, Jyväskylä, Finland|Pfizer Investigational Site, Kuopio, Finland|Pfizer Investigational Site, Kuopio, Finland|Pfizer Investigational Site, Kuopio, Finland|Pfizer Investigational Site, Lahti, Finland|Pfizer Investigational Site, Oulu, Finland|Pfizer Investigational Site, Turku, Finland|Pfizer Investigational Site, Lyon Cedex 03, France|Pfizer Investigational Site, Orleans cedex 1, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Muenchen, Germany|Pfizer Investigational Site, Zerbst, Germany|Pfizer Investigational Site, Athens, Greece|Pfizer Investigational Site, Hong Kong, Hong Kong|Pfizer Investigational Site, PRC, Hong Kong|Pfizer Investigational Site, Sai Ying Pung, Hong Kong|Pfizer Investigational Site, Bekescsaba, Hungary|Pfizer Investigational Site, H-6720 Szeged, Hungary|Pfizer Investigational Site, Kecskemet, Hungary|Pfizer Investigational Site, Mako, Hungary|Pfizer Investigational Site, Roma, Italy|Pfizer Investigational Site, Roma, Italy|Pfizer Investigational Site, Roma, Italy|Pfizer Investigational Site, Siena, Italy|Pfizer Investigational Site, Kaunas, Lithuania|Pfizer Investigational Site, Vilnius, Lithuania|Pfizer Investigational Site, Vilnius, Lithuania|Pfizer Investigational Site, seccion de Lomas Verdes, Estado de Mexico, Mexico|Pfizer Investigational Site, Mexico City, Mexico|Pfizer Investigational Site, Mexico D.F., Mexico|Pfizer Investigational Site, Emmen, Dr, Netherlands|Pfizer Investigational Site, Nijmegen, GA, Netherlands|Pfizer Investigational Site, Amsterdam, HV, Netherlands|Pfizer Investigational Site, Nijmegen, SZ, Netherlands|Pfizer Investigational Site, Eindhoven, Netherlands|Pfizer Investigational Site, Rotterdam, Netherlands|Pfizer Investigational Site, Milford, Auckland, New Zealand|Pfizer Investigational Site, Christchurch, NZ, New Zealand|Pfizer Investigational Site, Auckland, New Zealand|Pfizer Investigational Site, Dunedin, New Zealand|Pfizer Investigational Site, Bergen, Norway|Pfizer Investigational Site, Hamar, Norway|Pfizer Investigational Site, Oslo, Norway|Pfizer Investigational Site, Oslo, Norway|Pfizer Investigational Site, Trondheim, Norway|Pfizer Investigational Site, Trondheim, Norway|Pfizer Investigational Site, Katowice, Poland|Pfizer Investigational Site, Krakow, Poland|Pfizer Investigational Site, Krakow, Poland|Pfizer Investigational Site, Krakow, Poland|Pfizer Investigational Site, Krakow, Poland|Pfizer Investigational Site, Krakow, Poland|Pfizer Investigational Site, Lublin, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Wroclaw, Poland|Pfizer Investigational Site, Cluj-, Napoca, Romania|Pfizer Investigational Site, Bucharesti, Romania|Pfizer Investigational Site, Bucharest, Romania|Pfizer Investigational Site, Bucuresti, Romania|Pfizer Investigational Site, Bucuresti, Romania|Pfizer Investigational Site, Cluj-Napoca, Romania|Pfizer Investigational Site, Iasi, Romania|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Saint Petersburg, Russian Federation|Pfizer Investigational Site, St Petersburg, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, Piestany, Slovak Republic, Slovakia|Pfizer Investigational Site, Bratislava, Slovakia|Pfizer Investigational Site, Bratislava, Slovakia|Pfizer Investigational Site, Bratislava, Slovakia|Pfizer Investigational Site, Bratislava, Slovakia|Pfizer Investigational Site, Groenkloof, 0181, Pretoria, South Africa|Pfizer Investigational Site, Bedford Gardens, South Africa|Pfizer Investigational Site, Johannesburg 2193, South Africa|Pfizer Investigational Site, Johannesburg, 2193, South Africa|Pfizer Investigational Site, Johannesburg, South Africa|Pfizer Investigational Site, Johannesburg, South Africa|Pfizer Investigational Site, Parow 7500, South Africa|Pfizer Investigational Site, Parow, South Africa|Pfizer Investigational Site, Pretoria, 0042, South Africa|Pfizer Investigational Site, Pretoria, 0181, South Africa|Pfizer Investigational Site, Pretoria, South Africa|Pfizer Investigational Site, Pretoria, South Africa|Pfizer Investigational Site, Somerset West, 7129, South Africa|Pfizer Investigational Site, Somerset West, 7130, South Africa|Pfizer Investigational Site, Somerset West, South Africa|Pfizer Investigational Site, Stellenbosch 7600, South Africa|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT00205777"
123,"NCT00005441","Lifestyle Management for Women With CHD and NIDDM",,"Completed","No Results Available","Cardiovascular Diseases|Coronary Disease|Heart Diseases|Diabetes Mellitus, Non-insulin Dependent|Postmenopause|Diabetes Mellitus",,,"Oregon Research Institute|National Heart, Lung, and Blood Institute (NHLBI)","Female","up to 100 Years   (Child, Adult, Older Adult)",,,"Other|NIH","Observational",,"4370|R29HL050181","April 1993","October 1997","March 1998","May 26, 2000",,"February 8, 2016",,,"https://ClinicalTrials.gov/show/NCT00005441"
124,"NCT00005466","Stroke and MI in Users of Estrogen/Progestogen",,"Completed","No Results Available","Cardiovascular Diseases|Heart Diseases|Coronary Disease|Cerebrovascular Accident|Myocardial Infarction|Postmenopause",,,"National Heart, Lung, and Blood Institute (NHLBI)","Male","up to 100 Years   (Child, Adult, Older Adult)",,,"NIH","Observational",,"4910|R01HL047043","August 1991",,"July 1995","May 26, 2000",,"February 18, 2016",,,"https://ClinicalTrials.gov/show/NCT00005466"
125,"NCT00005220","Postmenopausal Progestins, MI and Stroke",,"Completed","No Results Available","Cardiovascular Diseases|Heart Diseases|Coronary Disease|Cerebrovascular Accident|Myocardial Infarction|Postmenopause",,,"University of Washington|National Heart, Lung, and Blood Institute (NHLBI)","Male","up to 100 Years   (Child, Adult, Older Adult)",,,"Other|NIH","Observational",,"1099|R01HL040628","April 1988",,"January 1999","May 26, 2000",,"February 10, 2016",,,"https://ClinicalTrials.gov/show/NCT00005220"
126,"NCT00005173","Myocardial Infarction and Past Oral Contraceptive Use",,"Completed","No Results Available","Cardiovascular Diseases|Coronary Disease|Myocardial Infarction|Heart Diseases|Menopause|Postmenopause",,,"National Heart, Lung, and Blood Institute (NHLBI)","Male","up to 100 Years   (Child, Adult, Older Adult)",,,"NIH","Observational",,"1048|R01HL030225","April 1985",,"April 1989","May 26, 2000",,"May 13, 2016",,,"https://ClinicalTrials.gov/show/NCT00005173"
127,"NCT00000605","Estrogen and Graft Atherosclerosis Research Trial (EAGER)",,"Completed","No Results Available","Cardiovascular Diseases|Coronary Arteriosclerosis|Coronary Disease|Heart Diseases|Myocardial Ischemia|Postmenopause","Drug: hormone replacement therapy|Drug: estrogens|Drug: medroxyprogesterone",,"National Heart, Lung, and Blood Institute (NHLBI)","Female","45 Years to 75 Years   (Adult, Older Adult)","Phase 3",,"NIH","Interventional","Allocation: Randomized|Masking: Double|Primary Purpose: Prevention","109|5U01HL050840","August 1996",,"July 2002","October 28, 1999",,"February 18, 2016",,,"https://ClinicalTrials.gov/show/NCT00000605"
128,"NCT00000555","Women's Angiographic Vitamin and Estrogen Trial (WAVE)",,"Completed","No Results Available","Cardiovascular Diseases|Coronary Arteriosclerosis|Coronary Disease|Heart Diseases|Myocardial Ischemia|Postmenopause","Drug: estrogen replacement therapy|Drug: estrogens, conjugated|Drug: progesterone|Drug: hormone replacement therapy|Drug: supplementation, food|Drug: ascorbic acid|Drug: vitamin e",,"National Heart, Lung, and Blood Institute (NHLBI)","Female","38 Years to 86 Years   (Adult, Older Adult)","Phase 3",,"NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Prevention","99|N01HV68165|N01HV68166|N01HV68167|N01HV68168|N01HV68169|N01HV68170","August 1996",,"May 2003","October 28, 1999",,"July 12, 2016",,,"https://ClinicalTrials.gov/show/NCT00000555"
129,"NCT00000549","Estrogen Replacement and Atherosclerosis (ERA) in Older Women",,"Completed","No Results Available","Cardiovascular Diseases|Coronary Arteriosclerosis|Coronary Disease|Heart Diseases|Myocardial Ischemia|Postmenopause","Drug: estrogen replacement therapy|Drug: hormone replacement therapy|Drug: estrogens|Drug: progestins",,"National Heart, Lung, and Blood Institute (NHLBI)","Female","45 Years to 75 Years   (Adult, Older Adult)","Phase 3",,"NIH","Interventional","Allocation: Randomized|Primary Purpose: Prevention","93|U01HL049488","August 1994",,"July 2000","October 28, 1999",,"March 16, 2016",,,"https://ClinicalTrials.gov/show/NCT00000549"
130,"NCT04561752","A Food Effect Study With ZN-c5 in Healthy Post-Menopausal Subjects",,"Completed","No Results Available","Healthy","Drug: ZN-c5","AUC0-t|Cmax|Tmax|AUC0-infinity|Assess the incidence, frequency, and severity of treatment-emergent adverse events (TEAEs)","Zeno Alpha Inc.","Female","45 Years and older   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","ZN-c5-006","November 2, 2020","December 11, 2020","December 16, 2020","September 24, 2020",,"December 23, 2020","Site 1, Christchurch, New Zealand",,"https://ClinicalTrials.gov/show/NCT04561752"
131,"NCT05446792","Comparison Between Pelvic Muscle Training and Pilates Exercises for UI in Postmenopausal Women",,"Recruiting","No Results Available","Urinary Incontinence","Other: PFMT|Other: PE","International Consultation of Urinary questionnaire Incontinence Short Form (ICIQ-UI-SF)|Pad-test|Voiding diary|Manometric assessment of muscle strength and PFM endurance|PERFECT test|FSFI Questionnaire (Female Sexual Function Index)|Feeling Scale - Pleasure and displeasure during exercise","Universidade Estadual do Norte do Parana","Female","50 Years to 70 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TMAP X Pilates in the UI","June 1, 2022","October 7, 2022","October 14, 2022","July 7, 2022",,"July 7, 2022","Universidade Estadual do Norte do Paraná, Jacarezinho, Paraná, Brazil",,"https://ClinicalTrials.gov/show/NCT05446792"
132,"NCT03786809","Vascular Effect of CIMICIFUGA RACEMOSA","CRDILA","Completed","No Results Available","Postmenopausal Symptoms","Drug: Cimifuga Racemosa|Drug: Placebo","Measurement of the brachial artery using flow-mediated dilation of post menopausal women, before and after use of Cimifuga Racemosa|Frequency of symptoms and side effects","Federal University of Minas Gerais","Female","45 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ETIC - CR-0417.0.203.000-09","June 2016","April 2019","May 2019","December 26, 2018",,"August 14, 2019","Hospital das Clinicas - Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil",,"https://ClinicalTrials.gov/show/NCT03786809"
133,"NCT03652584","Effects of High Protein Diet on Muscle Mass, Strength, and Physical Performance in Postmenopausal Women",,"Completed","No Results Available","Muscle Loss|Physical Disability","Other: High Protein Diet|Other: Control Diet","Change in whole-body and appendicular lean mass|Change in isometric hand grip strength|Change in usual gait speed|Change in systolic blood pressure|Change in diastolic blood pressure|Change in fat mass|Change in resting metabolic rate|Change in total cholesterol, high-density lipoprotein cholesterol, and triglycerides|Change in glucose|Change in insulin|Change in high-sensitivity C-reactive protein","Hospital de Clinicas de Porto Alegre|Conselho Nacional de Desenvolvimento Científico e Tecnológico|Brazilian National Institute of Hormones and Women's Health","Female","65 Years and older   (Older Adult)","Not Applicable","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","170019","January 9, 2017","December 21, 2018","December 2019","August 29, 2018",,"August 4, 2020",,,"https://ClinicalTrials.gov/show/NCT03652584"
134,"NCT01774591","Effect of Azilsartan on Aldosterone in Postmenopausal Females",,"Completed","Has Results","Hypertension","Drug: Azilsartan medoximil|Drug: Placebo","24-hour BP (Systolic)|24-hour BP (Diastolic)|Difference in 24-hour Urine Aldosterone Change From Baseline","University of Chicago|Takeda","Female","45 Years to 70 Years   (Adult, Older Adult)","Not Applicable","21","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12-1179","January 2013","November 2015","January 2016","January 24, 2013","November 9, 2017","November 9, 2017","University of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01774591"
135,"NCT05351476","Exercise Training and Fat Metabolism in Postmenopausal Women",,"Recruiting","No Results Available","Postmenopausal Symptoms|Obesity|Prediabetic State","Behavioral: Resistance Exercise|Behavioral: Endurance Exercise","Change from baseline subcutaneous abdominal adipose tissue glycerol concentration at 12 weeks|Change from baseline gluteal adipose tissue glycerol concentration at 12 weeks|Change from baseline whole-body lipolysis at 12 weeks|Change in blood flow as measured by ethanol concentrations in dialysate samples from subcutaneous abdominal adipose tissue|Change in dialysate ethanol data in subcutaneous gluteal adipose tissue|Change in the ratio of 13CO2 to 12CO2 in breath samples|change in body composition|Change in blood growth hormone concentrations|Change in lipogenesis|Change in adipogenesis","Florida State University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Pennington Biomedical Research Center|University of Arkansas","Female","50 Years to 70 Years   (Adult, Older Adult)","Not Applicable","120","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","STUDY00001939|R01DK125728","May 20, 2022","May 2026","December 2026","April 28, 2022",,"July 21, 2022","Florida State University, Tallahassee, Florida, United States",,"https://ClinicalTrials.gov/show/NCT05351476"
136,"NCT02860910","Cognitive Behavioral Group Therapy for the Management of Menopause Symptoms in Mood Disorders","Conklin MWW","Completed","No Results Available","Bipolar Disorder|Major Depressive Disorder|Menopause","Behavioral: Cognitive Behavioral Group Therapy","Number of participants who begin cognitive group behavioral therapy|Change in Hot Flush Rating Scale: Frequency and Problem Rating (HFRS) total score|Change in Hot Flash Daily Interference Scale (HFRDIS) total score|Change in Menopause Representation Questionnaire (MRQ) total score","Danette Conklin, PhD|University Hospitals Cleveland Medical Center","Female","40 Years to 65 Years   (Adult, Older Adult)","Not Applicable","59","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","04-16-11","July 2016","October 2018","October 2018","August 9, 2016",,"September 30, 2019","University Hospitals Cleveland Medical Center - Mood Disorders Program, Cleveland, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT02860910/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02860910"
137,"NCT01724658","Effectiveness of Testosterone Undecanoate to Improve Sexual Function in Postmenopausal Women",,"Completed","No Results Available","Female Sexual Dysfunction","Drug: Testosterone undecanoate|Drug: placebo","female sexual function index score|adverse effects of the drug","Chulalongkorn University","Female","40 Years to 60 Years   (Adult)","Phase 2","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CU0115","June 2012","April 2013","May 2013","November 12, 2012",,"January 29, 2014","King Chulalongkorn memorial hospital, Bankok, Thailand",,"https://ClinicalTrials.gov/show/NCT01724658"
138,"NCT01497977","Phytoestrogen Supplementation in Postmenopausal Women",,"Completed","No Results Available","Low Serum Lipid Levels","Drug: phytoestrogens","Change from baseline of serum lipids","American Medical Academy, Serbia","Female","40 Years to 65 Years   (Adult, Older Adult)","Phase 4","74","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","175062","September 2008","June 2010","June 2010","December 23, 2011",,"December 29, 2011","Ultramedica Clinic, American Medical Academy, Belgrade, Serbia",,"https://ClinicalTrials.gov/show/NCT01497977"
139,"NCT01069211","Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women","LETTER","Unknown status","No Results Available","Breast Cancer",,"Disease free survival|Adverse effect|Overall Survival|Time to Distant Recurrence (TTDR)","Korean Breast Cancer Study Group","Female","Child, Adult, Older Adult",,"876","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","KBCSG006","January 2010","January 2017","January 2017","February 17, 2010",,"May 11, 2011","Joon Jeong, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01069211"
140,"NCT00005152","Nurses' Health Study (Cardiovascular Component)",,"Active, not recruiting","No Results Available","Cardiovascular Diseases|Diabetes Mellitus|Coronary Disease|Heart Diseases|Cerebrovascular Accident|Pulmonary Embolism|Angina Pectoris|Myocardial Infarction|Menopause|Postmenopause",,"Coronary heart disease (CHD)","Brigham and Women's Hospital|National Heart, Lung, and Blood Institute (NHLBI)","Female","Child, Adult, Older Adult",,"121700","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","2008P000327|R01HL034594-28","August 1980","March 31, 2024","March 31, 2024","May 26, 2000",,"March 15, 2022",,,"https://ClinicalTrials.gov/show/NCT00005152"
141,"NCT00000613","CVD Risk and Health in Postmenopausal Phytoestrogen Users",,"Completed","No Results Available","Bone Diseases|Cardiovascular Diseases|Coronary Disease|Depression|Heart Diseases|Myocardial Ischemia|Osteoporosis|Postmenopause","Behavioral: dietary supplements|Drug: genistein|Behavioral: diet, soy proteins",,"National Heart, Lung, and Blood Institute (NHLBI)","Female","45 Years to 74 Years   (Adult, Older Adult)","Phase 2",,"NIH","Interventional","Allocation: Randomized|Masking: Double|Primary Purpose: Prevention","116|R01HL057790","April 1997",,"December 2004","October 28, 1999",,"February 29, 2016",,,"https://ClinicalTrials.gov/show/NCT00000613"
142,"NCT00000611","Women's Health Initiative (WHI)",,"Completed","No Results Available","Bone Diseases|Breast Neoplasms|Cardiovascular Diseases|Colonic Neoplasms|Coronary Disease|Heart Diseases|Myocardial Ischemia|Osteoporosis|Postmenopause","Drug: hormone replacement therapy|Drug: estrogens|Drug: progestins|Drug: estrogen replacement therapy|Behavioral: diet, fat-restricted|Drug: calcium|Drug: vitamin D|Behavioral: dietary supplements",,"National Heart, Lung, and Blood Institute (NHLBI)|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|National Cancer Institute (NCI)|National Institute on Aging (NIA)","Female","50 Years to 79 Years   (Adult, Older Adult)","Phase 3",,"NIH","Interventional","Allocation: Randomized|Primary Purpose: Prevention","114",,"March 2005",,"October 28, 1999",,"April 15, 2016",,,"https://ClinicalTrials.gov/show/NCT00000611"
143,"NCT00000532","Women's Healthy Lifestyle Project: Cardiovascular Risk Factors and Menopause",,"Completed","No Results Available","Cardiovascular Diseases|Diabetes Mellitus|Heart Diseases|Hypercholesterolemia|Hypertension|Obesity|Menopause|Postmenopause","Behavioral: diet, fat-restricted",,"National Heart, Lung, and Blood Institute (NHLBI)","Female","45 Years to 50 Years   (Adult)","Phase 3",,"NIH","Interventional","Allocation: Randomized|Primary Purpose: Prevention","75|R01HL045167","February 1992",,"January 2000","October 28, 1999",,"May 13, 2016",,,"https://ClinicalTrials.gov/show/NCT00000532"
144,"NCT00000466","Postmenopausal Estrogen/Progestin Interventions (PEPI)",,"Completed","No Results Available","Bone Diseases|Cardiovascular Diseases|Coronary Disease|Diabetes Mellitus|Heart Diseases|Hypercholesterolemia|Hypertension|Myocardial Ischemia|Osteoporosis|Thrombosis|Postmenopause","Drug: estrogens, conjugated|Drug: medroxyprogesterone|Drug: progesterone|Drug: estrogen replacement therapy",,"National Heart, Lung, and Blood Institute (NHLBI)|National Institute on Aging (NIA)|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","45 Years to 64 Years   (Adult)","Phase 3",,"NIH","Interventional","Allocation: Randomized|Masking: Double|Primary Purpose: Prevention","55|U01HL040232","September 1987",,"October 2000","October 28, 1999",,"May 13, 2016",,,"https://ClinicalTrials.gov/show/NCT00000466"
145,"NCT05058313","Evaluation of the Safety and Performance of the MILTA GYNECO Vaginal Probe in Postmenopausal Women With Vaginal Atrophy","SIVAM","Recruiting","No Results Available","Menopause|Urinary Incontinence|Atrophic Vaginitis","Device: Photobiomodulation","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of the use of the MILTA™ GYNECO vaginal probe|Performance of the MILTA™ GYNECO vaginal probe on pain linked to vaginal atrophy|Performance of the MILTA™ GYNECO vaginal on the vaginal mucosa|Vaginal pH|Vaginal flora|Patient satisfaction Patient satisfaction","Centre Hospitalier Universitaire de Nīmes|PHYSIOQUANTA","Female","Child, Adult, Older Adult","Not Applicable","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","IDIL/2020/PM-001","March 29, 2022","June 2024","June 2024","September 27, 2021",,"February 13, 2023","CHU Nîmes, Nîmes, France|Centre Médical KARIS, Perpignan, France|Centre Hospitalier de Valenciennes, Valenciennes, France",,"https://ClinicalTrials.gov/show/NCT05058313"
146,"NCT02033512","TRANSDERMAL HRT RELIEVING POSTMENOPAUSAL SYMPTOMS","THRT","Completed","No Results Available","Menopause","Drug: Transdermal Hormone Replacement Therapy|Drug: Transdermal Nanoformulation|Drug: Transdermal formulation","Estradiol Levels|Effect of Progesterone (10%) associated with Estriol (0.1) +Estradiol (0.25%) Nanoparticles formulation on postmenopausal complaints","University Potiguar|Universidade Federal de Sergipe","Female","51 Years to 70 Years   (Adult, Older Adult)","Phase 2","66","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CNPQ202316|CNPq","January 2003","January 2004","April 2008","January 10, 2014",,"January 10, 2014","Gynelogical Center, Fortaleza, CE, Brazil",,"https://ClinicalTrials.gov/show/NCT02033512"
147,"NCT05463081","Clinical Trial of ""Magic Gyno"" Laser Device",,"Recruiting","No Results Available","Female Urogenital Diseases|Urinary Incontinence|Prolapse Genital|Menopausal Syndrome|Postmenopausal Period|Vaginal Atrophy|Vaginal Prolapse|Postpartum Period|Sexual Dysfunction|Preoperative Care|Postoperative Care","Device: Laser treatment|Diagnostic Test: Blood test|Diagnostic Test: Clinical urine test|Diagnostic Test: Vaginal smear|Diagnostic Test: Pelvic ultrasound|Other: Female Sexual Function Index|Other: International Consultation on Incontinence Questionnaire - Short Form|Other: The Short Form Health Survey|Diagnostic Test: Vaginal Health Index|Diagnostic Test: Vital signs determination|Diagnostic Test: pH of vagina determination|Diagnostic Test: Physical parameters determination","Mean Change from Baseline of Vaginal Health Index Score|Mean Change from Baseline of ""Desire"" Score on the Female Sexual Function Index Questionnaire|Mean Change from Baseline of ""Arousal"" Score on the Female Sexual Function Index Questionnaire|Mean Change from Baseline of ""Lubrication"" Score on the Female Sexual Function Index Questionnaire|Mean Change from Baseline of ""Orgasm"" Score on the Female Sexual Function Index Questionnaire|Mean Change from Baseline of ""Satisfaction"" Score on the Female Sexual Function Index Questionnaire|Mean Change from Baseline of ""Pain"" Score on the Female Sexual Function Index Questionnaire|Mean Change from Baseline of Total Score on International Consultation on Incontinence Questionnaire - Short Form|Mean Change from Baseline of ""Physical Health Component Score"" on The Short Form Health Survey|Mean Change from Baseline of ""Mental Health Component Score"" on The Short Form Health Survey|Mean Change from Baseline of pH of vagina|Mean Change from Baseline of Lactobacilli quantity","MeLSyTech, Ltd","Female","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","70","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","CTMGLD-2022","August 5, 2022","January 25, 2023","February 25, 2023","July 18, 2022",,"October 10, 2022","Tver State Medical Academy, Tver, Tver Oblast, Russian Federation",,"https://ClinicalTrials.gov/show/NCT05463081"
148,"NCT03316950","Radiofrequency and Hybrid Fractional Laser for Vaginal Rejuvenation",,"Completed","Has Results","Vaginal Atrophy","Device: IntraGen RF|Device: DiVA|Device: Placebo (DIVA/IntraGen combined)","Vulvovaginal Symptoms Questionnaire|Vaginal Laxity Questionnaire|Perceived Changes in Vaginal Laxity as Measured by Zimmern Probe at 3 Months Post Treatment|Perceived Changes in Vaginal Laxity as Measured by Zimmern Probe at 6 Months Post Treatment|Urogenital Distress Short Form (UDI-6)|Incontinence Impact Questionnaire Short Form (IIQ-7)|Female Sexual Function Index (FSFI)|Gene Expression- Col1A1 as Measured by Fold Change|Gene Expression- Col3A1 as Measured by Fold Change|Gene Expression- ELN as Measured by Fold Change|Gene Expression- LOX as Measured by Fold Change","University of Texas Southwestern Medical Center|American Society for Aesthetic Plastic Surgery","Female","40 Years to 65 Years   (Adult, Older Adult)","Not Applicable","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","STU 012017-006","June 15, 2018","April 8, 2021","April 8, 2021","October 23, 2017","January 4, 2023","January 4, 2023","University of Texas Southwestern Medical Center, Dallas, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT03316950/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03316950"
149,"NCT01742000","Study of Anti-atherosclerotic Activity of Karinat in Postmenopausal Women","PEARS-POST","Completed","No Results Available","Atherosclerosis","Dietary Supplement: Karinat|Drug: Placebo","B-mode ultrasound of carotid arteries|Measure of serum atherogenicity","Institute for Atherosclerosis Research, Russia","Female","Child, Adult, Older Adult","Phase 3","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","IAR-KT-POST","January 2007","June 2012","October 2012","December 5, 2012",,"December 6, 2012",,,"https://ClinicalTrials.gov/show/NCT01742000"
150,"NCT02434185","The Bilateral Deficit Phenomenon, Functional and Dynamometric Assessment in Postmenopausal Women",,"Completed","No Results Available","Postmenopausal Syndrome|Muscle Weakness",,"Assess the maximum force of lower limbs during bilateral and unilateral contraction|Assess the force-time curve during climbing a step|Assess the force-time curve during climbing rising from a chair|Assess bone mineral-free lean tissue mass by dual energy X-ray absorptiometry|Assess the fragility phenotype of the subjects|Assess the rate of force developed in time intervals (0-50, 50-100, 100-150ms) of lower limbs during bilateral and unilateral contraction|Assess fat-tissue mass and lean-tissue mass composition","Universidad Católica San Antonio de Murcia","Female","50 Years to 70 Years   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","UCAM-BLD-1","March 2015","April 2015","April 2015","May 5, 2015",,"October 15, 2018","Catholic University of Murcia, Murcia, Spain",,"https://ClinicalTrials.gov/show/NCT02434185"
151,"NCT01429636","Applied Relaxation (AR) Technique Versus Its Modified Version for Treating Menopausal Symptoms",,"Completed","No Results Available","Hot Flashes|Night Sweats|Sleep Disturbances","Behavioral: Modified Relaxation (MR)|Behavioral: Applied Relaxation (AR)","Changes in global scores of Menopausal Rating Scale (MRS).|Change in the frequency and severity of hot flushes.|Change in the frequency and severity of night sweats.|Change in the frequency and severity of sleep disturbances.","Chiang Mai University","Female","45 Years to 65 Years   (Adult, Older Adult)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARMR-Sympts","August 2011","December 2011","December 2011","September 7, 2011",,"December 30, 2011","Mahassarakham Hospital, Maha Sarakam, Northeast, Thailand",,"https://ClinicalTrials.gov/show/NCT01429636"
152,"NCT02372864","Psychosexual Consequences of Risk-reducing Salpingo-oophorectomy","PURSUE","Completed","No Results Available","Ovarian Cancer","Behavioral: Mindfulness based stress reduction (MBSR)","Change from baseline in the menopause-specific quality of life questionnaire (MENQOL) score.|Change from baseline in the female sexual function index questionnaire (FSFI) score.|Change from baseline in the female sexual distress scale (FSDS) score.","University Medical Center Groningen","Female","Child, Adult, Older Adult","Not Applicable","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","PURSUE2014","February 2015","December 2016","December 2016","February 26, 2015",,"October 26, 2017","University Medical Centre Groningen, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT02372864"
153,"NCT00900653","Low Dose Estriol With Lactobacilli Treatment for Preventing Recurrent Urinary Tract Infection in Postmenopausal Women",,"Unknown status","No Results Available","Urinary Tract Infections","Drug: Gynoflor E (low dose estriol with lactobacillus)","Incidence of urinary tract infection|vaginal pH|lactobacillus colonization","Yonsei University","Female","40 Years and older   (Adult, Older Adult)","Phase 4","142","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","4-2009-0022","May 2009","May 2010","July 2010","May 13, 2009",,"June 1, 2009","Yonsei University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00900653"
154,"NCT03240081","Treating Postmenopausal Dyspareunia Where it Hurts",,"Active, not recruiting","Has Results","Dyspareunia","Drug: 50mcg estradiol cream|Drug: 100mcg estradiol cream","Change in Median Dyspareunia Pain Scores After 4 Weeks Using Study Drug|Change in Median Pain Scores for Intercourse After 12 Weeks Using Study Drug","Oregon Health and Science University","Female","40 Years to 70 Years   (Adult, Older Adult)","Phase 4","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","OHSU IRB 16770","June 20, 2017","November 21, 2019","March 21, 2023","August 4, 2017","January 20, 2021","October 4, 2022","Oregon Health & Science Univerity, Portland, Oregon, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT03240081/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03240081"
155,"NCT01824433","Comparison of Venlafaxine and Fluoxetine in the Treatment of Postmenopausal Women With Major Depression",,"Completed","No Results Available","Major Depression","Drug: venlafaxine|Drug: fluoxetine","Overall Improvement|Improvement of individual symptoms","Capital Medical University","Female","50 Years to 80 Years   (Adult, Older Adult)","Phase 4","189","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","VFPWMDD","March 7, 2013","March 16, 2017","March 16, 2017","April 4, 2013",,"September 14, 2017","Beijing Anding Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01824433"
156,"NCT03280693","Relationships Among Body Mass Index, Body Balance and Bone Mineral Density in Postmenopausal Women",,"Completed","No Results Available","Osteoporosis|Fall Patients|Postmenopausal Disorder","Diagnostic Test: Diagnostic test","correlation between BMI and body balance|correlation between BMI and BMD","Cairo University","Female","50 Years to 60 Years   (Adult)",,"48","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","P.T.REC/012/00731","May 2015","November 2015","November 2015","September 12, 2017",,"September 12, 2017",,,"https://ClinicalTrials.gov/show/NCT03280693"
157,"NCT01635218","Homeopathic Treatment for Depression in Peri- and Postmenopausal Women","HOMDEP-MENOP","Completed","Has Results","Moderate Depression|Menopausal and Postmenopausal Disorders","Drug: Individualized homeopathic treatment|Drug: Fluoxetine|Drug: Placebo","Change From Baseline in 17-item Hamilton Rating Scale for Depression at 6 Weeks.|Change From Baseline in Beck Depression Inventory at 6 Weeks.|Responder Rates at 6 Weeks.|Change From Baseline in Greene´s Scale at 6 Weeks.|Remission Rates at 6 Weeks","Hospital Juarez de Mexico","Female","40 Years to 65 Years   (Adult, Older Adult)","Phase 2","133","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HJM2030/12-A","March 2012","February 2014","March 2014","July 9, 2012","September 23, 2014","October 9, 2014","Hospital Juárez de México, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT01635218"
158,"NCT01472315","Postmenopausal Women,Treatment of Sleep Apnea and Co-morbidities",,"Completed","No Results Available","Sleep Apnea","Drug: medroxyprogesterone acetate|Drug: Placebo","polysomnography measures of sleep apnea and sleep|subjective questionnaires","Turku University Hospital","Female","42 Years to 77 Years   (Adult, Older Adult)","Phase 2|Phase 3","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1/2000-15","January 2000","November 2000","November 2000","November 16, 2011",,"March 11, 2013","Sleep Research Unit, Department of Physiology, Turku University, Turku, Finland",,"https://ClinicalTrials.gov/show/NCT01472315"
159,"NCT00341614","Exercise Training in Older Diabetic Women",,"Completed","No Results Available","Cardiovascular Diseases|Diabetes Mellitus, Type 2","Behavioral: 3-month Exercise Training and Diet Education","VO2max at 3 months|C-reactive protein at 3 months|Blood lipids (total cholesterol, LDL, HDL, TC/HDL ratio, triglycerides) at 3 months|Fasting glucose at 3 months|Fasting insulin (insulin resistance) at 3 months|HbA1C at 3 months|Body fat % at 3 months|Blood pressure (SBP, DBP) at 3 months|Waist-hip ratio at 3 months|Total kcal and fat kcal at 3 months|Bone-mineral density at 3 months","University of San Francisco|University of California, San Francisco","Female","45 Years to 75 Years   (Adult, Older Adult)","Phase 1","35","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","FDF-05-06","June 2006",,"May 2007","June 21, 2006",,"August 16, 2007","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT00341614"
160,"NCT00220454","Effect of Estrogen & Stress for Postmenopausal Women",,"Completed","No Results Available","Aging","Drug: Climara|Drug: Hydrocortone","Change in cognitive test scores at months 1 & 3 vs. baseline|Correlation between change in blood levels of cortisol & estradiol and cognitive scores|Correlation between change in cognitive score and treatment-induced change in beta-amyloid","Seattle Institute for Biomedical and Clinical Research|National Alliance for Research on Schizophrenia and Depression","Female","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","RDIS 0007|Baker-Y02 (Sponsor)|BL17 (Supporting Institution)","December 2002",,"March 2005","September 22, 2005",,"February 27, 2007",,,"https://ClinicalTrials.gov/show/NCT00220454"
161,"NCT02501031","Flaxseed Intervention Study to Assess Sex Hormone Levels Among Post-Menopausal Women",,"Completed","No Results Available","Healthy","Dietary Supplement: Ground flaxseed","Change in circulating levels of sex steroid hormones at Day 0 (baseline) compared with ~Day 50 (end of study period)|Change in serum enterolignan levels at Day 0 (baseline) compared with ~Day 50 (end of study period)","Cancer Care Ontario|Canadian Breast Cancer Foundation, Ontario Region (funder)|University of Toronto|York University, Institute for Social Research|Mount Sinai Services|Roswell Park Cancer Institute","Female","57 Years to 64 Years   (Adult)","Not Applicable","99","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","CBCF 2014-grant","September 2015","June 2016","January 2018","July 17, 2015",,"January 12, 2018","Cancer Care Ontario, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02501031"
162,"NCT03032185","Evaluation of the Effect of Transcutaneous Electrical Nerve Stimulation (TENS) in Postmenopausal Women",,"Unknown status","No Results Available","Menopause","Device: Transcutaneous Elevtrical Nerve Stimulation","Autonomic changes in postmenopausal women's health|Psychophysical changes in postmenopausal women´s health|Descendent Inibitory System Pain changes in postmenopausal women´s health","Secretaria Municipal de Saúde de Rolante|Centro Universitario La Salle","Female","45 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","48302915.1.0000.5307","January 2017","July 2017","July 2017","January 26, 2017",,"January 26, 2017","Andressa de Souza, Canoas, Rio Grande do Sul, Brazil",,"https://ClinicalTrials.gov/show/NCT03032185"
163,"NCT03872258","Effectiveness of an Intensive Intervention to Improve Physical Activity in Postmenopausal and Sedentary Women",,"Completed","No Results Available","Healthy","Behavioral: Control|Behavioral: Intervention group","Physical activity|Self-reported physical activity|Self-reported sedentary|Body composition|Body mass index","Fundacion para la Investigacion y Formacion en Ciencias de la Salud|Castilla-León Health Service","Female","45 Years to 70 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","GRS 1823/B/18","April 1, 2019","December 31, 2020","May 31, 2021","March 13, 2019",,"August 31, 2022","Instituto Biosanitario de Salamanca. Research unit La Alamedilla, Salamanca, Spain",,"https://ClinicalTrials.gov/show/NCT03872258"
164,"NCT01501422","Effect of Estrogen Therapy on Objective Sleep Quality in Postmenopausal Women",,"Completed","No Results Available","Insomniac Postmenopausal Women","Drug: Estrogen patch|Drug: Placebo","Sleep efficiency (SE)|Sleep latency (SL)|Total sleep time (TST)|Wake time after sleep onset (WASO)|Number of awakening|Score of two sleep quality assessment questionnaires.","Chulalongkorn University","Female","40 Years to 60 Years   (Adult)","Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MRU CU-1/2011","July 2011","January 2012","January 2012","December 29, 2011",,"December 28, 2012","Menopause Clinic, Menopause research unit, King Chulalongkorn Memorial Hospital, Pathumwan, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT01501422"
165,"NCT05464654","Polynucleotides Efficacy in the Genitourinary Syndrome of Menopause",,"Recruiting","No Results Available","Genitourinary Syndrome of Menopause|Postmenopausal Disorder|Menopause|Vagina Atrophy","Drug: 3 g Polynucleotide vaginal suppositories|Drug: Conjugated estrogens cream 1g Tube","Change from baseline Item 9 Menopause Rating Scale (MRS) total score at 3 months|Change from baseline Item 10 Menopause Rating Scale (MRS) total score at 3 months|Change from baseline Item 11 Menopause Rating Scale (MRS) total score at 3 months|Change from baseline Vaginal Maturity Index (VMI) at 3 months","Hospital Regional 1o de Octubre|Institut d'Investigacions Biomèdiques August Pi i Sunyer|Hospital General Regional No. 1 IMSS|Universidad Nacional Autonoma de Mexico|National Polytechnic Institute, Mexico","Female","40 Years to 70 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","012-20170421","June 23, 2021","November 23, 2022","December 23, 2022","July 19, 2022",,"July 20, 2022","Peri-postmenopause and bone metabolism clinic. Regional Hospital October 1st ISSSTE, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT05464654"
166,"NCT00234676","POETRY: Study of Estrogen Replacement Therapy in Postmenopausal Women With Parkinson's Disease",,"Completed","No Results Available","Parkinson's Disease","Drug: Premarin ®","Safety - Adverse event frequency, vital signs (change from Baseline to Month 2)|Tolerability - Proportion of participants who complete the trial|Motor|Cognition|Behavior|Serum estradiol levels - change from Baseline to Month 2","The Parkinson Study Group|Wyeth is now a wholly owned subsidiary of Pfizer|Joseph and Rosalyn Newman Foundation","Female","up to 75 Years   (Child, Adult, Older Adult)","Phase 2","23","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","POETRY06032003","October 2003","March 2006","March 2006","October 7, 2005",,"January 8, 2008","The Parkinson's Institute, Sunnyvale, California, United States|Emory University, Atlanta, Georgia, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|University of Maryland, Baltimore, Maryland, United States|University of Rochester, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00234676"
167,"NCT03260803","Oligopin Supplementation and Bone Turnover Markers and Antioxidant Changes in Postmenopausal Osteopenic Women",,"Completed","No Results Available","Osteopenia","Drug: Oligopin|Drug: Placebo","Plasma Osteocalcin Concentration|Plasma Carboxyl terminal collagen type I Concentration|Osteocalcin/Carboxyl terminal collagen type I ratio|MnSOD activity in peripheral blood mononuclear cells|Catalase activity in peripheral blood mononuclear cells|MnSOD mRNA expression peripheral blood mononuclear cells|Catalase mRNA expression peripheral blood mononuclear cells|NrF2 mRNA expression peripheral blood mononuclear cells|Plasma Malondialdehide Concentration|total antioxidant capacity|protein carbonyl content|Plasma Total thiol concentration|Catalase activity in Plasma|MnSOD activity in Plasma","Tehran University of Medical Sciences|Iran University of Medical Sciences","Female","50 Years to 65 Years   (Adult, Older Adult)","Phase 3","43","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","34606","February 1, 2018","December 1, 2018","March 1, 2019","August 24, 2017",,"May 20, 2020","Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT03260803"
168,"NCT03227458","DHEA Augmentation of Musculoskeletal Adaptations to Exercise in Older Women",,"Recruiting","No Results Available","Low Bone Mass|Osteoporosis, Postmenopausal","Other: DHEA|Other: Placebo|Behavioral: Exercise","Change in lumbar spine aBMD|Change in total hip aBMD|Change in regional hip aBMD|Change in Vertebral (L1-2) total volumetric bone mineral density (vBMD)|Change in Vertebral (L1-2) cortical vBMD|Change in Vertebral (L1-2) trabecular vBMD|Change in Femoral total vBMD|Change in Femoral cortical vBMD|Change in Femoral trabecular vBMD|Change in Vertebral (L1-2) strength, stance model|Change in Vertebral (L1-2) strength, fall model|Change in Proximal femur strength, stance model|Change in Proximal femur strength, fall model|Change in Total body fat-free mass","University of Colorado, Denver|National Institute on Aging (NIA)","Female","55 Years to 85 Years   (Adult, Older Adult)","Not Applicable","225","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","16-2427|R01AG053489","February 12, 2018","April 2024","April 2024","July 24, 2017",,"February 15, 2022","University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT03227458"
169,"NCT01553773","Postmenopausal Facial Skin After Estradiol and Genistein Topical Treatment",,"Completed","No Results Available","Atrophy","Drug: isoflavone|Drug: Estradiol","Analysis of hyaluronic acid concentration in postmenopausal facial skin","Federal University of São Paulo|Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.","Female","45 Years to 55 Years   (Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UNIFESPMP#1","July 2004","March 2005","March 2005","March 14, 2012",,"March 14, 2012","Department of Gynecology - UNIFESP, Sao Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT01553773"
170,"NCT00000400","Alendronate and/or Parathyroid Hormone for Osteoporosis",,"Completed","No Results Available","Osteoporosis","Drug: Human parathyroid hormone [hPTH-(1-34)]|Drug: alendronate","change in spine bone mineral density|change in hip bone mineral density|change in forearm bone mineral density|change in total body bone mineral|change in femoral shaft bone mineral density|change in serum PINP|change in serum osteocalcin|change in serum NTX|incidence of hypercalcemia|incidence of hypercalciuria|incidence of symptoms","Massachusetts General Hospital|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","All","45 Years to 85 Years   (Adult, Older Adult)","Phase 2","176","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P50 AR44855 NIAMS-023|P50AR044855","August 1999","April 2006","June 2006","November 4, 1999",,"December 9, 2013","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00000400"
171,"NCT03752060","The Clinical Utility of Resistance Training for Improving Cardiovascular Disease Risk in Post-Menopausal Women",,"Completed","No Results Available","Cardiovascular Risk Factor|Menopause Related Conditions|Neuromuscular Function|Aerobic Capacity|Inflammation","Behavioral: Resistance Exercise|Behavioral: Aerobic Exercise","Change in Aerobic Capacity|Change in Metabolic and Inflammatory responses to a Meal Tolerance Test (MTT)|Changes in Vascular Function|Changes in Body Composition","Oklahoma State University","Female","45 Years to 65 Years   (Adult, Older Adult)","Not Applicable","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ED18101","January 15, 2019","November 15, 2019","November 22, 2019","November 23, 2018",,"March 3, 2021","192 Colvin Recreation Center, Stillwater, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT03752060"
172,"NCT04258410","Quercetin for Cardio-Skeletal Muscle Health and Estrogen Deficiency","QUICKENED","Withdrawn","No Results Available","Menopause Related Conditions","Drug: Placebo oral soft chew|Drug: Quercetin","Feasibility: Number of enrolled participants per month|Eligibility: Proportion eligible after screening|Adherence: Percent adherence to study visits|Adherence: Percent adherence to intervention|Retention: Number of Subjects Lost to Follow Up|Retention: Number of Subjects Discontinued|Acceptability: Changes in patient satisfaction","Wake Forest University Health Sciences","Female","60 Years to 74 Years   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IRB-PENDING-LG","September 2022","December 2023","January 2024","February 6, 2020",,"October 10, 2022",,,"https://ClinicalTrials.gov/show/NCT04258410"
173,"NCT01429662","Modified Relaxation (MR) Technique for Treating Hypertension in Postmenopausal Women",,"Completed","No Results Available","Postmenopausal Syndrome|Hypertension","Behavioral: Modified Relaxation (MR)|Behavioral: Lifestyle Education (LE)","Changes in SBP.|Changes in DBP.|Continuation rate of MR practice.|Drop-out rates.|Numbers of subjects who require anti-hypertensive medication.","Chiang Mai University","Female","45 Years to 65 Years   (Adult, Older Adult)","Phase 3","429","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MRLE-HTN","August 2011","March 2012","March 2012","September 7, 2011",,"May 30, 2012","Mahasarakham Hospital, Maha Sarakham, Northeast, Thailand",,"https://ClinicalTrials.gov/show/NCT01429662"
174,"NCT02771834","Evaluation of the Association Between Osteoporosis and Postural Balance in Postmenopausal Women",,"Completed","No Results Available","Postural Balance","Other: Biomechanical analysis|Other: Kiphosis analysis|Other: Vitamin D level","International Physical Activity Questionnaire|Functional mobility","University of Sao Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo","Female","55 Years to 65 Years   (Adult, Older Adult)",,"126","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","320/09","July 2009","July 2012","December 2012","May 13, 2016",,"May 13, 2016",,,"https://ClinicalTrials.gov/show/NCT02771834"
175,"NCT01282320","WHAT (Women, Hot-flashes, Activity, Trial) - Physical Activity for Treatment of Hot Flushes Among Postmenopausal Women","WHAT","Completed","No Results Available","Postmenopausal Symptoms|Hot Flashes","Behavioral: Physical activity intervention program","Change in mean hot-flashes frequency and intensity (per 24/hours).|Quality of life measured with Women's Health Questionnaire (WHQ) 23 items.|Depressive symptoms are measured with Beck Depression Inventory -II (BDI-II)|Dysfunctional attitudes related to cognitive vulnerability to depression.|Increased physical fitness, measured as 10 % increase in VO2-max|Motivation for change in physical activity - Stages of Change|Physical activity, motivation and experiences","University Hospital of North Norway|University of Tromso","Female","Child, Adult, Older Adult","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","REK2009/1429","January 2011","March 2012","December 2013","January 24, 2011",,"July 1, 2019","University Hospital of North Norway, Tromsø, Troms, Norway",,"https://ClinicalTrials.gov/show/NCT01282320"
176,"NCT00288262","Melatonin Effects on Luteinizing Hormone",,"Terminated","No Results Available","Hot Flashes","Drug: melatonin 0.5 mg","Hot flashes log|Sleep log|QIDS|CESD|Luteinizing hormone (urine)|Luteinizing hormone (blood)|SAFTEE inventory of symptoms and adverse effects|Other adverse events","Scripps Health|University of California, San Diego","Female","50 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","03-101 (Scripps SOPRS #)|NIH M01 RR00833 (in part)","June 2004",,"February 2005","February 7, 2006",,"February 7, 2006","Scripps Clinic Sleep Center, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT00288262"
177,"NCT02865538","Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms","RELENT-1","Completed","Has Results","Post-menopausal Vasomotor Symptoms","Drug: BAY3427080|Drug: Placebo (for BAY3427080)","Maximum Observed Plasma Concentration (Cmax) of BAY3427080|Time to Reach Maximum Observed Drug Concentration in Plasma (Tmax) of BAY3427080|Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of BAY3427080|Area Under the Concentration-time Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-τ) of BAY3427080|Terminal Elimination Half-life (t½) of BAY3427080|Apparent Clearance (CL/F) of BAY3427080|Number of Participants With Clinically Significant Abnormalities Detected Upon Physical Examination.|Number of Participants With Clinically Significant Abnormalities on the 12-lead ECGs|Number of Participants With Arrhythmias as Assessed by Continuous Holter Monitoring.|Change From Baseline at Day 14 in Vital Signs: Diastolic Blood Pressure (Standing)|Change From Baseline at Day 14 in Vital Signs: Diastolic Blood Pressure (Sitting)|Change From Baseline at Day 14 in Vital Signs: Systolic Blood Pressure (Standing)|Change From Baseline at Day 14 in Vital Signs: Systolic Blood Pressure (Sitting)|Change From Baseline at Day 14 in Vital Signs: Pulse Rate|Change From Baseline at Day 14 in Vital Signs: Respiratory Rate|Change From Baseline at Day 14 in Vital Signs: Oxygen Saturation|Change From Baseline at Day 14 in Vital Signs: Oral Body Temperature|Change From Baseline at Day 14 in Vital Signs: Weight|Change From Baseline at Day 15 for Laboratory Hormones Results : Adrenocorticotropic Hormone (ADTH) and Estradiol.|Change From Baseline at Day 15 for Laboratory Hormones Results: Follicle Stimulating Hormone|Change From Baseline at Day 15 for Laboratory Hormones Results : Triiodothyronine Uptake|Change From Baseline at Day 15 for Laboratory Hormones Results: Thyrotropin|Change From Baseline at Day 15 for Laboratory Hormones Results : Cortisol, Testosterone, Thyroxine and Triiodothyronine|Change From Baseline at Day 14 for Clinical Laboratory Parameters LIPIDS : Cholesterol, Triglycerides, HDL Cholesterol and LDL Cholesterol.|Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils and Immature Granulocytes.|Change From Baseline at Day 14 for Clinical Laboratory Parameters HEMATOLOGY: Leukocytes, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, Immature Granulocytes and Platelets.|Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Hemoglobin and Erythrocytes Mean Corpuscular Hemoglobin Concentration|Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Erythrocytes|Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Erythrocytes Mean Corpuscular Volume and Mean Platelet Volume.|Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Erythrocytes Mean Corpuscular Hemoglobin|Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Erythrocytes Distribution Width.|Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Hematocrit.|Change From Baseline at Day 14 for Laboratory Parameters CHEMISTRY: Protein and Albumin.|Change From Baseline at Day 14 for Laboratory Parameters CHEMISTRY: Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, Gamma Glutamyl Transferase and Creatine Kinase|Change From Baseline at Day 14 for Laboratory Parameters CHEMISTRY: Urate, Bilirubin and Creatinine.|Change From Baseline at Day 14 for Clinical Laboratory Parameters CHEMISTRY: Sodium, Potassium, Chloride, Bicarbonate, Calcium, Phosphate, Glucose, Magnesium and Urea Nitrogen.|Laboratory Parameters CHEMISTRY: Glomerular Filtration Rate African at Baseline|Laboratory Parameters CHEMISTRY: Glomerular Filtration Rate Caucasian at Baseline|Change From Baseline at Day 14 for COAGULATION: Prothrombin International Normalized Ratio (INR)|Change From Baseline at Day 14 for COAGULATION: Prothrombin Time and Activated Partial Thromboplastin Time|Heart Rate (HR) - Change From Baseline (Day -1) at Day 14|Mean PR Interval - Change From Baseline (Day -1) at Day 14|Mean QRS Duration - Change From Baseline (Day -1) at Day 14|Mean QT Interval - Change From Baseline (Day -1) at Day 14|Mean QTcF Interval (Fridericia's Correction Formula, QTcF) - Change From Baseline (Day -1) at Day 14|Mean QTcB Interval (Bazett's Correction Formula, QTcB) - Change From Baseline (Day -1) at Day 14|Nature and Severity of Adverse Events (AEs) up to Day 21|Withdrawals Due to AEs up to Day 21|Change in Frequency of Hot Flushes From Baseline (Day -1) at Days 7, 14 as Assessed by Skin Conductance|Change From Baseline (Week -1) at Weeks 1, 2 in Frequency of Moderate to Severe Hot Flushes as Measured by Twice Daily Paper Diary Throughout Study|Change From Baseline (Week -1) at Weeks 1, 2 in Average Daily Severity of Hot Flushes as Measured by Twice Daily Paper Diary|Change From Baseline (Week -1) at Weeks 1, 2 in Average Daily Hot Flushes Severity Score as Measured by Twice Daily Paper Diary.|Change in Frequency From Baseline (Day -1), at Days 7, 14 of Hot Flushes as Measured by Continuous Day Time Diary.|Change From Baseline (Week -1) at Weeks 1, 2 in Night-time Awakenings (NTA) Secondary to Hot Flushes as Measured by Paper Diary|Change From Baseline (Day-1) to Day 1 and Day 7 in Luteinizing Hormone (AUC0-8)","Bayer|Nerre Therapeutics Ltd.","Female","45 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","76","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","21681","August 1, 2016","March 28, 2017","March 28, 2017","August 12, 2016","February 16, 2021","February 16, 2021","Avail Clinical Research, DeLand, Florida, United States|QPS/MRA (Miami Clinical Research), Miami, Florida, United States|ICON Clinical Research Unit, San Antonio, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02865538/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02865538/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02865538"
178,"NCT05346419","Antiresorptive Effect of Treatment With Risedronate and Vitamin D in Postmenopausal Patients",,"Completed","No Results Available","Postmenopausal Osteoporosis|Hypovitaminosis D|Hyperparathyroidism","Drug: Risedronate|Drug: Vitamin D","Remission of hyperparathyroidism|Remission of hypovitaminosis D|Remission of osteopenia|Remission of Osteoporosis|Change from baseline serum calcium at 6 months|Change from baseline serum phosphorus at 6 months|Change from baseline urinary calcium at 6 months|Change from bone resorption biomarker at 6 months|Fracture Risk Assessment Tool (FRAX®) for hip fracture|Fracture Risk Assessment Tool for major osteoporotic fracture (FRAX® Mo)","Hospital Regional 1o de Octubre|National Polytechnic Institute, Mexico|Universidad Nacional Autonoma de Mexico","Female","40 Years to 78 Years   (Adult, Older Adult)","Not Applicable","33","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","118.2021","July 1, 2021","February 3, 2022","February 26, 2022","April 26, 2022",,"April 26, 2022","Peri-postmenopause and bone metabolism clinic. Regional Hospital October 1st ISSSTE, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT05346419"
179,"NCT04893226","Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women",,"Recruiting","No Results Available","Metabolic Syndrome|Postmenopausal Symptoms","Behavioral: Time-Restricted Feeding (TRF)","Change in Insulin Sensitivity|Change in Body Mass Index|Change in Triglycerides|Change in Hemoglobin A1c|Change in C-Reactive Protein|Change in Mid-sleep|Change in Sleep Fragmentation Index","Julie Pendergast|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Kentucky","Female","45 Years to 65 Years   (Adult, Older Adult)","Not Applicable","164","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","BIO-21-TRF|1R01DK124774-01A1","October 19, 2021","February 27, 2026","February 27, 2026","May 19, 2021",,"November 17, 2022","University of Kentucky, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT04893226"
180,"NCT04045379","LASER and Radiofrequency and Genitourinary Syndrome of Menopause","EPMLARF-arm1","Not yet recruiting","No Results Available","Postmenopausal Atrophic Vaginitis|Postmenopausal Symptoms|Genitourinary Symptoms","Procedure: LASER|Procedure: Microablative Radiofrequency|Drug: Estriol","Clinical Improvement of signs and symptoms postmenopausal genitourinary syndrome with intravaginal LASER, Microablative Radiofrequency, and topic estriol|Satisfaction of postmenopausal women with genitourinary syndrome with the treatment by intravaginal LASER, Micro ablative Radiofrequency, and topic estriol|Evaluation of Microbiota before and after the use of intravaginal LASER, Micro Ablative radiofrequency or topic estriol.|Evaluation of vaginal pH before and after the use of intravaginal LASER, Micro ablative radiofrequency or topic estriol.|Histologic evaluation of vagina and vulva before and after the use of intravaginal and vulvar LASER, Micro Ablative radiofrequency or topic estriol.|Evaluation of impact in Quality of life after treatment with intravaginal and vulvar LASER, Micro Ablative radiofrequency or topic estriol.|Evaluation of impact in Sexual function after treatment with intravaginal and vulvar LASER, Micro Ablative radiofrequency or topic estriol.|Evaluation of extracellular matrix before and after the use of intravaginal and vulvar LASER, Micro Ablative radiofrequency or topic estriol.|Evaluation of matrix metalloproteinases(MMP) in remodeling of vulvovaginal collagen induced by intravaginal and vulvar LASER, Micro Ablative radiofrequency or topic estriol.|Evaluation of visual aspect of vulva after the use of intravaginal and vulvar LASER, Micro Ablative radiofrequency or topic estriol.","Federal University of São Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo","Female","40 Years to 65 Years   (Adult, Older Adult)","Not Applicable","195","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CEP0431/2018 arm 1","August 5, 2019","August 2021","August 2023","August 5, 2019",,"August 5, 2019","Federal University of Sao Paulo - Unifesp, São Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT04045379"
181,"NCT01826656","Bone Healing in Healthy and Post-menopausal Osteoporotic Women",,"Withdrawn","No Results Available","Post-menopausal Osteoporosis","Procedure: tooth extraction|Radiation: CBCT scan|Radiation: DXA scan|Radiation: Panoramic radiograph","alveolar bone width and height alveolar bone changes in width and height|- Clinical changes of soft and hard tissue and of periodontal parameters in the neighbouring teeth; - Accuracy of panoramic morphometric indexes in detecting osteoporosis","University College, London","Female","50 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","OsteoporosisTrial","May 2014","December 2014","November 2015","April 8, 2013",,"October 27, 2017","Eastman Clinical Investigation Centre, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01826656"
182,"NCT01389102","Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms",,"Completed","Has Results","Hot Flashes","Drug: Estradiol transdermal one 90 μL spray|Drug: Estradiol transdermal spray, two 90 μL sprays|Drug: Estradiol transdermal three 90 μL sprays|Drug: Placebo transdermal two 90 μL sprays|Drug: Placebo transdermal three 90 μL sprays|Drug: Placebo transdermal one 90 μL spray","Mean Change in the Number of Moderate to Severe Vasomotor Symptoms Per Day|Mean Change the Severity of Moderate to Severe Vasomotor Symptoms","Lumara Health, Inc.","Female","35 Years and older   (Adult, Older Adult)","Phase 3","454","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EST-01","December 2004","November 2006","November 2006","July 7, 2011","June 11, 2012","June 11, 2012","Alabama Clinical Therapeutics, Birmingham, Alabama, United States|Costal Clinical Research, Mobile, Alabama, United States|Harmony Clinic, Oro Valley, Arizona, United States|Hope Research Institute, Phoenix, Arizona, United States|Radiant Research, Phoenix, Arizona, United States|Radiant Research, Tucson, Arizona, United States|NEA Womens Clinic, Jonesboro, Arkansas, United States|Arkansas Women's Center, Little Rock, Arkansas, United States|Speciality Care for Women, Redding, California, United States|Sacramento Research Medical Grp, Sacramento, California, United States|Dr. Steven Drosman, San Diego, California, United States|Medical Center for Clinical Research, San Diego, California, United States|Benchmark Research, San Francisco, California, United States|Pacific Clinical Research, Santa Monica, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|Downtown Women's Health Care, Denver, Colorado, United States|South Florida Medical Research, Aventura, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Radiant Research, Pinellas Park, Florida, United States|Comprehensive Clinical Trials, West Palm Beach, Florida, United States|Radiant Research, Atlanta, Georgia, United States|Atlanta West Women's Center, Douglasville, Georgia, United States|Radiant Research, Chicago, Illinois, United States|Benchmark Research, Metairie, Louisiana, United States|Clinical Trials Management, Metairie, Louisiana, United States|Women's Health Research Ctr., Laurel, Maryland, United States|Ridgeview Research, Chaska, Minnesota, United States|Meridian Clinical Research, Omaha, Nebraska, United States|Mid Dakota Clinic, Bismark, North Dakota, United States|Radiant Research, Cincinnati, Ohio, United States|Radiant Research, Columbus, Ohio, United States|TriPhase Research, Franklin, Ohio, United States|Radiant Research, Mogadore, Ohio, United States|PMG-South/OB-Gyn Health Ctr., Medford, Oregon, United States|Center for Women's Medicine, Greenville, South Carolina, United States|Clinical Research Associates, Nashville, Tennessee, United States|Benchmark Research, Austin, Texas, United States|Advanced Research Associates, Corpus Christi, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Radiant Research, San Antonio, Texas, United States|J. Lewis Research, Salt Lake City, Utah, United States|University of Eastern Virginia, Norfold, Virginia, United States|Tacoma Women's Specialists, Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01389102"
183,"NCT01048606","Exercise and Phytoestrogens: Effect on Factors Predisposing to Cardiovascular Disease(CVD) in Postmenopausal Women",,"Completed","Has Results","Overweight","Behavioral: Placebo + exercise|Dietary Supplement: Phytoestrogens without exercise|Other: Phytoestrogens + exercise","Body Composition: Dual-energy X-ray Absorptiometry Method|Plasma Lipid Profile: the Apolipoproteins (Apo-AI, Apo-AII, Apo-B), Cholesterol HDL, LDL and Triglycerides Levels Will be Determined by Clinical Analyses of Blood Sample (Obtained After 12 h Fasting State)|Glucose Metabolism: 2h-75g Oral Glucose Tolerance Test (OGTT) + Plasma Insulin and Glucose Concentrations (Blood Sample Analysis).|Markers of Oxidative Stress: Conjugated Diene Formation, Malondialdehyde, Alpha-tocopherol and Its Oxidised Form Alpha-tocopheryl Quinone. TAS Constitutes the Most Reliable Method for the Evaluation of Oxidative Stress in Vivo.|Quality of Life: Assessed With Questionnaires (SF-36 (General Health Perceptions), Kupperman Index, Perceived Stress Scale.|Plasma Fibrinogen Levels Measured With Luminescence.|Sex-hormone Levels. Estradiol, Estrone, Progesterone, Testosterone and SHBG Will be Obtained by Enzyme Immuno Assay (EIA)|Quality of Life: Assessed With Questionnaires (SF-36 (General Health Perceptions), Kupperman Index, Perceived Stress Scale|Dietary Intakes: 3-days Food Record. Dietary Analyses Will be Completed Using the Nutifiq Software (Université Laval)|Physical Activity Level: Physical Activity Scale for the Elderly (PASE)|Plasma Isoflavones (Diadzein) - a Marker of Phytoestrogen Compliance - Will be Measured by the ELISA Method|Metabolic Rate at Rest: During 30 Minutes With a Breathing Mask by Indirect Calorimetry (CCM/D, Medgraphics Corp, St-Paul, MN, USA) After a 12-hour Fast, in the Early Morning.|Maximal Oxygen Uptake Measured Using a Continuous, Incremental Protocol (Balke Modified Protocol) on a Treadmill With a Breathing Mask by Indirect Calorimetry (CCM/D, Medgraphics Corp, St-Paul, MN, USA).|Physical Capacity: 3 Tests From the Senior Fitness Test (Chair Stand Test, Chair Sit-and-Reach Test, Back Scratch Test) + Handgrip Strength Test (Lafayette Hand Dynamometer, Indiana)","Université de Sherbrooke|Canadian Institutes of Health Research (CIHR)","Female","50 Years to 70 Years   (Adult, Older Adult)","Phase 4","45","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IDionne_phyto_2008-2011","January 2009","November 2012","November 2012","January 13, 2010","February 12, 2014","February 12, 2014","Centre de recherche sur le vieillissement du CSSS-IUGS, Sherbrooke, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01048606"
184,"NCT01314586","Flax Lignans and Heart Health","ISULignan","Completed","No Results Available","Hypercholesterolemia","Dietary Supplement: secoisolariciresinol diglucoside-containing extract of flaxseed","Change in serum total cholesterol from baseline to 12 weeks after intervention treatments|Change in serum glucose from baseline to 12 weeks after intervention treatments|Change in blood pressure from baseline to end of treatment|Changes in serum clinical chemistry from baseline to end of treatment","Iowa State University|Archer Daniels Midland Co.","All","40 Years to 65 Years   (Adult, Older Adult)","Not Applicable","93","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","ADM Beneflax ISU-1","December 2007","July 2009","November 2009","March 14, 2011",,"March 14, 2011","Nutrition & Wellness Research Center, Ames, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT01314586"
185,"NCT03427957","Evaluation of a New Hysteroscopic Grasper for Endometrial Biopsy in Post-menopausal Patients",,"Completed","No Results Available","Post-Menopausal Bleeding|Post-Menopausal Endometrial Thickness","Diagnostic Test: Endometrial biopsy with the new hysteroscopic grasper with knurled terminal end and cutting jaws|Diagnostic Test: Endometrial biopsy with the hysteroscopic spoon grasper|Diagnostic Test: Endometrial biopsy with the hysteroscopic alligator grasper","Duration of the hysteroscopy|Pain perceived by the patient|Number of attempts|Size of the specimen|Feasibility assessment by the operator|Precision","Università degli Studi dell'Insubria","Female","45 Years to 70 Years   (Adult, Older Adult)","Not Applicable","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","HYGREB-1","June 1, 2019","January 30, 2020","March 1, 2020","February 9, 2018",,"April 20, 2020","University of Catania, Catania, Italy|University of Insubria, Varese, Italy",,"https://ClinicalTrials.gov/show/NCT03427957"
186,"NCT03336437","Estrogen and the Urogenital Microbiome in GSM",,"Completed","No Results Available","Menopause","Drug: Estradiol vaginal ring|Other: Placebo vaginal ring","Urinary Microbiome: change in the relative abundance of urinary lactobacillus between baseline and 12 weeks post intervention|Change in prevalence of GSM symptoms","Oregon Health and Science University","Female","40 Years to 89 Years   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","OHSU IRB# 17056","February 1, 2018","August 23, 2019","August 23, 2019","November 8, 2017",,"November 22, 2019","Women's Health Research Unit at Oregon Health and Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT03336437"
187,"NCT05442463","Hormone Therapy and Angiotensin-Dependent Arterial and Renal Vasoconstriction in Humans",,"Recruiting","No Results Available","Hormone Therapy","Drug: Angiotensin II","First association in transgender women and cis women|Second association in transgender men and cis men","University of Calgary|Dr. Sandra Dumanski","All","18 Years to 90 Years   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","REB19-0460","November 30, 2020","November 30, 2025","November 30, 2025","July 5, 2022",,"November 3, 2022","University of Calgary, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT05442463"
188,"NCT04219722","Efficacy and Safety of Hyaluronic Acid Injection on Symptoms of Vulvovaginal Atrophy in Postmenopausal Women","SYLIVA","Active, not recruiting","No Results Available","Vulvovaginal Atrophy","Device: Injection of DESIRIAL®|Other: Injection of placebo","Variation of most bothersome symptom|Variation of most bothersome symptom (MBS)|Variation of other moderate to severe symptoms|Percentage of responders|Variation of sexual function|Variation of vaginal pH|Report of adverse events","Laboratoires Vivacy","Female","45 Years and older   (Adult, Older Adult)","Not Applicable","121","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2019-A00034-53","January 21, 2020","September 29, 2021","June 30, 2022","January 7, 2020",,"May 18, 2022","Gynecology private office, Antwerpen, Belgium|Cabinet Gynécologie Obstétrique, Liège, Belgium|Gynaecologisch Centrum, Mechelen, Belgium|Gynaecologie Dr Deniz Gulcan, Meise, Belgium|Cabinet Dr Ali Bennani, Wavre, Belgium|MIRHA, Zaventem, Belgium|Clinique Georges V, Bordeaux, France|CHRU Jeanne de Flandres, Lille, France|Cabinet de gynécologie, Marseille, France|Cabinet de Gynécologie, Paris, France|Cabinet de gynécologie, Perpignan, France|Polyclinique de l'Atlantique, Saint-Herblain, France|Cabinet de Gynécologie, Tarnos, France|Cabinet de gynécologie, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT04219722"
189,"NCT00825994","Omega-3 for Peri- and Postmenopausal Depression","O3Meno","Completed","Has Results","Depression","Drug: Omega-3 Fatty Acids","Change in MADRS Score|Change in Hot Flash Daily Interference Scale (HFRDIS)","Massachusetts General Hospital|GlaxoSmithKline","Female","40 Years and older   (Adult, Older Adult)","Not Applicable","31","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008-P-001313","November 2008","June 2009","June 2009","January 21, 2009","August 21, 2014","August 21, 2014","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00825994"
190,"NCT00687739","Prevention of Obesity in Women Via Estradiol Regulation","POWER","Completed","Has Results","Obesity","Drug: leuprolide acetate|Drug: Estradiol Transdermal|Behavioral: progressive resistance exercise training","Resting Energy Expenditure (REE)|Cortisol Response (Area Under the Curve) to CRH Under DEX Suppression|Total Energy Expenditure (TEE)|Fat Mass|Fat-free Mass","University of Colorado, Denver|National Institute on Aging (NIA)","Female","18 Years to 49 Years   (Adult)","Phase 3","79","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","06-0512|R01AG018198","May 2008","June 2014","June 2014","June 2, 2008","December 9, 2019","December 9, 2019","University of Colorado Denver, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT00687739"
191,"NCT01116310","Clinical Trial to Evaluate the Efficacy of FITOGYN Versus Placebo on the Vasomotor Symptomatology Associated With Menopause","TRYSEM","Unknown status","No Results Available","Postmenopausal Women With Moderate Vasomotor Symptoms","Drug: Soy isoflavones (Glycine max L) and red clover extract (Trifolium pretense L)|Drug: Placebo","Mean Change in the number of symptoms of hot flashes (including night sweats) at the end of the study (week 22) with respect to baseline (week 6).|Intensity of Hot Flashes|Impact of the treatment with FITOGYN on the overall symptoms of menopause: fatigue, joint pain, vaginal dryness and sleep disturbances among others.|Effect of the treatment with FITOGYN in the level of anxiety of postmenopausal women.|Effect of the treatment with FITOGYN in the quality of life of postmenopausal women.|Evaluate the change in the subject's lipidic profile.|Evaluation of the safety and tolerability.","Laboratorios Casen-Fleet S.L.U.|Apices Soluciones S.L.|Asociacion Colaboracion Cochrane Iberoamericana","Female","45 Years to 60 Years   (Adult)","Phase 4","166","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LCF-GIN-2008-EC02","April 2010","May 2012","July 2012","May 4, 2010",,"September 28, 2011","Hospital Central de Asturias, Asturias, Spain|Hospital del Cruces, Barakaldo, Spain|Assir CAP Sant Martí, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|USP Instituto Universitario Dexeus, Barcelona, Spain|ASSIR CAP San Andreu, Barcelona, Spain|Hospital Universitari Vall d'Hebrón, Barcelona, Spain|Hospital Monteprincipe, Boadilla del Monte, Madrid, Spain|Hospital General de Ciudad Real, Ciudad Real, Spain|Centro Diatros, Gavá (Barcelona), Spain|Hospital Universitario de Guadalajara, Guadalajara, Spain|Consorci Sanitari d l´Anoia-H. de Igualada, Igualada, Barcelona, Spain|Centro de Estudios de Obstetricia y Ginecología Asociado Lugo, Lugo, Spain|Gabinete Médico Velázquez, Madrid, Spain|Instituto Palacios, Madrid, Spain|Hospital Mateu Orfila, Mao, Spain|H. San Joan d'Alacant, San Juan, Alicante, Spain|Hospital Universitario La Fe, Valencia, Spain|Hospital Doctor Pesset, Valencia, Spain|Hospital Miguel Servet, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT01116310"
192,"NCT01731340","A Study on the Impact of Calcium on Woman's Vascular Health",,"Completed","No Results Available","Cardiovascular Diseases|Osteoporosis","Dietary Supplement: Calcium Citrate|Other: Low Dietary Calcium|Other: High Dietary Calcium","Vascular System|Hemodynamics","McGill University Health Centre/Research Institute of the McGill University Health Centre","Female","50 Years and older   (Adult, Older Adult)","Phase 4","123","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","GEN-11-231","June 2012","November 14, 2018","November 14, 2018","November 21, 2012",,"September 18, 2019","Department of Internal Medicine; Montreal General Hospital, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01731340"
193,"NCT00150969","Vitamin K Supplementation in Post-Menopausal Osteopenia",,"Completed","Has Results","Post-Menopausal Osteoporosis|Post-Menopausal Osteopenia","Dietary Supplement: vitamin K1 (phylloquinone)|Dietary Supplement: placebo","Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine (L1-L4) Between Treatment Arms.|Percent Change in Bone Mineral Density (BMD) at the Total Hip Between Treatment Arms.|Percent Change in Bone Mineral Density (BMD) at the Femoral Neck Between Treatment Arms.|Percent Change in Bone Mineral Density (BMD) at the Ultra-distal Radius Between Treatment Arms.|Effect of Vitamin K1 Supplementation on Levels of Bone Formation Marker|Effect of Vitamin K1 Supplementation on Level of Bone Resorption Markers (C-telopeptide: CTX)|Effect of Vitamin K1 Supplementation on Percent of Carboxylation of Osteocalcin|Difference in Serious Adverse Events|Difference in Number of New Cancers by Treatment Arm.|Difference in Number of New Clinical Fractures by Treatment Arm.","University Health Network, Toronto|Canadian Institutes of Health Research (CIHR)","Female","Child, Adult, Older Adult","Phase 3","440","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CIHR-50422","January 2002","September 2006","September 2007","September 8, 2005","March 26, 2012","November 22, 2012","St. Michael's Hospital Health Centre, Toronto, Ontario, Canada|Mt. Sinai Hospital, Toronto, Ontario, Canada|University Health Network, Osteoporosis Department, Toronto, Ontario, Canada|Sunnybrook & Women's College Health Sciences Centre, Toronto, Ontario, Canada|University of Toronto, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00150969"
194,"NCT00412022","HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.","HOBOE","Active, not recruiting","No Results Available","Breast Cancer","Drug: tamoxifen|Drug: triptorelin|Drug: letrozole|Drug: zoledronic acid","disease free survival in premenopausal patients|bone mineral density|Bone mineral density measured|disease free survival in postmenopausal patients|overall survival|toxicity of letrozole + triptorelin and letrozole + zoledronic acid + triptorelin in premenopausal patients","National Cancer Institute, Naples|University of Campania ""Luigi Vanvitelli""","Female","18 Years and older   (Adult, Older Adult)","Phase 3","1294","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HOBOE","March 2004","November 2021","November 2022","December 15, 2006",,"March 4, 2021","S. Giuseppe Moscati, Avellino, AV, Italy|Azienda Ospedaliera Treviglio - Caravaggio, Treviglio, BG, Italy|Azienda Ospedaliera G. Rummo, Benevento, BN, Italy|Ospedale Senatore Antonio Perrino, Brindisi, BR, Italy|Istituto Romagnolo per lo Studio e la Cura dei Tumori, Meldola, FC, Italy|Presidio Ospedaliero Di Saronno Aziendo Ospedaliera di Busto Arsizio, Saronno, VA, Italy|Ospedale Santa Maria Annunziata, Bagno a Ripoli, Italy|Istituto Nazionale per la ricerca Sul Cancro, Genova, Italy|Ospedale Riuniti, Livorno, Italy|Ospedale Unico della Versilia, Lucca, Italy|Istituto Nazionale dei Tumori,, Napoli, Italy|Ospedale Cardarelli, Napoli, Italy|Seconda Università di Napoli, Napoli, Italy|Università Federico II, Cattedra di Oncologia Medica, Napoli, Italy|Casa di Cura La Maddalena, Palermo, Italy|Ospedale Silvestrini, Perugia, Italy|Ospedale Santa Chiara, Pisa, Italy|Università di Sassari, Sassari, Italy|Ospedale Santa Chiara, Trento, Italy|ASL Viterbo Ospedale Belcolle, Viterbo, Italy",,"https://ClinicalTrials.gov/show/NCT00412022"
195,"NCT00522262","Alberta Physical Activity and Breast Cancer Prevention (ALPHA) Trial",,"Completed","No Results Available","Breast Neoplasms","Behavioral: Aerobic exercise intervention","Changes in estrone, estradiol and adiposity levels|Changes in mammographic density, insulin resistance and inflammatory markers|The effect of the exercise intervention on exercise adherence and quality of life.","AHS Cancer Control Alberta|Canadian Breast Cancer Research Alliance|University of Alberta|University of Calgary","Female","50 Years to 74 Years   (Adult, Older Adult)","Not Applicable","320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","16649","June 2002","June 2006","July 2007","August 29, 2007",,"January 15, 2015","Alberta Cancer Board, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT00522262"
196,"NCT00000419","Safety of Estrogens in Lupus: Hormone Replacement Therapy",,"Terminated","No Results Available","Systemic Lupus Erythematosus","Drug: Premarin and Provera",,"NYU Langone Health|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|Office of Research on Women's Health (ORWH)","Female","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","350","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment","U01 AR42540 NIAMS-028A|U01AR042540","April 1996",,"August 2002","November 4, 1999",,"May 3, 2013","UAB Medical Center, Birmingham, Alabama, United States|UCLA Medical Center, Dept. of Rheumatology, Los Angeles, California, United States|University of Chicago Pritzker School of Medicine, Chicago, Illinois, United States|Louisiana School of Medicine, Shreveport, Louisiana, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Univ. of Michigan Med. Ctr., Rheumatology Div., Ann Arbor, Michigan, United States|Albert Einstein College of Medicine, Jacoby Hospital, Dept. of Rheumatology, Bronx, New York, United States|Hospital for Joint Diseases, New York, New York, United States|Hospital for Special Surgery, New York, New York, United States|UNC Medical Center, Dept. of Rheumatology, Chapel Hill, North Carolina, United States|Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States|Univ. of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States|Univ. of Pittsburgh, Dept. of Rheumatology, Pittsburgh, Pennsylvania, United States|University of Texas Health Sciences Center, Houston, Texas, United States|Medical College of Virginia, Ambulatory Care Center, Richmond, Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00000419"
197,"NCT00044837","Hormone Replacement Therapy and Anti-HIV Drugs in HIV-Infected, Postmenopausal Women",,"Terminated","No Results Available","HIV Infections","Drug: Medroxyprogesterone acetate|Drug: Estradiol",,"National Institute of Allergy and Infectious Diseases (NIAID)","Female","18 Years and older   (Adult, Older Adult)","Phase 1","120","NIH","Interventional","Primary Purpose: Treatment","ACTG A5119|AACTG A5119",,,,"September 9, 2002",,"June 4, 2015","Barbara Brizz, Rockville, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00044837"
198,"NCT03176238","Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer","EVEREXES","Completed","Has Results","Post Menopausal Breast Cancer","Drug: everolimus|Drug: exemestane","Summary of Number of Participants With Treatment Emergent Adverse Events (TEAE) - All Grades|Percentage of Participants Response Rates (Best Overall and Overall)|Percentage of Participants Clinical Benefit Rate|Progression Free Survival (PFS)|Percent of Participants Event-free Probability Estimates of Deterioration of Eastern Cooperative Oncology Group (ECOG) Performance Status","Novartis Pharmaceuticals|Novartis","Female","18 Years and older   (Adult, Older Adult)","Phase 3","235","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CRAD001JIC06","March 29, 2013","January 29, 2019","January 29, 2019","June 5, 2017","April 7, 2020","April 7, 2020","Novartis Investigative Site, Garran, Australian Capital Territory, Australia|Novartis Investigative Site, Caringbah, New South Wales, Australia|Novartis Investigative Site, Liverpool, New South Wales, Australia|Novartis Investigative Site, Box Hill, Victoria, Australia|Novartis Investigative Site, Heidelberg, Victoria, Australia|Novartis Investigative Site, Ringwood East, Victoria, Australia|Novartis Investigative Site, St Albans, Victoria, Australia|Novartis Investigative Site, Karamsad, Gujarat, India|Novartis Investigative Site, Nashik, Maharashtra, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Cuttack, Orissa, India|Novartis Investigative Site, Bandung, Indonesia|Novartis Investigative Site, Jakarta, Indonesia|Novartis Investigative Site, Jogyakarta, Indonesia|Novartis Investigative Site, Semarang, Indonesia|Novartis Investigative Site, Amman, Jordan|Novartis Investigative Site, Suwon, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Gyeonggi do, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Seocho Gu, Korea, Republic of|Novartis Investigative Site, Busan, Korea, Republic of|Novartis Investigative Site, Jeollanam-do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Taegu, Korea, Republic of|Novartis Investigative Site, Kuala Lumpur, MYS, Malaysia|Novartis Investigative Site, Kota Kinabalu, Sabah, Malaysia|Novartis Investigative Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Novartis Investigative Site, Casablanca, Morocco|Novartis Investigative Site, Rabat, Morocco|Novartis Investigative Site, Cape Town, Western Cape, South Africa|Novartis Investigative Site, George, Western Cape, South Africa|Novartis Investigative Site, Western Cape, South Africa|Novartis Investigative Site, New Taipei City, TWN, Taiwan|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Kaohsiung City, Taiwan|Novartis Investigative Site, Kaoshiung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiang Mai, Thailand|Novartis Investigative Site, Ariana, Tunisia|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Gaziantep, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kartal, Turkey|Novartis Investigative Site, Pendik / Istanbul, Turkey|Novartis Investigative Site, Ho Chi Minh, Vietnam","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03176238/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03176238/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03176238"
199,"NCT00000399","Bone Estrogen Strength Training",,"Completed","No Results Available","Osteoporosis","Drug: Hormone replacement therapy|Procedure: Strength training",,"University of Arizona|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","Female","40 Years to 65 Years   (Adult, Older Adult)","Phase 2","300","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R01AR039559|NIAMS-006","August 1995",,"January 2001","November 4, 1999",,"May 20, 2013","Ina Gittings Bldg. Body Composition Laboratory, Tucson, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT00000399"
200,"NCT05571514","Study of the Impact of Mother-of-pearl Nutritional Supplementation on the Prevention of Post-menopausal Osteoporosis","NUTRANACRE","Not yet recruiting","No Results Available","Post Menopausal Osteoporosis","Dietary Supplement: Mother-of-pearl|Dietary Supplement: Calcium Carbonate","Change in bone loss at lumbar site|Tolerance to oral mother-of-pearl powder supplementation|Change in bone loss at the upper end of the femur|Change in bone remodeling of the femur","Centre Hospitalier Universitaire de Saint Etienne|Ministry of Health, France","Female","50 Years to 65 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","20PH256|ANSM","January 2023","April 2024","April 2024","October 7, 2022",,"October 7, 2022","Hôpital Gabriel Montpied, Clermont-Ferrand, France|Clinique Universitaire de Rhumatologie, Grenoble, France|Hôpital Edouard Herriot, Lyon, France|CH Roanne, Roanne, France",,"https://ClinicalTrials.gov/show/NCT05571514"
201,"NCT04676074","Effect of Upper Limb Ergometer on the AIP in Post Menopausal Obese Women.",,"Completed","No Results Available","Post Menopausal Obese Women","Device: Electronic Upper limb( body) ergometer","Effect of the upper body ergometer on arthrogenic index ( triglyceride/ high density lipoprotein)|Effect of the upper body ergometer on total body weight kg.|Effect of the upper body ergometer on estimated maximum heart rate(beat/min).","Cairo University","Female","45 Years to 60 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Rana Hesham","November 15, 2020","February 15, 2021","March 31, 2021","December 19, 2020",,"June 8, 2021","Outpatient clinic faculty of physical therapy at Cairo University, Giza, Egypt",,"https://ClinicalTrials.gov/show/NCT04676074"
202,"NCT01415050","Safety and Efficacy of Whole-body Vibration as add-on Treatment of Osteoporosis in Post-menopausal Women",,"Completed","No Results Available","Osteoporosis in Post-menopausal Women","Device: Whole body vibration","Biomarkers of bone formation and resorption|Fall risk|Low back pain","X-pert Med GmbH","Female","Child, Adult, Older Adult","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","XPM-022","January 2009","April 2011","July 2011","August 11, 2011",,"August 11, 2011","GP Office Dr. Baumann, Annaberg- Buchholz, Germany|X-pert Med GmbH, MUC, Gräfelfing, Germany|X-pert Med GmbH, Jena, Jena, Germany|Sportmedizin Stockach, Stockach, Germany|Sophien- und Hufeland- Klinikum GmbH, Weimar, Germany",,"https://ClinicalTrials.gov/show/NCT01415050"
203,"NCT00545207","A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia.",,"Completed","No Results Available","Post-Menopausal Osteopenia","Drug: ibandronate [Bonviva/Boniva]|Drug: Placebo","Trabecular BV/TV at distal radius of non-dominant arm|Bone density, trabecular BV/TV at distal tibia|Serum CTX|Lumbar hip and wrist BMD|AEs and laboratory parameters","Hoffmann-La Roche","Female","55 Years to 75 Years   (Adult, Older Adult)","Phase 3","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ML19357",,"September 2010","September 2010","October 17, 2007",,"January 26, 2017","Lyon, France|Paris, France|Saint-priest En Jarez, France|Toulouse, France",,"https://ClinicalTrials.gov/show/NCT00545207"
204,"NCT01224717","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women",,"Completed","No Results Available","Post-menopausal Osteoporosis","Drug: PTH134|Drug: Placebo|Drug: Forsteo","Measure: Effects of treatment on bone biomarkers. Measure levels of PINP, CTX-1, and serum calcium levels, serum phosphate, P1CP, bone-specific alkaline phosphatase, osteocalcin.|Change from baseline in serum calcium levels after 12 weeks of treatment","Novartis","Female","45 Years to 80 Years   (Adult, Older Adult)","Phase 1","104","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CPTH134A2102|2009-015933-64","September 2010","April 2011",,"October 20, 2010",,"May 13, 2011","Novartis Investigative Site, Aalborg, Denmark|Novartis Investigative Site, Ballerup, Denmark|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Munich, Germany",,"https://ClinicalTrials.gov/show/NCT01224717"
205,"NCT01814865","Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer",,"Withdrawn","No Results Available","Post-menopausal ER+ Stage I-IIIA Primary Operable Breast Cancer","Drug: Abiraterone Acetate|Drug: Prednisone|Drug: Aromatase Inhibitor","Differences in genomic expression and biological activity|Change in proliferation|Resulting adverse events of two weeks of abiraterone acetate|Changes in plasma hormone levels","British Columbia Cancer Agency|Janssen Research & Development, LLC","Female","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","212082BCA2004","May 2013","December 2013","December 2013","March 20, 2013",,"December 20, 2013","BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|London Regional Cancer Program, London, Ontario, Canada|The Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada|Segal Cancer Centre, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01814865"
206,"NCT00545480","SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis.",,"Completed","No Results Available","Post Menopausal Osteoporosis","Drug: ibandronate [Bonviva/Boniva]","Comparison of percentage of patients with persistence to >=10/12 administrations of Bonviva in feedback and no feedback group|Differences between groups in persistence|QoL and patient satisfaction","Hoffmann-La Roche|GlaxoSmithKline","Female","55 Years and older   (Adult, Older Adult)","Phase 4","596","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML19358","July 2006","March 2009","March 2009","October 17, 2007",,"August 18, 2015","Agen, France|Aix Les Bains, France|Albert, France|Amboise, France|Amiens, France|Amiens, France|Andernos Les Bains, France|Andrezieux Boutheon, France|Angers, France|Angouleme, France|Annecy, France|Antibes, France|Antony, France|Arcachon, France|Argeles Sur Mer, France|Arles, France|Armentieres, France|Auch, France|Auray, France|Aurillac, France|Avignon, France|Avranches, France|Bayonne, France|Beaumont S/oise, France|Belfort, France|Besancon, France|Beziers, France|Billere, France|Blanquefort, France|Bolbec, France|Bordeaux, France|Bordeaux, France|Brest, France|Bruz, France|Caen, France|Cagnes-sur-mer, France|Cannes, France|Carpentras, France|Cavaillon, France|Cenon, France|Chalon Sur Saone, France|Chalons En Champagne, France|Charenton Le Pont, France|Chartres, France|Chelles, France|Chilly-mazarin, France|Choisy Le Roi, France|Clamart, France|Clermont-ferrand, France|Clichy, France|Clichy, France|Colmar, France|Cornebarrieu, France|Davezieux, France|DAX, France|Decines, France|Dijon, France|Dole, France|Fontaine, France|Fontenay S/bois, France|Gourdon, France|Granville, France|Grenoble, France|Hyeres, France|Issy Les Moulineaux, France|Istres, France|L'isle Sur Sorgue, France|L'union, France|La Madeleine, France|La Roche Sur Yon, France|La Rochelle, France|La Trinité, France|Lagny-sur-marne, France|Landivisiau, France|Langon, France|Laval, France|Lavaur, France|Le Mans, France|Le Perreux Sur Marne, France|Les Mureaux, France|Libourne, France|Lille, France|Lille, France|Limoges, France|Lisieux, France|Longwy, France|Loos, France|Lorient, France|Lyon, France|Lyon, France|Lyon, France|Maisons-alfort, France|Mandelieu La Napoule, France|Marignane, France|Maromme, France|Marseille, France|Marseille, France|Marseille, France|Marseille, France|Martigues, France|Meaux, France|Mennecy, France|Merignac, France|Meylan, France|Millau, France|Miribel, France|Montbrisson, France|Montelimar, France|Montgeron, France|Montlucon, France|Montpellier, France|Mulhouse, France|Muret, France|Nancy, France|Nantes, France|Narbonne, France|Neuilly-sur-seine, France|Nice, France|Nimes, France|Nogent Le Rotrou, France|Noisy Le Sec, France|Oloron, France|Orleans, France|Ormesson Sur Marne, France|Orthez, France|Oyonnax, France|Pantin, France|Paris, France|Paris, France|Paris, France|Paris, France|Paris, France|Paris, France|Paris, France|Paris, France|Paris, France|Paris, France|Perpignan, France|Plan de Cuques, France|Poissy, France|Poitiers, France|Pont A Mousson, France|Puteaux, France|Quimper, France|Reims, France|Rennes, France|Rochefort, France|Ronchin, France|Roquebrune Cap Martin, France|Rouen, France|Rueil-malmaison, France|Saint Brieuc, France|Saint Doulchard, France|Saint Etienne, France|Saint Etienne, France|Saint Flour, France|Saint Jacques de La Lande, France|Saint Lo, France|Saint Nazaire, France|Saint Pierre de Coutances, France|Saint Quentin, France|Saint-affrique, France|Saint-etienne, France|Saint-malo, France|Saint-mande, France|Sainte Maxime, France|Saintes, France|Sarrebourg, France|Sartrouville, France|Sedan, France|Selestat, France|Senlis, France|Strasbourg, France|Strasbourg, France|Tassin La Demi-lune, France|Thionville, France|Toulon, France|Toulouse, France|Toulouse, France|Toulouse, France|Tourcoing, France|Tournon Sur Rhone, France|Tours, France|Valenciennes, France|Vandoeuvre-les-nancy, France|Vence, France|Venissieux, France|Vernet Les Bains, France|Villeneuve-sur-lot, France|Villeurbanne, France|Vincennes, France",,"https://ClinicalTrials.gov/show/NCT00545480"
207,"NCT01050634","Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST)","FAST","Completed","Has Results","Post Menopausal Women With Early Breast Cancer","Drug: Aromasin (exemestane)","Change From Baseline in International Breast Cancer Study Group (IBCSG) Linear Analogues Self-Assessment (LASA) Quality of Life (QoL) Core Questionnaire Scores|Change From Baseline in Thickness of Endometrium|Change From Baseline in IBCSG LASA Items Scores - QoL Module 24-26|Change From Baseline in 12-Item Short Form Health Survey (SF-12) Summary Subscales (Physical Summary Scale Derived From Items 1-5, 8 and Mental Summary Scale Derived From Items 6, 7, 9-11) Scores|Change From Baseline in IBCSG Vaginal Symptoms - QoL Module 24-26","Pfizer","Female","Child, Adult, Older Adult",,"980","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","A5991079","November 2005","April 2009","April 2009","January 15, 2010","July 23, 2010","July 23, 2010",,,"https://ClinicalTrials.gov/show/NCT01050634"
208,"NCT01384188","A Study to Investigate the Effects of Food and Morning Versus Evening on Single and Multiple Doses of ONO-5334 in Healthy Post Menopausal Women",,"Completed","No Results Available","Healthy Post Menopausal Women","Drug: ONO-5334","Part 1: Compare pharmacodynamic effect (i.e. urine CTX) of morning versus evening multiple dosing of ONO-5334|Part 2: Compare the effects of food on the pharmacodynamics (i.e., AUC, Cmax) of a single dose of ONO-5334|Safety and tolerability of single or multiple dose of ONO-5334 in healthy post menopausal women","Ono Pharmaceutical Co. Ltd","Female","55 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","ONO-5334POE010|2010-018282-36","June 2011","December 2011","December 2012","June 28, 2011",,"January 18, 2013","Guildford Clinical Site, Guildford, Surrey, United Kingdom|London Clinical Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01384188"
209,"NCT01573637","Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women",,"Completed","No Results Available","Negative Symptoms of Schizophrenia in Post-menopausal Women.","Drug: Raloxifene|Drug: Lactosa (placebo arm)","To assess the efficacy of raloxifene (SERM - Selective Estrogen Receptor Modulator) as an adjuvant of antipsychotic treatment in the management of negative symptoms of schizophrenia in post-menopausal women.|To assess the efficacy of raloxifene as an adjuvant of antipsychotic treatment in the management of global symptoms of schizophrenia in postmenopausal women.|To assess the efficacy of raloxifene as an adjuvant of antipsychotic treatment in the global functioning of postmenopausal women with schizophrenia.|To assess the efficacy of raloxifene as an adjuvant of antipsychotic treatment in the neuropsychological functioning of post-menopausal women with schizophrenia|To control response to treatment as a function of genetic variants in the form of SNP (Single Nucleotide Polymorphisms) that patients present in the alfa (ESR1) and beta (ESR2) estrogenic receptor genes.|To assess the safety of the medication used in this patient population.","Fundació Sant Joan de Déu|Hospital Sant Joan de Deu|Parc Sanitari Sant Joan de Déu|Stanley Medical Research Institute","Female","45 Years and older   (Adult, Older Adult)","Phase 3","78","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","FSJD-RAL-2010","July 2011","July 2014","July 2014","April 9, 2012",,"August 24, 2015","Corporació Sanitària Parc Taulí, Sabadell, Barcelona, Spain|Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Barcelona, Spain|Hospital Psiquiàtric Institut Pere Mata, Reus, Tarragona, Spain",,"https://ClinicalTrials.gov/show/NCT01573637"
210,"NCT01105910","Efficacy of Systane Ultra in Post Menopausal Women With Dry Eye",,"Completed","No Results Available","Post Menopausal Dry Eye Subjects","Other: Systane Ultra Lubricant Eye Drops|Other: Sensitive Eyes Eye Drops (Bausch & Lomb)","Reduction in corneal staining|Patient acceptability / comfort","Alcon Research","All","18 Years and older   (Adult, Older Adult)","Phase 4","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care","SMA-09-21","February 2010","December 2010",,"April 19, 2010",,"November 18, 2016",,,"https://ClinicalTrials.gov/show/NCT01105910"
211,"NCT02940522","Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women",,"Completed","Has Results","Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women","Drug: Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)","Comparison of Areas Under the Curve (AUC) to the Last Time With a Concentration ≥ LLOQ [AUC0-t] and to Infinity [AUCinf]|Comparison of the Maximum Plasma Concentration (Cmax)|Comparison of Tmax|Comparison of AUC (0-168)|Comparison of t1/2|Comparison of Elimination Rate Constant","AMAG Pharmaceuticals, Inc.","Female","50 Years to 75 Years   (Adult, Older Adult)","Phase 1","122","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMAG-HPC-PK-010","September 2016","December 2016","March 2017","October 21, 2016","November 30, 2018","April 28, 2022","Anaheim, California, United States|DeLand, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02940522"
212,"NCT02937766","Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women",,"Terminated","Has Results","Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) in Healthy Post-menopausal Women","Drug: Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)","Comparison of Average Pain Intensity|Clinician Assessment of Ease of Injection Technique|Clinician Assessment of Ease of Drug Preparation","AMAG Pharmaceuticals, Inc.","Female","50 Years to 75 Years   (Adult, Older Adult)","Phase 3","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMAG-HPC-HPM-301","October 7, 2016","January 6, 2017","March 27, 2017","October 19, 2016","December 12, 2018","April 21, 2022","Lotus Clinical Research, LLC, Pasadena, California, United States",,"https://ClinicalTrials.gov/show/NCT02937766"
213,"NCT00718861","3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs",,"Completed","Has Results","Post-menopausal Osteoporosis","Drug: Placebo|Drug: Zoledronic acid","Percentage Change in Total Hip Bone Mineral Density BMD at Year 6 (Baseline) and Year 9|Percentage Change of Total Hip Bone Mineral Density (BMD) at Year 7 and 8 Compared to Year 6|Percentage Change of Femoral Neck Bone Mineral Density (BMD) at Year 7, 8 and 9 Compared to Year 6|Percentage Change of Total Hip Bone Mineral Density (BMD) at Year 7, 8 and 9 Compared to Year 0|Percentage Change of Femoral Neck Bone Mineral Density (BMD) at Year 7, 8 and 9 Compared to Year 0|Biomarkers (Bone Markers) Serum C-terminal Telopeptide of Type I Collagen (CTx) at Year 6 (Extension 2 Baseline), Year 7, Year 8, Year 9|Biomarkers (Bone Markers)Serum N-terminal Propeptide of Type I Collagen (P1NP) at Year 6 (Extension 2 Baseline), Year 7, Year 8, Year 9|Biomarkers (Bone Markers) Serum Bone-specific Alkaline Phosphatase (BSAP). at Year 6 (Extension 2 Baseline), Year 7, Year 8, Year 9|Number of Participants With New/Worsening Morphometric Vertebral Fractures at Year 9 Compared to Year 6|Mean of Time to First Clinical Fracture|Change in Height at Years 7, 8 and 9 Relative to Year 6","Novartis Pharmaceuticals|Novartis","Female","65 Years and older   (Older Adult)","Phase 3","190","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CZOL446H2301E2|2007-005383-27","May 2008","April 2013","April 2013","July 21, 2008","December 30, 2013","October 9, 2014","Novartis Investigative Site, San Diego, California, United States|Novartis Investigative Site, Lakewood, Colorado, United States|Novartis Investigative Site, Gainesville, Georgia, United States|Novartis Investigative Site, Indiamapolis, Indiana, United States|Novartis Investigative Site, Bangor, Maine, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Fargo, North Dakota, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Quilmes, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, St. Leonards, New South Wales, Australia|Novartis Investigative Site, Geelong, Victoria, Australia|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sainte-Foy, Quebec, Canada|Novartis Investigative Site, Barranquilla, Colombia|Novartis Investigative Site, Bogotá, Colombia|Novartis Investigative Site, Medellín, Colombia|Novartis Investigative Site, Helsinki, Finland|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Braunfels, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Balatonfured, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Gyor, Hungary|Novartis Investigative Site, Arenzano, GE, Italy|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Siena, SI, Italy|Novartis Investigative Site, Valeggio Sul Mincio, VR, Italy|Novartis Investigative Site, Grafton, Auckland, New Zealand|Novartis Investigative Site, Bergen, Norway|Novartis Investigative Site, Hamar, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Bialystok, Poland|Novartis Investigative Site, Warsaw, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Goteborg, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Bern, Switzerland|Novartis Investigative Site, Zuerich, Switzerland|Novartis Investigative Site, Chaingmai, Thailand|Novartis Investigative Site, Khonkaen, Thailand",,"https://ClinicalTrials.gov/show/NCT00718861"
214,"NCT03981341","Impact of Estrogen + Estradiol Receptor Alpha Modulator Therapy on Oxidative Stress in Post-menopausal Women With and Without Sleep Apnea","Alpha MenoX","Recruiting","No Results Available","Sleep Apnea|Post Menopausal|Oxidative Stress","Drug: Duavive (0.45 estrogens mg and 20 mg bazedoxifene)","oxidative stress|glucose homeostasis|total cholesterol|triglycerides|aspartate aminotransferase (AST)|gamma-glutamyl transferase (∂-GT)|Orexin-A|C-reactive protein|arterial blood pressure|heart rate variability","Laval University|V Joseph|C Minville|C Rheaume","Female","45 Years to 65 Years   (Adult, Older Adult)","Phase 3","36","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IUCPQ220519","November 1, 2019","December 1, 2023","December 1, 2023","June 10, 2019",,"April 8, 2022","IUCPQ, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03981341"
215,"NCT05325775","Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause",,"Recruiting","No Results Available","Post-menopausal Vasomotor Symptoms","Drug: ACER-801 50 mg BID|Drug: ACER-801 100 mg BID|Drug: ACER-801 200 mg BID|Drug: Placebo","Peak Plasma Concentration (Cmax) of ACER-801|Time to reach maximum concentration (tmax) of ACER-801|Area under the concentration curve from dosing to the time of the last measured concentration (AUClast) of ACER-801|Area under the concentration curve from t0 to infinite time (AUCinf) of ACER-801|Metabolite:parent ratio of Cmax (MRCmax) of ACER-801|Metabolite:parent ratio of AUC (MRauc) of ACER-801|Half-life (t1/2) of ACER-801|Accumulation ratio for Cmax (ARcmax) of ACER-801|Accumulation ratio for AUC (ARcauc) of ACER-801|Peak Plasma Concentration (Cmax) of ACER-801 metabolite|Time to reach maximum concentration (tmax) of ACER-801 metabolite|Area under the concentration curve from dosing to the time of the last measured concentration (AUClast) of ACER-801 metabolite|Area under the concentration curve from t0 to infinite time (AUCinf) of ACER-801 metabolite|Metabolite:parent ratio of Cmax (MRcmax) of ACER-801 metabolite|Accumulation ratio for AUC (MRauc) of ACER-801 metabolite|Half-life (t1/2) of ACER-801 metabolite|Accumulation ratio for Cmax (ARcmax) of ACER-801 metabolite|Accumulation ratio for AUC (ARcauc) of ACER-801 metabolite|Number of patients with a clinically significant change from baseline in abnormalities detected during physical examination|Number and percentage of Adverse Events ≥ 5%|Number and percentage of Serious Adverse Events (SAE)|Number and percentage of subjects who discontinued from the study|Number of subjects with a clinically significant change from baseline for clinical laboratory evaluations: HEMATOLOGY|Number of subjects with a clinically significant change from baseline for clinical laboratory evaluations: COAGULATION|Number of subjects with a clinically significant change from baseline for clinical laboratory evaluations: SERUM CHEMISTRY|Number of subjects with a clinically significant change from baseline for clinical laboratory evaluations: HORMONES|Number of subjects with a clinically significant change from baseline for clinical laboratory evaluations: BONE DENSITY MARKERS|Number of subjects with a clinically significant change from baseline for clinical laboratory evaluations: URINALYSIS|Change in frequency of vasomotor symptoms (hot flashes) from baseline|Change in severity of vasomotor symptoms (hot flashes) from baseline|Change in severity score vasomotor symptoms (hot flashes) from baseline","Acer Therapeutics Inc.","Female","40 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACER-801-201","March 30, 2022","March 31, 2023","March 31, 2023","April 13, 2022",,"February 1, 2023","Spaulding Clinical Research, West Bend, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT05325775"
216,"NCT01290094","A Study of Bonviva/Boniva (Ibandronate) in Biphosphonate-Naïve Women With Post-Menopausal Osteoporosis",,"Completed","Has Results","Post Menopausal Osteoporosis","Drug: ibandronate [Bonviva/Boniva]","Percent Change From Baseline in Mean Lumbar Spine Bone Mineral Density (BMD) at Month 12|Percent Change From Baseline in Mean Lumbar Spine BMD at Month 24|Percent Change From Baseline in Mean Hip Bone BMD at Month 12|Percent Change From Baseline in Mean Hip BMD at Month 24|Percent Change From Baseline in Lumbar Spine T-score at Month 12 and 24|Percent Change From Baseline in Total Hip T-score at Month 12 and 24|Percentage of Participants Who Received All Planned Study Medication (Compliance)|Correlation Coefficient of Participant's Profile With Compliance","Hoffmann-La Roche","Female","50 Years and older   (Adult, Older Adult)","Phase 3","41","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML25399","April 2011","July 2014","July 2014","February 4, 2011","August 13, 2015","August 13, 2015","Banja Luka, Bosnia and Herzegovina|Sarajewo, Bosnia and Herzegovina",,"https://ClinicalTrials.gov/show/NCT01290094"
217,"NCT00129623","A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia",,"Completed","Has Results","Post-Menopausal Osteopenia","Drug: Placebo|Drug: ibandronate [Bonviva/Boniva]","Relative Change From Baseline in Mean Bone Mineral Density (BMD) of the Lumbar Spine (L2 to L4) at Month 12|Absolute Change From Baseline in Mean Lumbar Spine BMD at Month 12|Relative Change From Baseline in Mean Proximal Femur BMD at Month 12|Absolute Change From Baseline in BMD of the Proximal Femur at Month 12|Relative Change From Baseline in Serum C-telopeptide Crosslinks of Type 1 Collagen (CTX)|Absolute Change From Baseline in sCTX|Percentage of Responders|Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Marked Laboratory Abnormalities","Hoffmann-La Roche","Female","45 Years to 60 Years   (Adult)","Phase 4","160","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BA18492","December 2005","December 2007","December 2007","August 12, 2005","January 11, 2016","January 11, 2016","Lakewood, Colorado, United States|Stuart, Florida, United States|Bethesda, Maryland, United States|Detroit, Michigan, United States|St Louis, Missouri, United States|Omaha, Nebraska, United States|Albuquerque, New Mexico, United States|Cincinnati, Ohio, United States|Portland, Oregon, United States|Amarillo, Texas, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00129623"
218,"NCT00545090","ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.",,"Completed","No Results Available","Post Menopausal Osteoporosis","Drug: ibandronate [Bonviva/Boniva]","SAEs, AEs including fractures, adherence to treatment, clinical improvement, osteoporosis symptoms","Hoffmann-La Roche","Female","up to 85 Years   (Child, Adult, Older Adult)","Phase 4","561","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML19937","August 2006","June 2008","June 2008","October 17, 2007",,"November 10, 2016","Hong Kong, Hong Kong|Jakarta, Indonesia|Makassar, Indonesia|Surabaya, Indonesia|Manila, Philippines|Quezon City, Philippines|Changhua, Taiwan|Taichung, Taiwan|Taichung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Bangkok, Thailand|Bangkok, Thailand|Chiang Mai, Thailand|Khon Kaen, Thailand",,"https://ClinicalTrials.gov/show/NCT00545090"
219,"NCT00551174","A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment",,"Completed","Has Results","Post-Menopausal Osteoporosis","Drug: ibandronate [Bonviva/Boniva]","Relative Percent Change From Baseline in Mean Lumbar Spine Bone Mineral Density (BMD) at 12, 24 and 36 Months|Relative Percent Change From Baseline in Mean Total Hip BMD at 12, 24 and 36 Months|Relative Percent Change From Baseline in Serum C-telopeptide Crosslinks of Type I Collagen (CTX) at Trough at 6, 12, 24 and 36 Months|Relative Percent Change From Baseline in Post-dose Suppression of Serum CTX at 6 Months","Hoffmann-La Roche","Female","Child, Adult, Older Adult","Phase 4","781","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MA17904","October 2004","November 2008","November 2008","October 30, 2007","May 30, 2011","July 22, 2011","Gainesville, Georgia, United States|St Louis, Missouri, United States|Omaha, Nebraska, United States|Bismarck, North Dakota, United States|Fargo, North Dakota, United States|Madison, Wisconsin, United States|St. Leonards, Australia|Sydney, Australia|Bruxelles, Belgium|Liege, Belgium|Plzen, Czech Republic|Praha, Czech Republic|Aalborg, Denmark|Ballerup, Denmark|København, Denmark|Vejle, Denmark|Århus, Denmark|Lyon, France|Orleans, France|Berlin, Germany|Essen, Germany|Hamburg, Germany|Budapest, Hungary|Arenzano, Italy|Siena, Italy|Valeggio Sul Mincio, Italy|Mexico City, Mexico|Monterrey, Mexico|Haugesund, Norway|Oslo, Norway|Stavanger, Norway|Grudziadz, Poland|Krakow, Poland|Krakow, Poland|Cape Town, South Africa|Pretoria, South Africa|Sommerset West, South Africa|Madrid, Spain|Aberdeen, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00551174"
220,"NCT00545779","BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.",,"Completed","Has Results","Post-Menopausal Osteoporosis","Drug: Ibandronate","Percentage of Participants Current Daily or Weekly Bisphosphonate Users in Part A Who Answer 'Yes' to Any of the Questions in the Candidate Identification Questionnaire (CIQ)|Percentage of Participants Who Reported Preference for Monthly Ibandronate|Percentage of Participants With Positive Change in Total Composite Satisfaction Score (CSS) at Month 6 in Part B by CIQ Fracture (Fr) Group|Percentage of Participants Eligible Current Daily or Weekly Bisphosphonate Users at Screening Who Elect to Enter Part B by CIQ|Percentage of Participants Who Reported an Improved Satisfaction Score After 6 Months in Part B|Percentage of Participants Who Have Greater Than or Equal to (>=) 80% Compliance With 6 Monthly Doses of Ibandronate in Part B|Percentage of Participants Who Choose a Monthly Reminder to Take Ibandronate in Part B|Percentage of Participants Who Reported an Improvement in the Frequency of Gastro-intestinal (GI) Symptoms Per Month in Part B|Percentage of Participants by Age and Activity Level Reporting High Satisfaction According to the Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q) in Part B|Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q) Domain Scores in Part B","Hoffmann-La Roche","Female","Child, Adult, Older Adult","Phase 3","677","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML20430","December 2006","October 2008","October 2008","October 17, 2007","October 28, 2016","October 28, 2016","Tirana, Albania|Banja Luka, Bosnia and Herzegovina|Sarajevo, Bosnia and Herzegovina|Sarajevo, Bosnia and Herzegovina|Tuzla, Bosnia and Herzegovina|Rijeka, Croatia|Slavonski Brod, Croatia|Split, Croatia|Zagreb, Croatia|Skopje, Macedonia, The Former Yugoslav Republic of|Belgrade, Serbia|Niska Banja, Serbia|Novi Sad, Serbia|Adana, Turkey|Ankara, Turkey|Ankara, Turkey|Antalya, Turkey|Aydin, Turkey|Bursa, Turkey|Denizli, Turkey|Erzurum, Turkey|Gaziantep, Turkey|Istanbul, Turkey|Istanbul, Turkey|Istanbul, Turkey|Istanbul, Turkey|Izmir, Turkey|Kayseri, Turkey|Konya, Turkey|Manisa, Turkey|Samsun, Turkey|Trabzon, Turkey",,"https://ClinicalTrials.gov/show/NCT00545779"
221,"NCT00377234","A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.",,"Completed","Has Results","Post Menopausal Osteoporosis","Drug: Risedronate|Drug: ibandronate [Bonviva/Boniva]","Percentage of Participants Who Preferred Ibandronate Monthly Dosing to Risedronate Weekly Dosing|Percentage of Participants Who Found Once-monthly Ibandronate to be More Convenient Than Once-weekly Risedronate|Intensity of Upper Gastrointestinal (GI) Symptoms|Mean Change From Baseline in Bone Resorption and Bone Formation Markers, Serum C-telopeptide of α-chain of Type I Collagen (CTX) and Bone Specific Alkaline Phosphatase (BSAP)|Median Change From Baseline in Bone Resorption and Bone Formation Markers, Serum C-telopeptide of α-chain of Type I Collagen (CTX) and Bone Specific Alkaline Phosphatase (BSAP)","Hoffmann-La Roche","Female","55 Years to 80 Years   (Adult, Older Adult)","Phase 4","356","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MA19547","May 2006","August 2008","August 2008","September 18, 2006","July 22, 2015","August 1, 2016","Birmingham, Alabama, United States|Mesa, Arizona, United States|Scottsdale, Arizona, United States|Jonesboro, Arkansas, United States|Anaheim, California, United States|San Diego, California, United States|Waterbury, Connecticut, United States|Boynton Beach, Florida, United States|Jupiter, Florida, United States|Largo, Florida, United States|Leesburg, Florida, United States|Merritt Island, Florida, United States|Ocala, Florida, United States|Pembroke Pines, Florida, United States|Spring Hill, Florida, United States|St Petersburg, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Douglasville, Georgia, United States|Gainesville, Georgia, United States|Marietta, Georgia, United States|Madisonville, Kentucky, United States|Bethesda, Maryland, United States|Missoula, Montana, United States|Omaha, Nebraska, United States|Morehead City, North Carolina, United States|New Bern, North Carolina, United States|Jamestown, North Dakota, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Mogadore, Ohio, United States|Tulsa, Oklahoma, United States|Duncansville, Pennsylvania, United States|Erie, Pennsylvania, United States|Feasterville, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Anderson, South Carolina, United States|Memphis, Tennessee, United States|Selmer, Tennessee, United States|Bedford, Texas, United States|Bryan, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Temple, Texas, United States|Richmond, Virginia, United States|Richmond, Virginia, United States|Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00377234"
222,"NCT00303485","A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)",,"Completed","Has Results","Post Menopausal Osteoporosis","Drug: Placebo|Drug: Vitamin D and calcium supplementation|Drug: ibandronate [Bonviva/Boniva]","Relative Percent Change in Serum C-terminal Telopeptide of Type 1 Collagen Concentration (sCTX) From Baseline to Day 3|Relative Percent Change in Serum C-terminal Telopeptide of Type 1 Collagen (sCTX) Concentration From Baseline Over Time|Relative Percent Change in Bone Specific Alkaline Phosphatase (BSAP) Concentration From Baseline Over Time|Relative Percent Change in Parathyroid Hormone (PTH) From Baseline to Post Treatment Assessments|Percentage of Participants With a Serum C-terminal Telopeptide of Type1 Collagen (sCTX) Concentration Between 0.011 and 0.631 ng/mL and Who Have Achieved a Decrease in sCTX Concentration of at Least 8 Percent|Percentage of Participants With a Serum C-terminal Telopeptide of Type 1 Collagen (sCTX) Concentration Between 0.011 and 0.476 ng/mL|Percentage of Participants With a Serum C-terminal Telopeptide of Type 1 Collagen (sCTX) Concentration Between 0.011 and 0.321 ng/mL|Difference Between the Minimum and Maximum Relative Percent Change in Serum C-terminal Telopeptide of Type 1 Collagen (sCTX) Concentrations|Number of Participants With Any Marked Abnormality in Laboratory Parameters|Number of Participants With Any Adverse Event or Serious Adverse Event","Hoffmann-La Roche","Female","65 Years and older   (Older Adult)","Phase 4","67","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ML19334","February 2006","June 2007","June 2007","March 17, 2006","May 2, 2016","May 2, 2016","Beverly Hills, California, United States|La Jolla, California, United States|Augusta, Georgia, United States|Woodbury, Minnesota, United States|Bronx, New York, United States|Hopwood, Pennsylvania, United States|Madison, Wisconsin, United States|Ponce, Puerto Rico|San Juan, Puerto Rico|San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00303485"
223,"NCT00081653","A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva",,"Completed","Has Results","Post-Menopausal Osteoporosis","Drug: ibandronate [Bonviva/Boniva]","Absolute Change From Baseline in Mean Lumbar Spine (L2 - L4) BMD|Relative Percent (%) Change From Baseline in Mean Lumbar Spine (L2 - L4) Bone Mineral Density (BMD)|Absolute Change From Baseline in Mean Total Hip BMD|Relative Percent Change From Baseline in Mean Total Hip BMD|Absolute Change From Baseline of Trough Serum CTX|Relative Percent Change From Baseline of Trough Serum CTX","Hoffmann-La Roche","Female","Child, Adult, Older Adult","Phase 4","719","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MA17903","May 2004","November 2007","May 2008","April 21, 2004","July 21, 2009","July 14, 2017","Loma Linda, California, United States|Lakewood, Colorado, United States|Omaha, Nebraska, United States|Livingston, New Jersey, United States|Portland, Oregon, United States|Liege, Belgium|Merksem, Belgium|Sao Paulo, Brazil|Plzen, Czechia|Praha, Czechia|Aalborg, Denmark|Ballerup, Denmark|Vejle, Denmark|Lyon, France|Berlin, Germany|Hannover, Germany|Balatonfuered, Hungary|Budapest, Hungary|Budapest, Hungary|Kiskunhalas, Hungary|Zalaegerszeg, Hungary|Siena, Italy|Leon, Mexico|Obregon, Mexico|Haugesund, Norway|Stavanger, Norway|Krakow, Poland|Warszawa, Poland|Barcelona, Spain|Madrid, Spain|Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00081653"
224,"NCT00048061","MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis",,"Completed","Has Results","Post Menopausal Osteoporosis","Drug: Ibandronate [Bonviva/Boniva]|Dietary Supplement: Calcium|Dietary Supplement: Vitamin D","Relative Change From Baseline at One Year (12 Months) in Mean Lumbar Spine (L2 - L4) Bone Mineral Density|Relative Change From Baseline at Two Years (24 Months) in Mean Lumbar Spine (L2-L4) BMD|Absolute Change From Baseline at One Year (12 Months) and Two Years (24 Months) in Mean Lumbar Spine (L2-L4) BMD|Relative Change From Baseline at One Year (12 Months) and Two Years (24 Months) in Mean Proximal Femur ( Total Hip, Trochanter, Femoral Neck) BMD|Absolute Change From Baseline at One Year (12 Months) and Two Years (24 Months) in Mean Proximal Femur ( Total Hip, Trochanter, Femoral Neck) BMD.|Percentage of Participants With Mean Lumbar Spine (L2 - L4) BMD Above or Equal to Baseline at Months 12 and 24|Percentage of Participants With Total Hip BMD Above or Equal to Baseline at Months 12 and 24|Percentage of Participants With Trochanter BMD Above or Equal to Baseline at Months 12 and 24|Percentage of Participants With Femoral Neck BMD Above or Equal to Baseline at Months 12 and 24|Percentage of Participants With Mean Total Hip and Lumbar Spine BMD Above or Equal to Baseline at Months 12 and 24|Percentage of Participants With Mean Trochanter and Lumbar Spine BMD Above or Equal to Baseline at Months 12 and 24|Percentage of Participants With Mean Femoral Neck and Lumbar Spine BMD Above or Equal to Baseline at Months 12 and 24|Relative Change In Baseline in Serum C-telopeptide of Alpha-chain of Type I Collagen [ CTX] ] to Months 3, 6, 12, and 24|Absolute Change In Baseline in Serum CTX to Months 12 and 24|Number of Participants With Any Adverse Events and Serious Adverse Event|Number Of Participants With Marked Laboratory Abnormalities","Hoffmann-La Roche","Female","55 Years to 80 Years   (Adult, Older Adult)","Phase 3","1609","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","BM16549","April 2002","December 2004","December 2004","October 25, 2002","May 30, 2016","March 29, 2018","Irvine, California, United States|Loma Linda, California, United States|Los Angeles, California, United States|Oakland, California, United States|Rancho Mirage, California, United States|Lakewood, Colorado, United States|Gainesville, Florida, United States|Bethesda, Maryland, United States|Wheaton, Maryland, United States|Saint Louis, Missouri, United States|Billings, Montana, United States|Omaha, Nebraska, United States|Livingston, New Jersey, United States|Albuquerque, New Mexico, United States|Portland, Oregon, United States|Wyomissing, Pennsylvania, United States|San Antonio, Texas, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Madison, Wisconsin, United States|Adelaide, Australia|Adelaide, Australia|Parkville, Australia|Perth, Australia|Liege, Belgium|Merksem, Belgium|Campinas, Brazil|Curitiba, Brazil|Porto Alegre, Brazil|Sao Paulo, Brazil|Calgary, Alberta, Canada|Vancouver, British Columbia, Canada|Toronto, Ontario, Canada|Quebec City, Quebec, Canada|Plzen, Czechia|Praha, Czechia|Praha, Czechia|Aalborg, Denmark|Ballerup, Denmark|Vejle, Denmark|Caen, France|Lyon, France|Berlin, Germany|Hannover, Germany|Balatonfuered, Hungary|Budapest, Hungary|Budapest, Hungary|Kiskunhalas, Hungary|Zalaegerszeg, Hungary|Siena, Italy|Valeggio Sul Mincio, Italy|Leon, Mexico|Obregon, Mexico|Haugesund, Norway|Oslo, Norway|Stavanger, Norway|Krakow, Poland|Warszawa, Poland|Bucharest, Romania|Cape Town, South Africa|Johannesburg, South Africa|Barcelona, Spain|Madrid, Spain|Zürich, Switzerland|Cardiff, United Kingdom|Liverpool, United Kingdom|London, United Kingdom|Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00048061"
225,"NCT00048074","DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis",,"Completed","Has Results","Post Menopausal Osteoporosis","Drug: ibandronate [Bonviva/Boniva]","Relative Percent Change From Baseline in Mean Bone Mineral Density (BMD) of Lumbar Spine (L2-L4) at 12 Months|Relative Percent Change From Baseline in Mean BMD of Lumbar Spine (L2-L4) at 24 Months|Absolute Change From Baseline in Mean BMD of Lumbar Spine (L2 - L4) at Month 12 and Month 24|Relative Percent Change From Baseline in BMD of Proximal Femur (Consisting of Total Hip, Trochanter, and Femoral Neck) at Month 12 and 24|Absolute Change From Baseline in BMD of Proximal Femur (Consisting of Total Hip, Trochanter, and Femoral Neck) at Month 12 and 24|Relative Change From Baseline in Serum C-telopeptide of Alpha-chain of Type I Collagen (CTX) at Month 6, 12, and 24|Absolute Change From Baseline in Serum CTX at Month 6, 12, and 24|Percentage of Participants With Mean Lumbar Spine (L2 - L4) BMD Above or Equal to Baseline at Month 12 and 24|Percentage of Participants With Total Hip BMD Above or Equal to Baseline at Month 12 and 24|Percentage of Participants With Trochanter BMD Above or Equal to Baseline at Month 12 and 24|Percentage of Participants With Femoral Neck BMD Above or Equal to Baseline at Month 12 and 24|Percentage of Participants With Mean Total Hip and Lumbar Spine BMD Above or Equal to Baseline at Month 12 and 24|Percentage of Participants With Mean Trochanter and Lumbar Spine BMD Above or Equal to Baseline at Month 12 and 24|Percentage of Participants With Mean Femoral Neck and Lumbar Spine BMD Above or Equal to Baseline at Month 12 and 24|Number of Participants Who Experienced Any Adverse Events (AEs) or Serious Adverse Events (SAEs)|Number of Participants With Any Marked Abnormality in Laboratory Parameters","Hoffmann-La Roche","Female","55 Years to 80 Years   (Adult, Older Adult)","Phase 3","1395","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","BM16550","June 2002","May 2005","May 2005","October 25, 2002","February 3, 2016","February 3, 2016","Little Rock, Arkansas, United States|Irvine, California, United States|Rancho Mirage, California, United States|Leesburg, Florida, United States|Gainesville, Georgia, United States|Coeur D'alene, Idaho, United States|Bethesda, Maryland, United States|St Louis, Missouri, United States|Billings, Montana, United States|Omaha, Nebraska, United States|Albuquerque, New Mexico, United States|New York, New York, United States|Bismarck, North Dakota, United States|Fargo, North Dakota, United States|Wyomissing, Pennsylvania, United States|Rapid City, South Dakota, United States|San Antonio, Texas, United States|Virginia Beach, Virginia, United States|Madison, Wisconsin, United States|Darlinghurst, Australia|Melbourne, Australia|Nedlands, Australia|St. Leonards, Australia|Sydney, Australia|Bruxelles, Belgium|Liege, Belgium|Toronto, Ontario, Canada|Laval, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Saskatoon, Saskatchewan, Canada|Plzen, Czech Republic|Praha, Czech Republic|Aalborg, Denmark|Ballerup, Denmark|København, Denmark|Vejle, Denmark|Århus, Denmark|Lyon, France|Orleans, France|Berlin, Germany|Bochum, Germany|Hamburg, Germany|Budapest, Hungary|Arenzano, Italy|Siena, Italy|Valeggio Sul Mincio, Italy|Mexico City, Mexico|Monterrey, Mexico|Haugesund, Norway|Oslo, Norway|Stavanger, Norway|Grudziadz, Poland|Krakow, Poland|Krakow, Poland|Cape Town, South Africa|Pretoria, South Africa|Sommerset West, South Africa|Barcelona, Spain|Madrid, Spain|Santander, Spain|Aberdeen, United Kingdom|Manchester, United Kingdom|Newcastle Upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00048074"
226,"NCT00543218","PTH Comparison in Post Menopausal Women",,"Completed","No Results Available","Osteoporosis, Post-Menopausal","Drug: teriparatide 20 micrograms/day subcutaneous|Drug: calcitonin 100 IU/day subcutaneous","To compare in postmenopausal women with established osteoporosis the effect of treatment with teriparatide 20 micrograms/day subcutaneous with the effect of salmon calcitonin 100 IU/day subcutaneous on change in lumbar spine BMD.|To compare in postmenopausal women with established osteoporosis the effect of treatment with teriparatide 20 micrograms/day with the effect of calcitonin 100 IU/day on change in femoral neck and total hip BMD|Compare the effect of teriparatide 20 micrograms/day with calcitonin 100 IU/day on change in biochemical bone markers (bone specific alkaline phosphatase[BSAP] and Osteocalcin) at 3 and 6 months after treatment with teriparatide versus calcitonin|Safety as determined by physical examinations, vital signs, clinical labs and reports of adverse events","Eli Lilly and Company","Female","55 Years to 85 Years   (Adult, Older Adult)","Phase 3","63","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6573|B3D-TW-GHCB","December 2002",,"June 2004","October 12, 2007",,"October 12, 2007","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559) Mon-Fri from 9 am - 5 pm Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Changhua, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559) Mon-Fri from 9 am - 5 pm Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Niao Sung Hsiang, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559) Mon-Fri from 9 am - 5 pm Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559) Mon-Fri from 9 am - 5 pm Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tao-Yuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT00543218"
227,"NCT01232647","Vitamin K as Additive Treatment in Osteoporosis","VITKANDOP","Unknown status","No Results Available","Post-menopausal Osteoporosis","Drug: Phylloquinone|Drug: Menatetrenone (MK4)|Drug: placebo","Primary outcome measures- Changes in BMD at the Lumber spine, hip, fore-arm at 18 months.|Secondary outcome measure- Bone Turnover as assessed by the biochemical markers (serum CTX, P1NP, BALP, carboxylated and undercarboxylated osteocalcin (OC), OPG). These markers will be measured at the same time point during each clinic visit.","Guy's and St Thomas' NHS Foundation Trust","Female","55 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","105","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Eudract number - 2010-02258712","April 2015","March 31, 2020","March 31, 2020","November 2, 2010",,"February 13, 2020","Guy's and St Thomas' Hospital NHS foundation Trust, London, United Kingdom|Osteoporosis Unit, Guy's Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01232647"
228,"NCT03432533","A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis",,"Completed","Has Results","Post-Menopausal Osteoporosis","Drug: romosozumab HCP administration with PFS|Device: romosozumab self-administration with AI/Pen","Percent Change From Baseline in Lumbar Spine BMD at Month 6|Percent Change From Baseline in Total Hip BMD at Month 6|Percent Change From Baseline in Femoral Neck BMD at Month 6|Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Device-Related AEs, Discontinuations Due to AEs, and Deaths|Number of Participants Developing Anti-Romosozumab Antibodies","Amgen","Female","55 Years to 90 Years   (Adult, Older Adult)","Phase 3","283","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20150120|2017-003512-40","February 6, 2018","April 11, 2019","January 8, 2020","February 14, 2018","April 10, 2020","November 23, 2020","Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Tuscaloosa, Alabama, United States|Research Site, Chandler, Arizona, United States|Research Site, Mesa, Arizona, United States|Research Site, Cypress, California, United States|Research Site, Fullerton, California, United States|Research Site, Glendale, California, United States|Research Site, Laguna Hills, California, United States|Research Site, Santa Maria, California, United States|Research Site, Tustin, California, United States|Research Site, Denver, Colorado, United States|Research Site, Golden, Colorado, United States|Research Site, Delray Beach, Florida, United States|Research Site, South Miami, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Bridgeton, Missouri, United States|Research Site, Springfield, Missouri, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Great Neck, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Wyomissing, Pennsylvania, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Summerville, South Carolina, United States|Research Site, San Antonio, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Chesapeake, Virginia, United States|Research Site, Danville, Virginia, United States|Research Site, Renton, Washington, United States|Research Site, Franklin, Wisconsin, United States|Research Site, Bialystok, Poland|Research Site, Lodz, Poland|Research Site, Swidnik, Poland|Research Site, Warszawa, Poland|Research Site, Chorley, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Romford, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03432533/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03432533/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03432533"
229,"NCT02347865","Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France","PILOTE","Completed","No Results Available","Post Menopausal Osteoporosis","Drug: AMG 162 - Prolia","patient occurence of persistence (persistence is defined in the outcome description) at 12 months|patient occurence of persistence (persistence is defined in the outcome description) at 24 months and time to non-persistence at 24 months|describe the use of Prolia in routine clinical practice during approximately 30 months from the first injection|patient occurence of Adverse Drug Reactions (ADRs) and Serious Adverse Drug Reactions (SADRs) as collected in routine clinical practice|Occurrence of patient reported osteoporosis related vertebral and non vertebral fractures reported during the study","Amgen","Female","40 Years to 95 Years   (Adult, Older Adult)",,"777","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","20130240","June 16, 2015","October 26, 2017","September 27, 2018","January 27, 2015",,"November 14, 2022","Amgen, Paris, France",,"https://ClinicalTrials.gov/show/NCT02347865"
230,"NCT04820738","Effects of Sensory Motor Training on Balance and Proprioception Among Post-Menopausal Obese Women",,"Completed","No Results Available","Post Menopaused Female","Other: Sensorimotor training exercises|Other: Without Sensorimotor training exercises","Functional Reach Test (FRT)|Time Up and Go Test (TUG)|One Leg Stance Test (OLS)","Riphah International University","Female","45 Years to 65 Years   (Adult, Older Adult)","Not Applicable","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","REC/Lhr/20/2050 Sehar Shabeer","February 15, 2020","October 20, 2020","December 20, 2020","March 29, 2021",,"March 30, 2021","Binash afzal, Lahore, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT04820738"
231,"NCT04141033","Assessment of Neopterin Levels in Pre- and Post-menopausal Women With Chronic Periodontitis",,"Completed","No Results Available","Menopause","Diagnostic Test: assessment of neopterin levels","assess salivary and gingival crevicular fluid neopterin levels in patients with chronic periodontitis in pre- and post-menopausal women|evaluate the value of neopterin as a biomarker","Ain Shams University","Female","35 Years to 60 Years   (Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Abeer Alaa 88","January 25, 2019","April 25, 2019","April 30, 2019","October 28, 2019",,"October 28, 2019","Ain Shams University- Faculty of Dentistry, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04141033"
232,"NCT01443455","Adherence and Health Effects of Video Dance in Postmenopausal Women",,"Completed","No Results Available","Post Menopausal","Behavioral: videodance|Behavioral: Brisk Walking|Behavioral: delayed entry control","Adherence|Endurance|body composition|vascular health|balance|personality|sleep quality|visuospatial/constructional function|attention domain|Useful Field of View|step reaction time","University of Pittsburgh|National Institute on Aging (NIA)","Female","50 Years to 65 Years   (Adult, Older Adult)","Not Applicable","168","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","PRO08080012|T32AG021885|P30AG024827","January 2010","July 31, 2012","September 30, 2012","September 29, 2011",,"October 2, 2017","University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01443455"
233,"NCT02679794","Impact of Egg Consumption on Carotenoid and Vitamin D Bioavailability in Pre- and Post-menopausal Women",,"Completed","No Results Available","Menopause","Behavioral: Egg consumption|Behavioral: Control","Contents of total and individual carotenoids in triglyceride-rich lipoprotein fractions|Vitamin D content in in triglyceride-rich lipoprotein fractions","Purdue University","Female","19 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Other","1507016290","December 2015","May 2017","August 2017","February 10, 2016",,"January 11, 2018","Purdue Clinical Research Center, West Lafayette, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT02679794"
234,"NCT02841137","Efficacy Study of Progesterone Tablet in Post-menopausal Women",,"Completed","No Results Available","Menopause","Drug: Progesterone","endometrial thickness change towards baseline (mm)|histological assessment of the endometrium (presence of hyperplasia or proliferation)|bleeding (presence or absence)|quality of life (MENQOL Questionnaire)|sleep scale from the Medical Outcomes Study (MOS)","IBSA Institut Biochimique SA","Female","40 Years to 65 Years   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16CDN-Prg02","June 2016","August 2, 2017","April 25, 2018","July 22, 2016",,"June 11, 2018","Algorithme Pharma, Mont-Royal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02841137"
235,"NCT03556800","Study to Investigate the Pharmacokinetics & Safety Following One Application of 3 Different Doses 0.5,0.75,& 1.25 gm,a Transdermal Estradiol Cream (VML-0203), in Comparison to a Single Dose of EstroGel 1.25 gm to Healthy Post-menopausal Women.",,"Recruiting","No Results Available","Menopause","Drug: Estrogel","To compare the bio-availability of estradiol and estrone.|To provide general safety information for VML-0203.","Viramal Limited|Simbec Research","Female","30 Years and older   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care","VML-0203-002","May 22, 2018","June 30, 2022","June 30, 2022","June 14, 2018",,"April 27, 2022","Simbec Research Ltd, Merthyr Tydfil, Wales, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03556800"
236,"NCT05275270","Role of Topical Oxytocin Gel in Post-Menopausal Women",,"Completed","No Results Available","Menopause Related Conditions","Other: oxytocin gel|Other: placebo gel","vaginal pallor|intravaginal potential of hydrogen (pH)|Cytological examination of vaginal smear|The Female Sexual Function Index (FSFI) questionnaire|questionnaire to assess the psychological function|Visual Analogue Scale (VAS)|Cholesterol|Triglyceride|HDL-C|LDL-C|C-Reactive Protein (CRP)|Random blood sugar (RBS)|HBA1C|Insulin|C-Peptide F|Cortisol at morning|Interleukin-6 (IL-6)|Tumor necrosis factor-Alfa (TNF-Alfa)","Al-Azhar University|National Research Centre, Egypt","Female","47 Years to 66 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care","Topical Oxytocin Gel","December 1, 2020","May 31, 2021","May 31, 2021","March 11, 2022",,"March 11, 2022","Al-Galaa Teaching Hospital, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT05275270"
237,"NCT02517801","Investigation on the Sustained Effect of Anthocyanins on Endothelial Function in Postmenopausal Women","Anthocyanins","Completed","No Results Available","Post-menopausal Women","Dietary Supplement: Anthocyanin capsules|Dietary Supplement: placebo capsules","Endothelial function|Pulse wave velocity|Central blood pressure|Heart rate|Ambulatory blood pressure","Heinrich-Heine University, Duesseldorf","Female","50 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Anthocyanins","January 2015","September 2015","September 2015","August 7, 2015",,"November 3, 2015","Division of Cardiology, Pulmonary Disease and Vascular Medicine, University Hospital Duesseldorf, Duesseldorf, Germany",,"https://ClinicalTrials.gov/show/NCT02517801"
238,"NCT03942276","Effects of Different Exercises Interventions in Post-menopausal Women",,"Terminated","No Results Available","Hypertension|Menopause","Other: High intensity interval training|Other: Moderate intensity continuous training|Other: Control","Changes in Ambulatorial Blood Pressure|Changes in Resting Blood Pressure|Changes in Heart Rate Variability|Changes in Ambulatorial Blood Pressure Variability|Changes in Blood pressure reactivity|Changes in salivary oxidative stress (umol/L)|Changes in salivary oxidative stress (units/mg prot)|Changes in salivary oxidative stress (μmol H2O2/min/g prot)|Changes in salivary oxidative stress (nM)|Changes in blood biomarkers (mg/dL)|Changes in blood biomarkers (nM)|Changes in blood biomarkers (pg/mL)|Changes in blood biomarkers (mg/L)|Changes in blood biomarkers (Units/mg de prot)|Changes in blood biomarkers (umol/L)","Federal University of Uberlandia","Female","50 Years to 70 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CEP UFU 07839218.8.0000.5152","September 1, 2019","March 31, 2020","September 30, 2020","May 8, 2019",,"January 11, 2021","Guilherme Morais Puga, Uberlandia, Minas Gerais, Brazil",,"https://ClinicalTrials.gov/show/NCT03942276"
239,"NCT02598934","A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis",,"Completed","Has Results","Post Menopausal Osteoporosis","Drug: Ibandronate","Percent Change From Baseline to Month 6 in Serum C-terminal Telopeptide of Type 1 Collagen (CTX)|Percent Change From Baseline to Month 6 in Urine N-terminal Telopeptide of Type 1 Collagen (NTX)|Percent Change From Baseline to Month 6 in Serum Procollagen Type 1 N-terminal Propeptide (P1NP)|Percent Change From Baseline to Month 6 in Serum Osteocalcin|Percent Change From Baseline to Month 6 in Serum Bone-Specific Alkaline Phosphatase (BSAP)|Percentage of Participants Who Were ""Very Confident"" or ""Confident"" to Items on the Boniva Confidence Scale (BCS) at Month 6","Hoffmann-La Roche","Female","Child, Adult, Older Adult","Phase 4","308","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML18057","August 2004","May 2006","May 2006","November 6, 2015","March 9, 2016","March 9, 2016","Montgomery, Alabama, United States|Chandler, Arizona, United States|Peoria, Arizona, United States|Hot Springs, Arkansas, United States|Pine Bluff, Arkansas, United States|Anaheim, California, United States|Beverly Hills, California, United States|Carmichael, California, United States|Wilmington, Delaware, United States|Deland, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Palm Habor, Florida, United States|Palm Springs, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Rome, Georgia, United States|Morton Grove, Illinois, United States|Indianapolis, Indiana, United States|Waterloo, Iowa, United States|Baltimore, Maryland, United States|Hagerstown, Maryland, United States|Reistertown, Maryland, United States|Olive Branch, Mississippi, United States|Jefferson City, Missouri, United States|St Louis, Missouri, United States|Omaha, Nebraska, United States|Bloomfield, New Jersey, United States|Bronx, New York, United States|New York, New York, United States|Morehead City, North Carolina, United States|Morganton, North Carolina, United States|Raleigh, North Carolina, United States|Oklahoma City, Oklahoma, United States|Medford, Oregon, United States|Doylestown, Pennsylvania, United States|Langhorne, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Mount Pleasant, South Carolina, United States|Spartanburg, South Carolina, United States|Morristown, Tennessee, United States|Murfreesboro, Tennessee, United States|Nashville, Tennessee, United States|Amarillo, Texas, United States|Fort Worth, Texas, United States|San Antonio, Texas, United States|Texarkana, Texas, United States|Richmond, Virginia, United States|Tacoma, Washington, United States|Madison, Wisconsin, United States|Ponce, Puerto Rico|San Juan, Puerto Rico|San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT02598934"
240,"NCT01272167","Effects of a Long-term Grapefruit Juice Consumption on Vascular Protection and Bone Metabolism",,"Completed","No Results Available","Post-menopausal Status","Behavioral: Long-term grapefruit juice consumption",,"University Hospital, Clermont-Ferrand|INRA de Clermont-Fd / Theix|UMR 1019 Unité de Nutrition Humaine|Equipe MiMes|63122 Saint-Genès Champanelle|FRANCE","Female","50 Years to 65 Years   (Adult, Older Adult)","Not Applicable","52","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","CHU-0085|2009-A00960-57","March 2010","December 2011","December 2011","January 7, 2011",,"July 8, 2014","CHU Clermont-Ferrand, Clermont-Ferrand, France",,"https://ClinicalTrials.gov/show/NCT01272167"
241,"NCT00119418","TU 025 Keishi Bukuryo Gan for Post-menopausal Hot Flash Management",,"Completed","No Results Available","Hot Flashes|Menopause","Drug: TU 025 Keishi Bukuryo Gan","frequency and severity of hot flashes by Mayo Hot Flash Diary|sleep quality by the Pittsburgh Questionnaire|bodyweight/BMI by standard measurements|quality of menopausal life by Greene Climacteric Scale|lipid profile by laboratory test|liver function profile by laboratory test|hormone profile by laboratory test","Plotnikoff, Gregory A., M.D.|Tsumura and Company, Tokyo, Japan|University of Minnesota","Female","45 Years to 58 Years   (Adult)","Phase 2","180","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","0402M56292|M01-RR00400 NIH","November 2004",,"February 2006","July 13, 2005",,"October 26, 2010","University of Minnesota General Clinical Research Center, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00119418"
242,"NCT02162160","Microbiological Impact of an Intimate Cream and Its Suitability to Contribute to the Feeling of Softness and Freshness in the Intimate Area of Women",,"Completed","No Results Available","Post Menopausal Dryness in the Intimate Area of Women","Device: probiotic creme|Drug: Placebo","Presence of at least one LN bacteria strain in the intimate area of women in the intervention group|Obtain information about the coliform bacteria flora in respect to E. coli flora in the external intimate area|subjective feeling of dryness and freshness in the intimate of women","Karolinska Institutet","Female","45 Years to 65 Years   (Adult, Older Adult)","Phase 2","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KI DS 2013","September 2013","March 2014","March 2014","June 12, 2014",,"November 26, 2015","Dept of Obstetrics and Gynecology, Dnderyds Hospital, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT02162160"
243,"NCT00666627","Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects",,"Completed","No Results Available","Post-menopausal Osteoporosis","Drug: Ibandronate|Drug: Risedronate|Drug: Alendronate","Change in heel broadband ultrasound attenuation|Changes in the percentage of MCSFR+ monocytes in the peripheral blood at baseline and after one week and 48 weeks of therapy|Change in SOS at finger and heel at 48 weeks.|Change in lumbar spine and total hip BMD measured by DXA at 48 weeks|Change in finger BMD measured by RA at 48 weeks|Change in heel BMD measured by DXL at 48 weeks|Change in distal tibia and ultradistal forearm cortical and trabecular volumetric BMD by pQCT at 48 weeks|Changes in cathepsin K and MM enzyme and OPG and RANK-L protein at 12 weeks|Changes in uNTX and uCTX. At 12 weeks|Change in disulfide bond content of nails at 48 weeks","Sheffield Teaching Hospitals NHS Foundation Trust|Procter and Gamble|University of Sheffield","Female","35 Years to 85 Years   (Adult, Older Adult)","Phase 2","410","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STH 14463","April 2007","September 2012","December 2014","April 25, 2008",,"March 6, 2018","Academic Unit of Bone Metabolism (Sheffield), Sheffield, South Yorkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00666627"
244,"NCT00560924","Preventive Effect of Treatment With Estradiol Vaginal Tablets on Recurrent Urinary Tract Infections in Post-menopausal Women",,"Terminated","No Results Available","Menopause|Urinary Infections","Drug: estradiol, 25 mcg","Time to first symptom of urinary tract infection (UTI)|Number of urinary tract infection (UTI)","Novo Nordisk A/S","Female","Child, Adult, Older Adult","Phase 3","6","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","VAG-1458","March 21, 2003","March 17, 2004","March 17, 2004","November 20, 2007",,"February 28, 2017","Novo Nordisk Investigational Site, Malmö, Sweden",,"https://ClinicalTrials.gov/show/NCT00560924"
245,"NCT04606550","MonaLisa Laser Intervention for Post-Menopausal Breast Cancer Patients: A SHE CAN Study",,"Withdrawn","No Results Available","Breast Cancer Female|Genitourinary Syndrome of Menopause","Device: Microablative Fractional CO2 Laser Therapy","MonaLisa Touch Impact on vaginal health in breast caner patients|VAS","Mount Sinai Hospital, Canada","Female","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","20-0140-A","September 1, 2021","December 1, 2021","July 1, 2022","October 28, 2020",,"October 13, 2022",,,"https://ClinicalTrials.gov/show/NCT04606550"
246,"NCT01808040","A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer",,"Completed","No Results Available","Post Menopausal, Hormone Receptor Positive Breast Cancer","Drug: TAK700","Number of Participants with Adverse Events as a Measure of Safety and Tolerability as a way to determine the recommended phase 2 dose.|decrease in serum estradiol level|Overall Response Rate|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|pharmacodynamic activity of orteronel with steroid and endocrine levels|response rate, progression-free survival and time to progression","University of Wisconsin, Madison|Millennium Pharmaceuticals, Inc.","Female","18 Years and older   (Adult, Older Adult)","Phase 1","8","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CO11109|2012-0355|NCI-2012-02022|A534260|SMPH\MEDICINE\HEM-ONC","November 2012","July 2014","December 9, 2016","March 8, 2013",,"November 18, 2019","University of Wisconsin, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01808040"
247,"NCT05556317","Effect of Resistive Exercise on Insomnia in Post Menopausal Women",,"Recruiting","No Results Available","Sleep Disturbances and Insomnia","Behavioral: Resistive exercise","Pittsburgh sleep quality index|Insomnia severity index","Cairo University","Female","50 Years to 65 Years   (Adult, Older Adult)","Not Applicable","56","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","P.T.REC/012/003873","September 30, 2022","November 1, 2022","November 15, 2022","September 27, 2022",,"September 27, 2022","Professor of physical therapy, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT05556317"
248,"NCT00925639","Effects of the Concentrated Extract of Soy on Coagulation Factors After Menopause",,"Unknown status","No Results Available","Menopause","Drug: Isoflavone|Drug: Placebo","Concentration of serum DDimer","Federal University of São Paulo","Female","45 Years to 65 Years   (Adult, Older Adult)","Phase 3","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CEP/UNIFESP 0728/08","August 2009","January 2010","August 2010","June 22, 2009",,"June 22, 2009","Ambulatório de Ginecologia Endócrina, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT00925639"
249,"NCT01732770","Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis",,"Completed","Has Results","Post Menopausal Osteoporosis","Biological: Denosumab|Drug: Zoledronic Acid|Drug: Placebo to Denosumab|Drug: Placebo to Zoledronic Acid","Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12 - Non-inferiority Analysis|Percent Change From Baseline in Total Hip BMD at Month 12 - Non-inferiority Analysis|Percent Change From Baseline in Lumbar Spine BMD at Month 12 - Superiority Analysis|Percent Change From Baseline in Total Hip BMD at Month 12 - Superiority Analysis","Amgen","Female","55 Years and older   (Adult, Older Adult)","Phase 4","643","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20110153|2012-001821-28","November 7, 2012","January 7, 2015","January 7, 2015","November 26, 2012","January 25, 2016","March 10, 2020","Research Site, Santa Monica, California, United States|Research Site, Lakewood, Colorado, United States|Research Site, Longmont, Colorado, United States|Research Site, Washington, District of Columbia, United States|Research Site, Bethesda, Maryland, United States|Research Site, Hagerstown, Maryland, United States|Research Site, Detroit, Michigan, United States|Research Site, West Haverstraw, New York, United States|Research Site, Houston, Texas, United States|Research Site, Maroubra, New South Wales, Australia|Research Site, Penrith, New South Wales, Australia|Research Site, St Leonards, New South Wales, Australia|Research Site, Box Hill, Victoria, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Brussels, Belgium|Research Site, Brussel, Belgium|Research Site, Bruxelles, Belgium|Research Site, Bruxelles, Belgium|Research Site, Genk, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Merksem, Belgium|Research Site, Tessenderlo, Belgium|Research Site, Wilrijk, Belgium|Research Site, Yvoir, Belgium|Research Site, Calgary, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Quebec, Canada|Research Site, Aalborg, Denmark|Research Site, Ballerup, Denmark|Research Site, Vejle, Denmark|Research Site, Bialystok, Poland|Research Site, Kraków, Poland|Research Site, Torun, Poland|Research Site, Warszawa, Poland|Research Site, Granada, Andalucía, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01732770"
250,"NCT01674621","Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis",,"Completed","Has Results","Post Menopausal Osteoporosis","Drug: Abaloparatide Transdermal (50 mcg)|Drug: Abaloparatide Transdermal (100 mcg)|Drug: Abaloparatide Transdermal (150 mcg)|Drug: Abaloparatide Injection (80 mcg)|Drug: Abaloparatide Placebo","Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at 6 Months|Percent Change From Baseline in BMD of Total Hip at 6 Months|Percent Change From Baseline in BMD of Forearm at 6 Months|Percent Change From Baseline in Serum Bone-Specific Alkaline Phosphatase (BSAP) at 6 Months|Percent Change From Baseline in Serum Procollagen Type I C Propeptide (PICP) at 6 Months|Percent Change From Baseline in Serum Osteocalcin at 6 Months|Percent Change From Baseline in Serum Procollagen Type I N Propeptide (PINP) at 6 Months|Percent Change From Baseline in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (CTXI) at 6 Months|Number of Participants With Abnormal Physical Examinations at Screening and End of Treatment (6 Months)|Number of Participants With Treatment Emergent Adverse Events (TEAEs) That Occurred During the Study That Were Associated With Vital Sign Changes|Number of Participants With a Clinically Meaningful Abnormal Electrocardiogram (ECG) Test Result|Number of Participants With an Abnormal Clinical Hematology Laboratory Parameter With an Eastern Cooperative Oncology Group (ECOG) Score of Grade 3 or Grade 4|Number of Participants With an Abnormal Clinical Chemistry Laboratory Parameter With an ECOG Score of Grade 3 or Grade 4|Number of Participants With an Abnormal Clinical Coagulation Laboratory Parameter With an ECOG Score of Grade 3 or Grade 4","Radius Health, Inc.|Nordic Bioscience A/S","Female","up to 85 Years   (Child, Adult, Older Adult)","Phase 2","250","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BA058-05-007|2012-001921-29","September 25, 2012","August 2, 2013","August 2, 2013","August 29, 2012","December 19, 2016","June 16, 2020","Lakewood, Colorado, United States|Atlanta, Georgia, United States|Bethesda, Maryland, United States|Aalborg, Denmark|Ballerup, Denmark|Vejle, Denmark|Tallinn, Estonia|Lodz, Poland|Warsaw, Poland",,"https://ClinicalTrials.gov/show/NCT01674621"
251,"NCT00984893","Intra-venous Zoledronic Acid Once Yearly","IVORY","Completed","No Results Available","Post-Menopausal Osteoporosis","Drug: zoledronic acid|Drug: Any oral bisphosphonates marketed in Canada","Percent change in lumbar spine BMD as measured by dual energy x-ray absorptiometry (DXA)|change in femoral neck BMD as measured by dual energy x-ray absorptiometry (DXA)|change in hip BMD as measured by dual energy x-ray absorptiometry (DXA)|Percent change in hip BMD as measured by dual energy x-ray absorptiometry (DXA)|Risk for fractures|Burden of illness, health care resource utilization, and loss of productivity","Novartis Pharmaceuticals|Novartis","Female","45 Years and older   (Adult, Older Adult)",,"1551","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CZOL446HCA10","November 2008","April 2014","April 2014","September 25, 2009",,"March 4, 2016","Vancouver, British Columbia, Canada|Hamilton, Ontario, Canada|Groupe de recherche en rhumatologie et maladies osseuses Inc, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00984893"
252,"NCT00533650","Proof of Concept (Bone Resorption/Bone Mineral Density) Study (0429-005)",,"Completed","No Results Available","Post-Menopausal Osteoporosis","Drug: MK0429",,"Merck Sharp & Dohme LLC","Female","50 Years to 75 Years   (Adult, Older Adult)","Phase 2","227","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","0429-005|2007_620","December 2000","October 2002","October 2002","September 21, 2007",,"July 29, 2016",,,"https://ClinicalTrials.gov/show/NCT00533650"
253,"NCT00503113","A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.",,"Completed","Has Results","Post-Menopausal Osteoporosis","Drug: ibandronate [Bonviva/Boniva]|Drug: Alendronate","Absolute Change From Baseline in Actual Glomerular Filtration Rate (GFR) (Using Abbreviated Modification of Diet in Renal Disease [MDRD] Formula)|Absolute Change From Baseline in Actual GFR (Using Cockcroft-Gault [CG] Formula)|Relative Change From Baseline in Actual GFR (Using Abbreviated MDRD Formula)|Relative Change From Baseline in Actual GFR (Using CG Formula)|Absolute Change From Baseline in Mean Serum Creatinine.|Relative Change From Baseline in Mean Serum Creatinine.|Absolute Change From Baseline in Urine Albumin-to-Creatinine Ratio.|Relative Change From Baseline in Urine Albumin-to-Creatinine Ratio.","Hoffmann-La Roche","Female","60 Years and older   (Adult, Older Adult)","Phase 4","801","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BA20341","July 2007","April 2010","April 2010","July 18, 2007","June 17, 2011","June 17, 2011","Birmingham, Alabama, United States|Riverside, California, United States|Lakewood, Colorado, United States|West Palm Beach, Florida, United States|Gainesville, Georgia, United States|Topeka, Kansas, United States|Bethesda, Maryland, United States|Omaha, Nebraska, United States|Albuquerque, New Mexico, United States|Morehead City, North Carolina, United States|Bismarck, North Dakota, United States|Fargo, North Dakota, United States|Cincinnati, Ohio, United States|Duncansville, Pennsylvania, United States|Norfolk, Virginia, United States|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Cordoba, Argentina|Santa Fe, Argentina|Brasilia, Brazil|Curitiba, Brazil|Goiania, Brazil|Porto Alegre, Brazil|Rio de Janeiro, Brazil|Sao Paulo, Brazil|Vitoria, Brazil|Guadalajara, Mexico|Mexico City, Mexico|Monterrey, Mexico|Obregon, Mexico|San Jerónimo Chicahualco, Mexico|Durban, South Africa|Johannesburg, South Africa|Parow, South Africa|Port Elizabeth, South Africa|Somerset West, South Africa|Basel, Switzerland|Bern, Switzerland|Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT00503113"
254,"NCT03363997","Pharmacokinetics and Pharmacodynamics of 3 Dosages of Estriol After Continuous Vaginal Administration for 21 Days",,"Completed","No Results Available","Menopause","Drug: Estriol 0.125 mg/day|Drug: Estriol 0.250 mg/day|Drug: Estriol 0.500 mg/day","Measurement of estriol plasma levels|Maximum Plasma Concentration (Cmax) of estriol|Area Under the Curve (AUC) for estriol|Characterisation of follicle stimulating hormone (FSH)|Characterisation of luteinising hormone (LH)|Characterisation of sex hormone binding globulin (SHBG)|Characterisation of cytology of vaginal smear|Calculation of maturation index|Determination of vaginal pH|Number of adverse events per participant","Galeno Desenvolvimento de Pesquisas Clínicas|SocraTec R&D GmbH","Female","45 Years and older   (Adult, Older Adult)","Phase 1","31","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GDN 005/16","September 23, 2016","December 15, 2016","June 6, 2017","December 6, 2017",,"December 6, 2017","Galeno Desenvolvimento de Pesquisas Clinicas Ltda. - ME, Campinas, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT03363997"
255,"NCT01487304","Impact of Professional Societies' Recommendations on Practical Use of Hormone Replacement Therapy",,"Completed","No Results Available","Menopause|Hormone Replacement Therapy, Post-Menopausal","Drug: Marketed low dose hormone replacement therapy","Breast tenderness|Patient treatment satisfaction after switch to low dose HRT","Novo Nordisk A/S","Female","Child, Adult, Older Adult",,"3760","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","KLIM-1937","April 2005","June 2006","June 2006","December 7, 2011",,"October 17, 2016","Novo Nordisk Investigational Site, Prague, Czech Republic",,"https://ClinicalTrials.gov/show/NCT01487304"
256,"NCT01051609","Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Non-Metastatic, Post Menopausal Breast Cancer Patients",,"Completed","No Results Available","Breast Cancer","Other: History and Physical Exam|Other: Grip Strength Measurement|Behavioral: Surveys|Other: Blood Collection|Procedure: Ultrasound of Hand/Wrist","Presence, severity, and change in severity of pain based on joint exam and joint ultrasound inflammatory score.","Jonsson Comprehensive Cancer Center","Female","18 Years and older   (Adult, Older Adult)",,"27","Other","Observational","Time Perspective: Prospective","09-09-058","May 2010","July 2013",,"January 18, 2010",,"September 9, 2016","UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01051609"
257,"NCT04596501","Exercise Training and Thrombotic Risk in Post-menopausal Women","TIME","Active, not recruiting","No Results Available","Thrombosis|Menopause|Exercise Training|Vascular Dilation","Other: Early and late postmenopausal women","Changes in clot microstructure in early and late postmenopausal women after 16 weeks of exercise training|Changes in platelet reactivity in early and late postmenopausal women after 16 weeks of exercise training|Plasma concentration of coagulation factors in early and late postmenopausal women after 16 weeks of exercise training|Changes in vascular function in early and late postmenopausal women after 16 weeks of exercise training|Changes in capillary density after 16 weeks of team sports in early and late postmenopausal women|Changes in proliferative capacity of endothelial cells after 16 weeks of exercise training in early and late postmenopausal women|Changes in mitochondrial function of endothelial cells after 16 weeks of exercise training in early and late postmenopausal women|Changes in skeletal muscle protein content important for vascular function after 16 weeks of exercise training in early and late postmenopausal women|Changes in blood pressure after 16 weeks of team sports in early and late postmenopausal women|Changes in maximal oxygen uptake after 16 weeks of team sports in early and late postmenopausal women|Changes in body composition after 16 weeks of team sports in early and late postmenopausal women","University of Copenhagen|Swansea University","Female","50 Years to 70 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","Thrombosis in PM Women","March 1, 2021","December 1, 2022","March 1, 2023","October 22, 2020",,"November 2, 2022","Ylva Hellsten, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT04596501"
258,"NCT00660244","Breast Cancer Tumor Care Observational Programme",,"Completed","No Results Available","Post Menopausal|Arthralgia","Drug: anastrozole","Progression of disease and tolerability in general|Patient questionnaire to collect data on Incidence, time of onset and treatment of arthralgia","AstraZeneca","Female","Child, Adult, Older Adult",,"150","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","NIS-OAT-ARI-2007/1","February 2008",,"December 2009","April 17, 2008",,"June 6, 2012","Research Site, Graz, Austria",,"https://ClinicalTrials.gov/show/NCT00660244"
259,"NCT00927186","Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women",,"Completed","Has Results","Osteoporosis, Post-menopausal","Drug: Teriparatide|Drug: Zoledronic Acid","Mineralizing Surface/Bone Surface (MS/BS) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 6 Months|Mineralizing Surface/Bone Surface (MS/BS) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 24 Months|Mineralizing Surface/Bone Surface(MS/BS) in the Endocortical Compartment (EC) of Iliac Crest Bone Biopsies at 6 and 24 Months|Activation Frequency (Ac.f) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 6 Months|Activation Frequency (Ac.f) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 24 Months|Activation Frequency (Ac.f) in the Endocortical Compartment (EC) of Iliac Crest Bone Biopsies at 6 and 24 Months|Bone Formation Rate (BFR) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 6 Months|Bone Formation Rate (BFR) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 24 Months|Bone Formation Rate (BFR) in the Endocortical Compartment (EC) of Iliac Crest Bone Biopsies at 6 and 24 Months|Mineral Apposition Rate (MAR) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 6 Months|Mineral Apposition Rate (MAR) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 24 Months|Mineral Apposition Rate (MAR) in the Endocortical Compartment (EC) of Iliac Crest Bone Biopsies at 6 and 24 Months|Adjusted Apposition Rate (Aj.AR) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 6 Months|Adjusted Apposition Rate (Aj.AR) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 24 Months|Adjusted Apposition Rate (Aj.AR) in the Endocortical Compartment (EC) of Iliac Crest Bone Biopsies at 6 and 24 Months|Mineralization Lag Time (Mlt) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 6 Months|Mineralization Lag Time (Mlt) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 24 Months|Mineralization Lag Time (Mlt) in the Endocortical Compartment (EC) of Iliac Crest Bone Biopsies at 6 and 24 Months|Osteoid Maturation Time (Omt) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 6 Months|Osteoid Maturation Time (Omt) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 24 Months|Osteoid Maturation Time (Omt) in the Endocortical Compartment (EC) of Iliac Crest Bone Biopsies at 6 and 24 Months|Total Formation Period (Tt.FP) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 6 Months|Total Formation Period (Tt.FP) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 24 Months|Total Formation Period (Tt.FP) in the Endocortical Compartment (EC) of Iliac Crest Bone Biopsies at 6 and 24 Months|Active Formation Period (a.FP) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 6 Months|Active Formation Period (a.FP) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 24 Months|Active Formation Period (a.FP) in the Endocortical Compartment (EC) of Iliac Crest Bone Biopsies at 6 and 24 Months|Percent of Single or Double Tetracycline Labels Per Bone Surface (sLS/BS), (dLS/BS) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 6 Months|Percent of Single or Double Tetracycline Labels Per Bone Surface (sLS/BS), (dLS/BS) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 24 Months|Percent of Single or Double Tetracycline Labels Per Bone Surface (sLS/BS), (dLS/BS) in the Endocortical Compartment of Iliac Crest Bone Biopsies at 6 and 24 Months|Number of Samples With Single or Double Tetracycline Labels, Single and Double Labels, or No Tetracycline Labels in the Cancellous Compartment of Iliac Crest Bone Biopsies at 6 Months|Number of Samples With Single or Double Tetracycline Labels, Single and Double Labels, or No Tetracycline Labels in the Cancellous Compartment of Iliac Crest Bone Biopsies at 24 Months|Number of Samples With Single or Double Tetracycline Labels, Single and Double Labels, or No Tetracycline Labels in the Endocortical Compartment of Iliac Crest Bone Biopsies at 6 and 24 Months|Average Length of Tetracycline Double Labels in the Cancellous Compartment of Iliac Crest Bone Biopsies at 6 Months|Average Length of Tetracycline Double Labels in the Cancellous Compartment of Iliac Crest Bone Biopsies at 24 Months|Average Length of Tetracycline Double Labels in the Endocortical Compartment of Iliac Crest Bone Biopsies at 6 and 24 Months|Percentage of Osteoid Volume (OV)/Bone Volume (BV) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 6 Months|Percentage of Osteoid Volume (OV)/Bone Volume (BV) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 24 Months|Percentage of Osteoid Surface (OS)/Bone Surface (BS) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 6 Months|Percentage of Osteoid Surface (OS)/Bone Surface (BS) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 24 Months|Percentage of Osteoid Surface (OS)/Bone Surface (BS) in the Endocortical Compartment of Iliac Crest Bone Biopsies at 6 and 24 Months|Osteoid Thickness (OTh.) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 6 Months|Osteoid Thickness (OTh.) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 24 Months|Osteoid Thickness (OTh.) in the Endocortical Compartment of Iliac Crest Bone Biopsies at 6 and 24 Months|Wall Thickness (WTh.) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 6 Months|Wall Thickness (WTh.) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 24 Months|Wall Thickness (WTh.) in the Endocortical Compartment of Iliac Crest Bone Biopsies at 6 and 24 Months|Percentage of Eroded Surface/Bone Surface (ES/BS) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 6 Months|Percentage of Eroded Surface/Bone Surface (ES/BS) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 24 Months|Percentage of Eroded Surface/Bone Surface (ES/BS) in the Endocortical Compartment of Iliac Crest Bone Biopsies at 6 and 24 Months|Change From Baseline in Serum Carboxyterminal Cross-Linking Telopeptide of Type I Collagen (CTX) at Month 1, 3 and 6 Endpoint|Change From Baseline in Serum Carboxyterminal Cross-Linking Telopeptide of Type I Collagen (CTX) at Month 12 Endpoint|Change From Baseline in Serum Procollagen Type I N-Terminal Propeptide (PINP) at Month 1, 3 and 6 Endpoint|Change From Baseline in Serum Procollagen Type I N-Terminal Propeptide (PINP) at Month 12 Endpoint|Change From Baseline in Serum Osteocalcin (OC) at Month 1, 3, and 6 Endpoint|Change From Baseline in Serum Osteocalcin (OC) at Month 12 Endpoint","Eli Lilly and Company","Female","55 Years to 89 Years   (Adult, Older Adult)","Phase 4","69","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","13032|B3D-US-GHDL","July 2009","October 2010","April 2012","June 24, 2009","March 2, 2012","April 4, 2013","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lakewood, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gainesville, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bethesda, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Detroit, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albuquerque, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Haverstraw, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Calgary, Alberta, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vancouver, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sainte-Foy, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00927186"
260,"NCT00543023","A Study of the Treatment of Postmenopausal Women With Osteoporosis",,"Completed","No Results Available","Osteoporosis, Post-Menopausal","Drug: teriparatide 20 micrograms/day subcutaneous|Drug: salmon calcitonin 100 IU/day subcutaneous","to compare the effect of treatment with teriparatide 20 micrograms/day subcutaneous with that of salmon calcitonin 100 IU/day subcutaneous on change in lumbar spine BMD in postmenopausal women with established osteoporosis.|to compare the effect of treatment with teriparatide 20 micrograms/day with that of calcitonin 100 IU/day on change in femoral neck and total hip BMD in postmenopausal women with established osteoporosis|to compare the effect of treatment with teriparatide 20 micrograms/day with that of calcitonin 100 IU/day on change in biochemical bone markers (bone specific alkaline phosphatase [BSAP] and Osteocalcin) at 3 and 6 months|to assess safety as determined by physical examination, vital signs, clinical laboratory data and reports of adverse events.","Eli Lilly and Company","Female","55 Years to 85 Years   (Adult, Older Adult)","Phase 3","104","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6972|B3D-AA-GHCF","June 2003",,"August 2004","October 12, 2007",,"October 12, 2007","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hong Kong, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shatin, China",,"https://ClinicalTrials.gov/show/NCT00543023"
261,"NCT00532545","Bone Marker Changes With Teriparatide/Postmenopausal Osteoporosis",,"Completed","No Results Available","Osteoporosis, Post-Menopausal","Drug: Teriparatide","To test the hypothesis that Teriparatide injections given 20 micrograms/daily subcutaneously, for one month, is able to produce reliable changes in the bone marker in a severe osteoporotic population in Puerto Rico.|To test the hypothesis that this group of patients will have a high score in the survey used by IOF as an instrument to check risk factors.|Test the hypothesis that patients will have a high score in the survey used by IOF as an instrument to check risk factors.","Eli Lilly and Company","All","50 Years and older   (Adult, Older Adult)","Phase 4","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6715|B3D-SU-S001","April 2003",,"April 2004","September 20, 2007",,"September 20, 2007","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bayamon, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Caguas, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Carolina, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fajardo, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Humacao, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponce, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00532545"
262,"NCT00532428","Long Term Effects of Raloxifene Treatment on Bone Quality",,"Completed","No Results Available","Osteoporosis, Post-Menopausal","Drug: Raloxifene|Drug: Placebo","To determine the histomorphometric effects on bone,by iliac crest bone biopsy, of long-term (7 &8 yrs) therapy with raloxifene or placebo in postmenopausal women with osteoporosis who were enrolled in the CORE trial|Find effect of long-term treatment with raloxifene or placebo on bone quality. Primary measures: primary mineralization defect absence, mean degree of mineralization of bone tissue, absence of woven bone, microCT, microcrack & nanoindentation analysis.","Eli Lilly and Company","Female","55 Years to 85 Years   (Adult, Older Adult)","Phase 4","31","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","8149|H3S-MC-GGLF","April 2003",,"September 2003","September 20, 2007",,"September 20, 2007","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Granada, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oviedo, Spain",,"https://ClinicalTrials.gov/show/NCT00532428"
263,"NCT00532246","Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo",,"Completed","No Results Available","Osteoporosis, Post-Menopausal","Drug: raloxifene|Drug: Placebo","Test the hypothesis that in postmenopausal women with osteoporosis who took lipid lowering meds for more than 6 months > 80% compliant with study drug during CORE trial, mean carotid IMT will be lower in patients treated with raloxifene than placebo|To test the hypothesis that, in postmenopausal women with osteoporosis, mean carotid IMT will be significantly lower in patients treated with raloxifene as compared to mean carotid IMT in patients treated with placebo in the following:|All enrolled patients who have not been exposed to lipid lowering medication for more than 6 months while in the CORE trial, regardless of study drug compliance.|All enrolled patients, regardless of lipid lowering drug exposure or compliance with study drug while in CORE|All enrolled patients who were at least 80% compliant with study drug while in CORE, regardless of use of lipid lowering therapy","Eli Lilly and Company","Female","55 Years and older   (Adult, Older Adult)","Phase 4","147","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","8135|H3S-MC-GGLE","March 2003",,"August 2003","September 20, 2007",,"September 20, 2007","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Jolla, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Menlo Park, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oakland, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Walnut Creek, California, United States",,"https://ClinicalTrials.gov/show/NCT00532246"
264,"NCT00532207","Study of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis",,"Completed","No Results Available","Osteoporosis, Post-Menopausal","Drug: teriparatide","To test the hypothesis that therapy for 12 months with once daily subcutaneous PTH 1-34 (teriparatide; TPTD) 20 micrograms will increase Bone Mineral Density (BMD) at the lumbar spine in postmenopausal women with osteoporosis|To test the hypothesis that therapy for 3 months with once daily subcutaneous teriparatide 20 micrograms will increase markers of bone formation (P1NP, BSAP) and bone resorption (serum CTX) in postmenopausal women with osteoporosis|To test the hypothesis that therapy for 12 months with once daily subcutaneous teriparatide 20 micrograms will increase markers of bone formation (P1NP, BSAP) and bone resorption (serum CTX) in postmenopausal women with osteoporosis.|To evaluate safety of once daily subcutaneous teriparatide 20 micrograms for 12 months.|To evaluate effect of teriparatide on changing in femoral neck and total hip BMD|To test the hypothesis that treatment with TPTD will favorably affect back pain within the natural course of the disease|To test the hypothesis that treatment with TPTD will favorably affect quality of life within the natural course of the disease","Eli Lilly and Company","Female","55 Years and older   (Adult, Older Adult)","Phase 3","50","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","8736|B3D-MW-GHCR","November 2003",,"December 2004","September 20, 2007",,"September 20, 2007","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00532207"
265,"NCT04766229","The Menopause After Cancer Study","MACS","Completed","No Results Available","Menopause|Cancer|Insomnia","Combination Product: Citalopram +/- Gabapentin + Sleepio + support person","Global Quality of Life scores as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ C30) instrument|Bother/Interference of vasomotor symptoms of menopause as measured by the Hot Flush Rating Scale|Sleep dysfunction as measured by the Sleep Condition Indicator","University College Dublin|Irish Cancer Society|Big Health Inc.|myPatientSpace","Female","18 Years and older   (Adult, Older Adult)","Phase 2","205","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","RS21-002","June 21, 2021","November 30, 2022","November 30, 2022","February 23, 2021",,"January 6, 2023","Mater Misericordiae University Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland",,"https://ClinicalTrials.gov/show/NCT04766229"
266,"NCT00544986","A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer",,"Completed","No Results Available","Breast Cancer","Drug: Anastrozole","1. Tolerability(safety) 2.Efficacy (a) Time to tumor progression TTP (b) Objective Response (OR) Rate (c) Symptom Evaluation|Efficacy (a) Time to treatment failure TTF (b)Duration of Response DOR (c) Duration of Clinical Benefit","AstraZeneca","Female","18 Years and older   (Adult, Older Adult)","Phase 4",,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D5391L00001","June 2005","November 2007","November 2007","October 16, 2007",,"January 30, 2013",,,"https://ClinicalTrials.gov/show/NCT00544986"
267,"NCT00018447","Combination Osteogenic Therapy in Established Osteoporosis",,"Completed","No Results Available","Osteoporosis, Post-Menopausal","Drug: PTH 1-34|Drug: MFPSR-fluoride",,"US Department of Veterans Affairs|VA Office of Research and Development","Female","60 Years to 80 Years   (Adult, Older Adult)","Phase 2",,"U.S. Fed","Interventional","Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","ENDO-022-98S","November 1998",,"October 2003","July 5, 2001",,"January 21, 2009","Jerry L. Pettis Memorial Veterans Medical Center, Loma Linda, California, United States",,"https://ClinicalTrials.gov/show/NCT00018447"
268,"NCT02718014","Evaluation of Periodontal Response to Non Surgical Therapy in Pre and Post Menopausal Women With Periodontitis","EPRNPPMP","Completed","No Results Available","Periodontitis|Menopause|Plaque|Inflammation","Other: scaling and root planing (srp)","Evaluation of periodontal response to non surgical therapy in pre and post menopausal women with periodontitis|Evaluation of periodontal response to non surgical therapy in pre and post menopausal","Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre","Female","40 Years to 60 Years   (Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","PMVIDSRC","January 2015","April 2015","August 2015","March 24, 2016",,"March 24, 2016",,,"https://ClinicalTrials.gov/show/NCT02718014"
269,"NCT03902132","Core Muscle Stability on Low Back Pain and Quality of Life in Post- Menopausal Women",,"Completed","No Results Available","Backache, Low","Other: Core Stability exercises group|Other: Traditional low back physical therapy group","Numeric pain rating scale (NPRS)|Utian Quality of Life (UQOL):|Oswestry disability Index (ODI):|Manual Muscle Testing (MMT)","Riphah International University","Female","40 Years to 60 Years   (Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","RiphahIU Sumaira Kanwal","March 1, 2018","June 1, 2018","June 1, 2018","April 3, 2019",,"May 6, 2019","Imran Amjad, Islamabad, Pakistan",,"https://ClinicalTrials.gov/show/NCT03902132"
270,"NCT05205057","Salivary Calcium in Post-menopausal Women and Prevalence of Dental Caries",,"Completed","No Results Available","Salivary Calcium","Other: Saliva","Salivary calcium|Dental caries","Ajman University","Female","40 Years to 70 Years   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","ABSM/EC22/2018","August 1, 2021","October 15, 2021","October 20, 2021","January 24, 2022",,"February 7, 2022","AB shetty Institute of dental sciences, Mangaluru, Karnataka, India",,"https://ClinicalTrials.gov/show/NCT05205057"
271,"NCT02792504","Post Marketing Surveillance To Observe Safety And Efficacy Of Duavive",,"Completed","Has Results","Severe Vasomotor Symptom Associated With Menopause",,"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Treatment Related Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants Classified According to Measures Taken for Adverse Events|Number of Participants With Change From Baseline in Moderate to Severe Vasomotor Symptoms Associated With Menopause at Month 3|Number of Participants With Change From Baseline in Moderate to Severe Vasomotor Symptoms Associated With Menopause at Month 6|Percentage of Participants With Improvement From Baseline in Moderate to Severe Vasomotor Symptoms Associated With Menopause at Last Visit|Number of Participants With Prevention of Post-menopausal Osteoporosis at Month 3|Number of Participants With Prevention of Post-menopausal Osteoporosis at Month 6|Percentage of Participants With Prevention of Post-menopausal Osteoporosis at Last Visit","Pfizer","Female","20 Years and older   (Adult, Older Adult)",,"669","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","B2311067","March 29, 2016","July 22, 2020","July 22, 2020","June 7, 2016","August 5, 2021","August 5, 2021","Kyungpook National University/Department of Internal Medicine (Cardiology), Jung-gu, Daegu, Korea, Republic of|Dr. Wang's OB & GY Clinic, Seoul, Dobong-gu, Korea, Republic of|Kimhyeonmi OBGY, Hwaseong-si, Dongtan, Korea, Republic of|Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea, Republic of|Bucheon St. Mary Hospital The Catholic University of Korea, Bucheon-si, Gyeonggi-do, Korea, Republic of|Baylor Ewha Obgyn Clinic, Seongnam-si, Gyeonggi-do, Korea, Republic of|Dongguk University Ilsan Medical Center Obstetrics, Goyang-si, Ilsandong-gu, Korea, Republic of|Obstetrics / Grace Women's Hospital, Goyong-si, Ilsandong-gu, Korea, Republic of|Kyungpook National University Hospital, Obstetrics, Daegu, Jung-gu, Korea, Republic of|Pusan University Hospital Obstetrics, Pusan, Seo-gu, Korea, Republic of|Catholic Universith of Korea, Seoul ST. Mary's Hospital, Seoul, Seocho-gu, Korea, Republic of|Samsung Medical Center, Sungkyunkwan Univ. School of Medicine, Kangnam-ku, Seoul, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital / Department of Internal Medicine, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Sanggye Paik Hospital-Inje University, Seoul, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Chungang University Hospital, Seoul, Korea, Republic of|AJOU University Hospital, Suwon, Korea, Republic of","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT02792504/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT02792504/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02792504"
272,"NCT05235061","HOme-Based Self-management and COgnitive Training CHanges Lives (HOBSCOTCH) -Post-Traumatic Epilepsy (PTE)","HOBSCOTCHPTE","Recruiting","No Results Available","Epilepsy, Traumatic|Brain Injuries, Traumatic","Behavioral: Home Based Self-management and Cognitive Training Changes lives in post traumatic epilepsy (HOBSCOTCH-PTE)|Behavioral: HOBSCOTCH-PTE for Caregivers","Change in quality of life as measured by comparing QOLIE-31 scores at baseline and 3 months post-intervention in participants with PTE|Change in subjective cognition as measured by comparing NeuroQOL - Cognitive Function sub-scale scores at baseline and 3 months post-intervention in participants with PTE|Change in caregiver burden as measured by comparing Zarit Burden Interview scores at baseline and at 3 months post-intervention in caregivers of PTE participants|Changes in PTE participant knowledge of their own epilepsy as measured by comparing scores on the Epilepsy Knowledge of Own Condition questionnaire at baseline and 6 months post-intervention.|Changes in PTE participants self-efficacy (subjective impression of managing their life with epilepsy) as measured by comparing scores on the Epilepsy Self-Efficacy Scale at baseline and at 3 months post-intervention.|Changes in PTE participants' objective cognition as measured by comparing scores on the Montreal Cognitive Assessment (MoCA) at baseline and at 3 months post-intervention.|Changes in PTE Participants' mood as measured by comparing scores on the Patient Health Questionnaire (PHQ-9) at baseline and at 3 months post- intervention.|Changes in seizure frequency (PTE participants) as measured by comparing daily self-reported seizures at baseline and at 3 months post-intervention|Changes in PTE participants' medication adherence as measured by a daily self-reported diary compared at baseline and at 3 months post-intervention.|Changes in PTE participants' use of memory strategies as measured by a daily self-reported diary compared at baseline and 3 months post-intervention.|Changes in PTE participants' self-reports of wellbeing as measured by comparing daily reports of well-being in a diary at baseline and at 3 months post-intervention.|Changes in Caregiver Participants' knowledge of epilepsy as measured by comparing scores on the [Caregiver] General Knowledge of Epilepsy questionnaire at baseline and at 6 months-post intervention.|Changes in caregiver self-reported health status as measured by comparing scores on the Short-Form 36 (SF-36) at baseline and 3 months-post intervention.|Changes in Caregiver Participants' mood as measured by comparing scores on the Patient Health Questionnaire (PHQ-9) at baseline and at 3 months post- intervention.|Sustainability of improvement on primary outcome measure for PTE Participants by comparing scores on the QOLIE-31 at 3 months and 6 months post-intervention.|Sustainability of improvement on primary outcome measures for PTE Participants by comparing scores on the Cognitive Function sub-scale of the NeuroQOL at 3 months and 6 months post-intervention.|Sustainability of improvement on primary outcome measures for Caregiver Participants by comparing scores on the Zarit Caregiver Burden at 3 months and 6 months post-intervention.|Engagement and Satisfaction for PTE Participants as measured by analyzing study attrition and a Participant Satisfaction Survey at the end of the study.|HOBSCOTCH Fidelity and Compliance as measured by completed sessions and completed homework for PTE Participants.|Feasibility of HOBSCOTCH program for Caregivers as measured by study attrition and a Participant Satisfaction Survey.","Dartmouth-Hitchcock Medical Center|United States Department of Defense","All","18 Years and older   (Adult, Older Adult)","Not Applicable","190","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","STUDY02001238|W81XW82110279","March 21, 2022","September 2023","September 2023","February 10, 2022",,"November 8, 2022","Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States",,"https://ClinicalTrials.gov/show/NCT05235061"
273,"NCT00280930","Letrozole in Postmenopausal Women at Increased Risk for Breast Cancer",,"Unknown status","No Results Available","Post-Menopausal|Breast Cancer","Drug: Letrozole","To determine the proportion of women with breast density of > grade 4 who have a decrease in breast density of at least one grade after treatment with letrozole for one year.|To determine if the decrease in breast density grade is sustained one year after cessation of therapy|to determine if there is a correlation between plasma estrogen profile and breast density at baseline|to determine the percentage of subjects with breast tissue hyperplasia and atypical hyperplasia before and after therapy|to assess change in estrogen profile from baseline and at 1 year and 1 year after cessation of therapy|to assess the general safety of the utilization of letrozole in healthy post-menopausal women for one year|to compare the effects on menopause-specific quality of life.","Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Massachusetts General Hospital","Female","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Prevention","05-183|NCIC CTG MAP.1","October 2005",,,"January 24, 2006",,"January 19, 2007","Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00280930"
274,"NCT00006399","Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: Donepezil|Drug: Estrogen|Drug: Progesterone",,"National Center for Research Resources (NCRR)|Alzheimer's Association|Pfizer|Eisai Inc.|National Institute on Aging (NIA)","Female","45 Years to 85 Years   (Adult, Older Adult)","Phase 2","45","NIH|Other|Industry","Interventional","Masking: Double|Primary Purpose: Treatment","IA0023|2R56AG021476","September 1999","March 2004","March 2004","August 21, 2000",,"January 15, 2009","Clinical Neuroscience Research Unit, University of Vermont, Burlington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT00006399"
275,"NCT00165204","Effects of Tibilone on Bone Density, Menopause Symptoms and Breast Density in Women After Prophylactic Oophorectomy",,"Completed","No Results Available","Menopause|Postmenopausal Bone Loss|Breast Cancer","Drug: Tibolone","To compare bone mineral density and markers of bone turnover following oophorectomy in patients receiving tibolone versus placebo|To compare changes in menopausal symptoms and mammographic breast density in women taking tibolone to women taking placebo","Dana-Farber Cancer Institute|Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|United States Department of Defense","Female","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment","03-363","April 2004","March 2006","March 2006","September 14, 2005",,"December 21, 2007","Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00165204"
276,"NCT03845153","Metformin Effect on Fracture Healing in Post-Menopausal Women",,"Completed","No Results Available","Bone Fracture","Drug: Metformin Retard 850 mg|Other: Placebo","Human Irisin (ng/ml)|Bone specific alkaline phosphatase (IU/L)|postoperative X-rays - Lane and Sandhu radiological scoring system","Damanhour University","Female","55 Years to 65 Years   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Metformin on Fracture healing","January 1, 2019","January 1, 2021","January 1, 2021","February 19, 2019",,"February 9, 2021","Damanhour Medical National Institute, Damanhūr, El-Bahairah, Egypt",,"https://ClinicalTrials.gov/show/NCT03845153"
277,"NCT03337971","Nutritional Supplement and Bone Health in Post-Menopausal Women","MBPS","Unknown status","No Results Available","Bone and Bones|Osteoporosis Risk|Osteoporosis, Postmenopausal","Dietary Supplement: PLACEBO|Dietary Supplement: MBPM","Bone turnover|Change in regulator of bone metabolism - PTH|Change in regulator of bone metabolism - RANKL|Change in regulator of bone metabolism - OPG|Incretin peptide (GIP)|Incretin peptide (GLP-1)","University of Limerick|Dairygold Cooperative Society Ltd","Female","50 Years to 70 Years   (Adult, Older Adult)","Not Applicable","16","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","IP2016_0476","October 3, 2017","December 28, 2018","April 4, 2019","November 9, 2017",,"November 9, 2017","University of Limerick, Limerick, Co Limerick, Ireland","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03337971/SAP_000.pdf|""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03337971/Prot_ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03337971"
278,"NCT00884143","Observational Triveneto Study on the Use of Adjuvant Hormonal Therapies in the Treatment of Hormone-responsive Breast Cancer","TIME 2 CHANGE","Completed","No Results Available","Post Menopausal|Breast Cancer",,"Relative frequencies of the first adjuvant hormonal treatment (tamoxifen vs aromatase inhibitor) started during two time periods of 12 months each - the years 2006 and 2008|Relative frequencies of the type of initial treatment: upfront (a single drug - tamoxifen or aromatase inhibitor) or early switch (planned sequence of tamoxifen and inhibitor)|Type of treatment and relative percentages of treatment undertaken by the patients after interruption of the first hormonal therapy","AstraZeneca","Female","Child, Adult, Older Adult",,"515","Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","NIS-OIT-ARI-2008/1","July 2009","January 2010","January 2010","April 20, 2009",,"April 20, 2010","Research Site, Aviano, PN, Italy|Research Site, Trento, Italy|Research Site, Verona, Italy",,"https://ClinicalTrials.gov/show/NCT00884143"
279,"NCT05331209","Acupuncture With/Without Self-acupressure for Post-oophorectomy Hot Flashes in BRCA Carriers","BRCA","Not yet recruiting","No Results Available","Hot Flashes|Menopause Surgical","Other: Acupuncture|Other: Acupuncture-Acupressure","Hot Flash Score - baseline to 8 weeks|Hot Flash Score - 8 to 16 weeks|Menopause Specific Quality of Life Questionnaire (MenQOL)|Measure Yourself Concerns and Wellbeing (MYCAW)","Shaare Zedek Medical Center","Female","25 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BRCA-ACP.2022","February 1, 2023","December 31, 2024","December 31, 2024","April 15, 2022",,"October 26, 2022","Center for Integrative Complementary Medicine, Shaare Zedek Medical Center, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT05331209"
280,"NCT00147524","Non-Comparative Study To Evaluate Changes In FMD After Quinapril Therapy In Hypertensive Women",,"Completed","No Results Available","Menopause|Hypertension","Drug: quinapril|Procedure: Laser Doppler imaging","To evaluate the effect of 10, 20 and 40 mg daily sequential quinapril doses in a 3 x 8 weeks treatment period as changes to baseline pathological FMD.|1.In a subgroup of about 30 patients to assess microvascular vasomotor function by laser Doppler (LD) techniques. For all patients: 2.Evaluation of changes of BP parameters. 3.Changes in PAI-1 level. 4.Collect safety data.","Pfizer","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","70","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A9061010","October 2003",,"May 2005","September 7, 2005",,"April 30, 2007","Pfizer Investigational Site, Hodmezovasarhely, Csongrad, Hungary|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Mateszalka, Hungary|Pfizer Investigational Site, Szeged, Hungary|Pfizer Investigational Site, Szombathely, Hungary",,"https://ClinicalTrials.gov/show/NCT00147524"
281,"NCT04458532","Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer",,"Recruiting","No Results Available","Early Stage Breast Cancer","Other: Aerobic Training","peak oxygen consumption (VO2peak; ml O2.kg-1.min) response rate","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Female","21 Years to 80 Years   (Adult, Older Adult)","Not Applicable","152","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-130","October 8, 2020","July 2025","July 2025","July 7, 2020",,"August 26, 2022","Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04458532"
282,"NCT05008991","Lung Functions in Menopausal Obese Women After COVID 19 Recovery",,"Completed","No Results Available","Lung Function Decreased|Obesity|Menopause|Covid19","Device: Spirometry","Forced expiratory volume in the first second (FEV1)|forced vital capacity (FVC)|FEV1/FVC ratio","Badr University","Female","45 Years to 55 Years   (Adult)",,"40","Other","Observational","Observational Model: Other|Time Perspective: Prospective","Hend 2","July 20, 2021","September 20, 2021","October 20, 2021","August 17, 2021",,"November 4, 2021","Faculty of Physical Therapy, Badr University, Cairo, New Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT05008991"
283,"NCT03242512","Assessment of Anti-RANKL Antibody in Post-menopausal Women",,"Unknown status","No Results Available","Osteoporosis","Biological: TK006","Incidence of adverse events （AEs）|Area under the plasma concentration-time curve from time zero to time 'last' where last is the last time point after administration [AUClast]|Area under the plasma concentration-time curve from time zero to infinity [AUC0-inf]|Maximum observed maximum plasma concentration [Cmax]|Time to reach the maximum observed plasma concentration [Tmax]|Terminal elimination half-life[T1/2]|Bioavailability corrected apparent volume of the central compartment cleared of drug per unit [Cl/F]|Bioavailability corrected apparent volume of distribution [Vd/F]|Serum type I collagen cross-link C telopeptide (sNTX)|serum bone alkaline phosphatase [bALP]|Intact Parathyroid Hormone (iPTH)|Bone density of lumbar vertebra and collum femoris|anti-drug antibody [ADA]","Jiangsu T-Mab Biopharma Co.,Ltd","Female","up to 65 Years   (Child, Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TK006-101","August 7, 2017","December 30, 2018","December 30, 2018","August 8, 2017",,"March 14, 2018","Peking Union Medical College Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03242512"
284,"NCT05255367","Effect of (Poly)Phenolic on Cardiometabolic Risk of Postmenopausal Women","CARDIOGENE","Completed","No Results Available","Post-menopausal Women|Overweight and Obesity","Combination Product: (poly)phenols rich foods","Changes in serum levels of glucose and insulin.|Changes in plasmatic lipid profile.|Changes in blood pressure.|Changes in biomarkers of inflammation in plasma.|Changes in biomarkers of oxidative stress in urine.|Changes in body mass index.|Changes in body composition.|Changes hip-to-waist ratio.|Dietary habits (total energy intake and macronutrient distribution).","Universidad de Murcia","Female","45 Years to 65 Years   (Adult, Older Adult)","Not Applicable","26","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","(Poly)phenol and menopause|20904/PI/2018","March 1, 2022","July 1, 2022","July 1, 2022","February 24, 2022",,"July 21, 2022","Edificio Pleyades-Vitalys 5ª y 6ª planta, Murcia, Spain",,"https://ClinicalTrials.gov/show/NCT05255367"
285,"NCT02383823","Postprandial Lipidemia After a Meal With Different Types of Fat, Estrogen Treatment, Age and Gender in Healthy Subjects",,"Unknown status","No Results Available","Menopause","Drug: Estrogens|Other: Placebo","Postprandial lipidemia|Postprandial glucose and insulin","Herning Hospital|Sygehus Lillebaelt","All","45 Years to 80 Years   (Adult, Older Adult)","Not Applicable","64","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Basic Science","M-2104-99","August 2019","December 2020","December 2020","March 9, 2015",,"December 13, 2017","Gynecology Dept. Herning Hospital, Herning, Denmark",,"https://ClinicalTrials.gov/show/NCT02383823"
286,"NCT05590949","Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors",,"Recruiting","No Results Available","Breast Cancer","Other: Physical Evaluation|Diagnostic Test: Dual-energy X-ray absorptiometry scans|Diagnostic Test: Trabecular Bone Score","Change in serum carboxy-terminal collagen crosslinks (CTX)|Change in bone specific alkaline phosphatase (ALK)","Memorial Sloan Kettering Cancer Center","Female","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","22-280","October 18, 2022","October 18, 2024","October 18, 2024","October 21, 2022",,"October 21, 2022","Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities), Commack, New York, United States|Memoral Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States",,"https://ClinicalTrials.gov/show/NCT05590949"
287,"NCT00701337","Effect of 17ß-estradiol on Inflammatory-immune Responses in Post-menopausal Women According to Administration Route",,"Completed","No Results Available","Postmenopausal","Drug: oestradiol","To determine the feasibility of a future multicentric randomized trial : estimation of the number of subjects required|variability and repeatability of the biological parameters studied|Feasibility of the recruitment, enrollment and follow-up of menopausal women","University Hospital, Toulouse","Female","45 Years to 60 Years   (Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0507402","September 2006","January 2010","January 2010","June 19, 2008",,"May 11, 2017","University Hospital Toulouse, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT00701337"
288,"NCT05319041","Herbal Medication to Treat Dry Eye in Peri/ Post-menopausal Women",,"Recruiting","No Results Available","Dry Eye","Drug: Wei's Qi Ju Gan Lu Formula|Drug: Placebo","Change in SPEED score|Change in Sleep score|Change in Depression score|Change in TCM score (Liver-Kidney Yin Deficiency)","Singapore National Eye Centre|Singapore Chung Hwa Medical Institute","Female","40 Years to 79 Years   (Adult, Older Adult)","Early Phase 1","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","R1675/72/2019|2019/2957","April 11, 2022","November 2024","November 2024","April 8, 2022",,"May 13, 2022","Singapore National Eye Centre, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT05319041"
289,"NCT02751944","NEM® Versus Placebo on Exercise-induced Joint Pain, Stiffness, & Cartilage Turnover In Healthy, Post-Menopausal Women",,"Completed","No Results Available","Exercise-induced Joint Pain Stiffness and Cartilage Turnover","Dietary Supplement: NEM|Dietary Supplement: Placebo","Exercise-induced Cartilage Turnover via CTX-II Biomarker|Exercise-induced Joint Pain via questionnaire|Exercise-induced Joint Stiffness via questionnaire","ESM Technologies, LLC","Female","40 Years to 75 Years   (Adult, Older Adult)","Not Applicable","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","ESM-CLN#2015T02","December 2015","January 2016","January 2016","April 26, 2016",,"August 17, 2018",,,"https://ClinicalTrials.gov/show/NCT02751944"
290,"NCT02749539","Post Mastectomy Shoulder Problems and Kinesio Taping",,"Completed","No Results Available","Post Mastectomy Complications","Device: Kinesio tape|Procedure: physiotherapy program","Visual Analogue Scale (VAS)|The Shoulder Pain and Disability Index (SPADI)","Cairo University","Female","35 Years to 50 Years   (Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","P.T.REC/012/001249","February 2015","January 2016","January 2016","April 25, 2016",,"April 25, 2016",,,"https://ClinicalTrials.gov/show/NCT02749539"
291,"NCT03036722","Flaxseed Consumption and Bone Metabolism in Postmenopausal Women.","FLAX","Unknown status","No Results Available","Bone Loss, Age Realted|Post Menopausal","Other: Flaxseed|Other: Placebo control porridge","Determine the benefits of phytoestrogen-rich flaxseeds on decreasing bone turnover in postmenopausal women.|Gut microbial","University of Reading","Female","50 Years to 70 Years   (Adult, Older Adult)","Not Applicable","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UOReading","May 10, 2017","November 1, 2018","November 1, 2018","January 30, 2017",,"May 16, 2018","University of Reading, Reading, Berkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03036722"
292,"NCT00429806","DHEA Bioavailability Following Administration of Vaginal Suppositories in Post-Menopausal Women With Vaginal Atrophy",,"Completed","No Results Available","Vaginal Atrophy","Drug: DHEA|Drug: Placebo","The evaluation of the systemic bioavailability of DHEA and its metabolites.|The pharmacokinetics of vaginal suppositories at four different DHEA concentrations.|The safety and tolerance of the suppositories.|The effect of treatment on maturation index and value","CHU de Quebec-Universite Laval","Female","40 Years to 75 Years   (Adult, Older Adult)","Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ERC-213","November 2006","March 2007","July 2007","February 1, 2007",,"April 7, 2017","Clinique des traitements hormonaux CHUL Research Center, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00429806"
293,"NCT01797120","Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI","PrE0102","Completed","Has Results","Metastatic Breast Cancer","Drug: Fulvestrant|Drug: Everolimus|Drug: Placebo","Progression-free Survival|Clinical Benefit Rate|Objective Response Rate|Overall Survival","PrECOG, LLC.|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","131","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PrE0102","May 31, 2013","March 22, 2017","September 12, 2017","February 22, 2013","April 30, 2018","May 30, 2018","Marin Cancer Care, Greenbrae, California, United States|Stanford University, Stanford, California, United States|SwedishAmerican Regional Cancer Center, Rockford, Illinois, United States|McFarland Clinic, PC, Ames, Iowa, United States|Johns Hopkins University, Baltimore, Maryland, United States|St. Joseph Mercy Hospital (MI Cancer Consortium), Ann Arbor, Michigan, United States|Metro MN, Saint Louis Park, Minnesota, United States|Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Montefiore Medical Center, Bronx, New York, United States|Beth Israel, New York, New York, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Toledo COP, Toledo, Ohio, United States|Hematology & Oncology Associates of Northeastern PA, PC, Dunmore, Pennsylvania, United States|Penn State University, Hershey, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh- Magee Women's Hospital, Pittsburgh, Pennsylvania, United States|Reading Hospital- McGlinn Family Regional Cancer Center, West Reading, Pennsylvania, United States|Main Line Heath System, Wynnewood, Pennsylvania, United States|University of Texas Southwestern, Dallas, Texas, United States|Charleston Area Medical Center (CAMC), Charleston, West Virginia, United States|St. Vincent Hospital, Green Bay, Wisconsin, United States|Gundersen Health System, La Crosse, Wisconsin, United States|ProHealth Care Inc. (Waukesha), Waukesha, Wisconsin, United States|Aurora Cancer Care, Wauwatosa, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT01797120/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT01797120/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01797120"
294,"NCT00471237","A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.",,"Terminated","Has Results","Osteoporosis","Drug: Ronacaleret|Drug: Teriparatide|Drug: Alendronate","Percent Change From Baseline in Bone Marrow Density (BMD) at Month 12 Measured by Dual-Energy X-Ray Absorptiometry (DXA) Scans of the Lumbar Spine (L1-L4)|Number of Participants With Hypercalcemia|Number of Participants Withdrew Due to Hypercalcemia|Number of Participant With Laboratory Abnormalities of Potential Clinical Concern at Any Post-baseline Visit|Number of Participant With Vital Signs of Potential Clinical Concern at Any Post-baseline Visit|Number of Participant With Electrocardiogram (ECG) Findings Reported as Adverse Event|Mean Change From Baseline in Height|Mean Change From Baseline in Weight|Percent Change From Baseline to Month 6 in BMD Measured by DXA Scans of the Lumbar Spine (L1-L4)|Percent Change From Baseline to Months 6 and 12 in BMD Measured by DXA Scans of the Hip (Total Hip, Femoral Neck and Trochanter).|Number of Participants Who Remained the Same or Had Any Improvement in DXA BMD (> Baseline)|Percent Change From Baseline to Month 12 in the Volumetric Integral, Cortical, and Trabecular Density (BMD) at the Hip and Lumbar Spine as Measured by Quantitative Computer Tomography (QCT) Scans|Percent Change From Baseline to Month 12 in the Total Vertebra Integral VOI at the Lumbar Spine as Measured by QCT Scans|Percent Change From Baseline to Month 12 in the Volumetric Integral, Cortical, and Trabecular Density (BMD) at the Hip as Measured by QCT Scans|Percent Change From Baseline to Month 12 in Cortical Thickness at the Hip as Measured by QCT Scans|Biochemical Markers of Bone Turnover: Levels of C-terminal Telopeptide α1 Chain of Type 1 Collagen (CTX1)|Biochemical Markers of Bone Turnover: Procollagen Type 1 N-terminal Propeptide (P1NP)|Biochemical Markers of Bone Turnover: Bone Specific Alkaline Phosphatase (BALP)|Blood Concentrations of Ronacaleret|Area Under the Concentration-time Curve Over the Dosing Interval (AUC 0-t) and Area Under the Concentration-time Curve Over the Dosing Interval (AUC 0-tau) of Ronacaleret|Maximum Blood Concentration (Cmax) of Ronacaleret|Time Required to Achieve Maximum Concentration of Ronacaleret in Blood (Tmax)","GlaxoSmithKline","Female","18 Years to 79 Years   (Adult, Older Adult)","Phase 2","564","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR9108963","May 14, 2007","December 26, 2008","December 26, 2008","May 9, 2007","September 5, 2017","November 7, 2017","GSK Investigational Site, Oakland, California, United States|GSK Investigational Site, Palm Desert, California, United States|GSK Investigational Site, Walnut Creek, California, United States|GSK Investigational Site, Decatur, Georgia, United States|GSK Investigational Site, Bethesda, Maryland, United States|GSK Investigational Site, Akron, Ohio, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Duncansville, Pennsylvania, United States|GSK Investigational Site, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autónoma de Buenos Aires, Argentina|GSK Investigational Site, St Leonards, New South Wales, Australia|GSK Investigational Site, Footscray, Victoria, Australia|GSK Investigational Site, Geelong, Victoria, Australia|GSK Investigational Site, Heidelberg, Victoria, Australia|GSK Investigational Site, Gent, Belgium|GSK Investigational Site, Liege, Belgium|GSK Investigational Site, Tienen, Belgium|GSK Investigational Site, Ballerup, Denmark|GSK Investigational Site, Frankfurt, Hessen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hong Kong, Hong Kong|GSK Investigational Site, Shatin, Hong Kong|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Suwon, Korea, Republic of|GSK Investigational Site, Mexico, D.F., Mexico|GSK Investigational Site, Bergen, Norway|GSK Investigational Site, Hamar, Norway|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Grudziadz, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Wroclaw, Poland|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Panorama, South Africa|GSK Investigational Site, Rosebank, South Africa|GSK Investigational Site, Somerset West, South Africa|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Santiago de Compostela, Spain|GSK Investigational Site, Santiago de Compostela, Spain",,"https://ClinicalTrials.gov/show/NCT00471237"
295,"NCT02154776","Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.","LeeBLet","Completed","No Results Available","Advanced or Metastatic Breast Cancer","Drug: LEE011|Drug: Buparlisib|Drug: Letrozole","Incidence of dose-limiting toxicities (DLTs)|Safety and tolerability of the combination of LEE011, buparlisib, and letrozole|Safety and tolerabiity of the combination of LEE011, buparlisib, and letrozole|Pharmacokinetic paramters such as AUClast and Cmax of LEE011, buparlisib, and letrozole in order to characterize the PK profiles|Disease control rate|PFS (progression free survival)","Novartis Pharmaceuticals|Novartis","Female","18 Years and older   (Adult, Older Adult)","Phase 1","13","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","CLEE011A2112C","June 27, 2014","October 26, 2016","October 26, 2016","June 3, 2014",,"December 19, 2020","University of California at Los Angeles UCLA SC, Los Angeles, California, United States|Horizon Oncology Center SC, Lafayette, Indiana, United States|Medical University of South Carolina SC, Charleston, South Carolina, United States|South Texas Accelerated Research Therapeutics SC, San Antonio, Texas, United States|University of Utah / Huntsman Cancer Institute SC-3, Salt Lake City, Utah, United States|Novartis Investigative Site, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02154776"
296,"NCT03006003","Osteoporosis Treatment in Post-menopausal Women",,"Unknown status","No Results Available","Depressive Syndrome","Drug: Raloxifene|Drug: Alendronate","Brain-derived neurotrophic factor|Vascular cell adhesion molecule-1|Orexin-A|Body components|Zung self-rating depression scale|5-Item Geriatric Depression Scale|The Mini Mental State Examination (MMSE)|The Barthel index|Instrumental Activities of Daily Living (IADL)|ankle-brachial index","Taichung Veterans General Hospital","Female","20 Years and older   (Adult, Older Adult)","Phase 4","500","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CE16256A","January 1, 2017","December 2021","December 2021","December 30, 2016",,"January 14, 2019","outpatient clinic of the Division of Endocrinology and Metabolism in Taichung Veterans General Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan",,"https://ClinicalTrials.gov/show/NCT03006003"
297,"NCT00489424","Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an Intravenous (i.v.) Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-menopausal Women With Low Bone Mass",,"Completed","Has Results","Osteoporosis","Drug: Placebo|Drug: Acetaminophen|Drug: Fluvastatin","Proportion of Patients With a Clinically Significant Increase in Oral Body Temperature or Use of Rescue Medication.|Proportion of Patients With a Clinically Significant Increase in Oral Body Temperature.|Proportion of Patients Who Used Rescue Medication.|Number of Rescue Medication Tablets Taken|Time to First Rescue Medication After Infusion of Zoledronic Acid 5 mg.|Proportion of Patients With a Major Increase (Worsening) in Severity of Questionnaire Symptoms.|Proportion of Patients Reporting Severe Questionnaire Symptoms.|Change From Baseline in Visual Analog Scale (VAS) Measurement of Symptom Severity","Novartis Pharmaceuticals|Novartis","Female","45 Years to 79 Years   (Adult, Older Adult)","Phase 4","793","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CZOL446HUS136","June 2007","December 2007","December 2007","June 21, 2007","September 14, 2009","February 18, 2011","Refer to the E-portal link for ZOL446HUS136, Http://www.osteoporosisclinicalresearch.com, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00489424"
298,"NCT02357745","Evaluation of Neopterin Levels in Pre and Post-menopausal Women With Periodontitis Following Non Surgical Therapy","ENLPPMNS","Unknown status","No Results Available","Periodontitis","Procedure: Non surgical periodontal therapy","Co-relating neopterin and periodontitis levels in pre and post menopausal women","Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre","Female","40 Years to 60 Years   (Adult)",,"30","Other","Observational","Time Perspective: Cross-Sectional","suma thesis","February 2015","May 2015","May 2015","February 6, 2015",,"February 6, 2015",,,"https://ClinicalTrials.gov/show/NCT02357745"
299,"NCT05002894","Effect of Pilates Exercises On Fatigue In Post Menopausal Women",,"Not yet recruiting","No Results Available","Fatigue","Other: Pilates exercises|Dietary Supplement: medical standard care for fatigue","change in Fatigue Assessment Scale|change in Intreluken-6 test","Cairo University","Female","50 Years to 55 Years   (Adult)","Not Applicable","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pilates Effect On Fatigue","September 2021","January 2022","February 2022","August 12, 2021",,"August 12, 2021",,,"https://ClinicalTrials.gov/show/NCT05002894"
300,"NCT02666105","Exemestane in Post-Menopausal Women With NSCLC",,"Completed","No Results Available","Non-Small Cell Lung Cancer","Drug: Exemestane","Disease Response|Toxicity severity will be graded using the Common Toxicity Criteria for Adverse Events (CTCAE) version 4|Response Duration|Progression-free survival|Overall survival|Quality of Life","Masonic Cancer Center, University of Minnesota","Female","Child, Adult, Older Adult","Phase 2","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015LS095","September 27, 2018","February 28, 2022","February 28, 2022","January 28, 2016",,"April 12, 2022","Mayo Clinic Health System, Albert Lea, Minnesota, United States|Essentia Health St. Joseph's Medical Center, Brainerd, Minnesota, United States|Essentia Health Deer River, Deer River, Minnesota, United States|Essentia Health St. Mary's Detroit Lakes, Detroit Lakes, Minnesota, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Essentia Health Fosston, Fosston, Minnesota, United States|Fairview Grand Itasca Clinic & Hospital, Grand Rapids, Minnesota, United States|Essentia Health Hibbing, Hibbing, Minnesota, United States|Fairview Range Medical Center, Hibbing, Minnesota, United States|Mayo Clinic Health System, Mankato, Minnesota, United States|Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States|Monticello Cancer Center (MMCORC), Monticello, Minnesota, United States|Essentia Health Park Rapids, Park Rapids, Minnesota, United States|Fairview Northland Medical Center, Princeton, Minnesota, United States|Essentia Health Sandstone, Sandstone, Minnesota, United States|Sanford Thief River Falls Medical Center, Thief River Falls, Minnesota, United States|Essentia Health Virginia, Virginia, Minnesota, United States|Sanford Worthington Medical Center, Worthington, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02666105"
301,"NCT02422069","Study of Post Menopausal Osteoporosis (PMO) Among Gynecology Outpatients in Pakistan",,"Completed","No Results Available","Postmenopausal Osteoporosis",,"Percentage of patients diagnosed with PMO based upon dual-energy X-ray absorptiometry (DXA) results|Use of various PMO treatment modalities","Hoffmann-La Roche","Female","50 Years and older   (Adult, Older Adult)",,"624","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","ML25212","April 2010","December 2011","December 2011","April 21, 2015",,"November 2, 2016","Islamabad, Pakistan|Karachi, Pakistan|Karachi, Pakistan|Karachi, Pakistan|Lahore, Pakistan|Lahore, Pakistan|Lahore, Pakistan|Rawalpindi, Pakistan",,"https://ClinicalTrials.gov/show/NCT02422069"
302,"NCT01653275","Mediterranean Diet for Post-menopausal Women: Effects on Bone Turnover","MedSD","Completed","No Results Available","Osteoporosis|Postmenopausal Bone Loss","Other: Mediterranean Diet","study adherence|Bone turnover markers","UConn Health|University of Connecticut","Female","65 Years and older   (Older Adult)","Not Applicable","22","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-136S-1","April 2012","December 2014","December 2014","July 30, 2012",,"May 10, 2017","UCHC, Farmington, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01653275"
303,"NCT00882141","Race, Menopause and Metabolism After Exercise and Diet",,"Completed","No Results Available","Obesity|Insulin Resistance|Sedentary Lifestyle","Behavioral: Diet modification|Behavioral: Aerobic exercise","Glucose Clamp|Fat biopsy","National Institute on Aging (NIA)","Female","45 Years to 80 Years   (Adult, Older Adult)","Not Applicable","103","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AG0116|R01AG019310|R01AG020116","March 2002","December 2008","December 2008","April 16, 2009",,"January 13, 2010","University of Maryland, VAMC, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00882141"
304,"NCT03304743","Dental Panoramic Radiographs to Screen for Post-menopausal Osteoporosis","OsteoPano","Completed","No Results Available","Osteoporosis, Postmenopausal","Diagnostic Test: Dental panoramic radiograph","sensitivity and specificity of Klemetti Index|sensitivity and specificity of mandibular cortical width|sensitivity and specificity of panoramic mandibular index|Precision and reproducibility of Klemetti index|Number of post-menopausal women attending a University Dental Hospital (Centro Universitario di Odontoiatria) and identified as osteoporotic with the help of the panoramic indices|number of osteoporotic women identified as osteoporotic with the help of panoramic indices and their risk of fractures","University of Parma|Queen Mary University of London","Female","65 Years and older   (Older Adult)",,"124","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","P-001","June 12, 2018","January 7, 2021","January 7, 2021","October 9, 2017",,"April 29, 2021","Centro Universitario di Odontoiatria, Parma, Italy",,"https://ClinicalTrials.gov/show/NCT03304743"
305,"NCT01806792","Post-menopausal Women Osteoporosis(Phase III)",,"Completed","No Results Available","Postmenopausal Women Osteoporosis","Drug: risedronate combine|Drug: Risedronate|Drug: Placebo(for Risedronate)|Drug: Placebo(for risedronate combine)","proportion of patients with 25(OH)D level < 20 ng/mL at 16 weeks.|proportion of patients with 25(OH)D level < 9 ng/mL at 16 weeks, change of 25(OH)D level and Bone Markers.","Hanlim Pharm. Co., Ltd.","Female","Child, Adult, Older Adult","Phase 3","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","HL_RSNPM_301","November 2009","August 2010","March 2011","March 7, 2013",,"March 7, 2013","Chung-ang university hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01806792"
306,"NCT03747042","Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer",,"Active, not recruiting","No Results Available","Breast Cancer Female","Drug: Letrozole","Measure Ki67 index in highly hormone-dependent breast cancers vs. those that are not","University of Texas Southwestern Medical Center|Cancer Prevention Research Institute of Texas","Female","18 Years and older   (Adult, Older Adult)","Phase 2","61","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCCC-11118; STU-2018-0015","November 27, 2018","November 30, 2023","November 30, 2024","November 20, 2018",,"June 9, 2022","Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03747042"
307,"NCT02884401","Peri-implant Bone Changes in Post-menopausal Osteoporotic Women",,"Completed","No Results Available","Osteoporosis, Postmenopausal","Device: Dental implant placement (Straumann® Bone Level Tapered, BLT, Roxolid® SLActive®)","Changes in peri-implant horizontal and vertical alveolar bone|changes in implant stability measured with resonance frequency analysis|Implant success","Queen Mary University of London","Female","50 Years and older   (Adult, Older Adult)","Not Applicable","27","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","010890","September 2016","March 15, 2022","August 30, 2022","August 31, 2016",,"November 10, 2022","Centre for Oral Clinical Research, Institute of Dentistry, Barts Health, QMUL, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02884401"
308,"NCT02184962","Periodontal Disease and Post-menopausal Osteoporosis",,"Completed","No Results Available","Osteoporosis|Osteopenia|Periodontal Disease",,"levels of RANKL and OPG","Universidad Nacional de Córdoba","Female","45 Years to 70 Years   (Adult, Older Adult)",,"81","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","MEV-2030|UNC-2013","May 2012","September 2013","September 2013","July 9, 2014",,"July 9, 2014","Facultad de Odontología - Universidad Nacional de Córdoba, Córdoba, Argentina",,"https://ClinicalTrials.gov/show/NCT02184962"
309,"NCT02945189","Urine Sample Collection From Non Pregnant Peri and Post-menopausal Women",,"Completed","No Results Available","Pregnancy",,"Individual urine samples obtained from 150 not pregnant women aged 41-55 years and 150 not pregnant women aged 56 - 65 years","SPD Development Company Limited|Richmond Pharmacology Limited","Female","41 Years to 65 Years   (Adult, Older Adult)",,"443","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Protocol-0842","October 2016","March 2017","August 2017","October 26, 2016",,"January 8, 2018",,,"https://ClinicalTrials.gov/show/NCT02945189"
310,"NCT05106010","The Effect of Yoga on Decreasing Risk of Fall-Related Injury in Peri and Post-Menopausal",,"Completed","No Results Available","Fall Injury|Incontinence|Balance; Distorted","Other: Balance Flow Yoga","Muscle Strength Grip Change|Muscle Strength Shoulder and Elbow Change|Muscle Strength Upper Body Change|Balance Change|30 second chair stand change|one leg stand change|modified clinical test of sensory interaction and balance change|balance confidence change|incontinence-ICIQ-UI short form and FLUTS change|incontinence-pad test change|range of motion change|kyphosis change|reaction time|biomechanical outcomes landing on outstretched hand|perceptions of experience","University of Saskatchewan","Female","50 Years to 70 Years   (Adult, Older Adult)",,"36","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","Bio 17-64","November 1, 2018","December 15, 2019","February 15, 2020","November 3, 2021",,"November 3, 2021","University of Saskatchewan, Saskatoon, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT05106010"
311,"NCT03357016","HIIT Versus MICT on Abdominal Fat Mass and Lipid Oxidation in Postmenopausal Women (MATISSE)","MATISSE","Completed","No Results Available","Overweight|Post Menopausal Women","Other: Training programs","Change from baseline abdominal fat mass (g) after 3 months of training (T3-T0/T0 x 100)|Lipids oxidation evaluated by gas exchange measurements|Visceral fat mass|Total fat mass|Fat-free mass|Plasma HbA1c|Glucose level|Plasma triglycerides|Plasma total cholesterol|Plasma HDL-cholesterol|Plasma LDL-cholesterol|Insulin level","Laboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques et Pathologiques|CREPS Vichy Auvergne|University Hospital, Clermont-Ferrand","Female","55 Years to 82 Years   (Adult, Older Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","AU1303|2016-A01742-49","February 1, 2017","June 8, 2018","June 8, 2018","November 29, 2017",,"August 10, 2018","CREPS Vichy Auvergne, Bellerive-sur-Allier, France",,"https://ClinicalTrials.gov/show/NCT03357016"
312,"NCT05203640","Effects of Resistance Exercise on Blood Glucose in Post-menopausal Women With Type 1 Diabetes",,"Recruiting","No Results Available","Type 1 Diabetes","Behavioral: High repetition (HI)|Behavioral: Moderate repetition (MOD)","Blood glucose|Mean continuous glucose monitoring (CGM) glucose|coefficient of variation (CV)|standard deviation (SD)|frequency of hypoglycemia|frequency of hyperglycemia|percent time in range|percent time in hypoglycemia|percent time in hyperglycemia|carbohydrate supplementation","University of Alberta","Female","45 Years to 75 Years   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00112972","April 1, 2022","December 30, 2022","June 30, 2023","January 24, 2022",,"April 4, 2022","Alberta Diabetes Institute, Edmonton, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT05203640"
313,"NCT04680325","Impact of Cranberry Juice Consumption on Gut and Vaginal Microbiota in Post-menopausal Women",,"Completed","No Results Available","Urinary Tract Infections","Dietary Supplement: Juice daily consumption","Changes in the vaginal microbiota profile assessed by sequencing of swab samples|Changes in the gut microbiota profile assessed by sequencing of stool samples","University of Arkansas, Fayetteville|Ocean Spray, Inc.","Female","Child, Adult, Older Adult","Not Applicable","23","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Ocean Spray","July 1, 2017","November 15, 2017","August 31, 2018","December 22, 2020",,"December 22, 2020","University of Arkansas, Fayetteville, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT04680325"
314,"NCT05182281","The Effect of Horizontal Whole-body Vibration Therapy in Post-menopausal Women",,"Completed","No Results Available","Osteoporosis|Whole Body Vibration","Device: Whole Body Vibration and Infrared Therapy|Device: Infrared Therapy|Other: Classical Treatment","Body Mass Density|Bone Turnover Markers|The Short Form-36|Visual analog scale|Berg Balance Test","Fatih Sultan Mehmet Training and Research Hospital","Female","45 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","feyzaakan","May 1, 2015","August 1, 2015","August 1, 2015","January 10, 2022",,"January 10, 2022","Feyza Akan BEGOGLU, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT05182281"
315,"NCT05169840","Genetic Risk Stratification for Primary Prevention of CAD in Men and Pre & Post-menopausal Women",,"Recruiting","No Results Available","Coronary Artery Disease|Genetic Predisposition to Disease","Other: Genetic Risk Score for Coronary Artery Disease","Genetic Risk Score (GRS)|Participant's response on the informed consent regarding their wish to learn about their genetic risk.|Spread of the Genetic Risk Score (GRS) in Hispanics or African Americans vs those of European descent.|Percentage of participants with a high Genetic Risk Score (GRS) who take action as a result.","St. Joseph's Hospital and Medical Center, Phoenix|Chandler Regional Medical Center|Mercy Gilbert Medical Center","All","40 Years to 60 Years   (Adult)",,"2000","Other","Observational","Observational Model: Other|Time Perspective: Prospective","19-500-384-50-17","August 23, 2021","June 15, 2023","June 15, 2031","December 27, 2021",,"December 27, 2021","Chandler Regional Medical Center, Chandler, Arizona, United States|Mercy Gilbert Medical Center, Gilbert, Arizona, United States|St Joseph's Hospital and Medical Center, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT05169840"
316,"NCT04362371","Post Marketing Follow Up Study To Evaluate Performance Safety Quality of Menopausal Transition Women Treated With Ainara",,"Completed","No Results Available","Vaginal Disease","Device: Ainara","Vaginal Health Index (VHI)|Visual Analogue Scale (VAS) for vaginal dryness evaluated by subjects|SF 12 questionnaire completed by the patient|ADE/SADE/USADE (adverse device event, serious adverse device event unexpected serious device event) and AE/SAE|Rate of subjective symptoms|Objective signs in vaginal mucosa|Vaginal pH|Global Symptom Score (GSS)|Female Sexual Function Index (FSFI)","Italfarmaco|Opera CRO, a TIGERMED Group Company","Female","45 Years to 70 Years   (Adult, Older Adult)","Not Applicable","73","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DMS/18/AINARA/03","June 27, 2019","December 9, 2019","December 9, 2019","April 24, 2020",,"May 11, 2021","Fizio Center, Timişoara, Timis, Romania",,"https://ClinicalTrials.gov/show/NCT04362371"
317,"NCT03225703","The Effect of High Impact Exercise on Bone and Articular Cartilage in Post-menopausal Women",,"Unknown status","No Results Available","Osteoporosis, Postmenopausal|Osteoarthritis, Knee|BMD","Behavioral: Hopping","Change in T2 Relaxation Time (ms)|Change in Femoral neck bone mineral density (g/cm2)|Change in Femoral neck bone mineral content (g)|Change in Spine bone mineral density (g/cm2)|Change in Spine bone mineral content (g)|Change in Postural sway (mm)|Change in Maximal hop height (mm)|Change in Ground Reaction force Maximal Hop (N)|Change in Ground Reaction force for a set of ten hops (N)|Change in BMD(D100) (mg HA/cm3)|Change in Total bone mass (mg)|Change in BV/TV (%)|Change in pBV/TV (%)|Change in rBV/TV (%)|Change in pBV/rBV (%)|Change in pBV/BV (%)|Change in rBV/BV (%)|Change in Bone surface(BS) (mm2)|Change in BS/TV (mm-1)|Change in Tb.Th (mm)|Change in Tb.Sp (mm)|Change in Tb.N (mm-1)|Change in Tb.Pf|Change in Conn.D (mm-3)|Change in DA|Change in τ|Change in SMI|Change in BRV (mm3)|Change in BFV (mm3)|Change in BRM (mg)|Change in BFM (mg)|Change in BRF (%)|Change in BFF(%)|Change in BRR(mm3/week)|Change in BFR(mm3/week)|Change in Trabecular orientation distribution (Tb.O.D) (angle in degrees)|Change in Ct.Th(mm)|Change in B.Po(%)|Change in Po.Dm(mm)|Change in Pore volume distribution|Change in Failure load (N)|Change in Strain|Change in Stiffness (N/mm)|Change in Young's Modulus (GPa)|Change in Mechanical anisotropic ratio|Change in Strain energy density (J/m3)|Change in Strain gradient (με/mm)","Loughborough University","Female","55 Years to 70 Years   (Adult, Older Adult)","Not Applicable","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","R16-P149","January 2017","June 2018","January 2019","July 21, 2017",,"July 21, 2017","Loughborough University, Loughborough, Leicestershire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03225703"
318,"NCT02416947","Soluble Corn Fiber Effect on Bone Resorption in Post Menopausal Women",,"Completed","No Results Available","Osteoporosis, Postmenopausal","Dietary Supplement: 0 g SCF|Dietary Supplement: 10g SCF|Dietary Supplement: 20g SCF","Change in 41Ca/Ca ratio in five 24 h urine collections during intervention periods compared to urinary 41Ca/Ca ratios during non-intervention periods|Fasting serum bone specific alkaline phosphatase (BSAP), a biochemical bone formation marker|Fasting serum osteocalcin (OC), a biochemical bone turnover marker|Fasting urine N-terminal telopeptide, a biochemical bone resorption marker","Purdue University|Tate & Lyle Health & Nutrition Sciences","Female","Child, Adult, Older Adult","Not Applicable","14","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","TateLyle Ca41","March 2012","January 2015","January 2015","April 15, 2015",,"April 15, 2015",,,"https://ClinicalTrials.gov/show/NCT02416947"
319,"NCT05221905","Effects of Inorganic Nitrate and Intensity of Exercise on Cardiovascular Health in Post-Menopausal Females",,"Recruiting","No Results Available","Vascular Dilation|Arterial Stiffness","Drug: BEET IT - Concentrate Beet root juice|Drug: BEET IT - Concentrate Beet root juice (nitrate depleted)","Baseline Flow-Mediated Dilation|Post-Exercise/Control Flow-Mediated Dilation (60 minutes)|Post-Exercise/Control Flow-Mediated Dilation (90 minutes)|Post-Exercise/Control Flow-Mediated Dilation (120 minutes)|Post-Exercise/Control Flow-Mediated Dilation (150 min)|Post-Exercise/Control Flow-Mediated Dilation (180 min)|Baseline Pulse Wave Velocity|Post-Exercise/Control Pulse Wave Velocity (60 min)|Post-Exercise/Control Pulse Wave Velocity (90 min)|Post-Exercise/Control Pulse Wave Velocity (120 min)|Post-Exercise/Control Pulse Wave Velocity (150 min)|Post-Exercise/Control Pulse Wave Velocity (180 min)","University of Virginia","Female","45 Years to 75 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","HSR210326","November 1, 2021","March 1, 2023","March 1, 2023","February 3, 2022",,"February 3, 2022","Student Health and Wellness Center, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT05221905"
320,"NCT02415868","Ex Vivo High-Throughput Assay for Vaginal Community Post-menopausal Women","FLORA","Completed","No Results Available","Postmenopausal Syndrome",,"Characterization of the microbiota","Kimberly-Clark Corporation|NIZO Food Research|University Medical Center Groningen","Female","45 Years to 75 Years   (Adult, Older Adult)",,"10","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","500-14-0004","December 2015","February 2016","February 2016","April 14, 2015",,"February 23, 2016","University Medical Center Groningen, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT02415868"
321,"NCT00290212","Natto Supplementation to Prevent Loss of Bone Mass in Women Immediately After Menopause",,"Completed","No Results Available","Perimenopausal Bone Loss","Drug: Natto capsules (food suppl.) cont. 360 microg. vit K2/day|Drug: Placebo capsules","Bone mass density","University Hospital of North Norway|University of Tromso|The International Osteoporosis Foundation|Haukeland University Hospital","Female","50 Years to 60 Years   (Adult)","Phase 2","304","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","REK V 77/2005","January 2006",,"June 2007","February 10, 2006",,"January 24, 2008","Haukeland University Hospital, Bergen, Norway|Clinical Research Center, University Hospital of North Norway, Tromsø, Norway",,"https://ClinicalTrials.gov/show/NCT00290212"
322,"NCT03626792","Effect of Mat Pilates Training on Women After Menopause",,"Completed","No Results Available","Physical Activity|Blood Pressure","Other: Hypertensive group|Other: Normotensive group","Blood pressure|Ambulatory blood pressure monitoring|Kupperman - Blatt Index|Cervical Scale|Menopause Rating Scale (MRS)|Sleep quality","Federal University of Uberlandia","Female","40 Years to 70 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","68408116.9.0000.5152","August 5, 2017","December 20, 2017","March 28, 2018","August 13, 2018",,"March 22, 2022","Jaqueline Pontes Batista, Uberlândia, Minas Gerais, Brazil",,"https://ClinicalTrials.gov/show/NCT03626792"
323,"NCT03821415","Effects of RP101 in Post-menopausal Women With Dry Eye Syndrome",,"Completed","No Results Available","Dry Eye Syndromes","Drug: RP101","Schirmer's test type II (with anaesthesia)|Visual analogue scale (VAS) for ocular tolerability (foreign body sensation, burning/stinging, itching, pain, sticky feeling, blurred vision, redness, tearing, eyelid swelling and photophobia)|Symptom assessment in Dry Eye (SANDE)|Visual acuity assessment using an Early Treatment Diabetic Retinopathy Study [ETDRS] chart|Slit lamp examination (SLE)|TFBUT|Fundus ophthalmoscopy|Corneal fluorescein staining|Treatment-emergent Adverse Event (TEAEs)|17-β-oestradiol serum concentrations","Redwood Pharma AB|Cross Research S.A.","Female","Child, Adult, Older Adult","Phase 2","104","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RP101-200","January 18, 2019","November 18, 2019","November 18, 2019","January 29, 2019",,"December 20, 2019","Medical University of Vienna - Department of Clinical Pharmacology, Vienna, Austria|Universitätsmedizin Greifswald, Klinik und Poliklinik für Augenheilkunde, Greifswald, Germany|Universitätsmedizin Mainz Augenklinik und Poliklinik Klinisches, Mainz, Germany|Klinikum rechts der Isar der Technischen Universität München, Anstalt des öffentlichen Rechts Klinik und Poliklinik für Augenheilkunde, München, Germany|Óbudai Egészség Centrum, Budapest, Hungary|Swan Med Hungary Kft., Létavértes, Hungary|MacroKlinika, Miskolc, Hungary|Mentaház Magánorvosi Központ, Székesfehérvár, Hungary",,"https://ClinicalTrials.gov/show/NCT03821415"
324,"NCT04276077","Electrical Muscle Stimulation on Muscle Stiffness and Functional Capacity in Post-menopausal Women",,"Active, not recruiting","No Results Available","Electric Stimulation Therapy|Frailty|Women","Other: High-frequency electrical muscle stimulation training|Other: Low-frequency electrical muscle stimulation training","Stiffness|Functional capacity","Universidad Complutense de Madrid","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","27","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","EMS_US","February 18, 2020","December 15, 2022","December 30, 2022","February 19, 2020",,"May 17, 2022","Universidad Francisco de Vitoria, Pozuelo De Alarcón, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04276077"
325,"NCT03503552","Body Composition and Risk for Development of Pre-diabetes in Post-menopausal Chinese Women in Singapore",,"Completed","No Results Available","Osteoporosis|Metabolic Syndrome",,"Body composition|Bone mineral density|Blood biomarkers|Urine Markers","JeyaKumar Henry|University of Auckland, New Zealand|Massey University|Institute of Materials Research and Engineering (IMRE)|Clinical Nutrition Research Centre, Singapore","Female","55 Years to 70 Years   (Adult, Older Adult)",,"97","Other","Observational","Observational Model: Other|Time Perspective: Other","2014/01066","February 13, 2015","February 2016","February 2016","April 20, 2018",,"April 20, 2018","Clinical Nutrition Research Centre, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT03503552"
326,"NCT01397838","Safety Study of an Oral Pro-boneTM, Administered to Post Menopausal Osteopenic Women",,"Unknown status","No Results Available","Osteopenia","Drug: Pro-Bone","Adverse events recorded throughout the study|Blood and urinalysis values assessed at pre-dose and according to study design.|Vital signs","OsteoBuild Ltd.","Female","45 Years to 65 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","OBCS-001","September 2011","December 2011","January 2012","July 20, 2011",,"July 20, 2011",,,"https://ClinicalTrials.gov/show/NCT01397838"
327,"NCT00005768","Estrogen Modulation of Mood and Cognition Following Monoaminergic Depletion in Post-Menopausal Women",,"Unknown status","No Results Available","Menopause","Drug: Estrogen",,"National Center for Research Resources (NCRR)","Female","50 Years and older   (Adult, Older Adult)","Phase 2",,"NIH","Interventional","Allocation: Randomized|Masking: Double|Primary Purpose: Treatment","NCRR-M01RR00109-0741|M01RR000109",,,,"June 2, 2000",,"June 24, 2005","University of Vermont, Burlington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT00005768"
328,"NCT03841058","Phase II Trial of Abaloparatide vs. Placebo in Post-Menopausal Women Receiving Initial Spinal Fusion Surgery",,"Recruiting","No Results Available","Spinal Fusion","Drug: Abaloparatide|Drug: Placebo","Difference in measure of fusion mass bridging from transverse process to transverse process|Difference in incidence of adverse surgical outcomes|Pain assessed by the Numeric Rating Scale|Pain assessed by the Oswestry Disability Index","Hospital for Special Surgery, New York","Female","50 Years and older   (Adult, Older Adult)","Phase 2","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2018-0287","August 14, 2019","January 2024","January 2024","February 15, 2019",,"March 31, 2022","Hospital for Special Surgery, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03841058"
329,"NCT04179903","Efficacy and Safety of the Physical Activity Program in Women With Post-menopausal Osteoporosis","ACTLIFE","Unknown status","No Results Available","Osteoporosis, Postmenopausal|Physical Activity","Other: Physical activity","Quality of life questionnaire|Disability|Fear of falls|Walking|standing balance|Muscle force|joint mobility|Body Mass Index","Istituto Ortopedico Rizzoli|University of Bologna","Female","40 Years and older   (Adult, Older Adult)","Not Applicable","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","45/18","February 1, 2019","September 30, 2020","June 30, 2021","November 27, 2019",,"February 8, 2021","Istituto Ortopedico Rizzoli, Bologna, Italy",,"https://ClinicalTrials.gov/show/NCT04179903"
330,"NCT05549505","A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery",,"Recruiting","No Results Available","Breast Cancer","Drug: ARV-471|Drug: Anastrozole|Procedure: Surgical resection of breast tumor","Evaluate the effects of ARV-471 and anastrozole, respectively, on Ki-67 expression in tumors after 2 weeks of treatment|Evaluate the safety/tolerability of ARV-471 and anastrozole, respectively|Evaluate the pathological response of ARV-471 and anastrozole, respectively (pathologic stage)|Evaluate the pathological response of ARV-471 and anastrozole, respectively (pathologic complete response rate)|Evaluate the pathological response of ARV-471 and anastrozole, respectively (modified Pre-operative Endocrine Prognostic Index score)|Evaluate the clinical response of ARV-471 and anastrozole, respectively (breast conserving surgery rate)|Evaluate the clinical response of ARV-471 and anastrozole, respectively (radiographic response)|Evaluate the clinical response of ARV-471 and anastrozole, respectively (caliper-based response)","Arvinas Inc.|Pfizer","Female","18 Years and older   (Adult, Older Adult)","Phase 2","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARV-471-BC-201|C4891025","January 2023","December 2023","June 2024","September 22, 2022",,"January 27, 2023","Clinical Trial Site, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT05549505"
331,"NCT05389943","The Effect of Vitamin D3 Therapy in Post Menopausal Women and Assessment of Changes in Bone Mineral Density After Orally Vitamin D3 Administration",,"Not yet recruiting","No Results Available","Vitamin D Deficiency","Drug: Oral administration of vitamin D3|Drug: Vitamin D3 50000 UNT Oral Capsule|Dietary Supplement: milk, Dietary and life style modifications.","Postmenopausal women BMD will be improved with oral vitamin D supplements","University of Sargodha|Government College University Faisalabad","Female","50 Years and older   (Adult, Older Adult)","Phase 1","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","USargodha","June 5, 2022","August 15, 2022","November 15, 2022","May 25, 2022",,"May 25, 2022","Arsalan Khalid, Faisalābad, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT05389943"
332,"NCT00491595","Phase I Clinical Study of Soy Isoflavones in Healthy, Post-Menopausal Women",,"Completed","No Results Available","Drug Toxicity","Drug: High Dose Soy isoflavones","DNA damage, apoptosis, estrogenic effects and changes in gene expression","University of North Carolina|National Cancer Institute (NCI)|University of North Carolina, Chapel Hill","Female","Child, Adult, Older Adult","Phase 1","36","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double","NCI-N01-CN-75035","March 2004",,"July 2005","June 26, 2007",,"June 26, 2007",,,"https://ClinicalTrials.gov/show/NCT00491595"
333,"NCT02385747","Uterine Cavity Assessment and Endometrial Hormonal Receptors in Women With Peri and Post Menopausal Bleeding",,"Completed","No Results Available","Vaginal Bleeding","Procedure: hystroscopy","detection of endometrial lesion","Cairo University","Female","45 Years to 65 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","130","March 2015","February 2016","February 2016","March 11, 2015",,"March 21, 2017","Kasr Alainy medical school, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT02385747"
334,"NCT02736019","Tramadol Versus Celecoxib for Reducing Pain During Office Hysteroscopy in Post Menopausal Women",,"Unknown status","No Results Available","Hysteroscopy","Drug: Celecoxib|Drug: Tramadol|Drug: Placebo 1|Drug: Placebo 2","Patient's perception of pain during the procedure|Pain after the procedure","Cairo University","Female","50 Years to 70 Years   (Adult, Older Adult)","Phase 3","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Hyst 7","June 2016","April 2017",,"April 13, 2016",,"July 6, 2016","Cairo University Hospitals, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT02736019"
335,"NCT00548496","A Phase IIa Study Of Men And Post-Menopausal Women With A Fractured Distal Radius",,"Terminated","No Results Available","Fracture Healing","Drug: SB-751689|Other: Placebo","Data from the study will be used to determine if fracture healing time at 16 weeks is decreased in patients receiving SB-751689 and will determine future studies.|Radiographic, functional, and quality of life assessments.","GlaxoSmithKline","All","35 Years to 80 Years   (Adult, Older Adult)","Phase 2","86","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR9108914","September 20, 2007","November 26, 2008","November 26, 2008","October 24, 2007",,"April 12, 2017","GSK Investigational Site, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Ciudad autónoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Mar del Plata, Buenos Aires, Argentina|GSK Investigational Site, Naciones Unidas 346, Córdova, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autónoma de Buenos Aires, Argentina|GSK Investigational Site, Quilmes, Argentina|GSK Investigational Site, Rosario, Argentina|GSK Investigational Site, San Juan, Argentina|GSK Investigational Site, Kogarah, New South Wales, Australia|GSK Investigational Site, St Leonards, New South Wales, Australia|GSK Investigational Site, Geelong, Victoria, Australia|GSK Investigational Site, Praha 2, Czech Republic|GSK Investigational Site, Praha 4, Czech Republic|GSK Investigational Site, Hong Kong, Hong Kong|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Almelo, Netherlands|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Leiden, Netherlands|GSK Investigational Site, Bucharest, Romania|GSK Investigational Site, Cluj-Napoca, Romania|GSK Investigational Site, Ekaterinburg, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Yaroslavl, Russian Federation|GSK Investigational Site, Bryanston, South Africa|GSK Investigational Site, Pinelands, South Africa|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Santiago de Compostela, Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, Göteborg, Sweden|GSK Investigational Site, Kungälv, Sweden|GSK Investigational Site, Mölndal, Sweden|GSK Investigational Site, Changhua, Taiwan|GSK Investigational Site, Taichung, Taiwan|GSK Investigational Site, Rhyl, Flintshire, United Kingdom|GSK Investigational Site, Edinburgh, Midlothian, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00548496"
336,"NCT00443716","Determination of Adipocyte Parameters in Iliac Crest Biopsies From Post Menopausal Women",,"Completed","No Results Available","Osteoporosis|Postmenopausal","Drug: estrogen","efficacy of estraderm treatment on osteoporotic women","Mayo Clinic","Female","30 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","05-004111|21b85","April 1985","April 1989","April 1989","March 6, 2007",,"January 15, 2010","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00443716"
337,"NCT01381588","The Prevalence of Osteoporotic Vertebral Compression Fractures (OVCF) in Korean Post Menopausal Women","TOP","Completed","No Results Available","Osteoporosis, Postmenopausal","Other: Fracture evaluation","The prevalence of OVCFs confirmed by history and X-ray|The prevalence of asymptomatic (or missed) fractures","GlaxoSmithKline","Female","50 Years to 79 Years   (Adult, Older Adult)",,"1136","Industry","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","114777","October 2010","February 2011","February 2011","June 27, 2011",,"May 16, 2017","GSK Investigational Site, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01381588"
338,"NCT04242953","Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects",,"Active, not recruiting","No Results Available","Healthy Volunteer Study","Drug: SCO-120|Drug: matching placebo","Part A: Number of subjects with treatment-related adverse events as assessed by CTCAE version 5.0|Part C: Number of subjects with treatment-related adverse events as assessed by CTCAE version 5.0|Part B: Number of subjects with treatment-related adverse events as assessed by CTCAE version 5.0","Sun Pharma Advanced Research Company Limited","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","SCO-120-19-18","March 4, 2020","May 13, 2022","February 28, 2023","January 27, 2020",,"December 23, 2022","AXIS Clinicals, Dilworth, Minnesota, United States|BioPharma Services USA Inc., Creve Coeur, Missouri, United States|BioPharma Services Inc., Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04242953"
339,"NCT03737656","Characterization of the Pharmacokinetics of a Vaginal Ring With 2.0 g Progesterone in Post-menopausal Women",,"Completed","No Results Available","Pharmacokinetics","Drug: Progesterone vaginal ring","Progesterone pharmacokinetic parameters (AUC0-t)|Progesterone pharmacokinetic parameters (AUC0-inf)|Progesterone pharmacokinetic parameters (Cmax)|Progesterone pharmacokinetic parameters (Tmax)|Progesterone pharmacokinetic parameters (AUC%extr)|Progesterone pharmacokinetic parameters (t1/2)|Progesterone pharmacokinetic parameters (MRT)","Grünenthal GmbH|Grünenthal, S.A.","Female","40 Years to 65 Years   (Adult, Older Adult)","Phase 1","106","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","PRG-02-GRU/PK-PVR-01|16-CI-19 039 043|HP8013-01","November 1, 2018","May 3, 2019","May 9, 2019","November 9, 2018",,"June 5, 2019","Investigacíon Farmacológica y Biofarmacéutica (IFaB), S.A.P.I. de C.V., Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT03737656"
340,"NCT04887701","Non-hormonal Medical Device for Treatment of Vulvovaginal Atrophy (VVA) in Post-Menopausal Women",,"Completed","No Results Available","Vulvovaginal Atrophy","Device: Non-hormonal vaginal device therapy|Device: Sham vaginal device therapy","Clinician Assessed Changes in VVA|Patient Reported VAS Score|Responder Rate PGI-I","Madorra","Female","21 Years to 65 Years   (Adult, Older Adult)","Not Applicable","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CLN-201","July 9, 2021","August 22, 2022","August 22, 2022","May 14, 2021",,"January 13, 2023","North Shore Private Hospital, Sydney, New South Wales, Australia|Goldfields Urology, Bendigo, Victoria, Australia|Royal Women's Hospital, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT04887701"
341,"NCT00163163","Carotid Atorvastatin Study in Hyperlipidemic Post-Menopausal Women",,"Completed","No Results Available","Hypercholesterolaemia","Procedure: Echographic measurements|Procedure: Blood samples","Mean change in carotid IMT from baseline to month 12.|Mean change from baseline to month 12 of carotid internal diameter (ID)|wall cross sectional area (WCSA); carotid arterial mass (AM)|pulse pressure (PP); cross sectional distensibility and compliance (DC and CC)|pulse wave velocity (PWV); Lipid profile","Pfizer's Upjohn has merged with Mylan to form Viatris Inc.|Pfizer","Female","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","A2581051","January 2003",,"July 2006","September 13, 2005",,"February 18, 2021","Pfizer Investigational Site, Afsnee GENT, Belgium|Pfizer Investigational Site, Assenede, Belgium|Pfizer Investigational Site, Brussels, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Ertvelde, Belgium|Pfizer Investigational Site, Gent, Belgium|Pfizer Investigational Site, Linkebeek, Belgium|Pfizer Investigational Site, Sint-niklaas, Belgium|Pfizer Investigational Site, Tielt, Belgium|Pfizer Investigational Site, Wetteren, Belgium|Pfizer Investigational Site, Wondelgem, Belgium|Pfizer Investigational Site, Achenheim, France|Pfizer Investigational Site, Ancerville, France|Pfizer Investigational Site, Augny, France|Pfizer Investigational Site, Bar Le Duc, France|Pfizer Investigational Site, Boersch, France|Pfizer Investigational Site, Bois-Colombes, France|Pfizer Investigational Site, Boissy Saint Leger, France|Pfizer Investigational Site, Bouzonville, France|Pfizer Investigational Site, Colombey-Les-Belles, France|Pfizer Investigational Site, Dammarie Les Lys, France|Pfizer Investigational Site, Docelles, France|Pfizer Investigational Site, Dourdan, France|Pfizer Investigational Site, Eckbolsheim, France|Pfizer Investigational Site, Epinay S/orge, France|Pfizer Investigational Site, Etampes, France|Pfizer Investigational Site, Frouard, France|Pfizer Investigational Site, Gambsheim, France|Pfizer Investigational Site, Haguenau, France|Pfizer Investigational Site, Kilstett, France|Pfizer Investigational Site, Laxou, France|Pfizer Investigational Site, le Grand Quevilly, France|Pfizer Investigational Site, Le Mesnil Esnard, France|Pfizer Investigational Site, Leuville Sur Orge, France|Pfizer Investigational Site, Lingolsheim, France|Pfizer Investigational Site, Longpont Sur Orge, France|Pfizer Investigational Site, Mars LA Tour, France|Pfizer Investigational Site, Metz, France|Pfizer Investigational Site, Moutiers, France|Pfizer Investigational Site, Nancy, France|Pfizer Investigational Site, Nancy, France|Pfizer Investigational Site, Nancy, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Pont a Mousson, France|Pfizer Investigational Site, Pont-a-mousson, France|Pfizer Investigational Site, Pulnoy, France|Pfizer Investigational Site, Rouen, France|Pfizer Investigational Site, Sainte Genevieve Des Bois, France|Pfizer Investigational Site, Sauvigny, France|Pfizer Investigational Site, Savigny Sur Orge, France|Pfizer Investigational Site, Sotteville Les Rouen Cedex, France|Pfizer Investigational Site, Souffelweyersheim, France|Pfizer Investigational Site, St Max, France|Pfizer Investigational Site, Strasbourg, France|Pfizer Investigational Site, Strasbourg, France|Pfizer Investigational Site, Terville, France|Pfizer Investigational Site, Toul, France|Pfizer Investigational Site, Vandoeuvre Les Nancy, France|Pfizer Investigational Site, Vandoeuvre, France|Pfizer Investigational Site, Verdun, France|Pfizer Investigational Site, Vincennes, France|Pfizer Investigational Site, ED Voerendaal, Netherlands|Pfizer Investigational Site, EN Vaals, Netherlands|Pfizer Investigational Site, VE Maastricht, Netherlands",,"https://ClinicalTrials.gov/show/NCT00163163"
342,"NCT02425709","Tramadol Versus Diclofenac for Reducing Pain Before Outpatient Hysteroscopy in Post Menopausal Women",,"Unknown status","No Results Available","Hysteroscopy|Pain","Drug: Diclofenac|Drug: Tramadol|Drug: Placebo","Pain during the procedure measured using a visual analogue scale|Pain immediately after the procedure measured using a visual analogue scale","Cairo University","Female","50 Years to 65 Years   (Adult, Older Adult)","Phase 3","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Hyst 4","April 2015","December 2017",,"April 24, 2015",,"January 23, 2017","Cairo university hospitals, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT02425709"
343,"NCT00797199","Monitoring of Breast Tissue Change Due to Hormone Replacement Therapy in Post-menopausal Women Using OBS","TiBS-HRT","Completed","No Results Available","Breast Cancer",,"Changes in OBS parameters","University Health Network, Toronto|Unity Health Toronto","Female","30 Years to 65 Years   (Adult, Older Adult)",,"14","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TiBS-HRT","September 2011","December 2014","January 2015","November 25, 2008",,"March 23, 2016","Princess Margaret Hospital, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00797199"
344,"NCT04123743","Efficacy of Extract of Trigonella Foenum-graceum as Topical Phytoestrogen in Skin Aging Treatment of Post Menopausal Women",,"Completed","No Results Available","Skin Aging","Drug: Trigonella foenum-graceum extract topical cream|Other: Facial Wash|Other: Sunscreen Cream|Other: Placebo","Visual Analogue Scale for Forehead Wrinkles|Visual Analogue Scale for Crow's Feet Wrinkles|Visual Analogue Scale for Nasolabial Wrinkles|High Resolution Ultrasound","Indonesia University","Female","Child, Adult, Older Adult","Phase 1|Phase 2","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00001","August 10, 2019","November 3, 2019","November 10, 2019","October 11, 2019",,"July 29, 2020","Faculty of Medicine, Universitas Indonesia, Jakarta Pusat, DKI Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT04123743"
345,"NCT02795039","Bioequivalence Study of Fulvestrant Injection 50 mg/mL in Healthy Post-menopausal Female Subjects",,"Completed","No Results Available","Healthy","Drug: Fulvestrant","Maximum observed plasma concentration|Area under the plasma concentration versus time curve (AUC0-238d) of fulvestrant|Area under the plasma concentration versus time curve (AUC0-28d) of fulvestrant|Area under the plasma concentration versus time curve from time zero to the last measurable concentration (AUC0-t)|Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC0-∞)|Time to Reach the Maximum Plasma Concentration (Tmax)|Elimination Half-life Period (t1/2)|Terminal Slope (λz)|Residual area in percentage (AUC_%Extrap_obs)|Injection site pain assessment","Fresenius Kabi","Female","40 Years to 65 Years   (Adult, Older Adult)","Phase 1","266","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","FULV-006-CP1","June 2016","March 3, 2017","March 3, 2017","June 9, 2016",,"March 9, 2017","Lambda Therapeutic Research Inc., Toronto, Ontario, Canada|BioPharma Services Inc., Toronto, Ontario, Canada|Algorithme Pharma Inc., Mount Royal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02795039"
346,"NCT01664754","Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer",,"Completed","No Results Available","Stage IV Non-small Cell Lung Cancer","Drug: exemestane|Drug: pemetrexed disodium|Drug: carboplatin|Other: laboratory biomarker analysis|Other: pharmacological study|Other: questionnaire administration|Procedure: quality-of-life assessment","Tabulation, grading, and attribution of serious adverse events (SAEs) and adverse events (AEs) using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0|Proportion achieving clinical response|Quality of life in patients treated with pemetrexed disodium, carboplatin and exemestane","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Phase 1","8","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-003323|NCI-2012-01250","September 7, 2012","January 11, 2019","January 11, 2019","August 14, 2012",,"May 7, 2019","Jonsson Comprehensive Cancer Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01664754"
347,"NCT00453089","VG101 Phase I/II to Treat Vulvar and Vaginal Atrophy in Post-Menopausal Women",,"Unknown status","No Results Available","Vaginal Atrophy|Vulvar Atrophy","Drug: VG101","Change in self-reported symptoms of vaginal atrophy from baseline to 12 weeks|Change in percent superficial vaginal epithelial cells from baseline 12 weeks|Change in the pH of vaginal secretions from baseline to 12 weeks","Bionovo","Female","45 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VG-101-001","June 2012","June 2013","August 2013","March 28, 2007",,"February 8, 2012","University of Alabama, Birmingham, Birmingham, Alabama, United States|University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT00453089"
348,"NCT04619485","Sexual and Vaginal Health in Breast Cancer Women Receiving Aromatase Inhibitors Before and After CO2 Laser Therapy","LIGHT","Active, not recruiting","No Results Available","Breast Cancer|Genitourinary Syndrome of Menopause","Device: CO2 LASER|Device: CO2 SHAM LASER","Female Sexual Function Index (FSFI)|Vaginal pH|Vaginal epithelium thickness|Resumption of sexual activity|Sexual activity frequency|Dyspareunia|Female sexual dysfunction|Body image perception","Hospital Clinic of Barcelona","Female","30 Years to 80 Years   (Adult, Older Adult)","Not Applicable","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HCB/2019/0786","October 30, 2020","August 30, 2021","August 30, 2022","November 6, 2020",,"June 7, 2022","Eduard Mension Coll, Barcelona, Spain","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT04619485/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04619485"
349,"NCT00611715","Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.",,"Terminated","Has Results","Breast Cancer","Drug: erlotinib hydrochloride|Drug: letrozole|Genetic: fluorescence in situ hybridization|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis","Number of Patients With Pathological Complete Response.|Median Time to Progression of Target Lesions|Number of Patients With Anti-tumor Activity: Complete Response (CR) and Partial Response (PR)|Number of Patients With Worst-grade Toxicities Per Grade","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Phase 2","48","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VICC BRE 0303|VU-VICC-BRE-0303|VU-VICC-030592|GENENTECH-VU-VICC-BRE-0303|NOVARTIS-VU-VICC-BRE-0303","November 2003","December 2008","December 2008","February 11, 2008","July 13, 2012","August 9, 2012","Central Georgia Hematology/Oncology Associates, P.C., Macon, Georgia, United States|Jennie Stuart Medical Center, Hopkinsville, Kentucky, United States|Purchase Cancer Group, Paducah, Kentucky, United States|Memorial Health Care System, Chattanooga, Tennessee, United States|The Jones Clinic - Germantown, Germantown, Tennessee, United States|Jackson-Madison County Hospital, Jackson, Tennessee, United States|Tennessee Cancer Specialists, Knoxville, Tennessee, United States|Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00611715"
350,"NCT04222647","Investigation of Efficacy and Tolerability of a Lactic Acid Containing Vaginal Suppository in Post-menopausal Women With VVA",,"Completed","No Results Available","Vulvovaginal Atrophy","Drug: WO533","VMI|Vaginal pH|Subjective vulvovaginal atrophy symptoms|Global judgment of the tolerability by the Investigator|Global judgment of the tolerability by the patient|Adverse events","Dr. August Wolff GmbH & Co. KG Arzneimittel|proDERM Institut für Angewandte Dermatologische Forschung GmbH|Bremer Pharmacovigilance Service GmbH","Female","18 Years and older   (Adult, Older Adult)","Phase 2","43","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VMP-03/2018|2019-002325-30","January 27, 2020","August 11, 2020","August 11, 2020","January 10, 2020",,"December 23, 2021","proDERM Institute for Applied Dermatological Research, Schenefeld, Germany",,"https://ClinicalTrials.gov/show/NCT04222647"
351,"NCT01791478","BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer",,"Active, not recruiting","No Results Available","Estrogen Receptor-positive Breast Cancer|HER2-negative Breast Cancer|Invasive Ductal Breast Carcinoma|Progesterone Receptor-positive Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer","Drug: PI3K inhibitor BYL719|Drug: letrozole|Other: laboratory biomarker analysis|Other: pharmacological studies","Maximum tolerated dose of BYL719 in combination with letrozole|Highest tolerated dose of BYL719 in combination with letrozole|Clinical benefit rate|Overall progression-free survival|Overall response|Worst grade toxicities","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Phase 1","46","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VICC BRE 12101|NCI-2013-00102","April 2013","December 2014","October 2023","February 15, 2013",,"October 18, 2022","Massachusetts General Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01791478"
352,"NCT03401320","Evaluation of IM Letrozole ISM® Pharmacokinetics, Safety, and Tolerability in Healthy Post-menopausal Women (LISA-1)",,"Active, not recruiting","No Results Available","Healthy","Drug: Letrozole ISM","λz|Cmax|Cmax/D|tmax|tlag|t½|AUC∞|AUC∞/D|AUCextrap|AUClast|Vz/F|CL/F|Cav|Cmin,ss|Cmax,ss|AUCτ|CLss/F|Hormones levels|AEs","Rovi Pharmaceuticals Laboratories","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","120","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other","ROV-LET-2017-01|LISA-1","November 6, 2017","March 17, 2023","March 17, 2023","January 17, 2018",,"February 3, 2023","Investigational Site Number 42001, Prague, Czech Republic, Czechia",,"https://ClinicalTrials.gov/show/NCT03401320"
353,"NCT01431872","Systemic Dickkopf-related Protein 1 (DKK1)During Estrogen Level Changes in Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors",,"Completed","No Results Available","Breast Cancer",,"Estrogen level suppresses DKK1","University of Arkansas","Female","18 Years and older   (Adult, Older Adult)",,"17","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","131471","April 2011","August 2015","August 2015","September 12, 2011",,"November 4, 2015","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT01431872"
354,"NCT00161291","Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer",,"Completed","No Results Available","Breast Cancer","Drug: Letrozole in combination with Bevacizumab","The primary objective is to estimate the pathological complete response rate of neoadjuvant therapy in operable newly diagnosed ER+ breast cancer patients using the combination of Avastin and Letrozole.|A clinical response will be based upon the Response Evaluation Criteria in Solid Tumors (RECIST Criteria).","University of Alabama at Birmingham|Genentech, Inc.","Female","60 Years and older   (Adult, Older Adult)","Phase 2","28","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","F041222006|UAB 0467","June 2005","November 2006","November 2006","September 12, 2005",,"January 4, 2011","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT00161291"
355,"NCT03770065","Exploratory Study on Two Different Doses of VML-0001 on the Effects on Vaginal pH in Healthy Post-Menopausal Women",,"Completed","No Results Available","Vaginal Atrophy","Device: VML-0001","To determine the duration of action measured on the ability of VML-0001 (base formulation) to reduce vaginal pH.","Viramal Limited","Female","45 Years and older   (Adult, Older Adult)",,"14","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","VML-0001-003","November 19, 2018","December 30, 2019","April 8, 2020","December 10, 2018",,"October 6, 2020","Medical Affiliated Research Center, Inc. (MARC), Huntsville, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT03770065"
356,"NCT02679755","Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer",,"Completed","Has Results","Breast Cancer","Drug: Palbociclib|Drug: Letrozole","Number of Participants With Treatment-Emergent Adverse Events (All Causalities)|Number of Participants With Treatment-Emergent Adverse Events by Severity (All Causalities)|Number of Participants With Treatment-Emergent Adverse Events (Palbociclib-Related)|Number of Participants With Treatment-Emergent Adverse Events by Severity (Palbociclib-Related)|Number of Participants With Serious Adverse Events (All Causalities and Palbociclib-Related)|Percentage of Participants With Complete Response and Partial Response|The Objective Response Rate (ORR)|EQ-5D Health Utility Index Score|Change From Baseline in EQ-5D Health Utility Index Score|EQ-VAS Score|Change From Baseline in EQ-VAS Score","Pfizer","Female","18 Years and older   (Adult, Older Adult)","Phase 4","252","Industry","Interventional","Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","A5481037","March 9, 2016","July 25, 2019","July 25, 2019","February 10, 2016","October 5, 2020","July 27, 2022","Benjamin Carl Forster, North Sydney, New South Wales, Australia|Dr. Alexander Maxwell Menzies, North Sydney, New South Wales, Australia|HPS Pharmacies - North Sydney, North Sydney, New South Wales, Australia|Mater Hospital Sydney, North Sydney, New South Wales, Australia|Professor Frances Mary Boyle, North Sydney, New South Wales, Australia|Royal North Shore Hospital - Clinical Trials Pharmacy, St Leonards, New South Wales, Australia|Royal North Shore Hospital, Dept. of Medical Oncology, St Leonards, New South Wales, Australia|Icon Cancer Care Wesley, Auchenflower, Queensland, Australia|River City Pharmacy, Auchenflower, Queensland, Australia|Icon Cancer Care Chermside, Chermside, Queensland, Australia|Icon Cancer Care South Brisbane, South Brisbane, Queensland, Australia|Icon Cancer Care, Corporate Office, South Brisbane, Queensland, Australia|Icon Cancer Care Southport, Southport, Queensland, Australia|Flinders Medical Centre-Pharmacy Department, Bedford Park, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Monash Health, Clayton, Victoria, Australia|Peter MacCallum Cancer Centre Pharmacy, Melbourne, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Sunshine Hospital, St Albans, Victoria, Australia|Sunshine Hospital Pharmacy, St. Albans, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Pharmacy Department, Murdoch, Western Australia, Australia|Rajiv Gandhi Cancer Institute And Research Centre, New Delhi, Delhi, India|Dr. B.R.A Institute Rotary Cancer Hospital, All India Institue of Medical Sciences, New Delhi, Delhi, India|The Gujarat Cancer & Research Institute, M.P Shah Cancer Hospital, Ahmedabad, Gujarat, India|Manipal Hospital, Bangalore, Karnataka, India|HealthCare Global Enterprises Ltd., Bangalore, Karnataka, India|Kasturba Hospital, Manipal, Karnataka, India|Tata Memorial Centre, Tata Memorial Hospital, Mumbai, Maharashtra, India|Meditrina Institute Of Medical Sciences, Nagpur, Maharashtra, India|Shatabdi Hospital, Nashik, Maharashtra, India|Deenanath Mangeshkar Hospital and Research Center, Pune, Maharashtra, India|Sahyadri Super Speciality Hospital, Pune, Maharashtra, India|Apollo Speciality Hospital, Chennai, Tamilnadu, India","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02679755/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02679755/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02679755"
357,"NCT05052164","Improvement Of Physical And Physiological Parameters In Menopausal Or Post-Menopausal Celiac Women",,"Completed","No Results Available","Celiac Disease|Diet, Gluten-Free|Exercise|Resistance Training|Quality of Life|Body Composition","Behavioral: Gluten-free nutrition plan + exercise group|Behavioral: Gluten-free nutrition plan group|Behavioral: Active Comparator: Celiac controls group","Quality of Life (QoL)|Body Composition - Fat Mass|Body Composition - Lean Body Mass|Body Composition - Visceral Fat|Weight|Strength|Adherence to gluten-free diet|Anthropometric assessment - Skinfolds|Anthropometric assessment - Perimeters|Anthropometric assessment - Diameters|Anthropometric assessment - Height|Resistance test|Balance test|Functional autonomy test|State of mind|Eating disorders|Heart rate variability|Maximum oxygen consumption|Glucose in blood|Cholesterol in blood|Creatinine in blood|Urea in blood","University of Alicante","Female","40 Years to 70 Years   (Adult, Older Adult)","Not Applicable","28","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","UA-2018-10-22","September 1, 2018","August 1, 2021","September 1, 2021","September 22, 2021",,"September 22, 2021","University of Alicante, Alicante, San Vicente Del Raspeig, Spain",,"https://ClinicalTrials.gov/show/NCT05052164"
358,"NCT03596762","A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms","SWITCH-1","Completed","No Results Available","Menopause|Hot Flashes|Night Waking","Drug: BAY3427080|Drug: Placebo","Mean change from baseline in frequency of moderate and severe hot flashes recorded in patient diary|Mean change from baseline in severity of moderate and severe hot flashes recorded in patient diary","Bayer|Nerre Therapeutics Ltd.","Female","40 Years to 65 Years   (Adult, Older Adult)","Phase 2","199","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","21686|2018-002763-26","November 20, 2018","November 21, 2019","November 21, 2019","July 24, 2018",,"November 18, 2020","Study Site 12, Mesa, Arizona, United States|Study Site 19, San Diego, California, United States|Study Site 13, Aventura, Florida, United States|Study Site 15, Lake Worth, Florida, United States|Study Site 18, Atlanta, Georgia, United States|Study Site 16, New Orleans, Louisiana, United States|Study Site 10, Boston, Massachusetts, United States|Study Site 11, Boston, Massachusetts, United States|Study Site 17, Las Vegas, Nevada, United States|Study Site 14, Houston, Texas, United States|Study Site 50, Red Deer, Alberta, Canada|Study Site 51, Mission, British Columbia, Canada|Study Site 54, Guelph, Ontario, Canada|Study Site 52, Scarborough, Ontario, Canada|Study Site 53, Toronto, Ontario, Canada|Study Site 37, Blackpool, United Kingdom|Study Site 34, Cannock, United Kingdom|Study Site 31, Glasgow, United Kingdom|Study Site 39, Leeds, United Kingdom|Study Site 38, Liverpool, United Kingdom|Study Site 30, London, United Kingdom|Study Site 36, Manchester, United Kingdom|Study Site 33, Poole, United Kingdom|Study Site 32, Southport, United Kingdom|Study Site 35, Stockton-on-Tees, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03596762"
359,"NCT04191382","Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer","AMEERA-4","Terminated","Has Results","Breast Cancer","Drug: Amcenestrant (SAR439859)|Drug: Letrozole","Percent Change From Baseline in Ki67 Level at Day 15|Percentage of Participants With Percent Change From Baseline in Ki67 Greater Than or Equal to (>=) 50 Percent at Day 15|Change From Baseline in Estrogen Receptor (ER) Expression as Measured by H-Score at Day 15|Number of Participants With Abnormalities: Hematological Parameters|Number of Participants With Abnormalities: Clinical Chemistry","Sanofi","Female","18 Years and older   (Adult, Older Adult)","Phase 2","105","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","ACT16106|2019-002015-26|U1111-1228-9473","February 4, 2020","April 30, 2021","May 28, 2021","December 9, 2019","June 29, 2022","June 29, 2022","Investigational Site Number 8400014, Tucson, Arizona, United States|Investigational Site Number 8400010, Los Angeles, California, United States|Investigational Site Number 8400018, Fort Wayne, Indiana, United States|Investigational Site Number 8400005, Lincoln, Nebraska, United States|Investigational Site Number 8400016, Winston-Salem, North Carolina, United States|Investigational Site Number 8400012, Tacoma, Washington, United States|Investigational Site Number 0560001, Leuven, Belgium|Investigational Site Number 0560002, Namur, Belgium|Investigational Site Number 2500001, Nantes, France|Investigational Site Number 2500004, Paris, France|Investigational Site Number 2500002, Saint Cloud, France|Investigational Site Number 2500003, Toulouse Cedex 9, France|Investigational Site Number 3800004, Meldola, Italy|Investigational Site Number 3800002, Milano, Italy|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3920002, Osaka-Shi, Japan|Investigational Site Number 3920003, Sapporo-Shi, Japan|Investigational Site Number 3920001, Yokohama-Shi, Japan|Investigational Site Number 8400007, Hato Rey, Puerto Rico|Investigational Site Number 6430006, Moscow, Russian Federation|Investigational Site Number 6430004, Moscow, Russian Federation|Investigational Site Number 6430002, Saint -Petersburg, Russian Federation|Investigational Site Number 6430003, Saint-Petersburg, Russian Federation|Investigational Site Number 6430007, St.Petersburg, Russian Federation|Investigational Site Number 7240005, Barcelona, Spain|Investigational Site Number 7240003, Córdoba, Spain|Investigational Site Number 7240001, Madrid, Spain|Investigational Site Number 7240002, Valencia / Valencia, Spain|Investigational Site Number 8040004, Kharkiv, Ukraine|Investigational Site Number 8040001, Uzhgorod, Ukraine|Investigational Site Number 8040002, Vinnytsia, Ukraine|Investigational Site Number 8040005, Zaporizhzhya, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT04191382/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT04191382/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04191382"
360,"NCT00493532","A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.",,"No longer available","No Results Available","Postmenopausal Osteoporosis","Drug: ibandronate [Bonviva/Boniva]",,"Hoffmann-La Roche","Female","up to 80 Years   (Child, Adult, Older Adult)",,,"Industry","Expanded Access",,"ML20882","June 2007","December 2010","December 2010","June 28, 2007",,"November 2, 2016","Chai Yi, Taiwan|Changhua, Taiwan|Kaohsiung, Taiwan|Kaohsiung, Taiwan|Kaohsiung, Taiwan|Taichung, Taiwan|Taichung, Taiwan|Taichung, Taiwan|Tainan, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT00493532"
361,"NCT02722980","Efficacy of a Probiotic Product on Bone Mineral Density (BMD) in Healthy Women in Early Post-menopausal Phase","ProBone16","Completed","No Results Available","Osteopenia","Dietary Supplement: Placebo|Dietary Supplement: : Probiotic capsules","Change in BMD at lumbar spine following an intervention period of 12 months and measured by DXA.","Probi AB","Female","45 Years to 70 Years   (Adult, Older Adult)","Not Applicable","249","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","ProBone16","April 2016","January 2018","January 2018","March 30, 2016",,"April 17, 2018","Gothenburg, Sweden|Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT02722980"
362,"NCT01613560","Clinical Study of Adjuvant Therapy on Post-menopausal Women With Breast Cancer Under the Guidance of the Results of Preoperative Endocrinotherapy",,"Active, not recruiting","No Results Available","Breast Cancer","Drug: AI adjuvant therapy|Drug: AI+chemotherapy adjuvant therapy","RFS|DDFS|BCSS|adverse reaction","Tao OUYANG|Peking University","Female","up to 75 Years   (Child, Adult, Older Adult)","Phase 2","404","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BCP08","May 5, 2012","December 2024","December 2024","June 7, 2012",,"November 29, 2021","Peking Cancer Hospital & Institute, Beijing, Beijing, China|301 Hospital of Pla, Beijing, Beijing, China|307 Hospital of Pla, Beijing, Beijing, China|Beijing Chao-Yang Hospital, Beijing, Beijing, China|Beijing Hospital, Beijing, Beijing, China|Cancer Institution and Hospital.Chinese Academy of Medical Sciences, Beijing, Beijing, China|Peking University First Hospital, Beijing, Beijing, China|The 2nd Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China|Henan Cancer Hospital, Zhengzhou, Henan, China|The First Hospital of Jilin University, Changchun, Jilin, China|The First Hospital of China Medical University, Shenyang, Liaoning, China|The Second Hospital of Shandong University, Jinan, Shandong, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China|Shanghai Ruijin Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT01613560"
363,"NCT02604836","A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia",,"Completed","No Results Available","Postmenopausal Osteoporosis","Drug: Ibandronate","Part A: Number of participants who currently use weekly biphosphonate who answer ""yes"" to any of the questions in Candidate Identification Questionnaire (CIQ)|Part B: Number of participants who demonstrate improvement from their baseline satisfaction score after 6 months of ibandronate|Part B: Percentage of participants who demonstrate improvement from their baseline satisfaction score after 6 months of ibandronate|Part B: Percentage of eligible weekly biphosphonate users at screening who elect to enter Part B|Part B: Percentage of participants who report an improved satisfaction score with monthly ibandronate compared to weekly alendronate or risendronate|Part B: Percentage of participants who report preference to monthly ibandronate or weekly alendronate or risedronate|Part B: Percentage of participants who have greater than or equal to (>=) 80 percent (%) compliance|Part B: Percentage of participants who report an improvement in the gastrointestinal (GI) symptoms|Part B: Percentage of participants by age and activity level who report high satisfaction according to Osteoporosis Patient Survey satisfaction Questionnaire (OPSAT-Q)|Part B: Individual Domain scores from Osteoporosis Patient Survey satisfaction Questionnaire (OPSAT-Q)|Part B: Number of eligible weekly biphosphonate users at screening who elect to enter Part B|Part B: Number of participants who report an improved satisfaction score with monthly ibandronate compared to weekly alendronate or risendronate|Part B: Number of participants who report preference to monthly ibandronate or weekly alendronate or risedronate|Part B: Number of participants who have >= 80% compliance|Part B: Number of participants who report an improvement in the GI symptoms|Part B: Number of participants by age and activity level who report high satisfaction according to Osteoporosis Patient Survey satisfaction Questionnaire (OPSAT-Q)","Hoffmann-La Roche","Female","Child, Adult, Older Adult","Phase 4","1711","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML18056","June 2004","April 2006","April 2006","November 13, 2015",,"November 2, 2016","Birmingham, Alabama, United States|Columbiana, Alabama, United States|Huntsville, Alabama, United States|Mobile, Alabama, United States|Montgomery, Alabama, United States|Chandler, Arizona, United States|Gilbert, Arizona, United States|Paradise Valley, Arizona, United States|Phoenix, Arizona, United States|Phoenix, Arizona, United States|Tempe, Arizona, United States|Tucson, Arizona, United States|Carlisle, Arkansas, United States|Jonesboro, Arkansas, United States|Little Rock, Arkansas, United States|Pine Bluff, Arkansas, United States|Rogers, Arkansas, United States|Searcy, Arkansas, United States|Sherwood, Arkansas, United States|Anaheim, California, United States|Beverly Hills, California, United States|Laguna Hills, California, United States|Mission Viejo, California, United States|Palm Desert, California, United States|Palo Alto, California, United States|Sacramento, California, United States|San Diego, California, United States|Tacoma, California, United States|Vista, California, United States|Westlake Village, California, United States|Colorado Springs, Colorado, United States|Lakewood, Colorado, United States|Avon, Connecticut, United States|Cromwell, Connecticut, United States|Hamden, Connecticut, United States|New London, Connecticut, United States|Waterbury, Connecticut, United States|Wilmington, Delaware, United States|Aventura, Florida, United States|Clearwater, Florida, United States|Deland, Florida, United States|Fort Myers, Florida, United States|Gainesville, Florida, United States|Gainesville, Florida, United States|Longwood, Florida, United States|Melbourne, Florida, United States|Miami, Florida, United States|Ocala, Florida, United States|Palm Bay, Florida, United States|Palm Harbor, Florida, United States|Port Orange, Florida, United States|Sarasota, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Decatur, Georgia, United States|Rome, Georgia, United States|Boise, Idaho, United States|Coeur D'alene, Idaho, United States|Champaign, Illinois, United States|Creve Coeur, Illinois, United States|Peoria, Illinois, United States|Evansville, Indiana, United States|Arkansas City, Kansas, United States|Newton, Kansas, United States|Wichita, Kansas, United States|Natchitoches, Louisiana, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Bethesda, Maryland, United States|Chelsea, Michigan, United States|Detroit, Michigan, United States|St Joseph, Michigan, United States|Chaska, Minnesota, United States|Jefferson City, Missouri, United States|Kansas City, Missouri, United States|Kansas City, Missouri, United States|Saint Louis, Missouri, United States|St Louis, Missouri, United States|St Louis, Missouri, United States|St Louis, Missouri, United States|Billings, Montana, United States|Omaha, Nebraska, United States|Clifton, New Jersey, United States|Middletown, New Jersey, United States|New Brunswick, New Jersey, United States|Princeton, New Jersey, United States|Brooklyn, New York, United States|East Syracuse, New York, United States|New York, New York, United States|Olean, New York, United States|Rochester, New York, United States|Stony Brook, New York, United States|Durham, North Carolina, United States|Durham, North Carolina, United States|Fayetteville, North Carolina, United States|Morehead City, North Carolina, United States|Morganton, North Carolina, United States|Raleigh, North Carolina, United States|Salisbury, North Carolina, United States|Wilmington, North Carolina, United States|Winston-salem, North Carolina, United States|Fargo, North Dakota, United States|Grand Forks, North Dakota, United States|Beachwood, Ohio, United States|Canfield, Ohio, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Medford, Oregon, United States|Portland, Oregon, United States|Bala Cynwyd, Pennsylvania, United States|Langhorne, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Wyomissing, Pennsylvania, United States|Charleston, South Carolina, United States|Mount Pleasant, South Carolina, United States|Spartanburg, South Carolina, United States|Bristol, Tennessee, United States|Memphis, Tennessee, United States|Murfreesboro, Tennessee, United States|Nashville, Tennessee, United States|Sevierville, Tennessee, United States|Carrollton, Texas, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|Denton, Texas, United States|San Antonio, Texas, United States|Wichita Falls, Texas, United States|Norfolk, Virginia, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Richmond, Virginia, United States|Renton, Washington, United States|Seattle, Washington, United States|Seattle, Washington, United States|Spokane, Washington, United States|Tacoma, Washington, United States|Madison, Wisconsin, United States|Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02604836"
364,"NCT01406548","Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density",,"Completed","No Results Available","Osteopenia|Osteoporosis","Drug: BPS804 20mg/Kg|Drug: Placebo to 20mg/Kg BPS804","Change from baseline to month 9 in bone mineral density at the lumbar spine for the individual BPS804 groups and pooled placebo arms.|The number (percent) of subjects experiencing adverse events or serious adverse events|Change from baseline during 9 months of serological bone biomarkers for the individual BPS804 groups and pooled placebo arms.|Characterization of the PK profile of BPS804: area under the plasma concentration-time curve (AUC)|Characterization of the PK profile of BPS804: time to reach the maximum Characterization of the PK profile of BPS804: maximum plasma concentration (Cmax)|Characterization of the PK profile: time to reach the maximum concentration (Tmax)|Characterization of the PK profile of BPS804: half-life (T1/2)","Ultragenyx Pharmaceutical Inc|Mereo BioPharma|Novartis","Female","45 Years to 85 Years   (Adult, Older Adult)","Phase 2","44","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CBPS804A2203","July 2011","October 2013","October 2013","August 1, 2011",,"September 15, 2022","Novartis Investigative Site, Anaheim, California, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Berlin, New Jersey, United States|Novartis Investigative Site, Duncansville, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01406548"
365,"NCT03306472","A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer","PIONEER","Unknown status","No Results Available","Breast Cancer","Drug: Megestrol Acetate 40 MG|Drug: Megestrol Acetate 160 MG|Drug: Letrozole","Determination of change in tumour proliferation measured by Ki67 immunohistochemical (IHC) assessment (%) at baseline compared to Day 15 (+ ≤4 days).|Change in tumour apoptosis, measured by Caspase 3 (IHC)|Change in expression of Androgen receptor and Progesterone receptor by IHC|Change in expression of Epithelial-Mesenchymal Transition (EMT) markers by IHC|Change in proliferation by Aurora Kinase A labeling by IHC|Absolute value of Ki67 at day 15 (+≤4 Days)|Incidence and Severity of Adverse Events","Cambridge University Hospitals NHS Foundation Trust|Anticancer Fund, Belgium","Female","18 Years and older   (Adult, Older Adult)","Phase 2","189","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PIONEER|2016-003752-79","July 20, 2017","October 31, 2021","November 30, 2022","October 11, 2017",,"January 13, 2021","Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03306472"
366,"NCT01248494","PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer",,"Completed","No Results Available","Metastatic Breast Cancer","Drug: BEZ235|Drug: BKM 120|Drug: Letrozole|Drug: BKM120","Maximum Tolerated Dose of BKM120 or BEZ235 given in combination with endocrine therapy|Number of Patients with Progression-free survival (PFS)|Response Rate (RR)","Vanderbilt-Ingram Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VICC BRE 1055","November 2010","December 2012","May 2016","November 25, 2010",,"July 25, 2016","University of Alabama, Birmingham, Alabama, United States|Massachusetts General Hospital, Dana Farber Cancer Center, Boston, Massachusetts, United States|Columbia University Medical Center, New York City, New York, United States|Vanderbilt Cool Springs, Nashville, Tennessee, United States|Vanderbilt Breast Center One Hundred Oaks, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01248494"
367,"NCT00530868","Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer",,"Completed","Has Results","Breast Cancer|Cancer of the Breast|Breast Neoplasm","Other: Letrozole (Femara)|Drug: Letrozole; Avastin","The Percentage of Participants With Pathologic Complete Response|Letrozole +Avastin","University of Alabama at Birmingham|Genentech, Inc.|Breast Cancer Research Foundation","All","19 Years and older   (Adult, Older Adult)","Phase 2","75","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","F061229006|UAB 0648","October 8, 2007","March 1, 2022","March 31, 2022","September 18, 2007","October 21, 2022","October 21, 2022","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California, San Francisco Comprehensive Cancer Center, San Francisco, California, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Georgia Cancer Specialists, Atlanta, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT00530868/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT00530868"
368,"NCT01208441","RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer",,"Terminated","No Results Available","Estrogen Receptor-positive Breast Cancer|HER2-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer","Drug: letrozole|Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097|Procedure: therapeutic conventional surgery|Procedure: breast biopsy|Other: diagnostic laboratory biomarker analysis|Other: pharmacological study","MTD defined as the dose level at which no more than 1 of 6 patients experience a DLT, and the dose below that at which at least 2/6 patients have DLT according to NCI CTCAE version 4.0|Measurement of NOTCH 1 and 4, activated NOTCH (ICN), Hey 1 and NOTCH ligands (DLL4 and Jagged 1)|Genomic analysis of RNA transcriptome, mirco-RNA transcriptome, and DNA methylation|Measurement of cell proliferation (Ki-67)|Measurement of appoptosis (TUNEL and activated caspase)|Measurement of angiogenesis (VEGF and CD31)","National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Phase 1","28","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2011-02487|UPCI-09-080|CDR0000683397|UPCI 09-080|8554|U01CA099168","November 2010","December 2011",,"September 24, 2010",,"September 30, 2013","University of Alabama at Birmingham, Birmingham, Alabama, United States|Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01208441"
369,"NCT00545909","BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis",,"Completed","No Results Available","Postmenopausal Osteoporosis","Drug: ibandronate [Bonviva/Boniva]","Comparison of percentage of patients with >=83% adherence to Bonviva in feedback vs no feedback group|Patient satisfaction by OPSAT-Q and OPPS.|Tolerability; SAEs.","Hoffmann-La Roche","Female","55 Years to 85 Years   (Adult, Older Adult)","Phase 4","585","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML19913","March 2006","August 2008","August 2008","October 17, 2007",,"November 2, 2016","Bregenz, Austria|Graz, Austria|Innsbruck, Austria|Linz, Austria|Salzburg, Austria|Vöcklabruck, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Aalst, Belgium|Antwerpen, Belgium|Antwerpen, Belgium|AYE, Belgium|Braine L'alleud, Belgium|Brugge, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|Charleroi, Belgium|Dinant, Belgium|Ekeren, Belgium|Genk, Belgium|Gent, Belgium|Godinne, Belgium|Hasselt, Belgium|Jambes, Belgium|Knokke, Belgium|Kortrijk, Belgium|La Louviere, Belgium|Liege, Belgium|Liege, Belgium|Mechelen, Belgium|Merksem, Belgium|Mons, Belgium|Oostende, Belgium|Roeselare, Belgium|Sijsele, Belgium|Tournai, Belgium|Turnhout, Belgium|Waremme, Belgium|Wilrijk, Belgium|Athens, Greece|Athens, Greece|Kifissia, Greece|Larissa, Greece|Thessaloniki, Greece|Thessaloniki, Greece|Thessaloniki, Greece|Gorey, Ireland|Tipperary, Ireland|Luxembourg, Luxembourg|Luxembourg, Luxembourg",,"https://ClinicalTrials.gov/show/NCT00545909"
370,"NCT00171314","The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer",,"Completed","Has Results","Breast Cancer","Drug: Zoledronic acid|Drug: Letrozole","Percent Change in Lumbar Spine (L2-L4) BMD After 12 Months of Letrozole Therapy|Percent Change in Lumbar Spine (L2-L4) BMD at 2 Years, 3 Years, 4 Years and 5 Years|Percent Change in Lumbar Spine (L1-L4) BMD at Year 1, Year 2, Year 3, Year 4 and Year 5|Percent Change in Total Hip BMD at Year 1, Year 2, Year 3, Year 4 and Year 5|Percentage of Participants With Radiological (Vertebra) Fractures Which Were Not Present at Baseline But Were Present at Year 3","Novartis Pharmaceuticals|Novartis","Female","18 Years and older   (Adult, Older Adult)","Phase 3","527","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CFEM345D2406","March 2004","November 2010",,"September 15, 2005","April 11, 2012","April 11, 2012","Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Rosario - Santa Fe, Argentina|Novartis Investigative Site, Aalst, Belgium|Novartis Investigative Site, Anderlecht, Belgium|Novartis Investigative Site, Bonheiden, Belgium|Novartis Investigative Site, Brasschaat, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Edegem, Belgium|Novartis Investigative Site, Hasselt, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Libramont-Chevigny, Belgium|Novartis Investigative Site, Liège, Belgium|Novartis Investigative Site, Mons, Belgium|Novartis Investigative Site, Ottignies, Belgium|Novartis Investigative Site, St. Niklaas, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Yvoir, Belgium|Novartis Investigative Site, Limoges, France|Novartis Investigative Site, Mougins, France|Novartis Investigative Site, Perigueux Cedex, France|Novartis Investigative Site, Rennes, France|Novartis Investigative Site, Saint Brieuc Cedex, France|Novartis Investigative Site, Saint-Herblain Cedex, France|Novartis Investigative Site, Toulon Cedex, France|Novartis Investigative Site, Vandoeuvre Les Nancy Cedex, France|Novartis Investigative Site, Genova, Italy|Novartis Investigative Site, Ivrea, Italy|Novartis Investigative Site, Lecco, Italy|Novartis Investigative Site, Monteforte Irpino (Av), Italy|Novartis Investigative Site, Pietra Ligure, Italy|Novartis Investigative Site, Roma, Italy|Novartis Investigative Site, Sassari, Italy|Novartis Investigative Site, Torino, Italy|Novartis Investigative Site, Vicenza, Italy|Novartis Investigative Site, Daegu, Korea, Republic of|Novartis Investigative Site, Jeollanam-do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Den Haag, Netherlands|Novartis Investigative Site, Eindhoven, Netherlands|Novartis Investigative Site, Hoogeveen, Netherlands|Novartis Investigative Site, Nijmegen, Netherlands|Novartis Investigative Site, Riyadh, Saudi Arabia|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Durban, South Africa|Novartis Investigative Site, Johannesburg, South Africa|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Cordoba, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT00171314"
371,"NCT04940026","Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal Women",,"Completed","No Results Available","Breast Cancer|Healthy Volunteers","Drug: amcenestrant|Drug: [14C]-SAR439859 microtracer|Drug: [14C]-SAR439859","Percentage of radioactive dose, SAR439859 and M7 excreted in urine and feces after IV administration|Percentage of radioactive dose excreted in urine and feces after oral administration|Assessment of Pharmacokinetic (PK) parameter: AUC for radioactivity and SAR439859 after IV administration|Assessment of PK parameter: t1/2z for radioactivity and SAR439859 after IV administration|Assessment of PK parameter: CL for SAR439859 after IV administration|Assessment of PK parameter: AUC ratios after IV administration|Assessment of PK parameter: Cmax for radioactivity and SAR439859 after oral administration|Assessment of PK parameter: tmax for radioactivity and SAR439859 after oral administration|Assessment of PK parameter: AUC for radioactivity and SAR439859 after oral administration|Assessment of PK parameter: t1/2z for radioactivity and SAR439859 after oral administration|Assessment of PK parameter: AUC ratios after oral administration|Assessment of PK parameter: Cmax for M7 after IV and oral administration|Assessment of PK parameter: AUC for M7 after IV and oral administration|Assessment of PK parameter: t1/2z for M7 after IV and oral administration|Assessment of PK parameter: Rmet Cmax after IV and oral administration|Assessment of PK parameter: Rmet AUC after IV and oral administration|Absolute oral bioavailability of SAR439859|Relative bioavailability of SAR439859 after oral administration|Number of participants with adverse events","Sanofi","Female","40 Years to 75 Years   (Adult, Older Adult)","Phase 1","6","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","BEX15859","June 15, 2021","August 19, 2021","August 19, 2021","June 25, 2021",,"April 25, 2022","Investigational Site Number 8260001, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04940026"
372,"NCT00878930","Parameters of Acceptability, Compliance and Efficacy of Fulvestrant in Post-menopausal Patients With Advance Breast Cancer","FRAME","Completed","No Results Available","Breast Cancer",,"To collect real life data of acceptability and compliance on the use of Faslodex in the Argentine population.|To collect real life data of efficacy on the use of Faslodex in the Argentine population.","AstraZeneca","Female","18 Years and older   (Adult, Older Adult)",,"500","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NIS-OAR-FAS-2008/1","April 2009","December 2010","December 2010","April 9, 2009",,"January 5, 2011","Research Site, Bahia Blanca, Buenos Aires, Argentina|Research Site, Campana, Buenos Aires, Argentina|Research Site, Ciudad de Buenos Aires, Buenos Aires, Argentina|Research Site, La Plata, Buenos Aires, Argentina|Research Site, Mar del Plata, Buenos Aires, Argentina|Research Site, Moron, Buenos Aires, Argentina|Research Site, Pergamino, Buenos Aires, Argentina|Research Site, San Martin, Buenos Aires, Argentina|Research Site, Tandil, Buenos Aires, Argentina|Research Site, Vicente Lopez, Buenos Aires, Argentina|Research Site, Santa Rosa, La Pampa, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, Rio Grande, Tierra del Fuego, Argentina|Research Site, Cordoba, Argentina|Research Site, Mendoza, Argentina|Research Site, Tucuman, Argentina",,"https://ClinicalTrials.gov/show/NCT00878930"
373,"NCT01854086","Compliance and Persistence With Osteoporosis Treatment and Attitude Towards Future Therapy Among Post-menopausal Israeli Women During Drug Treatment or Drug Holiday","CONTINUITY","Unknown status","No Results Available","Osteoporosis","Other: Questionnaires about compliance and persistence with bisphosphonates treatment","Compliance and persistence to osteoporosis drug therapy","Meir Medical Center","Female","40 Years to 90 Years   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","MMC130009-13CTIL","September 2013","February 2014",,"May 15, 2013",,"May 15, 2013","Meir medical center the clalit health care services group, Kfar Saba, Israel",,"https://ClinicalTrials.gov/show/NCT01854086"
374,"NCT00542594","Survey in Post-menopausal Women Followed up After Treatment With Anastrozole as Adjuvant Therapy","ARIES","Terminated","No Results Available","Breast Cancer",,,"AstraZeneca","Female","Child, Adult, Older Adult",,"1840","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NIS-OFR-ARI-2005/1","November 2005","June 2011","June 2011","October 11, 2007",,"February 7, 2013",,,"https://ClinicalTrials.gov/show/NCT00542594"
375,"NCT00545363","A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP)",,"Completed","Has Results","Postmenopausal Osteoporosis","Drug: Ibandronate","Percentage of Participants With Adherence to Treatment|Percentage of Participants With Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q) Composite Satisfaction High Scores|Percentage of Participants With Osteoporosis Patient Perception Survey (OPPS) and Osteoporosis Medical Care Satisfaction Questionnaire (OMSQ) Composite Satisfaction High Score|Percent Change From Baseline in CTX Based on Adherence to Ibandronate","Hoffmann-La Roche","Female","55 Years to 85 Years   (Adult, Older Adult)","Phase 4","716","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML19982|2005-005529-74","April 2006","January 2008","January 2008","October 17, 2007","October 24, 2016","October 24, 2016","Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Békéscsaba, Hungary|Debrecen, Hungary|Miskolc, Hungary|Pecs, Hungary|Szeged, Hungary|Szekesfehervar, Hungary|Szombathely, Hungary|Liepaja, Latvia|Riga, Latvia|Riga, Latvia|Riga, Latvia|Gliwice, Poland|Krakow, Poland|Lodz, Poland|Poznan, Poland|Warszawa, Poland|Warszawa, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Cluj-napoca, Romania|Constanta, Romania|Craiova, Romania|Timisoara, Romania|Ekaterinburg, Russian Federation|Irkutsk, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|St Petersburg, Russian Federation|St Petersburg, Russian Federation|Voronezh, Russian Federation|Yaroslavl, Russian Federation|Banska Bystrica, Slovakia|Bratislava, Slovakia|Lubochna, Slovakia|Piestany, Slovakia|Presov, Slovakia|Ljubljana, Slovenia",,"https://ClinicalTrials.gov/show/NCT00545363"
376,"NCT00145275","To Assess the Efficacy of Over-the-counter Analgesics in the Prevention/Treatment of Transient Post-dose Symptoms Following Zoledronate Infusion in Post-menopausal Women",,"Completed","No Results Available","Osteopenia","Drug: zoledronic acid","Temperature increase|Questionnaires|VAS (visual analog scale)","Novartis","Female","45 Years to 75 Years   (Adult, Older Adult)","Phase 3","455","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CZOL446H2407","December 2004","October 2005","October 2005","September 5, 2005",,"April 27, 2012","Unavailable, Georgia, United States|Unavailable, Illinois, United States|Unavailable, Indiana, United States|Unavailable, Iowa, United States|Unavailable, Kansas, United States|Unavailable, Washington, United States|Multiple, Australia|Multiple, Canada|Multiple, Russian Federation|Multiple, South Africa",,"https://ClinicalTrials.gov/show/NCT00145275"
377,"NCT02296801","A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer","PALLET","Completed","Has Results","Breast Cancer|Breast Carcinoma|Breast Tumors","Drug: Letrozole|Drug: palbociclib","Measurement of the Proliferation Marker Ki67 (% Positive Tumor Cells)|Clinical Response : Number of Patients Who Have Resolution of Measurable Lesions or no New Lesions or Other Signs of Disease Progression Compared to Baseline.|Pathological Complete Response (pCR): Number of Patients With no Lesions in Breast and Nodes at Time of Surgery|Preoperative Endocrine Prognostic Index (PEPI) Score:|Number and Severity of Adverse Events|Measurement of Ki67 Marker|Comparison of Surgical Intent (Mastectomy; Breast Conservation)","NSABP Foundation Inc|Pfizer|Royal Marsden NHS Foundation Trust|Institute of Cancer Research, United Kingdom","Female","18 Years and older   (Adult, Older Adult)","Phase 2","307","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NSABP FB-11|WI180455","January 2015","July 2018","March 2019","November 20, 2014","January 13, 2022","January 13, 2022","Long Beach Memorial Medical Center-Todd Cancer Institute, Long Beach, California, United States|University of Miami Hospital and Clinics - Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States|Norton Healthcare Pavillion, Louisville, Kentucky, United States|Norton Cancer Institute - Suburban, Norton Medical Plaza II, Louisville, Kentucky, United States|Norton Cancer Institute - Brownsboro Medical Plaza I, Louisville, Kentucky, United States|Metro-Minnesota CCOP, Saint Louis Park, Minnesota, United States|Hope Women's Cancer Centers, Asheville, North Carolina, United States|Providence Oncology and Hematology Clinic, Portland, Oregon, United States|Pinnacle Health Ortenzio Cancer Center, Mechanicsburg, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Women and Infants Hospital of Rhode Island, Providence, Rhode Island, United States|Baylor College of Medicine, Houston, Texas, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States|Sentara Martha Jefferson Hospital-Phillips Family Cancer Center, Charlottesville, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Swedish Cancer Institute, Seattle, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|McGill University Health Center, Montreal, Quebec, Canada|CHU de Quebec - Universite Laval, Quebec City, Quebec, Canada|Milton Keynes Hospital, Milton Keynes, Buckinghamshire, United Kingdom|Hinchingbrooke Hospital, Huntingdon, Cambridgeshire, United Kingdom|Royal Cornwall Hospital, Treliske, Truro, Cornwall, United Kingdom|Royal Devon and Exeter Hospital, Exeter, Devon, United Kingdom|Royal Sussex County Hospital, Brighton, East Sussex, United Kingdom|Southend Hospital, Westcliff-on-Sea, Essex, United Kingdom|Darent Valley Hospital, Dartford, Kent, United Kingdom|Maidstone Hospital, Maidstone, Kent, United Kingdom|Royal Liverpool University Hospital, Liverpool, Merseyside, United Kingdom|James Paget University Hospital, Great Yarmouth, Norfolk, United Kingdom|Musgrove Park Hospital, Taunton, Somerset, United Kingdom|Weston General Hospital, Weston-Super-Mare, Somerset, United Kingdom|The Royal Marsden Hospital, Sutton, Surrey, United Kingdom|Salisbury Hospital, Salisbury, Wiltshire, United Kingdom|Kidderminster Hospital, Kidderminster, Worcestershire, United Kingdom|Alexandra Hospital, Redditch, Worcestershire, United Kingdom|Worcestershire Royal Hospital, Worcester, Worcestershire, United Kingdom|Belfast City Hospital, Belfast, United Kingdom|Royal Bournemouth Hospital, Bournemouth, United Kingdom|Western General Hospital (Edinburgh Cancer Centre), Edinburgh, United Kingdom|St James' University Hospital, Leeds, United Kingdom|Barnet Hospital, London, United Kingdom|Whittington Hospital, London, United Kingdom|University College London Hospitals, London, United Kingdom|The Royal Marsden Hospital, London, United Kingdom|Charing Cross Hospital, London, United Kingdom|Nottingham University Hospitals NHS Trust, City Campus, Nottingham, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Singleton Hospital, Swansea, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT02296801/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02296801"
378,"NCT02142868","Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate",,"No longer available","No Results Available","Advanced Breast Cancer (Female)","Drug: Palbociclib|Drug: Letrozole",,"Pfizer","Female","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Individual Patients",,"A5481034",,,,"May 20, 2014",,"December 21, 2018","CBCC Global Research, Inc. at Comprehensive Blood & Cancer Center Research Center, Bakersfield, California, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Washington Cancer Institute at MedStar Washington Hospital Center, Washington, District of Columbia, United States|Gwinnett Hospital System Inc. -d/b/a - The Center for Cancer Care, Duluth, Georgia, United States|Gwinnett Hospital System Inc. -d/b/a - The Center for Cancer Care, Lawrenceville, Georgia, United States|Presence Saint Joseph Hospital, Chicago, Illinois, United States|North Shore Oncology-Hematology Associates, Ltd., Crystal Lake, Illinois, United States|North Shore Oncology-Hematology Associates, Ltd., Libertyville, Illinois, United States|Presence Medical Group Hematology Oncology, Northbrook, Illinois, United States|Illinois CancerCare, P.C., Peoria, Illinois, United States|Presence Infusion Care - Skokie, Skokie, Illinois, United States|Metairie Oncologist, LLC, Metairie, Louisiana, United States|SKCCC at Johns Hopkins, The Harry and Jeannette Weinberg Building, Baltimore, Maryland, United States|SKCCC at Johns Hopkins, Green Spring Station, Lutherville, Maryland, United States|The West Clinic, P.C., Corinth, Mississippi, United States|Jackson Oncology Associates, PLLC, Jackson, Mississippi, United States|Mississippi Baptist Health Systems, Jackson, Mississippi, United States|Jackson Oncology Associates, PLLC, Jackson, Mississippi, United States|The West Clinic, P.C. d/b/a West Cancer Center, Southaven, Mississippi, United States|ProHealthCARE Associates, LLP, Lake Success, New York, United States|Northwest Cancer Specialists dba Compass Oncology, Portland, Oregon, United States|Northwest Cancer Specialists dba Compass Oncology, Portland, Oregon, United States|UPMC Cancer Center Beaver, Beaver, Pennsylvania, United States|UPMC Cancer Center Arnold Palmer at Mountainview, Greensburg, Pennsylvania, United States|UPMC Cancer Center Greenville, Greenville, Pennsylvania, United States|UPMC Cancer Center Monroeville, Monroeville, Pennsylvania, United States|Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States|UPMC Cancer Center St. Margarets, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute, Investigational Drug Service, William M. Cooper Pavilion, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, William M. Cooper Pavilion, Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|UPMC Cancer Center Passavant (HOA), Pittsburgh, Pennsylvania, United States|UPMC Cancer Center Passavant (OHA), Pittsburgh, Pennsylvania, United States|UPMC Cancer Center Northwest, Seneca, Pennsylvania, United States|Mount Nittany Medical Center, State College, Pennsylvania, United States|The West Clinic, P.C. d/b/a West Cancer Center, Germantown, Tennessee, United States|The West Clinic, P.C. d/b/a West Cancer Center, Memphis, Tennessee, United States|The West Clinic, P.C. d/b/a West Cancer Center, Memphis, Tennessee, United States|Texas Oncology -Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology - Memorial City, Houston, Texas, United States|Medical Oncology & Hematology Associates of Northern Virginia, Ltd., Fairfax, Virginia, United States|Medical Oncology & Hematology Associates of Northern Virginia, Ltd., Reston, Virginia, United States|Swedish Cancer Institute, Seattle, Washington, United States|Northwest Cancer Specialists dba Compass Oncology, Vancouver, Washington, United States|Northwest Cancer Specialists dba Compass Oncology, Vancouver, Washington, United States|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Holy Cross Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Queen Elizabeth II (QEII) Health Sciences Centre, Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada|London Regional Cancer Program, London, Ontario, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Sunnybrook health Sciences Centre, Toronto, Ontario, Canada|Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada|SunnyBrook Research Institute, Toronto, Ontario, Canada|McGill University Health Centre (MUHC), Glen Site, Royal Victoria Hospital, Cedars Cancer Centre, Montreal, Quebec, Canada|CHU de Quebec - Hospital du Saint-Sacrement, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02142868"
379,"NCT00279448","Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer","TEAM","Completed","No Results Available","Breast Neoplasms","Drug: exemestane|Drug: tamoxifen","To compare recurrence free survival between two treatment groups.|The quality of life of patients treated with exemestane to that of patients treated with tamoxifen|Overall survival between the 2 treatment groups|Incidence of a second breast cancer (contralateral) between the 2 treatment groups|General tolerance in the short- and long-term between the 2 treatment groups","Pfizer","Female","50 Years and older   (Adult, Older Adult)","Phase 3","9779","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EXEAPO-0028-118|A5991081","January 2002","November 2008","June 2009","January 19, 2006",,"December 23, 2011","Pfizer Investigational Site, Marseille, Be1 01971, France|Pfizer Investigational Site, Compiegne, Be1 02256, France|Pfizer Investigational Site, Rennes, Be1 03677, France|Pfizer Investigational Site, Brest, Be1 04292, France|Pfizer Investigational Site, Aix en Provence, France|Pfizer Investigational Site, Amiens, France|Pfizer Investigational Site, Annecy Cedex, France|Pfizer Investigational Site, Avignon Cedex 2, France|Pfizer Investigational Site, Bayonne, France|Pfizer Investigational Site, Blois, France|Pfizer Investigational Site, Bordeaux CEDEX, France|Pfizer Investigational Site, Bordeaux, France|Pfizer Investigational Site, Brest, France|Pfizer Investigational Site, Cagne sur Mer, France|Pfizer Investigational Site, Chalon sur Saone, France|Pfizer Investigational Site, Chaumont, France|Pfizer Investigational Site, Croix, France|Pfizer Investigational Site, Dijon, France|Pfizer Investigational Site, Douai, France|Pfizer Investigational Site, Draguignan, France|Pfizer Investigational Site, Dunkerque, France|Pfizer Investigational Site, Evreux, France|Pfizer Investigational Site, Hyres, France|Pfizer Investigational Site, L'Union, France|Pfizer Investigational Site, Le Havre, France|Pfizer Investigational Site, Lille, France|Pfizer Investigational Site, Lorient, France|Pfizer Investigational Site, Lyon, France|Pfizer Investigational Site, Mareuil les Meaux, France|Pfizer Investigational Site, Marseille, France|Pfizer Investigational Site, Marseille, France|Pfizer Investigational Site, Marseille, France|Pfizer Investigational Site, Metz, France|Pfizer Investigational Site, Montauban, France|Pfizer Investigational Site, Montbeliard, France|Pfizer Investigational Site, Montelimar, France|Pfizer Investigational Site, Montpellier, France|Pfizer Investigational Site, Mougins, France|Pfizer Investigational Site, Nancy, France|Pfizer Investigational Site, Nantes Cedex 2, France|Pfizer Investigational Site, Neuilly, France|Pfizer Investigational Site, NICE Cedex 1, France|Pfizer Investigational Site, Nimes, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Pessac, France|Pfizer Investigational Site, Quincy sous Senart, France|Pfizer Investigational Site, Reims, France|Pfizer Investigational Site, Ris Orangis, France|Pfizer Investigational Site, Saint Brieuc, France|Pfizer Investigational Site, Saint Nazaire, France|Pfizer Investigational Site, St Cloud, France|Pfizer Investigational Site, St Herblain, France|Pfizer Investigational Site, Strasbourg, France|Pfizer Investigational Site, Toulon, France|Pfizer Investigational Site, Toulouse, France|Pfizer Investigational Site, Toulouse, France|Pfizer Investigational Site, Vandoeuvre les Nancy, France|Pfizer Investigational Site, Vannes, France|Pfizer Investigational Site, Vannes, France",,"https://ClinicalTrials.gov/show/NCT00279448"
380,"NCT05631795","Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment","ALPINIST","Recruiting","No Results Available","Advanced Breast Cancer","Drug: Alpelisib|Drug: Fulvestrant","Percentage of participants with at least one on-treatment adverse events (AEs)|Percentage of participants with Serious AEs (SAEs)|Percentage of participants with Adverse Drug Reactions (ADRs)","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CBYL719CIN01","August 10, 2022","November 15, 2024","November 15, 2024","November 30, 2022",,"November 30, 2022","Novartis Investigative Site, Thalassery, Kerala, India",,"https://ClinicalTrials.gov/show/NCT05631795"
381,"NCT02000375","A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)","ARTT","Terminated","No Results Available","Metastatic Breastcancer|Estrogen Receptor Positive Breast Cancer|Estrogen Receptor Negative Neoplasm|Progesterone Receptor Positive Tumor|Progesterone Receptor Negative Neoplasm|Androgen Receptor Gene Overexpression","Drug: DHEA","Clinical benefit rate (CB)|Time to tumor progression (TTP)|Duration of response (DOR)|Overall survival (OS)|Quality of life Quality of life Quality of life Quality of life|Correlation between AR expression and clinical and biological features|Evaluation of AR expression on primitive and/or metastatic site in the two distinct populations of patients ( ER/PgR- negative/ARpositive and ER-positive and/or PgR-positive/AR-positive)|Evaluation of ER, PgR, HER2 expression on tumor cells of metastatic sites (when it is possible) and comparison with the same features of the the primary site.|Circulating Tumor Cells (CTCs) analysis [Optionally, only for patients enrolled at IRCCS IRST of Meldola and who signed additional informed consent ]|Safety","Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRST174.08|2012-003510-13","March 2013","February 2016","February 2016","December 4, 2013",,"September 29, 2016","Irccs Irst, Meldola, FC, Italy|Oncologia medica , PO FAENZA, Ausl della Romagna, Faenza, RA, Italy|Oncologia Medica PO Lugo, AUSL della Romagna, Lugo, RA, Italy|Oncologia medica PO Ravenna AUSL della Romagna, Ravenna, RA, Italy|Oncologia Medica PO Cattolica AUSL della Romagna, Cattolica, Italy|Oncologia Medica,E.O. Ospedali Galliera, Genova, Italy|Oncologia Medica AOU Policlinico di Modena, Modena, Italy|Oncologia medica PO Rimini AUSL della Romagna, Rimini, Italy",,"https://ClinicalTrials.gov/show/NCT02000375"
382,"NCT01189500","Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects",,"Completed","Has Results","Pharmacokinetics","Drug: Tamoxifen|Drug: Tamoxifen and Desvenlafaxine Succinate Sustained Release","Tamoxifen Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Tamoxifen Alone and When Coadministered With DVS SR|Endoxifen (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Endoxifen Alone and When Coadministered With DVS SR|Tamoxifen Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR|Tamoxifen Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR|Tamoxifen Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR|Tamoxifen Apparent Clearance (CL/F) Following Tamoxifen Alone and When Coadministered With DVS SR|Tamoxifen Apparent Volume of Distribution (Vz/F) Following Tamoxifen Alone and When Coadministered With DVS SR|Endoxifen (Metabolite) Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR|Endoxifen (Metabolite) Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR|Endoxifen (Metabolite) Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR|Endoxifen (Metabolite) Apparent Clearance (CL/F) Following Tamoxifen Alone and When Coadministered With DVS SR|Endoxifen (Metabolite) Apparent Volume of Distribution (Vz/F) Following Tamoxifen Alone and When Coadministered With DVS SR|N-desmethyl-tamoxifen (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Tamoxifen Alone and When Coadministered With DVS SR|N-desmethyl-tamoxifen (Metabolite) Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR|N-desmethyl-tamoxifen (Metabolite) Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR|N-desmethyl-tamoxifen (Metabolite) Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR|N-desmethyl-tamoxifen (Metabolite) Apparent Clearance (CL/F) Following Tamoxifen Alone and When Coadministered With DVS SR|N-desmethyl-tamoxifen (Metabolite) Apparent Volume of Distribution (Vz/F) Following Tamoxifen Alone and When Coadministered With DVS SR|4-hydroxy-tamoxifen (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Tamoxifen Alone and When Coadministered With DVS SR|4-hydroxy-tamoxifen (Metabolite) Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR|4-hydroxy-tamoxifen (Metabolite) Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR|4-hydroxy-tamoxifen (Metabolite) Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR|4-hydroxy-tamoxifen (Metabolite) Apparent Clearance (CL/F) Following Tamoxifen Alone and When Coadministered With DVS SR|4-hydroxy-tamoxifen (Metabolite) Apparent Volume of Distribution (Vz/F) Following Tamoxifen Alone and When Coadministered With DVS SR|Plasma Tamoxifen Concentration Versus Time Summary: Tamoxifen Alone and When Coadministered With DVS SR|Plasma Endoxifen (Metabolite) Concentration Versus Time Summary: Tamoxifen Alone and When Coadministered With DVS SR|Plasma N-desmethyl-tamoxifen (Metabolite) Concentration Versus Time Summary: Tamoxifen Alone and When Coadministered With DVS SR|Plasma 4-hydroxy-tamoxifen (Metabolite) Concentration Versus Time Summary: Tamoxifen Alone and When Coadministered With DVS SR","Pfizer","Female","45 Years and older   (Adult, Older Adult)","Phase 4","30","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","B2061027|3151A1-1206","August 2010","October 2010","October 2010","August 26, 2010","October 17, 2011","November 6, 2011","Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01189500"
383,"NCT00696072","Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic",,"Completed","Has Results","Metastatic Breast Cancer","Drug: Dasatinib|Drug: Letrozole","Number of Participants With Clinical Benefit (CBR) and Number of Participants With CBR Having a Disease Free Interval (DFI) Greater Than 2 Years - Evaluable Population|Number of Participants With Complete Response, Partial Response, Stable Disease, and Disease Progression|Median Progression Free Survival (PFS) - Intent to Treat (ITT) Population|Percentage of Participants Best Overall Response After Change From Letrozole to Letrozole Plus Dasatinib|Percentage of Participants With PFS At 6 Months and At 12 Months - ITT Population|Median Time to Treatment Failure (TTF) - ITT Population|Number of Participants With Adverse Events (AEs) Leading to Discontinuation, Serious Adverse Events (SAEs), and Deaths","Bristol-Myers Squibb|US Oncology Research","Female","18 Years and older   (Adult, Older Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA180-185|USOR 06-185","August 2008","June 2014","June 2014","June 12, 2008","May 11, 2016","June 13, 2016","Northern Arizona Hematology & Oncology Associates, Sedona, Arizona, United States|Arizona Oncology Associates D.B.A. Hematology Oncology, Tucson, Arizona, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Florida Cancer Institute - New Hope, Hudson, Florida, United States|Central Indiana Cancer Centers, Carmel, Indiana, United States|New York Oncology Hematology, Pc, Troy, New York, United States|Dayton Oncology And Hematology, Kettering, Ohio, United States|Willamette Valley Cancer Center, Eugene, Oregon, United States|Northwest Cancer Specialists, Pc, Portland, Oregon, United States|Medical Oncology Associates, Kingston, Pennsylvania, United States|Texas Oncology-Central Austin Cancer Center, Austin, Texas, United States|Texas Oncology, Bedord, Texas, United States|Texas Cancer Center At Medical City, Dallas, Texas, United States|Texas Oncology, Dallas, Texas, United States|Texas Oncology Sammons Cancer Center, Dallas, Texas, United States|El Paso Cancer Treatment Ctr - East, El Paso, Texas, United States|Texas Oncology, Fort Worth, Texas, United States|Texas Oncology, Garland, Texas, United States|Texas Oncology, Houston, Texas, United States|Texas Oncology-Plano East, Plano, Texas, United States|Cancer Care Centers Of South Texas, San Antonio, Texas, United States|Texas Oncology Cancer Center - Sugar Land, Sugar Land, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States|Texas Oncology Cancer Care And Research Center, Waco, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Oncology & Hematology Associates Of Southwest Virginia, Inc., Salem, Virginia, United States|Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00696072"
384,"NCT03075956","Safety, Tolerability and Pharmacokinetics of Estetrol (E4) After Single and Multiple Oral Doses in Healthy Female Volunteers",,"Completed","No Results Available","Contraception|Menopause","Drug: 5 mg E4 single-dose|Drug: 15 mg E4 single-dose|Drug: 45 mg E4 single-dose|Drug: 15 mg E4 multiple-dose","Maximum concentration (Cmax) of estetrol in plasma after single dose regimen|Area under the plasma concentration versus time curve from time 0 to 72 hours (AUC0-72h) of estetrol after single dose regimen|Cmax at steady state (Cmaxss) of estetrol after multiple dose regimen|AUC during a dosage interval (τ) of estetrol after multiple dose regimen|Number of subjects with adverse events as a measure of safety and tolerability|AUC0-24h of estetrol after single dose regimen|AUC from time 0 to infinity (AUC0-inf) of estetrol after single dose regimen|Time of the maximum measured plasma concentration (Tmax) of estetrol after single dose regimen|Apparent first-order terminal elimination half-life (T1/2) of estetrol after single dose regimen|Minimum measured plasma concentration of estetrol at steady state (Cminss) after multiple dose regimen|Tmax of estetrol at steady state (Tmaxss) after multiple dose regimen","Estetra","Female","18 Years to 55 Years   (Adult)","Phase 1","31","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","MIT-Es0001-C102|2016-001808-32","January 31, 2017","August 2, 2017","August 2, 2017","March 9, 2017",,"September 8, 2017","COMAC, Sofia, Bulgaria",,"https://ClinicalTrials.gov/show/NCT03075956"
385,"NCT00990886","The Effect of Extended-Release Oxybutynin Chloride on Vasomotor Symptoms in Healthy Post-Menopausal Women",,"Completed","No Results Available","Menopause|Hot Flashes","Drug: Placebo|Drug: Oxybutynin chloride","The co-primary endpoints in this study are the change in daily frequency of moderate to severe hot flashes from baseline to Week 12 and the change in severity of moderate to severe hot flashes from baseline to Week 12.|Change in daily frequency of moderate to severe hot flashes from baseline to Week 4 and 12|Change in severity of moderate to severe hot flashes from baseline to Week 4 and 12|Change of daily composite score of moderate to severe hot flashes from baseline to Week 4 and Week 12|Change in daily frequency of any hot flashes from baseline to Week 4 and Week 12|Subject Global Assessment (SGA) score","Ortho-McNeil Janssen Scientific Affairs, LLC","All","40 Years to 65 Years   (Adult, Older Adult)","Phase 2","148","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR002878|CAPSS 300","April 2004","January 2005","January 2005","October 7, 2009",,"December 12, 2012",,,"https://ClinicalTrials.gov/show/NCT00990886"
386,"NCT00880009","Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer",,"Terminated","Has Results","Breast Cancer","Drug: Bosutinib|Drug: Letrozole","Progression-Free Survival (PFS) Based on Independent Radiologist|Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Progression-Free Survival (PFS) Based on Investigator|Percentage of Participants With Objective Response|Overall Survival (OS)|Duration of Response (DR)|Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B)|Maximum Observed Plasma Concentration (Cmax)|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-24)]","Pfizer","Female","18 Years and older   (Adult, Older Adult)","Phase 2","16","Industry","Interventional","Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","3160A6-2207|B1871010|2008-006252-21","July 30, 2009","May 31, 2010","May 31, 2010","April 13, 2009","November 4, 2012","September 27, 2021","American Institute of Research, Whittier, California, United States|Joliet Oncology Hematology Associates, Joliet, Illinois, United States|Oncology Specialists SC, Niles, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|AZ Sint-Augustinus, Wilrijk, Belgium|Cancer Hospital, Academy of Med Science and Peking Union Med, Beijing, Beijing, China|UNIMED Medical Institute, Hong Kong, Hong Kong|Orszagos Onkologiai Intezet ""B"" Belgyogyaszati osztaly, Budapest, Hungary|Centrum Medyczne Ostrobramska Niepubliczny Zaklad Opieki Zdr, Warszawa, Poland|Johns Hopkins Singapore International Medical Centre, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT00880009"
387,"NCT02907983","Stellate Ganglion Blockade in Post-Menopausal Women","R01","Active, not recruiting","No Results Available","Hot Flashes|Hot Flushes|Vasomotor Symptoms","Drug: Stellate Ganglion Block Injection with Bupivicaine|Drug: Saline injection","Changes from baseline and intensity of subjective hot flashes (HF)|Changes from baseline of frequency of objective hot flashes|Composite changes from baseline of scores of neurocognitive measures|Composite changes from baseline of scores of measures of mood|Composite changes from baseline of scores of measures of quality of life|Changes from baseline of scores of measures of sleep|Changes from baseline of actigraph measures of sleep|Changes from baseline of Skin Sympathetic Nerve Activity (SKNA)|Changes from baseline of Functional MRI","David Walega|University of Illinois at Chicago|Indiana University|Northwestern University","Female","40 Years to 70 Years   (Adult, Older Adult)","Phase 2","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Supportive Care","STU00203490","July 10, 2018","August 31, 2023","August 31, 2023","September 20, 2016",,"November 2, 2022","Mia Zubeck, Chicago, Illinois, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02907983"
388,"NCT03162068","Cushing's Osteoporosis Specificities","SOCS","Recruiting","No Results Available","Osteoporosis in Cushing's Syndrome|Osteoporosis in Post-menopausal Women","Other: Osteodensitometry and pQCT","Comparison of volumetric bone mineral density|Assessment of strength bone of radius and tibia of the non-dominant limb|Assessment of trabecular and cortical compartment|Comparison of muscle area and surface, adipose tissue","University Hospital, Clermont-Ferrand|Unité de recherche GReD CNRS UMR6293 / Inserm","All","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","CHU-334|2016-A01482-49","April 4, 2017","May 2019","May 2024","May 22, 2017",,"May 22, 2017","CHU Clermont-Ferrand, Clermont-Ferrand, Auvergne, France",,"https://ClinicalTrials.gov/show/NCT03162068"
389,"NCT05312567","FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms",,"Recruiting","No Results Available","Vasomotor Symptoms|Menopause","Drug: FP-101","Change in the frequency (average daily number) of moderate-to-severe hot flashes.|Change in the severity (average daily rating) of moderate-to-severe hot flashes.|Change in nighttime awakenings (average daily number) with or without night sweats.|Evaluate the clinical meaningfulness of VMS changes after 1-week of treatment.","Fervent Pharmaceuticals|ICON plc","Female","46 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2021-FERV","March 24, 2021","September 30, 2022","December 31, 2022","April 5, 2022",,"April 29, 2022","Torrance Clinical Research Institute, Lomita, California, United States|Cary Medical Group, Cary, North Carolina, United States|Raleigh Medical Group, Raleigh, North Carolina, United States|Clinical Research of Philadelphia, Philadelphia, Pennsylvania, United States|Coastal Carolina Research Center, North Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT05312567"
390,"NCT00995631","Following Lipectomy to Understand Adipose Tissue Re-accumulation","FLARE","Completed","No Results Available","Menopause|Pre-menopause","Procedure: Femoral lipectomy","Postprandial triglyceride excursions (incremental areas)|Abdominal and femoral fat mass accumulation|Triglyceride storage (14C-oleic acid incorporation into abdominal and femoral adipose tissue)|Lipoprotein lipase activity (abdominal and femoral adipose tissue)","University of Colorado, Denver","Female","35 Years to 60 Years   (Adult)","Not Applicable","53","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","07-0339|NIH DK077992","January 2008","August 2013","December 2014","October 15, 2009",,"January 11, 2017","University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT00995631"
391,"NCT04910906","Non-Interventional Multicentre Post-market Study of Ectoin® Vaginal Gel for Symptomatic Treatment of Vaginal Atrophy","EIC01-PMCF","Completed","No Results Available","Vaginal Atrophy","Device: Ectoin® Vaginal Gel","Change in Vaginal Health Index (VHI) Score|Change in vaginal pH|Change in severity of VA symptoms (vaginal irritation, itching, vaginal dryness, and dyspareunia)|Change in total score in Quality of Life evaluation parameters|Change in score of overall vaginal atrophy condition|Change in score of symptoms based rating on need for treatment|Overall tolerability assessments|Number of AEs and assessment of intensity, causality and seriousness of Adverse Events","Bitop AG","Female","50 Years and older   (Adult, Older Adult)",,"155","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","btph-045-2020-EIC01","May 3, 2021","February 9, 2022","February 9, 2022","June 2, 2021",,"April 7, 2022","bitop AG, Dortmund, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT04910906"
392,"NCT05453227","Zinc Containing Vaginal Topical "" Suppository """,,"Recruiting","No Results Available","Genitourinary Syndrome of Menopause","Drug: Zinc","The using of novel zinc-containing vaginal suppositories","Egymedicalpedia","Female","55 Years to 65 Years   (Adult, Older Adult)","Phase 1","50","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Bahaa Mohamed","December 1, 2021","December 1, 2022","December 30, 2022","July 12, 2022",,"July 12, 2022","Al-Azhar University Hospitals and Ashmoun central hospital, Cairo, Elmenofia, Egypt",,"https://ClinicalTrials.gov/show/NCT05453227"
393,"NCT05440617","Biorepository in Participants Who Undergo OTC for Gonadotoxic Therapy",,"Recruiting","No Results Available","Acute Ovarian Failure|Infertility|Early Menopause And Infertility In Females After Treatment For Childhood Cancer",,"create a databank of human ovarian tissue|create a databank of human ovarian tissue to elucidate histology and function in human ovaries","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Female","4 Years to 35 Years   (Child, Adult)",,"100","NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","10000715|000715-CH","July 22, 2022","September 21, 2041","September 21, 2041","July 1, 2022",,"November 3, 2022","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT05440617"
394,"NCT01347905","Changes in Iron Absorption and Availability Before and After Weight Loss in Obese Pre-menopausal Women and Men.",,"Completed","No Results Available","Obesity","Other: Stable-isotope techniques","Fractional iron absorption before and after weight loss, based on 57Fe and 58Fe isotope concentrations in erythrocytes.|Iron status and regulatory markers (Hb, serum ferritin, transferrin receptor, hepcidin),(pro)inflammatory markers (CRP, AGP, TNF-α, IL-6, leptin), blood volume, body composition (DXA).","Wageningen University|Universidad de Monterrey|Mexican National Institute of Public Health|Swiss Federal Institute of Technology|Unilever R&D","All","18 Years to 50 Years   (Adult)",,"43","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","Iron absorption and obesity","February 2011","September 2013","December 2013","May 5, 2011",,"June 9, 2015","Universidad de Monterrey (UDEM) División de Ciencias de la Salud, San Pedro Garza García, Nuevo Leon, Mexico",,"https://ClinicalTrials.gov/show/NCT01347905"
395,"NCT01805674","Isoflavones and Magnolia Extract in the Quality of Life in Menopausal Women","ESTROCALVI","Completed","No Results Available","Menopause","Dietary Supplement: isoflavones combined with magnolia","the quality of life measured by the scale of Cervantes|Clinical changes in vasomotor symptomatology","Rottapharm Spain","Female","45 Years to 59 Years   (Adult)",,"100","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ESTROCALVI","March 2013","July 2013","October 2013","March 6, 2013",,"November 5, 2014","Grupo hospitalario Quirón, Erandio, Vizcaya, Spain|Somdex S.L., Barcelona, Spain|Centro Médico Teknon, Barcelona, Spain|Surgery of Dr. Sánchez Muñoz, Ciudad Real, Spain|Gabinete Médico Velazquez, Madrid, Spain|Clínica ginecológica Cecchini, Oviedo, Spain|Instituto Sevillano de Ginecología y Obstetricia, Sevilla, Spain|Surgery of Dr. Mahiques, Valencia, Spain|Surgery of Dr. Raga, Valencia, Spain|Centro Ginecológico Dr. García Pérez-Llantada SL, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT01805674"
396,"NCT00064961","Obesity Prevention After Smoking Cessation in Menopause",,"Completed","No Results Available","Obesity|Menopause","Behavioral: Individualized dietary-control and exercise program|Behavioral: Weight-management and smoking cessation maintenance|Behavioral: Smoking Cessation program",,"National Institute on Aging (NIA)","Female","45 Years to 59 Years   (Adult)","Not Applicable","100","NIH","Interventional","Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Prevention","AG0004","March 2000","February 2006","February 2006","July 17, 2003",,"December 11, 2009","LSU Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT00064961"
397,"NCT01605071","Timing Estrogen After MenoPaUSe","TEMPUS","Completed","Has Results","Insulin Resistance","Drug: Estradiol","Insulin-mediated Glucose Disposal Rate (Hyperinsulinemic-euglycemic Clamp)|Skeletal Muscle Estrogen Receptor Expression|Skeletal Muscle Estrogen Receptor Expression (Protein/Cyto Protein)|Adipose Tissue Estrogen Receptor Expression|Adipose Tissue Estrogen Receptor Expression (ERα:ERβ)","University of Colorado, Denver|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Female","45 Years to 70 Years   (Adult, Older Adult)","Not Applicable","53","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Other","11-0788|R01DK088105","September 2011","November 2015","January 2017","May 24, 2012","March 1, 2021","March 1, 2021","University of Colorado Denver, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT01605071"
398,"NCT00787904","Role of T-cells in Post-Menopausal Osteoporosis",,"Completed","Has Results","Osteoporosis",,"Changes in T-cell Activation Measured by Flow Cytometry, Specifically the Percentage of CD3+CD69+ T-cells|Percent Change in Thymus Size Measured by CT Scan|Bone Mineral Density","Atlanta VA Medical Center|Emory University","All","18 Years to 55 Years   (Adult)",,"19","U.S. Fed|Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","T-cells in osteoporosis","December 2006","June 2011","December 2012","November 10, 2008","December 13, 2016","December 13, 2016","Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00787904"
399,"NCT05332626","Lactobacillus Acidophilus and Postmenopausal Osteoporosis Women","LaBon","Enrolling by invitation","No Results Available","Bone Loss|Post Menopausal Osteoporosis|Mineralization","Dietary Supplement: Probiotic group|Dietary Supplement: Placebo group","calcium|DXA|body mass|height|calcium intake|biomarkers of bone turnover: CTX|biomarkers of bone turnover: TRAP5b|biomarkers of bone resorption: BSAP|biomarkers of bone resorption: PINP|biomarkers of bone metabolism: PTH|biomarkers of bone metabolism: IGF 1|biomarkers of bone metabolism: high-molecular-weight adiponectin|gene polymorphism","Poznan University of Life Sciences|Poznan University of Medical Sciences","Female","45 Years to 70 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","668/21","February 1, 2022","December 2024","December 2024","April 18, 2022",,"May 2, 2022","Poznan University of Life Sciences, Poznań, Wielkopolskie, Poland",,"https://ClinicalTrials.gov/show/NCT05332626"
400,"NCT00307775","Vaginal Estrogen for the Treatment of Faecal Incontinence in Women",,"Terminated","No Results Available","Fecal Incontinence","Drug: oestradiol","Improvement of symptoms and quality of life (QoL) as measured by QoL questionnaires and physiological assessment|Acceptance of treatment mode delivery, through questionnaire","London North West Healthcare NHS Trust","Female","45 Years and older   (Adult, Older Adult)","Not Applicable","43","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06/VO1/6","March 2006","October 2011","October 2011","March 28, 2006",,"May 1, 2012","North West London Hospitals NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00307775"
401,"NCT05522621","A Muticenter Clinical Study of Chinese Herbal Compound TJAOA102 in Alleviating Menopausal Syndrome",,"Not yet recruiting","No Results Available","Menopausal Syndrome","Drug: TJAOA102","Evaluating the change of Kupperman Index Score（KMI）|recovery rate of ovarian function","Tongji Hospital","Female","18 Years to 55 Years   (Adult)","Early Phase 1","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TJ-IRB20220634-MS","October 1, 2022","October 1, 2024","October 1, 2025","August 31, 2022",,"August 31, 2022",,,"https://ClinicalTrials.gov/show/NCT05522621"
402,"NCT00626340","Brain Imaging Study in Menopausal Women With and Without Major Depressive Disorder",,"Completed","Has Results","Menopause|Depression","Drug: MDD diagnosis and Estrogen treatment|Drug: MDD diagnosis and Fluoxetine treatment|Drug: MDD diagnosis with both Estrogen and Fluoxetine treatment|Drug: No depression and estrogen treatment","Comparison of Cortical GABA Levels in 4 Groups of Subjects Using Estrogen Alone, Fluoxetine Alone, Estrogen and Fluoxetine Combined in Pre and Post 4.0T Magnetic Resonance Spectroscopy Sessions.","University of Pennsylvania","Female","40 Years to 70 Years   (Adult, Older Adult)","Phase 4","18","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9907010780","July 1999","July 2008","July 2008","February 29, 2008","June 1, 2017","June 1, 2017","Yale University, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00626340"
403,"NCT02668796","To Study Generic Estradiol 10 mcg Vaginal Tablets in the Treatment of Vulvar and Vaginal Atrophy in Post Menopausal Women.",,"Completed","No Results Available","Vulvar and Vaginal Atrophy","Drug: Estradiol Vaginal Tablets 10 mcg (Glenmark)|Drug: Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk)|Drug: Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark)","The proportion of subjects with at least 25% reduction from baseline in the sum of % basal/parabasal + %intermediate cells on vaginal cytology and vaginal pH <5.0 with a change from baseline vaginal pH of at least 0.5|The proportion of subjects with treatment success at the end of study where treatment success is defined as a subject who achieves a score of 0 (none) or 1 (mild) at Visit 3/End of Study for the MBS","Glenmark Pharmaceuticals Ltd. India","Female","30 Years to 75 Years   (Adult, Older Adult)","Phase 3","522","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","GLK-1502","January 2016","September 21, 2016","September 21, 2016","January 29, 2016",,"November 14, 2017","Glenmark Pharmaceuticals Inc., Mahwah, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02668796"
404,"NCT04016090","An Evaluation of Folic Acid to Improve Endothelial Sensitivity to Shear Stress in Seniors",,"Recruiting","No Results Available","Healthy Aging|Aging|Menopause","Dietary Supplement: Folic Acid|Other: Placebo","Endothelial sensitivity to shear rate|Neurovascular transduction","Montreal Heart Institute","All","50 Years to 80 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","ICM-2019-2596","May 16, 2019","April 2024","April 2024","July 11, 2019",,"December 12, 2022","Cardiovascular Prevention and Rehabilitation Centre of the Montreal Heart Institute, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04016090"
405,"NCT04048031","Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Peri-menopausal and Menopausal Women With Thinning Hair",,"Unknown status","No Results Available","Hair Thinning","Dietary Supplement: Nutrafol Supplement Capsules|Other: Placebo Capsules","Number of Terminal Hairs in the Target Area of the Scalp|Number of Vellus Hairs in the Target Area of the Scalp|Number of Total Hairs in the Target Area of the Scalp|Number of terminal hairs, number of vellus hairs, and number of total hairs in the target area of the scalp|Dino-Lite microscopic photographs for terminal hair diameter measurements in the target area|Hair Washing Procedure in clinic for Hair Shedding Counts|Blinded Physician Global Hair Assessment for Hair Growth and Hair Quality|Women's Hair Loss Quality of Life Questionnaire|Self-Assessment Questionnaire|Subject Treatment Satisfaction and Ease of Use Questionnaires|Subject Hair Satisfaction Questionnaire|Menopausal Rating Scale Questionnaire","Ablon Skin Institute Research Center|Nutraceutical Wellness Inc.","Female","40 Years to 65 Years   (Adult, Older Adult)","Not Applicable","70","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ASIRC-NW-02","June 18, 2019","January 2021","January 2021","August 7, 2019",,"August 9, 2019","Ablon Skin Institute & Research Center, Manhattan Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT04048031"
406,"NCT02834312","E4Relief (Response to Estetrol in Life Improvement for MEnopausal-associated Hot Flushes)",,"Completed","No Results Available","Hot Flushes","Drug: Estetrol|Drug: Placebo","Change in weekly frequency of moderate to severe VMS from baseline to week 4.|Change in weekly frequency of moderate to severe VMS from baseline to week 12.|Change in severity of moderate to severe VMS from baseline to week 4.|Change in severity of moderate to severe VMS from baseline to week 12.|Change from baseline to week 12 in genitourinary symptoms (GSM) of menopause|Change in the Menopause Rating Scale (MRS) from baseline to week 5.|Change in the Menopause Rating Scale (MRS) from baseline to week 12.|Change from baseline to week 12 in Vaginal pH.|Change from baseline to week 12 in Vaginal Maturation Index (MI) (parabasal and superficial cells)|Serum concentration of triglycerides.|Serum concentration of low density lipoprotein (LDL)-cholesterol.|Serum concentration of high density lipoprotein (HLD)-cholesterol.|Serum concentration of total cholesterol.|Fasting glycemia.|Serum concentration of glycated hemoglobin.|Homeostasis model assessment-estimated insulin resistance [HOMA-IR]|Serum concentration of prothrombin fragment 1 + 2.|Activated protein C sensitivity ratio (APCsr) (Endogenous Thrombin Potential [ETP]-Based).|Serum concentration of D-dimers.|Serum concentration of sex-hormone binding globulin (SHBG).|Serum concentration of antithrombin.|Serum concentration of protein-C.|Serum concentration of free protein-S.|Serum concentration of factor VIII.|Serum concentration of free tissue factor pathway inhibitor [TFPI].|Serum concentration of osteocalcin.|Serum concentration of C-terminal telopeptide [CTX-1]|Percentage of subjects who had a change in endometrial thickness at each study visit.|Percentage of subjects with adverse events as a measure of safety and tolerability.|Maximum concentration (Cmax) of E4 in plasma.|Time to Cmax (Tmax) of E4 in plasma.|Terminal half-life (T1/2) of E4 in plasma.|Area under the plasma concentration-time curve from baseline to the last quantifiable concentration following dosing (AUCtau) of E4.","Donesta Bioscience|SynteractHCR","Female","40 Years to 65 Years   (Adult, Older Adult)","Phase 2","260","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MIT-Do0001-C201|2015-004018-44","May 2016","January 22, 2018","January 22, 2018","July 15, 2016",,"January 26, 2018","Donesta Bioscience BV, Liège, Belgium",,"https://ClinicalTrials.gov/show/NCT02834312"
407,"NCT00162370","A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary Disease",,"Completed","Has Results","Coronary Artery Disease|Heart Disease","Drug: Perflutren Lipid Microsphere Injectable Suspension","Number of Participants With Abnormal Contrast Stress Echocardiography and With Future Major Adverse Cardiac Events (MACE) at 2 and 5 Years Follow-Up|Number of Participants With Abnormal ECG and With Major Adverse Cardiac Events (MACE) at 2 Year Follow-Up|Change in Brain Natriuretic Peptide (BNP) in Subjects With and Without Major Adverse Cardiac Events at 2-year Follow-up.|Change in Atrial Natriuretic Peptide (ANP) in Subjects With and Without Major Adverse Cardiac Events at 2-year Follow-up.|Change in Brachial Artery Reactivity Was Assessed in in a Subset of Participants With and Without Major Adverse Cardiac Events at 2-year and 5-year Follow-up.|Mean Baseline Calcium Score of Participants With and Without Major Cardiac Events at 2-year Follow up.|The Presence of Wall Motion Abnormalities on Definity Stress Echocardiography Assessed for Participants With Both Normal and Abnormal Angiography|Participants With Positive and Negative Angiography Compared With Their ECG Results|Number of Participants With Abnormal ECG and With Future Major Adverse Cardiac Events (MACE) at 5 Years Follow-Up|Change in Brain Natriuretic Peptide (BNP) in Participants With and Without Major Adverse Cardiac Events at 5-year Follow-up.|Change in Atrial Natriuretic Peptide (ANP) in Participants With and Without Major Adverse Cardiac Events at 5-year Follow-up.|Mean Calcium Score of Participants With and Without Major Cardiac Events at 5-year Follow up.","Lantheus Medical Imaging","Female","40 Years to 65 Years   (Adult, Older Adult)","Phase 4","400","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","DMP 115-407","April 2004","September 2012","October 2012","September 13, 2005","December 8, 2016","March 15, 2021","Local Institution, Scottsdale, Arizona, United States|Local Institution, Jacksonville, Florida, United States|Local Institution, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00162370"
408,"NCT04719598","Effects of Internet - Based Cognitive Behavioral Therapy on Sleep Problems Among Sample of Post- Menopausal",,"Unknown status","No Results Available","Sleep Problem","Behavioral: congnitive behavioural therapy","change sleep quality post intervention|change insomnia related to post menpausal symptoms post intervention|change menopausal symptoms post intervention","Jouf University","Female","45 Years to 65 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","1384754968","January 25, 2021","April 30, 2021","June 15, 2021","January 22, 2021",,"February 2, 2021",,,"https://ClinicalTrials.gov/show/NCT04719598"
409,"NCT00892268","Acupuncture or Medication in Reducing Pain in Postmenopausal Women With Breast Cancer and Joint Pain",,"Terminated","No Results Available","Breast Cancer|Menopausal Symptoms|Pain","Procedure: acupuncture therapy|Procedure: pain therapy","Improvement in pain, as defined by the WOMAC global score at 6 weeks|Acupuncture efficacy as defined by bio-correlates, e.g., changes in BDNF and STGP levels|Menopausal symptoms as defined by the FACT-ES","University of Arizona|National Cancer Institute (NCI)","Female","Child, Adult, Older Adult","Phase 2","68","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CDR0000629150|P30CA023074|UARIZ-07-0792-04|IRUSANAS0084","January 2008","October 2009","October 2009","May 4, 2009",,"April 27, 2010",,,"https://ClinicalTrials.gov/show/NCT00892268"
410,"NCT05669469","Upper Airway of Women With Obstructive Sleep Apnea After Bariatric Surgery",,"Completed","No Results Available","Sleep Apnea|Obesity","Procedure: Bariatric surgery","Upper airway changes after surgical weight loss|Obstructive sleep apnea parameters measured thought polysomnographic changes after weight loss|Changes in volumes and areas of upper airway|Correlation between the changes on upper airway with the changes on obstructive sleep apnea|Evaluation if the menstrual status interfere on outcomes","Michel Burihan Cahali|Carolina Ferraz de Paula Soares|University of Sao Paulo General Hospital","Female","18 Years to 70 Years   (Adult, Older Adult)",,"38","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","66609117.9.0000.0065","August 15, 2017","March 25, 2021","April 2, 2022","December 30, 2022",,"December 30, 2022","Fundação Hospitalar São Lucas, Cascavel, Paraná, Brazil",,"https://ClinicalTrials.gov/show/NCT05669469"
411,"NCT01840488","BN83495 Phase I in Post-menopausal Women",,"Completed","No Results Available","Breast Cancer","Drug: Irosustat (BN83495)","Change in percentage of steroid sulphatase (STS) inhibition in circulating Peripheral Blood Mononuclear Cells (PBMCs) after repeated daily therapy|Percentage of steroid sulphatase (STS) inhibition in circulating Peripheral Blood Mononuclear Cells (PBMCs) after a single dose","Ipsen","Female","18 Years and older   (Adult, Older Adult)","Phase 1","50","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","X-55-58064-002|2006-005347-28","April 2007","September 2010","September 2010","April 25, 2013",,"November 22, 2019","Institut Jules Bordet, Bruxelles, Belgium|Centre Paul Papin, Angers, France|Institut Georges François Leclerc, Dijon, France|Centre Eugène Marquis, Rennes, France|Imperial College Healthcare NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01840488"
412,"NCT02467231","Ovarian Reserve After Cancer: Longitudinal Effects","ORACLE","Active, not recruiting","No Results Available","Effects of Chemotherapy|Premature Ovarian Failure",,"Change from baseline in reproductive hormone measures, during and after chemotherapy.|Change from baseline in antral follicle counts, during and after chemotherapy.","University of Pennsylvania|Children's Hospital of Philadelphia","Female","11 Years to 35 Years   (Child, Adult)",,"196","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","809406","February 2009","April 2023","December 2023","June 9, 2015",,"May 13, 2022","University of Pennsylvania, Reproductive Research Unit, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02467231"
413,"NCT00853723","Comparison Study of PTHrP and PTH to Treat Osteoporosis",,"Completed","Has Results","Osteoporosis","Drug: Parathyroid hormone related protein (1-36)|Drug: Parathyroid hormone related protein(1-36)|Drug: Parathyroid hormone (1-34)","Procallagen-1 Amino-terminal Peptide (P1NP)|Carboxy-terminal Telopeptides of Collagen-1 (CTX)|Changes in Bone Mineral Density of the Lumbar Spine.|Changes in Bone Mineral Density of the Total Hip.|Changes in Bone Mineral Density of the Femoral Neck.|Changes in Bone Mineral Density of the Forearm.|Changes in Bone Mineral Density of the Distal 1/3 Radius.|Total Serum Calcium (mg/dl)|Serum Phosphorous|24 Hour Urine Calcium|1,25 Vitamin D|Fractional Excretion of Calcium|Tubular Maximum for Phosphorous/Glomerular Filtration Rate (TMP/GFR)","University of Pittsburgh|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Female","45 Years to 75 Years   (Adult, Older Adult)","Phase 2","105","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","PRO08100148|R01DK051081","May 2009","February 2012","June 2012","March 2, 2009","February 24, 2016","March 24, 2016","UPMC Clinical & Translational Research Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00853723"
